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Occurrence of mutations in the Polycomb (PcG) gene; EZH2 (Enhancer of Zeste 
Homologue 2) represent a new class of molecular lesions associated with instability in the 
epigenome of patients with Myelodysplastic Syndrome (MDS). Detection of 
microdeletion at 7q36.1 or 7q Copy Neutral Loss of Heterozygosity [CN (LOH)] led to 
the identification of EZH2 mutations. EZH2 is the catalytic component of Polycomb 
Repressive Complex 2 (PRC2) that trimethylates lysine 27 of histone 3 (H3K27) resulting 
in gene silencing and recruitment of the sister complex i.e. Polycomb Repressive 
Complex 1 (PRC1) to target genes. Discovery of EZH2 mutations have shed light on the 
involvement of other PcG and PcG interacting proteins i.e. Jumonji (jmj) family of 
demethylases and DNA methyltrasferase 3A (DNMT3A) in MDS. Investigation of Single 
Nucleotide Polymorphism (SNP) array abnormalities and mutational analysis of these 
genes have not been ascertained and therefore I examined cytogenetic aberrations 
affecting twelve Polycomb (PRC1) and seventeen Jumonji genes using high density SNP 
6 arrays. SNP6 data analyzed in this study was generated by our group for previous 
research projects. I visualised this data using CHromosome Analysis Suite (Chas) from 
Affymetrix and identified five PRC1 genes (BMI1, PHC1, PHC2, RING1A and RING1B) 
in 17/91 (19 %) patients with either Copy Number Variations (CNVs) like deletions or 
amplifications or CN (LOH).  Interestingly, the frequency of SNP6 aberrations was high 
(two times) in Jumonji genes as compared to PRC1. 29/91 patients (31 %) showed either 
CNVs or CN (LOH) in fifteen (JMJD3, JMJD4, JMJD1B, JMJD2A, JARID2, JMJD1C, 
JARID1B, JMJD2C, UTX, JARID1C, JARID1A, JMJD2D, JHJD1A, JARID1D and 
JHJD1B) Jumonji genes. Mutational analysis of patients with SNP6 aberrations was 
carried out using Sanger or 454 sequencing but no mutations were detected in either the 
PRC1 or Jumonji genes. To elucidate changes in gene expression as a result of 
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amplification or deletion of genomic material, qPCR was performed on 22/29 patients for 
thirteen Jumonji genes. Gene expression of JARID1A, JARID1C and UTX were 
modulated concomitant to the CNVs. Deletion of JARID1A locus was associated with 
reduced gene expression (p value <0.0001) in two patients while trisomy of JARID1C 
(n=1) and UTX (n=2) were associated with increased expression (p value <0.0001) of 
both the genes.  
Mutational analysis of PRC2 core components (SUZ12, EED, EZH1) and DNMT3A was 
carried out in a cohort of 61 MDS patients previously sequenced by our group for EZH2 
mutations to examine their mutational overlap. 10/61 patients had heterozygous DNMT3A 
mutations (clone size 20-44 %) with two patients showing mutations at the R882 site. 
Interestingly, these mutations were seen predominantly (n= 6) in patients with monosomy 
7/del 7q however only one patient had both DNMT3A (R882H) and EZH2 (V626M) 
mutations suggesting that there is no specific association between mutations of the two 
genes. In contrast, PRC2 genes were not mutated in this cohort emphasizing the 
importance of EZH2 mutations alone in MDS pathogenesis. Therefore I examined the 
functional consequences of the commonly occurring EZH2 (R690C/R690H) and 
DNMT3A (R882H) mutations in myeloid cell lines. 
To achieve this, numerous attempts were made to clone DNMT3A R882H mutation into 
p3XFLAG-myc-CMV-26 to allow transfection and in vitro assessment of the mutant in 
myeloid cells but all attempts to ligate the plasmid failed and therefore work on DNMT3A 
was discontinued. 
EZH2 (R690C/R69H) and Flag tagged wild type EZH2 were constructed in p3XFLAG-
myc-CMV-26 vector using a PCR based cloning strategy and transfected into K562 cells. 
Western blot analysis at 72 hr post transfection, showed elevated levels of both 
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R690C/R690H mutants and Flag tagged wild type EZH2 but no alterations in its target 
H3K27me3 levels. Affymetrix Human Transcriptome 2.0 gene expression profiling was 
used to identify modulation of gene signature as result of elevated EZH2 levels and 
MLLT10 gene was found to be up regulated in cells transfected with Flag-tagged wild 
type EZH2 (2.3 fold) as well as R690C/ R690H (3.6 – 4.6 fold) mutants. In contrast, PML 
(promyelocytic leukaemia) (2.16 fold) and FANCL (Fanconi Anaemia, Complementation 
Group L) (2.18 fold) genes were up regulated exclusively in cells over expressing the 
Flag tagged wild type EZH2. To compare this gene signature to gene expression changes 
as a result of EZH2 knock out (KO), shRNA mediated inhibition of EZH2 was carried out 
in myeloid cells and 95 % KO of both EZH2 and H3K27me3 levels were observed at Day 
7 post transduction. Microarray gene expression profiling identified BCL2 (-2.14 fold), 
FLT1 (-4.03 fold), HOXA10 (-2.2 fold), CD44 (-8.2 fold), CD83 (-2.1 fold), TLSP (-3.24 
fold), IFI16 (-3.11 fold) and PAG1 (-3.37 fold) inhibition in cells transduced with shRNA 
against EZH2 compared to the scrambled and wild type K562 cells. There were no 
overlapping genes in K562 cells with EZH2 KO and EZH2 mutants R690C/R690H. The 
differences in expression profiling could be due to the difference in H3K27me3 levels 
modulated by EZH2. Comparison of gene signature obtained by EZH2 KO on patient 
samples carrying the R690H mutation, showed contrasting results i.e. up regulation of 
HOXA10, FLT1, PAG1B, EZH1 and TLSP compared to patients with wild type EZH2 
suggesting that EZH2 R690C/R690H mutants do not mimic the transcriptional changes 
seen in EZH2 KO.  This strongly suggests the presence of other mechanisms to 
compensate for the loss of EZH2 in myeloid cells. However the results obtained here 
should be examined in additional other myeloid cell lines to validate the findings obtained 




Table of Contents 
Declaration .............................................................................................................................................. 1 
Acknowledgement .................................................................................................................................. 2 
Abstract ................................................................................................................................................... 3 
Table of Contents .................................................................................................................................... 6 
List of Figures ........................................................................................................................................ 13 
List of Tables ......................................................................................................................................... 15 
List of Abbreviations ............................................................................................................................. 17 
1 Chapter: Introduction ................................................................................................................... 20 
1.1 Myelodysplastic syndrome (MDS) ........................................................................................ 21 
1.1.1 Disease classification and prognostic scoring system ................................................... 21 
1.1.2 Implication of  Cytogenetics in MDS ............................................................................. 26 
1.1.3 Mutational analysis in MDS .......................................................................................... 27 
1.2 Epigenetic aberrations in MDS .............................................................................................. 30 
1.2.1 Post translational histone modifications ...................................................................... 31 
1.3 Polycomb proteins and polycomb repressive complexes ..................................................... 33 
1.3.1 Classification of PcG proteins ........................................................................................ 33 
1.3.2 Mechanism of action of Canonical  PcG proteins ......................................................... 36 
1.3.3 PcG and DNA methylation ............................................................................................ 39 
1.3.4 Expression patterns of PcG proteins ............................................................................. 42 
1.4 Subunits of PRC2 ................................................................................................................... 44 
1.4.1 Embryonic ectoderm enhancement protein ................................................................ 44 
1.4.2 Suppressor of Zeste protein .......................................................................................... 45 
1.4.3 Enhancer of Zeste proteins ........................................................................................... 46 
1.5 Subunits of PRC1 ................................................................................................................... 47 
1.5.1 Posterior sex comb proteins ......................................................................................... 47 
1.5.2 Ring proteins ................................................................................................................. 49 
1.5.3 Polyhomeotic proteins .................................................................................................. 50 
1.5.4 Chromobox proteins ..................................................................................................... 52 
1.6 Role of PcG proteins in DNA damage .................................................................................... 54 
1.7 Role in Haematological malignancies ................................................................................... 55 
1.8 Role in Haematopoietic system ............................................................................................ 59 
1.9 Therapeutic role of PcG proteins .......................................................................................... 63 
1.10 Project Aims .......................................................................................................................... 65 
7 
 
2 Chapter: Materials and Methods .................................................................................................. 67 
2.1 Reagents ................................................................................................................................ 68 
2.1.1 Enzymes and Buffer ...................................................................................................... 68 
2.1.2 Plasmids ........................................................................................................................ 68 
2.1.3 Antibodies ..................................................................................................................... 69 
2.1.4 PCR, Gel electrophoresis and Sequencing Materials .................................................... 69 
2.1.5 DNA and RNA extraction reagents ................................................................................ 70 
2.1.6 Cloning reagents ........................................................................................................... 70 
2.1.7 Transfection reagents ................................................................................................... 71 
2.1.8 Tissue culture reagents & equipment ........................................................................... 71 
2.1.9 Cell lines ........................................................................................................................ 72 
2.1.10 qPCR reagents ............................................................................................................... 72 
2.1.11 Western Blot reagents .................................................................................................. 72 
2.1.12 Cell viability, proliferation and cell cycle reagents ....................................................... 72 
2.1.13 Buffers and Solutions .................................................................................................... 73 
2.2 siRNA ..................................................................................................................................... 74 
2.3 shRNA used with pSUPER...................................................................................................... 74 
2.4 Patient samples ..................................................................................................................... 75 
2.5 DNA Techniques .................................................................................................................... 75 
2.5.1 DNA Extraction .............................................................................................................. 75 
2.5.2 Determination of DNA concentration ........................................................................... 75 
2.5.3 DNA Amplification ......................................................................................................... 76 
2.5.4 DNA quality Testing ....................................................................................................... 76 
2.6 Primer Designing ................................................................................................................... 77 
2.6.1 Primer Testing and PCR optimisation ........................................................................... 77 
2.7 Mutational analysis by Sanger Sequencing ........................................................................... 78 
2.8 Next-generation sequencing of PRC2, DNMT3A and Jumonji genes .................................... 80 
2.8.1 Patient Cohort ............................................................................................................... 80 
2.8.2 Gel extraction and purification ..................................................................................... 81 
2.8.3 Bead Purification ........................................................................................................... 82 
2.8.4 Library preparation ....................................................................................................... 82 
2.8.5 Sequencing .................................................................................................................... 82 
2.8.6 Emulsion PCR ................................................................................................................ 83 
2.8.7 Vaccum assisted emulsion breaking ............................................................................. 84 
8 
 
2.8.8 DNA library Bead Enrichment ....................................................................................... 85 
2.8.9 Preparation of Enrichment Beads ................................................................................. 85 
2.8.10 Collection of Enriched DNA beads ................................................................................ 86 
2.8.11 Determine Bead enrichment ........................................................................................ 86 
2.8.12 Sequencing Primer Annealing ....................................................................................... 86 
2.8.13 Preparation of Bead Buffer 2 (BB2)............................................................................... 87 
2.8.14 Bead Preparation [Titanium Sequencing Kit LR70 CatNo: 04932315001] .................... 87 
2.8.15 Layer Preparation .......................................................................................................... 88 
2.8.16 Assembling the BDD ...................................................................................................... 89 
2.8.17 Run  Requirements ........................................................................................................ 90 
2.9 Total RNA isolation ................................................................................................................ 90 
2.10 cDNA synthesis ...................................................................................................................... 90 
2.11 Real Time PCR analysis .......................................................................................................... 91 
2.12 Affymetrix Human Transcriptome 2.0 gene expression profiling ......................................... 92 
2.12.1 Reverse transcription to synthesise first-strand cDNA ................................................. 93 
2.12.2 Second-strand cDNA synthesis ..................................................................................... 94 
2.12.3 In Vitro Transcription (IVT) to synthesise cRNA ............................................................ 96 
2.12.4 cRNA Purification .......................................................................................................... 96 
2.12.5 2
nd
-Cycle single-strand cDNA synthesis......................................................................... 96 
2.12.6 Hydrolyze RNA by RNase H ........................................................................................... 97 
2.12.7 Purification of 2
nd
- Cycle single-strand cDNA ................................................................ 97 
2.12.8 Fragmentation & Labelling single-strand cDNA ............................................................ 98 
2.12.9 WT Array Hybrdization .................................................................................................. 99 
2.12.10 Expression microarray data analysis ....................................................................... 100 
2.13 Protein Blotting ................................................................................................................... 101 
2.13.1 Cell lysis ....................................................................................................................... 101 
2.13.2 Western blot analysis .................................................................................................. 101 
2.14 Cloning ................................................................................................................................ 102 
2.14.1 Restriction Digests ...................................................................................................... 102 
2.14.2 Conversion of extended DNA termini to blunt ends ................................................... 103 
2.14.3 Isolation and purification of DNA from agarose gels .................................................. 103 
2.14.4 Topo cloning ................................................................................................................ 104 
2.14.5 TraŶsforŵatioŶ iŶto DHϱα-T1 E.Coli ........................................................................... 104 
2.14.6 Ligation ........................................................................................................................ 105 
9 
 
2.14.7 Transformation into DH10B cells ................................................................................ 105 
2.14.8 Miniprep: Alkaline lysis method ................................................................................. 105 
2.14.9 Miniprep: Wizard Plus SV miniprep ............................................................................ 106 
2.14.10 Maxiprep: Qiagen Plasmid kit ................................................................................. 106 
2.15 Cell culture .......................................................................................................................... 107 
2.15.1 Culturing non-adherent myeloid cells lines ................................................................ 107 
2.15.2 Transfection using Lipofectamine LTX reagent ........................................................... 108 
2.15.3 RNAiMAX transfection protocol for siRNA experiment .............................................. 108 
2.15.4 Electroporation ........................................................................................................... 108 
2.16 Knockdown of EZH2 ............................................................................................................ 108 
2.16.1 Constructing shRNA in pSUPER vector ........................................................................ 108 
2.17 Lentivirus short-hairpin RNA (LVshRNA) virus particle production & concentration of the 
lentivirus vector .............................................................................................................................. 110 
2.18 Mtt cell proliferation assay ................................................................................................. 111 
2.19 Cell Cycle analysis ................................................................................................................ 112 
2.19.1 Cell cycle staining ........................................................................................................ 112 
2.19.2 Cell cycle analysis by flow cytometry .......................................................................... 112 
2.20 Annexin V staining............................................................................................................... 113 
3 Chapter: SNP6 and Mutational Analysis of PRC1, PRC2, DNMT3A & JUMONJI genes ............... 114 
3.1 Introduction ........................................................................................................................ 115 
3.2 Involvement of PRC subunits, DNMT3A and the Jumonji genes in MDS/AML ................... 115 
3.3 PRC and interacting proteins .............................................................................................. 115 
3.3.1 DNMT3A ...................................................................................................................... 115 
3.3.2 Jumonji ........................................................................................................................ 116 
3.4 SNP6 Analysis ...................................................................................................................... 117 
3.5 Aim ...................................................................................................................................... 118 
3.6 Patient samples ................................................................................................................... 118 
3.6.1 Amplification of patient samples ................................................................................ 119 
3.7 SNP6 and Chas analysis ....................................................................................................... 120 
3.7.1 PRC1 ............................................................................................................................ 122 
3.7.2 Sanger sequencing ...................................................................................................... 123 
3.7.3 Jumonji genes.............................................................................................................. 124 
3.8 PRC2 and DNMT3A.............................................................................................................. 135 
3.8.1 Primer testing and PCR optimisation (PRC2) .............................................................. 135 
10 
 
3.8.2 454 parallel sequencing (PRC2) ................................................................................... 136 
3.8.3 Primer testing and PCR optimisation (DNMT3A) ........................................................ 140 
3.8.4 454 parallel sequencing (DNMT3A) ............................................................................ 142 
3.8.5 Mapping of DNMT3A mutations ................................................................................. 144 
3.8.6 Correlation with EZH2 mutations................................................................................ 145 
3.9 Discussion ............................................................................................................................ 146 
3.9.1 SNP6 and mutational analysis of PRC1 and Jumonji  genes ....................................... 146 
3.9.2 Mutational analysis of PRC2 and DNMT3A ................................................................. 150 
3.9.3 Mutational overlap ..................................................................................................... 152 
3.10 Conclusion ........................................................................................................................... 152 
4 Chapter: Role of EZH2 mutations (R690C & R690H) in Myeloid Malignancies .......................... 154 
4.1 Introduction ........................................................................................................................ 155 
4.2 Aim ...................................................................................................................................... 155 
4.3 Constructing the R690C & R690H mutations in pCMV sport6 vector ................................ 156 
4.3.1 Generation of fragment containing R690C & R690H mutation .................................. 158 
4.3.2 Three-way ligation ...................................................................................................... 160 
4.4 Cloning R690C & R690H mutants into p3XFLAG-myc-CMV-26 expression vector ............. 163 
4.4.1 Linearise the p3XFLAG-myc-CMV-26 expression vector for ligation .......................... 163 
4.4.2 Isolation of EZH2 cDNA from pCMV sport6 vector ..................................................... 164 
4.4.3 Ligation of EZH2 cDNA and p3XFLAG-myc-CMV-26 expression vector ...................... 164 
4.5 Transfection of R690C/R690H & wild type EZH2 into myeloid cell lines ............................ 166 
4.5.1 Electroporation& Lipofectamine transfection methods ............................................. 167 
4.6 Cloning EZH2 cDNA into p3XFLAG-myc-CMV-26 containing GFP and puromycin .............. 171 
4.6.1 Construction of  wild type EZH2 .................................................................................. 171 
4.6.2 Construction of R690C and R690H EZH2 mutants ...................................................... 173 
4.7 Transfection of R690C/R690H/wild type EZH2 in p3XFLAG-myc-CMV-26 (GFP + 
Puromycin) into myeloid cell lines .................................................................................................. 175 
4.8 Impact of EZH2 mutation on H3K27me3 ............................................................................ 177 
4.9 Microarray analysis of EZH2 mutants and over expressed wild type EZH2 reveals novel 
EZH2 targets .................................................................................................................................... 179 
4.10 Discussion ............................................................................................................................ 184 
4.10.1 Cloning R690C/R690H and Flag tagged wild type EZH2 into p3XFLAG-myc-CMV-26 
(neomycin) .................................................................................................................................. 185 
4.11 Conclusion ........................................................................................................................... 190 
5 Chapter: Role of EZH2 inhibition in Myeloid malignancies ......................................................... 191 
11 
 
5.1 Introduction ........................................................................................................................ 192 
5.2 Knock out (KO) of EZH2 in cancer ....................................................................................... 192 
5.3 RNA interference ................................................................................................................ 193 
5.4 Aim ...................................................................................................................................... 195 
5.5 Transient knockdown of EZH2 ............................................................................................ 196 
5.5.1 Silencing Efficiency of siRNA (Dharmacon) in MOLM13 & K562 cells using RNAiMAX
 196 
5.5.2 Silencing Efficiency of siRNA (Dharmacon) in MOLM13 & K562 cells using 
electroporation ........................................................................................................................... 197 
5.6 Impact of EZH2 KO on H3K27me3 ...................................................................................... 200 
5.7 Cell Cycle analysis ................................................................................................................ 201 
5.8 Silencing Efficiency of siRNA (Santacruz) in MOLM13 & K562 cells using electroporation 202 
5.9 Stable knockdown of EZH2 using shRNA in pSUPER ........................................................... 203 
5.10 Stable knockdown of EZH2 using shRNA in lentivirus ......................................................... 206 
5.10.1 shRNA (Insight Biotechnology) .................................................................................... 206 
5.10.2 shRNA (Fisher Scientific) ............................................................................................. 207 
5.11 Effect of shRNA_D on EZH1 expression .............................................................................. 209 
5.12 Impact of EZH2 KO on H3K27me3 ...................................................................................... 211 
5.13 Microarray gene expression analysis of shRNA transduced cells reveals novel EZH2 targets
 212 
5.13.1 Validation of EZH2 targets .......................................................................................... 215 
5.14 Impact of EZH2 KO on cell viability & proliferation ............................................................ 218 
5.14.1 Trypan blue staining .................................................................................................... 218 
5.14.2 MTT  tetrazolium cell proliferation assay ................................................................... 219 
5.14.3 Annexin V staining ....................................................................................................... 220 
5.14.4 Cell Cycle analysis ........................................................................................................ 222 
5.15 Confirmation of gene signature in patient samples ........................................................... 223 
5.16 Discussion ............................................................................................................................ 225 
5.16.1 Transcription and gene expression profiling ............................................................... 225 
5.16.2 Effect of EZH2 on cell cycle, cell viability and cell cycle kinetics ................................. 229 
5.16.3 Gene signature in patient samples ............................................................................. 233 
5.17 Conclusion ........................................................................................................................... 235 
6 Chapter: Role of DNMT3A (R882H) mutation in Myeloid malignancies ..................................... 236 
6.1 Introduction ........................................................................................................................ 237 
6.2 Aim ...................................................................................................................................... 237 
12 
 
6.3 Constructing the R88H mutant in pCMV sport6 vector ...................................................... 237 
6.3.1 Generating the fragment containing the R882 mutation ........................................... 239 
6.3.2 Ligation of mutation into pCMV-SPORT6 .................................................................... 242 
6.3.3 Cloning R882H mutation into p3XFLAG-myc-CMV-26 expression vector .................. 244 
6.3.4 Ligation of DNMT3A cDNA and p3XFLAG-myc-CMV ................................................... 249 
6.3.5 Ligation of Flag tag into pCMV-SPORT6 ...................................................................... 249 
6.4 Transfection of R882H-mutant into myeloid cell lines ....................................................... 251 
6.4.1 Electroporation ........................................................................................................... 251 
6.4.2 Lipofectamine LTX reagent ......................................................................................... 252 
6.5 Discussion ............................................................................................................................ 254 
6.5.1 Literature survey ......................................................................................................... 255 
6.6 Conclusion ........................................................................................................................... 257 
7 Chapter: General Conclusions and Future work ......................................................................... 258 
7.1 Identification of SNP6 abnormalities and mutations affecting Polycomb genes and their 
binding partners (DNMT3A and Jumonji) ....................................................................................... 259 
7.2 Functional analysis in myeloid malignancies: R690C/R690H mutations, over expression and 
knock down of EZH2. ...................................................................................................................... 262 
7.3 Functional analysis of DNMT3A in myeloid malignancies .................................................. 266 









List of Figures 
Figure Name Page No 
Figure 1.1: Epigenetic regulation of transcription 30 
Figure 1.2: Post translational modifications of overhanging N-terminal of histone tails 32 
Figure 1.3:  Canonical and non canonical PRC1 and PRC2 complexes 35 
Figure 1.4: Mechanism of action; PRC1 and PRC2. 38 
Figure 1.5: Interaction of PRC2 and DNMT3A. 40 
Figure 1.6: Illustrates inhibitory effect of PcG proteins on the INK4A/ARF locus. 44 
Figure 1.7: Deletion of BMI-1 domains.  48 
Figure 1.8: Polyubiquitination of RING1B 50 
Figure 1.9: Propagation of transcriptional repression 51 
Figure 1.10: Identification 7q CN (LOH) and EZH2 involvement.  55 
Figure 1.11: Dual effect of KO of RING1B on the haematopoietic system 61 
Figure 2.1: Assembled set-up for vaccum assisted emulsion breaking and bead recovery 85 
Figure 2.2: Assembling the BDD 89 
Figure 2.3: Work-flow for Affymetrix Human Transcriptome 2.0 gene expression array 93 
Figure 2.4: Components of the array chip. The square in the centre indicates the probe arrays. 100 
Figure 2.5: Four shRNAs were designed against different positions along the gene 109 
Figure 3.1:Human DNA OK results. 120 
Figure 3.2:Visualisation of SNP6 data for the Jumonji and PRC1 genes by Chromosome 
Analysis Software (ChAS). 121 
Figure 3.3: Total number of patients with SNP6 abnormalities.  125 
Figure 3.4: Visualisation of PCR product for JMJD4 and JMJD1B on 2 % agarose for 454 
sequencing. 129 
Figure 3.5: Gene expression analysis of Jumonji genes by qPCR. 132 
Figure 3.6: Primer optimisation for EZH1, EED & SUZ12 using different primer and template 
DNA concentrations. 135 
Figure 3.7: Visualisation of the PCR product  for EED after second round of PCR 136 
Figure 3.8: SUZ12, EED, EZH1 library purification 138 
Figure 3.9: Optimisation of DNMT3A primers 139 
Figure 3.10: DNMT3A library preparation 140 
Figure 3.11: DNMT3A (R882C) mutation in patient (LSL4062) visualised by Vnode. 143 
Figure 3.12: Mapping of the mutations to the different domains of the DNMT3A protein. 143 
Figure 4.1: Cloning strategy for introducing the R690C and R690H mutation in pCMV-SPORT6 157 
Figure 4.2: Digestion of pCMV-SPORT6 vector containing EZH2 cDNA 157 
Figure 4.3: Generation of mutational fragment R690C and R690H 159 
Figure 4.4: Verification of the correct colony after cloning the PCR fragment in pCRII- TOPO 
vector 160 
Figure 4.5: Confirmation of R690C and R690H mutant in pCMV-SPORT6 vector.  162 
Figure 4.6: Cloning Strategy.  163 
Figure 4.7: Cloning EZH2 cDNA into p3XFLAG-myc-CMV 164 
Figure 4.8: Verification of accurate ligation of EZH2 cDNA into p3XFLAG-myc-CMV plasmid. 165 
Figure 4.9: Endogenous expression of EZH2 in myeloid cell lines  166 
Figure 4.10: Experimental workflow for transfection by Lipofectamine LTX 167 
Figure 4.11: qPCR analysis of EZH2 expression in MOLM13 cells, 48 hr and 21 days after 
transfection 168 
Figure 4.12: qPCR analysis of EZH2 expression in Molm13 cells, 48 and 72 hr after 5-
Azacytidine treatment 169 
Figure 4.13: Cloning EZH2 cDNA into p3XFLAG-myc-CMV-26 (GFP+puro)  171 
Figure 4.14: Confirmation of accurate ligation of wild type EZH2 cDNA into p3XFLAG-myc-
CMV plasmid 172 
14 
 
Figure 4.15: Confirmation of the FLAG and EZH2 sequences by Sanger sequencing.  173 
Figure 4.16: Ligation of fragment containing R690C or R690H mutant in to wt Flag pX3FLAG-
myc-CMV (GFP+puromycin).  174 
Figure 4.17: FACS BD Fortessa analysis of GFP+ K562 cells transfected with R690C mutant.  176 
Figure 4.18: Western blot analysis at 72 hr post transfection.  177 
Figure 5.1:Schematic representation of RNA interference in cells 194 
Figure 5.2: EZH2 expression levels at 48 hr by qPCR 197 
Figure 5.3: EZH2 expression levels by qPCR using 150 nM siRNA (Dharmacon) concentration 
198 
Figure 5.4: Measurement of EZH2 expression levels by qPCR using 200 nM concentration of 
siRNA (Dharmacon) 199 
Figure 5.5: Western blot analysis of siRNA mediated KO of ezh2 in Molm13 cells at 24 and 48 
hr 200 
Figure 5.6: Cell cycle profile of Molm13 at 24 hr post transfection 201 
Figure 5.7: EZH2 expression levels at 24 hr after transfection with siRNA from Santacruz 
biotechnology by qPCR 202 
Figure 5.8:Experimental workflow for transfection of pSUPER containing shRNA against EZH2 
into Molm13 and K562 cells 204 
Figure 5.9: EZH2 expression levels after puromycin selectionin cells transfected with shRNA in 
pSUPER vector by qPCR 205 
Figure 5.10: qPCR analysis of EZH2 expression after puromycin selectionin cells transfected 
with shRNA in pSUPER vector 205 
Figure 5.11: qPCR analysis of EZH2 expression levels at day7 post infection by shRNA (Insight 
Biotechnology) 206 
Figure 5.12: qPCR analysis of EZH2 expression levels at 48 hr and 7 days after transduction 
with lentivirus containing shRNA (Fisher Scientific) in K562 cells 208 
Figure 5.13: qPCR analysis of EZH2 expression at day 7 after infection with the concentrated 
(add titre) lentivirus containing shRNA (Fisher Scientific) in K562 cells 209 
Figure 5.14:qPCR analysis of EZH1 expression levels at day 7 after infection with shRNA_D in 
K562 cells 210 
Figure 5.15: Western blot analysis of shRNA mediated KO of ezh2 in K562 cells on day 7 post 
FACs sorting for GFP positive cells 211 
Figure 5.16: Illustrates schematic representation of top enriched pathways (a) (P<) and 
processes (b) for all up and down regulated genes after EZH2 KO 213 
Figure 5.17: qPCR validation of genes modulated due to loss of EZH2 in K562 cells 216 
Figure 5.18: Cell count of K562 cells using Trypan blue staining post shRNA lentiviral infection. 
218 
Figure 5.19:Cell proliferation assessment by MTT assay on day 7 after transduction in K562 
cells 220 
Figure 5.20: Annexin V and 7-AAD staining of K562 cells at 48 hr post shRNA infection (top 
panel) and on day 7 post sorting for GFP positive cells (bottom panel). 221 
Figure 5.21: Cell cycle profile in K562 cells on day 7 after sorting for GFP positive cells. 222 
Figure 5.22: qPCR analysis of patient samples with (R690H) or without EZH2 mutation 224 
Figure 6.1: Coning strategy for introducing the R882H mutation in pCMV-SPORT6 238 
Figure 6.2: Digestion of pCMV-SPORT6 vector containing DNMT3A cDNA 239 
Figure 6.3: PCR based generation of the mutational (R882H) fragment in DNMT3A cDNA 240 
Figure 6.4: Second PCR to generate the mutational (R882H) fragment in DNMT3A cDNA 241 
Figure 6.5 Visualisation of four colonies on 1 % agarose gel aftertreatment with XbaI-NruI 
restriction enzymes. 242 
Figure 6.6: Confirmation of the presence of R882H mutant in pCMV-SPORT6 vector using 
sanger sequencing. 244 




Figure 6.8: Digestion of pCMV-SPORT6 containing R882H mutant by SalI-Bpu10I restriction 
enzymes. 246 
Figure 6.9: Digestion of colonies obtained after ligation of DNMT3AcDNA into p3XFLAG-myc-
CMV-26 expression vector by HindIII-NotI restriction enzymes. 249 
Figure 6.10: Second attempt to ligate DNMT3A into p3XFLAG-myc-CMV-26 plasmid. 247 
Figure 6.11: Plasmid DNA from six colonies was digested by ScaI-NotI restriction enzymes 
followed by partial digest by HindIII 248 
Figure 6.12: Digestion of pX3FLAG-myc-CMV-26 plasmid by HindIII-NotI restriction enzymes. 
249 
Figure 6.13: Cloning strategy for inserting the FLAG tag from pX3FLAG-myc into pCMV-
SPORT6. 250 
Figure 6.14: (a) Digestion of pX3FLAG-myc-CMV by SnabI-HindIII restriction enzymes(b) SnabI 
digest followed by HindIII partial digest on pCMV-SPORT6. 250 
Figure 6.15: Experimental workflow for transfection by electroporation. 252 
Figure 6.16: DNMT3A expression in Molm13 (48hr post transfection) and in Kg1(48hr/ Day 9 
post transfection) cell lines 253 
 
List of Tables 
Table name Page No 
Table 1.1: WHO classification of MDS into its sub types based on changes in bone 
marrow and peripheral blood 
23 
Table 1.2: IPSS assignment of score based on bone marrow blasts, karyotype and 
cytopenia 25 
Table 1.3: IPSS-R assignment of score based on bone marrow blasts, karyotype and 
cytopenia. 25 
Table 1.4: Common cytogenetic abnormalities and their frequency of incidence in 
MDS  
27 
Table 1.5: Summary of genes commonly mutated in MDS 29 
Table 1.6: Sub-units of canonical PRC 1 and PRC2 36 
Table 1.7: Expression patterns of the PcG proteins in HSC 43 
Table 1.8: Summarization of different CBX proteins.  53 
Table 2.1: Preparation of D1 and N1 buffer. 76 
Table 2.2: Preparation of Human DNAOK multiplex PCR master mix. 77 
Table 2.3: a) PCR reaction mixture b) PCR programme on the thermocycler 78 
Table 2.4: ExoSAP-IT clean–up programme. 79 
Table 2.5: a) PCR reaction mixture b) PCR programme. 79 
Table 2.6:  Programme for the second round of PCR for 454 sequencing. 81 
Table 2.7: Preparation of a) Live Amplification mix per capture bead solution b) Mock 
Amplification mix c) 1X Capture bead wash buffer. 
83 
Table 2.8: PCR conditions for clonal amplification in the emulsions. 84 
Table 2.9: Coulter Counter Z1 models settings for bead counting 86 
Table 2.10: Components of DBIM buffer 87 
Table 2.11:  Dilution of beads for layer preparation. 88 
Table 2.12:  Preparation of master mix for cDNA synthesis 91 
Table 2.13: Preparation of Real-time PCR master mix 91 
Table 2.14: PCR conditions for qPCR 91 
16 
 
Table 2.15: Reaction mixture for topo cloning 104 
Table 3.1: Clinical characteristics of the patients studied (n=60) 119 
Table 3.2: SNP6 aberrations [deletion, amplification and CN (LOH)] in PRC1 genes 123 
Table 3.3: Gain/ del/ copy neutral loss of heterozygosity the Jumonji genes 127 
Table 3.4: Mutational analysis of DNMT3A in ten patients with MDS/tAML using 454 
sequencing 
143 
Table 4.1: Reaction mix for treatment of plasmid DNA with SuperTaq to add dNTP "A" 
to the fragment. 
159 
Table 4.2 :Ligation mixture for three fragments (SalI-NotI, SalI-EcoRI & EcoRI-NotI) of 
pCMV-SPORT6.  
161 
Table 4.3 :Ligation of EZH2 cDNA (R690C /R690H/ wild type EZH2) into p3XFLAG-myc-
CMV-26 expression vector.  
165 
Table 4.4: Ligation ofwild type EZH2 into p3XFLAG-myc-CMV-26 expression vector  172 
Table 4.5: Ligation of EZH2 cDNA (R690C /R690H/ wild type EZH2) into p3XFLAG-myc-
CMV-26 expression vector containing GFP+Puromycin. 
175 
Table 4.6: List of genes modulated by  over expression of wild type and mutant EZH2 
by micro array gene expression profiling.  
182 
Table 5.1: List of genes modulated by loss of EZH2 expression 214 
Table 5.2: Characteristics of patients used for confirmation of gene signature obtained 
by microarray gene expression profiling 
223 
Table 5.3: Gene expression profiling in different cell types/ cancers after KO of EZH2 227 
Table 6.1:  Reaction mix for treatment of plasmid DNA with SuperTaq to add dNTP "A" 
to the fragment 
241 





List of Abbreviations 
 
ASXL1  Additional Sex Combs Like 1 
AML  Acute Myeloid Leukaemia 
BCL2  B-cell CLL/Lymphoma 2 
BSA  Bovine serum albumin 
Chas  Chromosome Analysis Suite 
CMML  Chronic Myelomonocytic Leukaemia 
CN (LOH) Copy Neutral Loss of Heterozygosity 
CNVs  Copy Number Variations 
CB  Chromobox proteins 
CFUS  Colony Forming Units in Spleen  
DLBCL  Diffuse Large B-cell Lymphoma 
DMSO  Dimethyl sulfoxide 
DNMT3A DNA methyltransferase 3A 
EZH2  Enhancer of Zeste Homologue 2 
EED  Embryonic ectoderm development 
EVI-1  Ecotropic Viral Integration site 1 
FAB  French-American British 
FANCL  Fanconi Anaemia,Complementation Group L 
FBRS  probable fibrinosin-1 
FCS  Fetal Calf serum 
FITC  Fluorescein isothiocyanate 
FLT1  Fms-Related Tyrosine Kinase 1 
FLT3  Fms-Related Tyrosine Kinase 3 
HOXA10                  Homeobox A10 
HOTAIR  HOX Transcript Antisense RNA 
HSCs  Haematopoietic Stem cells 
HMEC  Human Mammary Epithelial cells 
HDFs  Human Diploid Fibroblasts 
18 
 
IFI16  Interferon, Gamma-Inducible Protein 16 
IPSS  International Prognostic Scoring System 
IPSS-R  International Prognostic Scoring System-R 
INK  Inhibitor of cyclin-dependent kinase 
IDH1/2  Isocitrate Dehydrogenase ½ 
Jmj  Jumonji 
JHDM  Jumonji Histone Lysine Demethylase 
JARID2  Jumonji, ARID domain-containing protein 2 
KDM2B  Lysine-specific demethylase 2B  
KO  Knock out 
L3MBTL2 Lethal (3) malignant brain tumour-like protein 
MAPKAP   MAPK-activated protein kinases 
MID  Multiplex Identifier 
MDS  Myelodysplastic Syndrome 
MDS-U  Myelodysplastic syndrome-unclassified 
MLLT10  Mixed Lineage Leukaemia T10 
MTT  Tetrazoliumsalt[3-(4,5-Dimethylthiazol-2-yl) 2,5diphenyltetrazolium- bromide] 
MPC  Magnetic Particle Concentrator 
MPN  Myeloproliferative neoplasm 
NPM1  Nucleophosmin 
NUP98  Nuclear pore complex protein 
OS  Overall Survival 
PAG1  Phosphoprotein Associated With Glycosphingolipid Microdomains 1 
PcG  Polycomb group 
PC  Polycomb 
PRC1  Polycomb Repressive Complex 1 
PRC2  Polycomb Repressive Complex 2 
PML  Promyelocytic Leukaemia 
PHC  Polyhomeotic 
PSC  Posterior Sex combs 
PHF1  PHD Finger protein 1 
19 
 
PREs  Polycomb Responsive Elements 
PTEN  Phosphatase and TENsin homolog 
PI  Propidium Iodide 
PBS  Phosphate Buffered Saline 
RA  Retionic acid 
RA  Refractory Anaemia 
RARS  Refractory Anaemia with Ringed Sideroblasts 
RAEB  Refractory Anaemia with Excess Blasts 
RAEB-T  Refractory Anaemia with Excess Blasts in Transformation 
RRM1  Ribonucleotide Reductase 
RUNX1  Runt-Related Transcription Factor 1 
RYBP1  Ring and YY1-binding protein 
RPMI  Roswell Park Memorial Institute Medium 
RFS  Relapse Free Survival 
SNP  Single Nucleotide Polymorphism 
SUZ12  Suppressor of Zeste12 
STAT3  Signal Transducer And Activator Of Transcription 3 
SET  Su (var), Enhancer of zeste, Trithorax 
S-AdoHcy S-adenosylhomocysteine 
S-AdoMet S-adenosylmethionine 
SRSF2  Serine/Arginine-Rich Splicing Factor 2 
TET2  Ten-Eleven Translocation-2 
tAML  Therapy Related AML 
TSLP  Thymic Stromal Lymphopoietin 
U2AF  U2 auxilliary Factor 
WHO  World Health Organisation 
X-Gal  5-bromo-4- chloro-3-indolyl-β-D-Galactoside 
5-hmc  5 hydroxymethylcytosine 
7-AAD  7-Aminoactinomycin D  
20 
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1.1 Myelodysplastic syndrome (MDS) 
 
1.1.1 Disease classification and prognostic scoring system 
 
MDS are characterized by abnormal clonal haematopoiesis, aberrant differentiation and 
increased apoptosis leading to peripheral blood cytopenias despite of a hyperplastic bone 
marrow (Acquaviva et al., 2010). Percentage of myeloblasts is an important parameter in 
prognosis, classification of MDS and is defined in terms of several nuclear and cytoplasmic 
characteristics including a high nuclear/cytoplasmic ratio, visibility of nucleoli and usually 
fine nuclear chromatin. The nuclear shape of myeoblasts is variable and the cytoplasmic 
characteristics include variable basophilia, with or without granules or Auer rods and absence 
of Golgi zone (except in AML linked to t (8; 21) (Mufti et al., 2008). The median age of 
patients with MDS  is 71 years (Meers, 2014) with treatments being tailored for patients 
because of the clinical heterogeneity of the disorder making accurate classification and 
prediction of prognosis an essential component of patient care. Classification system by the 
World Health Organization (WHO) is (Table 1.1) currently in use for stratification of the 
patients is based on clinical features, peripheral blood/bone marrow findings, and cytogenetic 
analysis. This system has developed from the French-American British (FAB) system [1982] 
but differs from it in the following aspects: (1) WHO criterion for diagnosis of acute myeloid 
leukaemia is 20 % blast percentage (FAB: 30 %). The WHO system does not have Refractory 
Anaemia with Excess Blasts in Transformation (RAEB-T) category (2) segregation of 
refractory anaemia (RA) and Refractory Anaemia with Ringed Sideroblasts (RARS) into two 
categories based on the presence of multilineage (2 or 3 cell lineages) or unilineage (usually 
affecting the erythroid lineage) dysplasia (3) Dividing Refractory Anaemia with Excess 
Blasts (RAEB) into RAEBI (5%-9% marrow blasts) and RAEBII (10%-19% marrow blasts) 
and (4) categorising Chronic Myelomonocytic Leukaemia (CMML) into a new category 
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Table 1.1: WHO classification of MDS into its sub types based on changes in bone 
marrow and peripheral blood. The table contains additional information on percentage of 
patients in each category progressing to AML and the incidence rate of each category in 
MDS. [This information has been collected from multiple research papers (Bennett et al., 




In addition to classification, assessing the prognosis of the patients and disease diagnosis is 
critical and is done by the International Prognostic Scoring System (IPSS) which considers  
Cytogenetic abnormalities, blasts ratio and cytopenia for this assessment (Greenberg et al., 
1997) [Table 1.2]. The IPSS was revised in 2012 to IPSS-R by addition of novel components 
to refine the old scoring system, however bone marrow cytogenetics, blast percentage, and 
cytopenias remained the basis of the new system. Some of the changes were classification of 
the cytogenetic prognostic subgroups into five instead of three categories, addition of a 
number of less common cytogenetic subsets, splitting the low marrow blast percentage value, 
and depth of cytopenias. Patient age, performance status, serum ferritin and lactate 
dehydrogenase were significant additive features for survival but not for transformation to 
acute myeloid leukaemia. This system comprehensively integrated the numerous known 
clinical features into a method analyzing MDS patient prognosis more precisely than the 





     Score           
Prognostic variable 0 0.5 1 1.5 2 
Bone Marrow Blast  <5  5 to 10 -- 
11 to 
20 
21 to 30 
Karyotype  Good  Intermediate  Poor     
Cytopenia  0 to 1 2 to 3       
b) 
   
Prognosis Score  IPSS Subgroup  
Median AML 
transformation (yrs) 
Median Survival (yrs) 
0 Low  9.4 5.7 
0.5-1.0  Intermediate-1 3.3 3.5 
1.5-2.0  Intermediate-2  1.1 1.2 
>2.5  High  0.2 0.4 
 
Table 1.2: (a) IPSS assignment of score based on bone marrow blasts, karyotype and 
cytopenia.(b) IPSS risk groups by sum of scores and there link to transformation to 




       
Score 
       
Prognostic variable 0 0.5 1 1.5 2 3 4 






  Good   Intermediate poor very poor 
Haemoglobin (g/dL) шϭϬ -- 8 -<10 <8 -- -- -- 
Absolute Neutrophil 
Count (x109/L) 
шϬ.ϴ <0.8 -- -- -- -- -- 
Platelet count шϭϬϬ 50- 
<100 
<50 -- -- -- -- 
 
†
 Very Good Karyotype: del(11q), -Y; Good karyotype: 46XX, 46XY, del(5q), del(20q); poor karyotype: 
Đoŵpleǆ ;ш ϯ uŶrelated aďŶorŵalitiesͿ or Đhroŵosoŵe ϳ aďŶorŵalities; iŶterŵediate karǇotǇpe: 
karyotypes not defined as good or poor. 
 
b) 
Risk Category Overall Score 
Median AML 
transformation (yrs) 
Median Survival (yrs) 
Very Low  чϭ.ϱ 15 8.8 
Low  2 to 3 10.8 5.3 
Intermediate  3.5-4.5 3.2 3 
High 5 to 6 1.4 1.6 
Very High  >6 0.73 0.8 
 
Table 1.3: (a) IPSS-R assignment of score based on bone marrow blasts, karyotype and 
cytopenia. (b) IPSS-R risk groups by sum of scores and there link to transformation to 
Acute Myeloid Leukaemia (AML) and median survival in patients. 
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1.1.2 Implication of  Cytogenetics in MDS 
 
Cytogenetic abnormalities are major determinants in the pathogenesis, diagnosis, prognosis 
of patients with MDS (as mentioned above) and are increasingly becoming the basis for 
selection of drugs in individual patients with MDS. Cytogenetic abnormalities are identified 
in the bone marrow of approximately 50% of patients diagnosed with primary MDS and 80% 
of patients with therapy-related MDS. These abnormalities can be characterized as being 
balanced (translocations, inversions & insertions) or unbalanced (gain or loss of 
chromosomal material). Unbalanced chromosomal abnormalities are particularly common in 
MDS and the nature of these abnormalities has a profound impact on disease pathogenesis, 
prognosis and response to treatment (Giagounidis et al., 2006). Amplifications or deletions 
are called Copy Number Variations (CNVs) and are caused due to gain or loss in genomic 
material due to error in DNA replication producing either duplications, removal of genetic 
sequences or unequal crossing-over that occurs during meiosis between misaligned 
homologous chromosomes. Gain leading to duplication of oncogenes have been associated 
with development of haematological malignancies, i.e. chr 11q 23 Mixed Lineage Leukaemia 
(MLL).Routine metaphase cytogenetics facilitates detection of chromosomal aberrations and 
mapping of recurrent lesions to narrow down on the minimally affected regions. However it 
is time consuming and the yield depends on the sensitivity (proportion of clonal cells in a 
sample) and resolution (size of the lesion) in the patient samples. In addition, requirement of 
the technique for dividing cells to obtain chromosomal spread is a limitation since it 
determines the proportion of abnormal cells in the dividing progenitor pool and may not 
reflect the actual percentage of abnormal cells. The biggest disadvantage of metaphase 
cytogenetics is its inability to identify Copy Neutral Loss of Heterozygosity [CN (LOH)] 
wherein the chromosomal number remains unaltered. These limitations of metaphase 
cytogenetics are overcome by Single Nucleotide Polymorphism (SNP) arrays which rely on 
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oligonucelotide based probes which correspond to allelic variants of the selected SNPs. The 
density of the probes (10K, 50K, 250K, 906K) determine the degree of resolution of the 
arrays. SNP-A have high resolution, are more sensitive (2-30%) and can therefore detect even 
low level cryptic chromosomal aberrations. It is not limited by dependence on dividing cells 
and can identify CN (LOH) (Maciejewski et al., 2009) depending upon the hybridisation of 
patient DNA to both probe variants (heterozygous) or to a single probe indicating 
homozygosity. CN (LOH) have been associated with myeloid malignancies i.e. chr 4q Ten-
Eleven Translocation-2 (TET2) and are associated with duplication of mutations in oncogenic 
or tumour suppressor genes. A systematic documentation of the abnormalities have been 
reported (Bejar et al, 2014; Haase et al., 2007) (Mohamedali et al., 2007; Tiu et al., 2011) and 
the most frequent cytogenetic abnormalities along with their frequency of incidence and 
prognostic impact are detailed in table 1.4. 
Chromosomal abnormalities Frequency (%)  Prognosis 
Trisomy 8  5 to 8 Good 
Trisomy 21  2.7 Good 
del 5q 15 Good  
del 20q 2 to 5 Good  
del Y  0.8 Good  
del 7/7q-  5 to 10 Intermediate to poor 
del 17p 10 Poor 
Coŵpleǆ ;шϯ  abnormalities) 13.4 Poor 
 
Table 1.4: Common cytogenetic abnormalities and their frequency of incidence in MDS 
and their impact on prognosis (Bejar et al, 2014; Haase et al., 2007) 
 
1.1.3 Mutational analysis in MDS 
 
Mutational analyses of patients with MDS have identified gene mutations recurrently 
associated with this disease. Mutational status of genes is not currently used in prognostic 
scoring systems but is likely to be key factor that govern clinical phenotypes and overall 
survival. High throughput DNA sequencing has revolutionised and vastly contributed to our 
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understandingof the clonal evolution, clone sizes and allele burden of the individual gene 
mutations as well as the interplay of different overlapping mutations to generate entire 
landscape of genetic leisions and their association to MDS(Bejar et al, 2014; Bejar et al., 
2011; Haferlach et al., 2014). Some of the common mutations and their clinical significance 



















Loss of enzymatic 
activity 
EZH2 6% LUC7L2 SF3B1 Poor  
Loss of histone 
methyltransferase 
activity 
IDH1/IDH2 rare SRSF2 TET2 Poor 
Alters function to 
ĐoŶǀert α-ketoglutarate 
to 2-hydroxyglutarate  
JAK2  5% in RA SF3B1   Unknown 
Constitutive activation 
of tyrosine 
NPM1 4% EZH2, LUC7L2 SF3B1 Poor 
Disruption of nucleolar 
localization signal 
leading to cytoplasmic 
redistribution of the 
protein 
NRAS/KRAS 10% STAG2 SF3B1 Poor 
Activation of 
serine/threonine kinase 
RUNX1 15 to 20 % SRSF2, ASXL1 SF3B1 Poor 




82 % in 
RARS 
DNMT3A, JAK2 TP53 Good  
Part of splicing 
machinery; loss of 
protein function 




Suppress the catalytic 
activity of the enzyme, 
low 5-hmC levels 
TP53 5 to 10 % NPM1, LUC7L2 SF3B1 Poor  




Table 1.5: Summary of genes commonly mutated in MDS.The frequency of mutations are 
indicated in percentages along with mutational overlap and exclusivity between these genes 
in patients with MDS (Bains et al., 2011; Bejar et al, 2014; Bejar et al., 2011; Haferlach et al., 




1.2 Epigenetic aberrations in MDS 
 
Epigenetic regulation of transcription (Fig: 1.1) has attracted particular attention, because of 
the relatively high frequency of mutations in genes like Isocitrate Dehydrogenase 1 (IDH1/2), 
TET2, Additional Sex Combs Like 1(ASXL1) and EZH2 (Table: 1.5) (Itzykson and Fenaux, 
2014). 
 
Figure 1.1: Epigenetic regulation of transcription.PRC2 complex (blue) causes 
trimethylation of H3K27 residues. These marks assist DNMT3A localization leading to CpG 
methylation at target genes. IDH1/IDH2 are responsible for conversion of isocitrate to α- 
ketoglutarate which is utilized by TET2 for hydroxymethylation of methylated CpG resulting 
in DNA demetylation. ASXL1 modulates recruitment of PRC2 to H3K27 and mutations in 
ASXL1 reduce methylation of H3K27. (Histone octamer is represented in purple while DNA 
is indicated by a brown string). 
 
Heterozygous mutations of IDH1/2 result in accumulation of 2-hydroxyglutarate instead of 
conversion of isocitrate to α-ketoglutarate. Elevated 2-hydroxyglutarate levels inhibit the 
function of TET2 (Xu et al., 2011) which is responsible for the conversion of 5 
methylcytosine to 5 hydroxymethylcytosine (5-hmC) (Fig: 1.1) which is an intermediary in 
DNA demethylation. This leads to DNA demethylation via specific molecular pathways or 
31 
 
passive demethylation (Itzykson et al, 2014), (Guo et al., 2011).In addition to an inhibitory 
effect on TET2, altered 2-hydroxyglutarate/α-ketoglutarate levels impede the demethylation 
activity of the Jumonji Histone lysine Demethylases (JHDM) (Xu et al., 2011). 
Mutations in TET2 suppress the catalytic activity of the enzyme leading to low levels of 5-
hmC (Ko et al., 2010).TET2 mutations are mutually exclusive of IDH1/2 mutations and share 
similar downstream effect (Verena et al, 2010), (Metzeler et al., 2011), (Mohamedali et al., 
2009) suggesting development of leukaemia through common mechanisms involving 
suppression of TET2 function.  
In addition to TET2 and IDH1/2, ASXL1 has recently emerged as an important epigenetic 
modulator associated with MDS. The role of ASXL1 is distinct from that of TET2 and 
IDH1/2. Mutations of ASXL1 reduce trimethylation of H3K27me3 and cause over expression 
of leukaemia promoting genes. It is believed to inhibit the recruitment of polycomb 
repressive complex 2 (PRC2) to H3K27 (Fig: 1.1) thus reducing trimethylation at this 
position (Conway O'Brien et al., 2014). This discovery has shed new light on the involvement 
of histone modifying enzymes in MDS. 
1.2.1 Post translational histone modifications 
 
In addition to changes in DNA methylation, epigenetic regulation also occurs at the 
chromatin level. Nucleosomes are the basic unit of chromatin consisting of a histone octamer 
(two each of H2A, H2B, H3 and H4) wrapped by 146 bp of double stranded DNA and kept 
tightly packed by the linker histone H1.These histones have an overhanging N-terminal tail 
which can be subjected to an array of post-translational modifications like phosphorylation of 
serine and threonine residues, methylation of arginine and lysine, acetylation of lysine or 
ubiquitination of lysine. 
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Histone methylation involves addition of methyl groups to the side chains of arginine (mono- 
or di-) or lysine (mono-, di-, tri-) creating binding sites either for a transcriptional activator or 
repressor protein. This association governs the ultimate function of the methyl mark at that 
location. Lysine methylation marks on H3 can be either repressive (H3K9, H3K27) or might 
activate transcription (H3K36, H3K79, and H3K4) [Fig 1.2].This study focuses on lysine 
methylation at position 27 on histone 3 which is caused by histone methyltransfearse 
EZH2 found to be mutated in MDS (detailed later).  
 
 
Figure 1.2: Post translational modifications of overhanging N-terminal of histone 
tails.Serine phosphorylation marks are illustrated in yellow, while lysine acetylation and 
arginine methylation marks are indicated in green and blue respectively. The focus of my 
thesis is on H3K27me3 marks (indicated by red arrow) which are caused by EZH2 histone 
methyltransferase which is mutated in MDS. Methylation of lysine provides binding sites or 
acts as sign posts for recruitment of proteins responsible for transcriptional repression 




1.3 Polycomb proteins and polycomb repressive complexes 
 
PcG proteins were first discovered in Drosophila Melanogaster and governed early 
embryonic development. They modulate the repression of the homeotic genes needed for 
embryogenesis via epigenetic mechanisms. This repression is opposed by the trithorax group 
proteins and the two groups work in tandem to maintain normal homeotic gene expression. 
In vertebrates, PcG homolog proteins are involved in somatic cell differentiation; especially 
in adult human haematopoiesis.  
1.3.1 Classification of PcG proteins 
 
PcG proteins form multimeric complexes called polycomb repressive complexes (PRC1 and 
PRC2) based on their interactions with other PcG proteins. The canonical PRC1 complex 
comprises of 4 core subunits; Polycomb (PC) or chromobox proteins (CB), Polyhomeotic 
(PHC) proteins, the posterior sex combs (PSC) proteins and the RING proteins [Fig: 1.3 
(A1)] (Gao et al., 2012). ring proteins especially RING1B can bind to other proteins like 
Ring and YY1-binding protein (RYBP) (Gao et al., 2012), lysine-specific demethylase 2B 
(KDM2B) (Farcas et al., 2012; He et al., 2013), lethal (3) malignant brain tumour-like 
protein (L3MBTL2) (Trojer et al., 2011) and  probable fibrinosin-1 (FBRS) to form non-
cannonical PRC1 complexes. KDM2B encodes a DNA binding domain that recognizes non-
methylated CpG dinucleotides in the DNA sequence. It interacts with a variant PRC1 
complex consisting of RYBP, RING and PSC proteins to direct PRC1 to CpG islands where 
PRC1 silences polycomb target genes (Farcas et al., 2012) [Fig 1.3 (A3)].  
On the other hand, KO of L3MBTL2 [Fig: 1.3 (A4)] was associated with reduced 
H2AK119Ub levels but it does not possess an E3 ligase activity and was therefore 
implicated in recruitment of the RING proteins to H2AK119. However, immunoprecipitation 
studies demonstrated that L3MBTL2 did not co-localize with H3K27me3 marks and hence 
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the recruitment of ring proteins by L3MBTL2 was considered independent of the presence of 
H3K27me3 marks and its mechanism of PRC1 recruitment needs further clarification 
(Trojer et al., 2011).Unlike L3MBTL2, RYBP and RYBP-FBRS [Fig 1.3 (A2,5)] containing 
non-canonical PRC1 complexes have a stimulatory effect on the E3 ligase activity of the 
ring proteins and do not participate in PRC1 recruitment (Gao et al., 2012). 
 
PRC2 contains three core subunits i.e. Enhancer of Zeste (EZH2), Suppressor of Zeste 
(SUZ12) and Embryonic Ectoderm Development (EED) [Fig: 1.3 (B1)] and associates with 
interchangeable components like PHD Finger protein 1 (PHF1) and Jumonji, ARID domain-
containing protein 2 (JARID2) [Fig: 1.3 (B2,3)].The role of JARID2 in non-canonical PRC2 
complex is controversial wherein two studies suggest that incorporation of JARID2 reduces 
PRC2 catalytic activity towards H3K27me3 (Shen et al., 2009), (Peng et al., 2009) while 
others demonstrate that JARID2 forms a stable complex with PRC2, promoting its binding to 
PcG-target genes (Pasini et al., 2010),(Li et al., 2010). Studies on human and mouse 
embryonic stem cells demonstrate that JARID2 interacts with PRC2 via SUZ12 and promotes 
its recruitment to target genes and simultaneously inhibits the histone methyltransferase 
activity of EZH2, suggesting that it acts as a “molecular rheostat” fine tuning the function of 
PRC2 (Peng et al., 2009). 
Unlike JARID2, PHF1 is involved in Tudor-dependent stabilization and extension of PRC2 
and H3K27me3 marks to H3K36me3 marks promoting the intrusion of PRC2 into active 
chromatin regions (Cai et al., 2013).Loss of PHF1 decreases H3K27me3 at PcG-target 









Figure 1.3:  Canonical (1) and non canonical (2, 3, 4, 5) PRC1 and PRC2 
complexes.(A) The RING and posterior sex comb (PSC) proteins form a back bone on 
which the non canonical complexes are assembled. Polycomb proteins can interact with 
only RYBP (A2), with KDM2B and RYBP (A3), with L3MBTL2 (A4) and FBRS, RYBP (A5) 
and to form non canonical complexes with diverse mechanism of action and function (See 
text for details). 
(B) PHF1 and JARID2 interact with the core components (EZH2, SUZ12 and EED) of 





The individual members of the canonical complexes along with their nomenclature (gene 
name) and chromosomal location are illustrated in Table 1.6.The multiplicity of the parallel 




Table 1.6: a) Sub-units of the canonical Polycomb Repressive Complex 1 (names used in 
the text are indicated in bold)b) Sub-units of the canonical Polycomb Repressive 
Complex 2along with their chromosomal location. 
(Reference: http://eprints.ucl.ac.uk/20210/1/20210.pdf) 
 
1.3.2 Mechanism of action of Canonical  PcG proteins 
 
PRC2 contains the histone methyltransferase (HMT); EZH2 that targets lysine at position 27 
of histone 3 and can recruit up to three methyl (CH3) groups at this position causing 
transcriptional repression. EZH2 contains the functional “SET [Su (var), Enhancerof zeste, 
Trithorax] domain” that is critical for its methyltransferase activity and disruption of this 
domain abolishes the function of PRC2. In addition to mediating extensive trimethylation of 
H3K27 at PcG target genes, PRC2 is also responsible for widespread dimethylation of 
H3K27 throughout the genome (Ferrari et al., 2014). In fact H3K27me2 mark accounts for 
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nearly 60% of all histone H3 in the genome and is probably accompanied by low levels of 
diffuse H3K27me3 (Peters et al., 2003). The methyltransferase activity of PRC2 depends on 
inputs from surrounding chromatin wherein the presence of H3K4me3, H3K36me2/3 
decreases the catalytic activity of PRC2 (Schmitges et al., 2011), (Yuan et al., 2011) while a 
basal level of H3K27me2 is a prerequisite for stimulating the timely onset of targeted PcG-
mediated repression, thus connecting the two H3K27 methylation states (Peters et al., 
2003).Although EZH2 is the prime histone methyltranferase,the interaction of SUZ12 and 
EED with EZH2 is essential for an increased methyltransferase activity of PRC2 (Ketel et al., 
2005; Montgomery et al., 2005; Xie et al., 2014). 
Apart from its main function of H3K27 trimethylation,PRC2 is also responsible for recruiting 
PRC1 to the target genes (Fig 1.4).The histone trimethylation marks (H3K27me3) caused by 
PRC2 are recognized by the CBX proteins which in turn directs PRC1 to specific regions of 







Figure 1.4: Mechanism of action; PRC1 and PRC2.H3K27me3 marks caused by PRC2 
(blue complex) assist localization of PRC1 (green complex) to its target genes. PRC1 is 
responsible for H2AK119Ub resulting in transcriptional repression (indicated by red “X”). 
Histone octamer is represented in purple and DNA is indicated by brown string. 
 
Once PRC1 is recruited, its subunitcauses ubiquitination of histone H2A at lysine 119 
(H2AK119Ub) (Cao et al., 2002).The large size of the ubiquitin groups interfere either 
directly with the other nucleosome dynamics to assist repression or employ other yet 
unknown effector proteins to H2AK119Ub which in turn repress transcription of downstream 
genes (de Napoles et al., 2004). In addition to transcriptional repression, RING1B-PRC1 also 
restrains RNA polymerase II at the promoters of target genes. Inactivation of the RING1 
proteins result in global loss of the H2AK119Ub mark and release of the RNA pol II enzyme 
(Stock et al., 2007).RNA polymerase II is also targeted by EZH1 (paralogue of EZH2) and 
depletion of EZH1 is associated with global loss of pol II occupancy of promoters in skeletal 
muscle cells (Mousavi et al., 2012). 
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PcG proteins can act as either tumour suppressors or oncogenes depending upon target genes 
(Federico et al., 2009; Scott et al., 2007), tumour microenvironment (stroma) etc. This ‘dual 
biological function’ has been identified for both the canonical and non-canonical PRC1.The 
varied association of PRC core components with other proteins to form non canonical 
complexes indicate a heterogeneous route of transcriptional repression. 
Apart from variations in binding partners directing the PRC complexes to different targets, 
the complexes also differ in their target localisations in relation to one another. Wang et al 
(2010) demonstrated that PRC1 and PRC2 may not always co-localize at the same target 
genes and additional elements such as the Polycomb Responsive Elements (PREs), might be 
required to recruit the PRC1 complex. PRE sequences are present in the target genes which 
can be directly recognized by PRC1 in the absence of PRC2 (Wang et al., 2010).Non coding 
RNAs like HOX Transcript Antisense RNA (HOTAIR) (Chiyomaru et al., 2014) and 
Kcnq1ot1(Pandey et al., 2008) also aid in directing PRC complexes to their targets. Studies 
on protein-protein interactions suggest a high occurrence of positively charged amino acids 
(Arginine/Lysine) in the interacting domains of PcG proteins especially CBX2 (M33 in mice) 
to be partly responsible for interacting with and inhibiting the negatively charged activation 
domains of the transcriptional machinery (Grau et al., 2011).Signalling pathways resulting in 
phosphorylation of the PcG proteins also impact their interaction with their binding partners 
and target genes (Kolybaba and Classen, 2014). The effects of phosphorylation on individual 
PcG sub-units are discussed later. This PRC1 independence suggests that H3K27me3 is not 
specifically required for transcriptional repression in all instances. 
1.3.3 PcG and DNA methylation 
 
DNA methylation involves addition of methyl groups to any of the four DNA bases. In 
mammals, only the 5th position of the cytosine bases undergo methylation (Li, 2002). This 
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methylation is catalyzed by DNA methyltransferase (DNMT) enzymes. De novo methylation 
is initiated by DNMT3A & 3B while DNMT1 has a preference for hemimethylated regions 
and hence involved only in maintenance (Jeltsch, 2006). However, this demarcation in 
function is not very clear. The H3K27me3 mark caused by PRC2 functions as a sign-posts for 
the recruitment of DNA methyltransferase (DNMT). The SET domain of EZH2 can bind with 
DNMT3A (Fig 1.5), affecting DNA methylation. DNMT3A in turn is responsible for further 
“deep silencing” of the target regions. Vire et al (2006) showed that loss of EZH2 causes a 
reduction in the H3K27me3 levels and a subsequent decrease in the DNA methylation. In the 
absence of EZH2 RNA poly II is recruited to the promoters of the target genes resulting in 
activation (Vire et al., 2006). 
 
Figure 1.5: Interaction of PRC2 and DNMT3A.PRC2 (blue complex) recognises H3K27 
sites from the histone octamer (purple) and the SET domain of EZH2 histone 
methyltransferase cause H3K27me3 marks that act as sign posts for recruitment of DNMT3A 
(cream). The SET domain of EZH2 interacts with DNMT3A to localise it to the target genes 




Epigenome profiling indicates that high levels of DNA methylation and H3K27me3 are 
rarely found at the same loci in mammalian genomes, suggesting the presence of one mark is 
antagonistic to other (Meissner et al., 2008).The removal of DNA methylation has profound 
influence on the distribution of the H3K27me3 mark throughout the genome (Brinkman et 
al., 2012; Kondo et al., 2008; Lindroth et al., 2008; Reddington et al., 2013). And results in 
accumulation of the PRC2 and H3K27me3 at genomic locations that were previously DNA 
methylated (Reddington et al., 2013), suggesting that DNA methylation is capable of 
attenuating PRC2 targeting to chromatin. However, reduction in PRC2 cause only modest 
changes in DNA methylation (Hagarman et al., 2013), suggesting that H3K27me3 mark does 
not have a similar reciprocal effect on DNA methylation.  
Another factor influencing the H3K27me3 marks is their proximity to existing H3K27me3 
which determines whether a gene gets targeted by PRC recruitment following loss of DNA 
methylation. DNA methylation surrounding PRC2 bound targets prevent the spread of 
H3K27me3 into adjacent regions (Hagarman et al., 2013; Simon et al, 2013). The correlation 
of histone and DNA methylation is convoluted in cancer  cells compared to normal cells due 
to elevated expression (hypermethylation of the genome as been observed in some cancers) 
and the presence of mutations in both EZH2 and DNMT3A genes adding a further layer of 
complexity to their association (Reddington et al., 2014). Unlike PRC2, there is no direct link 
between DNA methylation and PRC1 but since the canonical PRC1 depends on PRC2 for its 
recruitment, reduction in H3K27me3 marks as a consequence of DNA methylation might 
impact PRC1 recruitment.  
In vivo studies on Haematopoietic Stem cells (HSCs) functional potential and DNA 
methylation in old versus young mice bone marrow has revealed slight high degree of global 
DNA hypermethylation in old HSCs.DNA methylation did not influence the function but 
affected ongoing developmental restriction. It concentrated on genomic regions associated 
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with open chromatin in lymphoid (B cell and T cell) and erythroid lineages, suggesting 
inhibition of differentiation towards these lineages. A concomitant reduced expression of the 
PRC2 core components at these loci was observed during aging, suggesting that PRC2 
mediated repression diminished with HSC age and allowed DNA methylation machinery to 
access these sites (Beerman et al., 2013). Thus an enhancer as well as inhibitory effect exists 
between these two important silencing mechanisms. 
1.3.4 Expression patterns of PcG proteins 
 
Different sub-units of PRCs aggregate in the sub nuclear foci as polycomb bodies. Polycomb 
bodies vary in number and appearance according to the different stages of development and 
cell types. The number of these bodies is smaller in magnitude compared to the frequency of 
the target genes suggesting that either numerous genes associate with a single polycomb body 
or, the formation of polycomb bodies takes place only at a small subset of target genes 
(Kerppola, 2009). The aggregation of the polycomb bodies was studied by Gonalez et al 
(2014) using RNAi and high-resolution microscopy wherein they demonstrated that the 
SUMO protease “velo” was essential for the formation of stable nuclear aggregates of PcG 
proteins. SUMOylation of CBX4 helps in targeting it to the relevant genes. A limited degree 
of SUMOylation prevents the coalescence of PRC1 complexes within the nucleus, whereas 
excess of SUMO solubilises CBX4 away from its target chromatin (Gonzalez et al., 2014). 
Expression patterns of different PcG proteins have been studied in purified populations of 
HSCs. EZH2 and BMI-1 are highly expressed in HSCs while CBX2, MEL18 and PHC1 were 
prominent in the mature bone marrow cells. The expression of these proteins varied based on 
the stage of maturation and the lineage of the marrow cells (Table: 1.7) (Lessard et al., 1998). 
Ezhkova et al (2009) examined EZH2 expression and concluded that it was expressed in 
proliferating epidermal progenitor cells and controlled their proliferative potential by 
43 
 
suppressing the inhibitor of cyclin-dependent kinase [(INK4A)/alternative reading frame 
(ARF)] (CDKN2A) locus (Fig: 1.6). Stage-specific expression of EZH2 suggests repression of 
undesirable differentiation programs to orchestrate establishment of other terminal 
differentiation programs (Ezhkova et al., 2009). 



























Moderate High Reduced High 
Not 
detected 
CD34- High Highest Lowest Highest High 
 
Table 1.7: Expression patterns of the PcG proteins in Haematopoietic Stem Cells (HSC). 
EZH2 and BMI-1 show similar trends in their expression patterns where both are high in the 
HSCs but their expression reduces as the cells differentiate into erythriod and granulocyte 
macrophage progenitors. While EZH2 expression recovers in mature CD34-cells, BMI-1 
expression remains low. Similar patterns of expression are also observed of CBX2 and 
MEL18 both of which are highly expressed in mature bone marrow CD34- cells but not 
detected in CD34+ HSCs. Unlike CBX2 and MEL18, PHC1 expressions are high in all 
erythriod, granulocyte and macrophage progenitor cells but absent in CD34+ cells. 
[CD34-= mature bone marrow cells, CD34+= HSC, CD34+ CD45-CD71hi = enriched in 
erythriod progenitors, CD34+CD45+CD71lo= enriched in granulocyte and macrophage 
progenitors] (Lessard et al., 1998) 
 
 
Similar studies on maturational stages of B-cells in the germinal centre have also confirmed a 




Figure 1.6: Illustrates inhibitory effect of PcG proteins on the INK4A/ARF locus. 
p16INK locus is involved in cell cycle regulation wherein it binds to and inhibits the CDK 4, 
6 kinase activity. This prevents the interaction of CDK kinases with cyclin D and 
downstream phosphorylation of pRB. Lack of phosphorylated pRB stalls the E2F 
transcription factor and causes S phase cell cycle arrest. Both PRC1 (green) and PRC2 (blue) 
inhibit p16INK locus allowing formation of CDK 4, 6 - cyclin D complexes and progression 
of cells through S phase of the cell cycle. PRC1 (green) has an additional inhibitory effect on 
p19ARF resulting inup regulation of the ubiquitin ligase MDM2 which causes degradation of 
p53. Reduced levels of p53 are associated with decreased apoptosis and increased cell 
proliferation. In the absence of PRC1 mediated p53 inhibition, p19ARF downregulates 
MDM2 and enhances p53 expression inducing cell cycle arrest at both G1/S and G2/M check 
points. Therefore it can be concluded that both PRC1 and PRC2 mediated inhibition of 
INK4A/ARF locus enhances cell proliferation and prevents apoptosis. 
1.4 Subunits of PRC2 
1.4.1 Embryonic ectoderm enhancement protein 
 
EED has four isoforms; EED1, EED2, EED3 and EED4, all differing in the length of the N-
terminal. PRC2 contains EED1 and EED2 which were believed to have an affinity for H1K26 
while EED3 and EED4 showed affinity towards H3K27 (Kuzmichev et al., 2004). However; 
Montgomery et al (2007) showed that there was no binding preference of the EED isoforms 
towards the different histones. The study also confirmed that  different states of histone 
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methylation like mono, di and tri methylation were not correlated to or were caused by any 
specific EED isoform (Montgomery et al., 2007). 
EED contains five WD-40 domains that allow interaction with HDACs and EZH2 (van der 
Vlag and Otte, 1999). The interaction of EED and EZH2 is crucial for inducing mono, di and 
tri methylation of specifically H3K27, suggesting that EED must be responsible for the 
histone methyltransferase activity of EZH2 and for the assembly, stability of PRC2 
(Montgomery et al., 2005). 
EED also binds to pre-existing H3K27me3 marks causing stimulation of the PRC2 
methyltransferase activity for the surrounding unmodified H3K27. The WD 40 repeats of 
EED mediate the recognition and binding to the N-terminal domains of the histone tails. It 
also has a weak binding affinity for H1K26me3, H3K9me3 and H4K20me3 but requires 
interaction with other PRC2 subunits for a stable conformation (Margueron et al., 2009). 
1.4.2 Suppressor of Zeste protein 
 
SUZ12 has unique structural features; It contains two significant stretches of amino acids; 
zinc finger binding motif and the VEFS box (Pasini et al., 2004). It also has two promoters, 
an upstream promoter having a bidirectional function that produces the majority of the 
SUZ12 mRNAs while the downstream promoter which works only in the forward direction 
(Kirmizis et al., 2003). SUZ12 is crucial for maintaining the integrity of PRC2 by inhibiting 
the proteolytic degradation of EZH2. Lack of SUZ12 causes complete absence of global di 
and trimethylated H3K27. However, the monomethylation levels remain unaffected. In the 
absence of SUZ12, EZH2 levels decrease while EED levels remain unchanged (Pasini et al., 
2004).SUZ12 is also essential for the formation of H3K9me3 in differentiated cells. Absence 
of SUZ12 causes 5-fold reduction in H3K9me3 levels and induces chromosomal instability 
(de la Cruz et al., 2007). 
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SUZ12 can be activated either by its translocation as seen in endometrial cancer or through 
the ȕ-catenin mediated pathway. WNT/ȕ catenin associate with SUZ12 promoters in solid 
tumours (Kirmizis et al., 2003) with non-canonical members of the WNT pathway (WNT5A 
and WNT11) being responsible for maximal transcriptional enhancing effect on SUZ12 
(Pizzatti et al., 2010).  
1.4.3 Enhancer of Zeste proteins 
 
Two proteins constitute this family namely; EZH1 and EZH2. Margueron et al (2013) 
demonstrated that EZH2 has a central role in catalysing H3K27me2/3 and its loss has a global 
effect on the H3K27 me2/3 status. On the other hand EZH1 containing PRC2 has a weak (20-
fold less) role in methylating and maintaining H3K27me3. EZH1 is found ubiquitously in all 
tissues including the G0 resting cells (Son et al., 2013) while EZH2 is strongly associated 
with proliferating tissues. There is an overlap between the target genes of EZH1 and EZH2, 
however, EZH1 recruitment is independent of EZH2. EZH1 also associates with EED and 
SUZ12 and hence is a part of a similar complex as EZH2. In contrast to EZH2, EZH1 
mediated repression is caused by direct alteration of the chromatin which is independent of 
covalent methylation marks on the histones (H3K27me3). Conservation of amino acids and 
SET domains of EZH1 and EZH2 is 65% and 94%, respectively. The presence of two 
paralogues in humans as opposed to just one in Drosophila may be explained by the function 
of EZH2  to maintain the H3K27me3 mark while that of EZH1 to be more involved in direct 
repression of target genes (Margueron et al., 2008). 
Analyses of PRC2-EZH2 substrates indicate a preferential bias towards oligonucleosomes 
with H1 rather than mononucleosomes, octamers and H3 alone. H1 may enhance the 
methyltransferase activity towards H3 (Martin, Cao et al., 2006). However, previous studies 
have shown contrasting results indicating that H1 incorporation into nucleosomes inhibits H3 
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methylation (Kuzmichev et al., 2004). These discrepancies may be due to the use of varying 
concentrations of histones or magnesium used in both studies. At low concentrations of 
magnesium, H1 has a stimulatory effect on H3 methylation while high magnesium 
concentrations inhibited H3 methylation stimulation by H1 (Martin et al., 2006). 
1.5 Subunits of PRC1 
 
1.5.1 Posterior sex comb proteins 
 
MEL18, BMI-1, NSPC1 and MBLR belong to the PSC group of proteins. This group is 
characterized by the presence of an N-terminal RING domain, two α helices that form the 
HTH domain and a C-terminal domain. MEL18 has both transcriptional repressor and 
enhancer activity and is therefore included in the enhancer of trithorax and polycomb (ETP) 
group (Miyazaki et al., 2005). BMI-1 and MEL18 have 93% homology but exhibit a 6 amino 
acid and a 30 amino acid difference between their N-terminal and the alpha helix respectively 
(Akasaka et al., 1997; Fujisaki et al., 2003).The RING finger and HTH (Fig: 1.7) domains of 
BMI-1 are required for down regulation of p16INK4A tumour suppressor gene while the 
Proline-Serine rich domain (PS) domain of BMI-1  is involved in its stability. ΔPS mutant of 
BMI-1 has an increased half-life and is physiologically more active augmenting its pro-
proliferative activity. Specifically, over expression of the ΔPS mutant in Human Mammary 
Epithelial cells (HMECs) results in AKT upregulation and its targets such as cyclin D1. In 
primary Human Diploid Fibroblasts (HDFs), which express p16INK4A, over expression of 
the ΔPS mutant results in a decrease of p16INK4A expression (Fig: 1.7) accompanied by 
increased proliferation and decreased senescence (Dimri et al., 2002; Itahana et al., 2003; 




Figure 1.7: Deletion of BMI-1 domains. Loss of BMI-1 domains result in varying effects on 
its activity in human diploid fibroblasts (HDFs) and human mammary epithelial cells 
(HMECs).Lack of HTH or RING domains of BMI-1 reduced its activity while absence of the 
proline-serine domain augments BMI-1 activity causing down regulation of p16INK4A and 
increased AKT levels. 
 
In addition to the effect on the INK4A/ARF locus, BMI-1 and MEL18 can enhance the E3 
ligase activity of ring1b. However, MEL18 has to be phosphorylated to form the PRC1 
complex. Phosphorylation of MEL18 is needed for a conformational change in PRC1 to 
enable ring1b to be in close contact with the nucleosome to induce ubiquitylation of 
H2AK119. While phosphorylation aids MEL18 to associate with other PRC1 proteins, BMI-1 
phosphorylation caused by MAPK-activated protein kinases (MAPKAP) causes its 
dissociation from PRC1 (Elderkin et al., 2007). 
NSPC1 (Nervous system polycomb1) contains the RING finger domain but lacks the HTH 
domain (Gong et al., 2005). Depletion of NSPC1 and DNMT1 does not modify the 
H3K27me3 marks by EZH2, but has a significant effect in decreasing the levels of 
H2AK119Ub (Wu et al., 2008). NSPC1 is highly expressed in the nervous system and exerts 
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a stronger repressional effect as compared to BMI-1 and MEL18 (Gong et al., 2005). NSPC1 
repression is responsible for enhanced cell growth and an increase in the S phase cells that is 
independent of the p53 pathway (Gong et al., 2006). 
The MBLR protein consists of three domains; the N-terminal RING domain which interacts 
with RING1B and histone H2A, HTH domain and the C-terminus which interact weakly with 
PHC2. Akasaka et al (2002) demonstrated that MBLR interacts with RING1B causing 
transcriptional repression. However, it does not aggregate at PcG bodies like other polycomb 
proteins and may be sequestered by other proteins (Akasaka et al., 2002).  
1.5.2 Ring proteins 
 
PcG protein family contains two isoforms of the RING1 proteins. The RING1A and RING1B 
proteins consisting of 406 and 336 amino acids respectively (Vidal, 2009) and have a C-
terminal domain which binds to both RYBP and chromobox of the CBX proteins. The CBX 
and the RYBP proteins exhibit differences in both amino acid sequences and structure 
suggesting that the RING proteins are capable of recognizing non-redundant nucleotide 
sequences. Therefore, the genomic target of RING1B and the mechanism of binding (either 
via histone or chromatin) depends critically on its binding partner (Wang et al., 2010). 
The primary function of RING1B is to regulate self polyubiquitination and more importantly 
to cause monoubiquitination of histone H2A (Fig: 1.8) at lysine 119 (H2AK119Ub) causing 
transcriptional repression as previously described (Stock et al. 2007). Self-ubiquitylation of 
RING1B is mediated by an unknown E3 ligase and must occur concurrently with 
H2AK119Ub. Prior ubiquitination of RING1B reduces the efficiency of the enzyme (Ben-




Figure 1.8: Polyubiquitination of RING1B. It leads to either degradation of RING1B or 
formation of H2AK119ub repressive marks.  
 
Cao et al (2005) observed that RING1A is essential for the optimal functioning of RING1B 
but does not have strong E3 ligase activity. BMI-1 and RING1B associate and stabilizes each 
other. This stabilization requires intact RING domains of both the proteins (Cao et al., 2005). 
However, BMI-1 can only enhance the E3 ligase activity of RING1B as previously 
mentioned. Conversely, the association of RING1A is independent of RING1B E3 ligase 
activity but is crucial in reducing self-polyubiquitination of RING1B thus preventing its 
degradation (Ben-Saadon et al., 2006). Though RING1A reduces self-polyubiquitination of 
RING1B,  caspase 3 and 9 can degrade RING1B reducing its repressive effects (Wong et al., 
2007). 
1.5.3 Polyhomeotic proteins 
 
The polyhomeotic family of proteins consists of PHC1, PHC2 and PHC3. PHC1 and PHC2 
form a part of the PRC1 complex and their absence abrogates its repressive effects suggesting 
that PHC is critical in the formation of the PRC1 complex (Isono et al., 2005). 
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PHC proteins consist of three highly conserved domains; the SAM domain at the C-terminal 
also known as HDII, the Cys-type Zn coordination domain and the HDI domain of unknown 
function (Tonkin et al., 2002).PHC2 and PHC3 have two N-terminal domains called N-A and 
N-B which are poorly conserved in PHC1. The SAM domains can associate with themselves 
or with other proteins with or without SAM domains (Fig: 1.9). The complex formed by this 
domain has a left-handed helical structure, suggesting that chromatin wraps itself around the 
six-fold screw like structure making it thermodynamically stable (Kim et al., 2002). 
 
Figure 1.9: Propagation of transcriptional repression. Interaction of polyhomeotic 
proteins with other PRC1 proteins through its SAM domain facilitates polymerisation of 
proteins leading to extension of transcriptional repression and gene silencing by PcG proteins 
to sites outside of the immediate target regions. 
 
Sex Comb on Midleg (SCM) is another protein belonging to the PcG proteins, but does not 
form part of the core PRC1 in all instances. Structural studies of PHC SAM domains indicate 
that PHC-Sam and SCM-SAM domains bind to each other with high affinity forming a single 
junction. The regulation of this interaction is unknown. PHC is usually localized around the 
targets but the exact location of SCM is unclear. Hence polymerisation can be used to extend 
the effect of the PcG proteins outside the immediate target regions (Kim et al., 2005). 
Martinez et al (2009) illustrated that the PHC proteins repress the Notch pathway in 
drosophila eye. Loss of PHC proteins caused reduction in the repression of members of the 
Notch pathway giving rise to uncontrolled proliferation, loss of cell polarity and failure to 
exit cell cycle (Martinez et al., 2009). Interestingly, a single nucleotide polymorphism in 
exon 27 of the NOTCH gene has been observed but no mutations are seen in MDS cases (Fu 
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et al., 2007). Mutational studies in Drosophila embryos have revealed that lack of PHC 
proteins lead to increased number of chromosome bridges not only in embryonic stages but 
also in subsequent cell cycles, alluding to a role in DNA damage checkpoint (Beck et al., 
2010). 
1.5.4 Chromobox proteins 
 
The CBX family of proteins form a part of the PRC1 complex and are responsible for 
recognising H3 lysine trimethylation. These proteins have a chromodomain and a chromobox 
that interacts with histones and other components of the PRC1, respectively(Vincenz and 
Kerppola, 2008). Different members of this family have different binding targets (Table: 1.8). 
CBX2 binds to K4 and K9 on H3 with high affinity as compared to K27 (Vincenz and 
Kerppola, 2008). Both K9me3 and K27me3 interact with CBX7 while CBX4 has a preference 
for K9me3. CBX6 and CBX8 does not bind to any of the known sites on the histones and the 
targets of these two proteins have yet to be ascertained (Bernstein et al., 2006). 
CBX2 has a unique hook like motif (AT-hook) present near its N-terminal chromodomain. 
Other CBX proteins also have a similar motif called AT-Hook-like domain. The AT-hook or 
AT-hook-like structures trap and stabilize the DNA between the CBX protein and the histone 
(Senthilkumar and Mishra, 2009). In CBX2, the phosphorylation of the AT-hook in the 
chromodomain also governs its target affinity.The AT-hookphosphorylation increases its 
interaction with H3K27me but also reduces its binding capacity to H3K9me3 (Hatano et al., 
2010). 
CBX proteins not only show variation in their target preferences but also in their distribution 
patterns (Table:1.8). CBX2-H3 is more localized in chromocentres in contrast to the total 
population of CBX2. On the other hand CBX6-H3 as well as the total population of CBX6 is 
homogenously distributed in the nucleoplasm. The CBX4, CBX7 and CBX8 show varied 
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distribution depending on the cell-type (Vincenz and Kerppola, 2008). Moreover, all of these 
proteins except CBX2 are capable of binding to RNA if their secondary structures are intact. 
CBX7 has a high affinity to bind to single stranded RNA. Hence these proteins can not only 
bind to histones but also to the DNA target sequences via non-coding RNAs (Bernstein et al., 
2006). 
PcG Binding partners Distribution Effect on Ink-Arf locus 
CBX2 
H3K4 and K9, K27 (low 
affinity) 
chromocentres Repression 
CBX4 H3K9 cell type dependant Weak repression 
CBX6 unknown Nucleoplasm Weak repression 
CBX7 H3K9 and K27 cell type dependant 
Stronger repression than CBX2. 
Causes immortalization of cells. Lack 
of repression cause cell cycle arrest 
in human fibroblasts. 
CBX8 unknown cell type dependant 
Weak repression compared to CBX7 
but stronger than CBX2. Lack of 
repression maintains cell cycle arrest 
in human fibroblasts 
 
Table 1.8: Summarization of different CBX proteins. Their binding preference to histones, 
distribution and effect on repression (Yap et al., 2010). 
 
CBX4 possesses a unique function to act as E3 ligase for DNMT3A. DNMT3A contains a 
PWWP region and a linker region of amino acids which interacts exclusively with CBX4. 
CBX4 also recognises H3K9 hence there is a possibility that it may assist in DNMT3A 




1.6 Role of PcG proteins in DNA damage 
 
Recent findings by Chandler et al (2014) question the role of PcG proteins in DNA damage 
repair, who demonstrated that there was no localization of PRC1 proteins at the sites of DNA 
damage in fibroblasts (Chandler et al., 2014). However earlier reports implicated BMI-1 in 
the maintenance of the redox balance and its deficiency in mice leads to increased levels of 
reactive oxygen species resulting in DNA damage and double strand repair activation (Liu et 
al., 2009). Ismail et al (2010, 2012) demonstrated that CBX4 is an early DNA Damage 
Response (DDR) protein that mediates SUMO conjugation of BMI-1 which is required for 
the accumulation of BMI-1 at DNA damage sites. RING1B is also recruited to sites of DNA 
double-strand breaks (DSBs) along with BMI-1 where both contribute to H2AK119Ub in 
osteosarcoma and kidney cells. In the absence of BMI-1, recruitment of several proteins 
dependent on ubiquitin signalling like BRAC1 to the DSBs is hampered with a concomitant 
increase in radiation sensitivity (Ismail et al., 2010; Ismail et al., 2012).Interestingly, other 
research groups have shown that BMI-1 mediated ubiquitylation of H2A does not affect the 
canonical ubiquitin pathway but impacts a alternative pathway involving the recruitment of 
yet unidentified factors (Ginjala et al., 2011).Unlike BMI-1 and RING1B, MEL18 is only 
transiently recruited to DSBs, indicating recruitment and maintenance of different PRC1 
complexes via distinct kinetics (Chou et al., 2010). In addition to PRC1, PRC2 has also been 
implicated in DNA damage repair. Role of EZH2 in DSB repair has also been demonstrated 
in breast cancer cells were it modulates repression of the homologous recombination enzyme 
RAD51 (Chang et al., 2011) DSBs  and of its paralogues (Zeidler et al., 2005) which are 
crucial for homologous recombination repair. Localization of PcG proteins at DNA DSBs 
might suggest an additional function of PcG proteins in preventing the transcription of broken 
genes that would otherwise lead to aggregation of defective mRNAs. 
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1.7 Role in Haematological malignancies 
 
EZH2 mutations are detected in 8 % of patients with MDS/MPN, 3 % each in MPN, MDS 
and 2 % in AML (Khan et al., 2013; Wang et al., 2013). These mutations were first 
discovered using SNP 6.0 arrays on peripheral blood /bone marrow samples and were 
associated with CN(LOH) 7q and 7q36.1 microdeletion (Fig: 1.10).  
 
Figure 1.10: Identification 7q CN (LOH) and EZH2 involvement. CN (LOH) was 
observed in 12 patients (left) with MDS/MPN using SNP6 analysis. (middle) Identification of 
7q36.1 microdeletion in one patient and (right) targeted aCGH analysis in the same patient 
reveal heterozygous microdeletion of EZH2 (the x axis indicates log copy number ratios) 
(Ernst et al., 2010). 
 
Truncation mutations were identified throughout the gene while missense mutations were 
commonly found in the conserved SET domain. A frame-shift mutation of exon 19 was 
detected with high frequency. Individuals with homozygous mutations have poor survival as 
compared to those with heterozygous mutations(Ernst et al., 2010; Khan et al., 2013; Xu et 
al., 2011) with increased risk of transformation to AML (Wang et al., 2013). EZH2 mutations 
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are observed in some cases of refractory anaemia indicating their acquisition in the early 
stages of MDS and have been associated with low blast percentage in the bone marrow (Ernst 
et al., 2010; Nikoloski et al., 2010; Wang et al., 2013).MDS is an evolutionary process, 
evolving over variable time frames and driven by stepwise acquisition of somatic cell 
mutations with sequential, sub-clonal selection. The genotype of patients with MDS shifts 
over time by obtaining additional mutations, changes in allele burden of existing mutations or 
complete disappearance of certain mutations post treatment. Sequential analysis of EZH2 
mutations in patient samples to study their clonal evolution and mutational overlap to would 
help conclude whether EZH2 mutations are “driver mutations” i.e. playing a major role in 
initiating and maintaining the disease or “passenger mutations” i.e. assisting the driver 
mutations in their role. Nikoloski et al (2010) sequenced 126 MDS patients and demonstrated 
that 8 patients had EZH2 mutations. In 5 of the 8 (40 %) of patients with EZH2 mutation an 
associated TET2 abnormality was also observed (Nikoloski et al., 2010), suggesting that 
EZH2 mutations may not be driver mutations (Makishima et al., 2010). Mutations of ASXL1, 
TET2, Runt-Related Transcription Factor 1 (RUNX1) and LUC7L2 (Haferlach et al., 2014) 
(Table: 1.5) overlap with EZH2 mutations in CD34+ cells obtained from AML cases (Khan et 
al., 2013). Other studies have shown no correlation between ASXL1, RUNX1, TET2 and 
EZH2 mutations nor do they suggest a poor prognosis of MDS patients related specifically to 
EZH2 mutations (Wang et al., 2013). Inactivation of EZH2 by these mutations has been 
correlated with absence of the H3K27me3 mark suggesting its role as a tumour suppressor 
gene (Ernst et al., 2010; Makishima et al., 2010). EZH2 dysfunction (reduced H3K27me3) 
can be attributed not just to its mutations (37 %) but also to mis-splicing in patients with U2 
auxiliary factor (U2AF1)/ Serine/Arginine-Rich Splicing Factor 2 (SRSF2) mutations (11 %) 
and in 24% of cases because of haploinsufficient expression (7q del) (Khan et al., 2013).  
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Apart from EZH2, mutational analysis of other PcG genes in MDS has not been carried 
out and therefore the aim of my PhD was to examine SNP6 and mutational status of 
PRC1, PRC2 genes. 
In addition to myeloid malignancies, EZH2 has also been implicated in lymphomagenesis 
wherein RNA sequencing studies recently identified heterozygous somatic point mutations 
targeting the EZH2 SET domain (Hot spot: Y641) in 30% of germinal centre Diffuse Large 
B-cell Lymphoma (DLBCL) and 10% of Follicular lymphoma (Morin et al., 2010). These 
mutations altered the enzymatic activity of EZH2 resulting in a protein that does not 
recognize unmodified H3K27 and causes increased H3K27 trimethylated state resulting in 
gain of function (Sneeringer et al., 2010; Yap et al., 2011). Increased expression of mutant 
EZH2 in mice induced germinal centre hyperplasia and accelerated lymphomagenesis 
(Beguelin et al., 2013). High-levels of EZH2 (70% increase) are associated with increased 
Overall Survival (OS) of 85.8% compared to low expression (70% reduction), with OS of 
44.5% (p=0.005) in DLBCL (Lee et al., 2014). Apart from its role in DLBCL, EZH2 
inhibition by DZNep/shRNA in MLL fusion leukaemia reduces proliferation of leukemic 
cells via u pregulation of p16 (Ueda et al., 2014) and its deletion in acquired aplastic anaemia 
decreased the production of destructive Th1 cells in vivo, decreased bone marrow-infiltrating 
Th1 cells, and rescued mice from bone marrow failure (Tong et al., 2014). 
Lack of EZH2 and EED is modulated by the pRB-E2F pathway and causes disturbances in 
the cell cycle cyclins. Down regulation of pRB is also seen in cases of acute leukaemia 
(Tonini et al., 2008). Signal Transducer And Activator Of Transcription 3 (STAT3), Oct-3/4 
transcription factors modulate EED expression by binding to the promoter and enhancing 
transcription. Suppression of these transcription factors cause a reduction of EED resulting in 
substantial loss of the H3K27me3 mark and incomplete differentiation, indicating that not all 
the differentiation genes are activated (Ura et al., 2008). STAT3, Oct-3/4 are oncogenic 
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transcriptional factors exhibiting elevated expression in some AML cases; their association 
with EED may have additional epigenetic consequences in haematological malignancies 
(Steensma et al., 2006). 
In adult life, EED regulates the development of myeloid and B cell precursors. Another 
significant impact of EED is in modulating the thymocyte differentiation and inhibiting 
lymphoma generation following carcinogen exposure. However, EED mutants do not cause 
spontaneous lymphomas. Additional genetic alterations are needed for lymphoma 
transformation (Richie et al., 2002). Conversely, lack of SUZ12 impacts granulocyte 
differentiation. It blocks the differentiation of CML cells and is over expressed in chronic 
myeloid leukaemic blasts cells (Pasini et al., 2004). 
Similar to PRC2, different sub-units of canonical PRC1 have also been reported in 
haematological malignancies. Flowcytometric analysis of bone marrow CD34+ cells from 50 
MDS patients revealed that increasing BMI-1 levels correlated with disease progression both 
by WHO and IPSS categorization. BMI-1 levels were high in cases of refractory anaemia and 
escalated as the disease progressed to RAEB suggesting that it could be used as a molecular 
marker for MDS patients. In contrast, BMI-1 over expression in breast tumours has been 
associated with a favourable impact on patient survival (Pietersen et al., 2008). 
In vivo transplantation studies in mice found that over expression of CBX7 in HSC and 
progenitor cells induced leukaemia (Klauke et al., 2013). However, the contribution of CBX 
to leukaemogenesis might vary depending on the tumour-initiating cells or the type of 
hematologic tumour. For example, MLL-induced leukaemogenesis is dependent on CBX8, but 
not on its orthologs (Chubb et al., 2013). CBX8 and BMI-1 bind to MLL fusion proteins 
independent of other canonical PRC1 members and induces MLL–AF9 lymphomagenesis 
(Smith et al., 2011). CBX8 is also implicated in leukaemia wherein chromobox on CBX8 
binds to MLL-AF9 fusion protein to up regulate HOXA9 expression which is a hallmark of 
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MLL pathogenesis. The loss of CBX8 protein prevents leukaemic transformation induced by 
MLL-AF9 but did not alter normal haematopoiesis (Tan et al., 2011).CBX7 on the other hand 
was identified as a risk locus for developing multiple myeloma (Chubb et al., 2013). Apart 
from the CBX proteins, high levels of RING1A were also observed in acute myeloid 
leukaemia (Ishikawa et al., 2007). 
1.8 Role in Haematopoietic system 
 
The role of PcG proteins in haematopoiesis was first suggested by the phenotype of BMI-1-/- 
mice, which displayed reduced numbers of hematopoietic progenitors and increased 
differentiated cells, eventually leading to haematopoietic failure (van der Lugt et al., 1994). It 
is associated with HSC self-renewal by regulating symmetrical cell division. Apart from 
normal haematopoiesis, BMI-1 is also important for leukemic stem cell self-renewal as 
evidenced by loss of self-renewal and induction of apoptosis upon BMI-1 knockdown in 
primary acute myeloid leukaemia samples (Iwama et al., 2004; Lessard et al., 1999; Park et 
al., 2003; Rizo et al., 2008; Rizo et al., 2009). Lessard et al (1999) established that EED and 
BMI-1 have antagonistic effects on the haematopoietic system; EED inhibited proliferation 
whereas, BMI-1-/- enhanced proliferation of progenitor cells. EED and BMI-1 mutant mice 
revealed that BMI-1 preceded EED in the control of primitive CD34+ cell proliferation. The 
interaction of EED and BMI-1 was tissue specific but were expressed in all the hematopoietic 
cell lines. Mutations in EED increased the susceptibility to cancer development; however, 
additional genetic alterations may be needed for complete transformation of hematopoietic 
stem cells. Though BMI-1 and EED were co-expressed in HSCs, these proteins did not share 
common down-stream mediators. The p16INK4A and p19ARF levels remained unaltered in 
EED mutants compared to BMI-1 mutants which primarily affect the INK4A-ARF locus as 
previously mentioned (Fig: 1.6). The mediators causing the proliferation inhibition by EED 
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are still unknown (Lessard et al., 1999). Recent studies using ChIP analysis have confirmed 
the presence of BMI-1 along with EZH2, SUZ12, EED, RING1A, RING1B and the 
transcriptional factor Ecotropic Viral Integration site 1 (EVI1) at the promoters of the 
Phosphatase and TENsin homolog (PTEN) gene (Yoshimi et al., 2011).The PTEN tumour 
suppressor gene is located at 10q23.31 and functions as a negative regulator of the 
phosphatidylinositol-3-OH kinase (PI (3) K)–Akt pathway, which is crucial in cell survival, 
differentiation, cell proliferation and migration (Zhang et al., 2006). EVI1 is essential for 
proliferation of haematopoietic stem cells and PTEN has a crucial role in restricting the 
activation of HSCs, in lineage determination, and prevention of leukaemogenesis. Both EVI1 
and PTEN have been implicated in myeloid leukaemogenesis (Yoshimi et al., 2011).PTEN 
mutants in mice demonstrate increased cell populations that match those that become 
dominant in acute myeloid leukaemia (Zhang et al., 2006).It would be important to 
comprehend the effect of the PcG proteins on PTEN and its relationship to the pathogenesis 
of MDS. 
MEL18 KO in vivo, produces a hypoplastic bone marrow phenotype with increased number 
of G0 phase cells (Kajiume et al., 2004). Re-expression of MEL18 normalises the HSC self-
renewal capacity (Kajiume et al., 2004; Mihara et al., 2006).In contrast to MEL18, lack of 
BMI-1 exhibits defective trabecular bone with a reduction in osteoblasts that are replaced by 
adipocyctes (Oguro et al., 2006). 
Unlike PSC subunits, the RING proteins have a dual function in the haematopoietic system 
(Fig: 1.11). Role of RING1B in mouse models indicates that it maintains equilibrium between 




Figure 1.11: Dual effect of KO of RING1B on the haematopoietic system. KO of RING1B 
causes up regulation of cyclin D2 and cdc6 which cause enhanced proliferation of the 
haematopoietic progenitor cells while a concomitant upregulation of p16 reduces the 
proliferation of mature myeloid and lymphoid cells. 
 
RING1B knock out leads to up-regulation of cyclin D2 and cdc6 which has a positive effect 
on proliferation. This is reflected in increased myeloid progenitor cells leading to premature 
lymphoma development. Moreover, RING1B also inhibits the expression of p16INK4A which 
is a proliferation inhibitor during haematopoiesis.  In the absence of RING1B, there is up-
regulation of p16INK4A and hence a decrease in the number of mature myeloid and lymphoid 
precursor cells (Cales et al., 2008). Mutations of RING1B have yet to be identified, but with 
the aberrant haematopoietic phenotype of conditional knockout mice and its crucial 
H2AK119Ub function, additional studies may be warranted to understand its impact in MDS. 
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Expression of PHC1/mouse PHC1 (MPH1) is significantly high in HSCs during adulthood. 
Some studies have demonstrated that PHC1/MPH1-/- mice display arrest of B-cell maturation 
(Tokimasa et al., 2001).Ohta et al (2002) observed that absence of PHC1/MPH1 was lethal in 
mouse embryos. However, reduction in its levels caused no significant differences in the 
myeloid and erythroid lineages in the mice neonates. FACs analysis showed no difference in 
the liver tissue but demonstrated a reduction in B-cells in the spleen. Colony forming units in 
spleen (CFU-S12) were decreased to one-tenth of their normal levels. A reduced activity of 
PHC1-/-HSCs was presumed to be at least in part responsible for the reduced expansion of the 
(CFU-S12) and the progressive decline of clonogenic progenitors during fetal development. 
However, detailed analysis revealed poor expansion of colony forming units in only a small 
population of HSCs indicating an overall conservation of haematopoiesis. The 
exactmechanisms of development of reduced numbers of aberrant HSCs remains ambiguous. 
The possible suggestions could be that PHC1/MPH1 controls repression of genes which are 
needed for the development of the HSCs and in their  absence the HSCs are unable to 
respond to cytokines essential for their normal regulation (Ohta et al., 2002). 
Interestingly, the CBX proteins function via an autoregulatory feedback loop wherein CBX 
proteins are PcG targets in stem cells; CBX7 represses its homolog proteins in HSCs and, in a 
negative feedback loop while CBX2, CBX4, and CBX8 repress CBX7 in differentiated cells 
(Klauke et al., 2013). CBX proteins dictate the balance between self-renewal and 
differentiation in HSC. CBX7 is mainly involved in self-renewal in HSCs which is replaced 
by its partners CBX2, CBX4, and CBX8 during lineage commitment (Klauke et al., 2013). 
Among the CBX paralogues, CBX2 knockdown resulted in the most prominent phenotype, 
reflected as loss of HSCs and progenitors, decreased cell proliferation, and an increase in 
apoptotic events (van den Boom et al., 2013). 
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Function of EZH2 in HSCs is to stabilize the chromatin structure and maintain long-term self 
renewal potential of HSCs by switching off pro-differentiation genes (Ezhkova et al., 2009; 
Kamminga et al., 2006) and promoting a shift toward proliferation by increasing expression 
of genes, which facilitate progression through the cell cycle (Bracken et al., 2003).In vivo 
studies based on deletion of EZH2 in transformed granulocyte macrophage progenitors 
indicate compromised growth and increased risk of progression to AML (Tanaka et al., 
2012). 
1.9 Therapeutic role of PcG proteins 
 
DZNep inhibits EZH2 by impairing the S-adenosylhomocysteine (S-AdoHcy) hydrolase 
activity and the synthesis of S-adenosylmethionine (S-AdoMet). DZNep-mediated inhibition 
of S-AdoMet results in global inactivation of diverse methyltransferases (Chiang, 
1998).Fujiwara et al (2014) studied DZNep and its association with erythroid differentiation. 
They examined differentiation of K562 cells by quantitative RT-PCR after treatment with 
DZNep which reduced EZH2 levels inducing erythroid-related genes like globins. The same 
effects were replicated in primary erythroblasts derived from cord blood CD34-positive cells. 
However they concluded that these effects were only partially due to EZH2 inhibition and 
that additional factor might also be involved (Fujiwara et al., 2014).This might be due to lack 
of specificity of DZNep towards EZH2.Apart from DZNep, small molecule inhibitors like 
EI1 and GSK126 have also been developed that bind to the  S-adenosylmethionine (SAM) 
pocket of the EZH2 SET domain and cause reduction of histone H3K27me3 mark. EI1 
inhibition EZH2 in memory B cells lead to G1 growth arrest and apoptosis (Qi et al., 2012). 
The EI1 molecule like the GSK126 inhibitor targets the SET domain of EZH2 for its 
inhibitory activity. Other research groups used a different approach by focusing on the EZH2-
EED interaction, disrupting it by using a stabilized alpha helix of EZH2 (SAH-EZH2) 
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peptides and therefore reducing the protein levels of EZH2 and H3K27me3 in MLL-AF9 cells 
causing cell cycle arrest and monocyte/macrophage differentiation (Kim et al., 2013). 
On the other hand Retionic acid (RA) has been shown to cause disruption of the SUZ12-
RARȖ multi-protein complexes removing SUZ12 from the target genes in embryonic stem 
cells. The translocation of nuclear to cytoplasmic SUZ12 is rapid with no net change of total 
SUZ12 protein levels. This activates transcription of genes associated with cellular 
differentiation (Amat et al, 2011). The role of EZH1 in HSCs is to repopulate the HSC pool 
thus protecting them from senescence. EZH1 ablation induces significant loss of adult HSCs, 
with concomitant impairment of their self-renewal capacity (Hidalgo et al., 2012).  
Apart from PRC2, PRC1 is also a promising target for anti cancer therapies. Zhang et al 
(2014) proved that RING1B and BMI-1 associate with Ribonucleotide Reductase (RRM1) 
which is predictive of gemcitabine’s therapeutic effect. Both the proteins cause 
polyubiquitination at position 224 and 548 of RRM1 leading to its proteosome-mediated 
degradation. Loss of RRM1 reduces resistance to gemcitabine treatment (Zhang et al., 2014). 
 The crucial role of the canonical polycomb proteins in haematological malignancies and 




1.10 Project Aims 
 
Loss of function mutations of the PcG gene EZH2 have been identified in MDS and are 
associated with SNP6 abnormalities i.e. CN (LOH) 7q and microdeletion 7q36.1. EZH2 is the 
catalytic component of PRC2 that causes H3K27me3 marks resulting in gene silencing. 
However identification of changes in gene signature as a result of these mutations has not 
been examined in myeloid cells. Apart from EZH2 other PcG family genes i.e. PRC1 and 
PRC2 have not been investigated for the presence of mutations and may contribute to the 
development of myeloid malignancies. Jumonji genes are histone demethylases which have 
opposing function to EZH2 and some members of this family of proteins form non-canonical 
complexes with PRC2. The effect of EZH2 mutations on the histone demethylases and the 
degree of their mutational overlap if present have not been ascertained till date.  
In addition to focusing on histone modifying enzymes, my PhD also examines DNA 
methyltransferase; DNMT3A because of its interaction with the SET domain of EZH2 and the 
presence of DNMT3A mutations previously reported in MDS. However, these reports have 
not examined the mutational overlap between EZH2 and DNMT3A. Based on the literature 
survey available on these genes the following project aims were examined. 
 To identify aberrations in Polycomb (PRC1, PRC2) and Jumonji genes using high 
density SNP array and to determine the prevalence, clonal size of mutations affecting 
these genes in a cohort of MDS cases pre-selected for SNP6 aberrations using 454 
sequencing. To correlate the mutational status of PRC and Jumonji genes to their SNP 
abnormalities.  




 To determine the prevelance and clonal size of DNMT3A gene mutations in patients 
with MDS using 454sequencing to identify mutational overlap between DNMT3A and 
EZH2. 
 To examine the functional consequences of SET domain mutant of EZH2 and KO of 
EZH2 in myeloid cells lines using microarray gene expression profiling and verifying 
this gene signature in patient samples. 









2.1.1 Enzymes and Buffer 
Restriction enzymes: 
 





SalI, ScaI, SfiI, SnaBI 
XbaI, XhoI 
NEB buffer 1/2/3/4 
New England Biolabs 
T4 DNA polymerase (3,000 units/ml) New England Biolabs 
SuperTaq (5U/ µl) Cambio 
dNTPs (10mM) New England Biolabs 
10X PCR buffer Sigma-Aldrich 
T4 DNA polymerase buffer (10X) New England Biolabs 
T4 DNA Ligase (400,000 units/ml) New England Biolabs 
BSA (100X) New England Biolabs 
Alkaline Phosphatase (CIP) New England Biolabs 
 
2.1.2 Plasmids 
Expression plasmid Plasmid description Manufacturer 
IRATp970F1210D cDNA EZH2 cloned in pCMV-SPORT6 
Source Bioscience 
(Genome cube) 
IRATp970A0473D cDNA DNMT3A cloned in pCMV-SPORT6 
Source Bioscience 
(Genome cube) 
pSUPER.retro.puro EZH2-ShRNA cloned in pSUPER.retro.puro Dr. Joop Gaken 
p3xFLAG-Myc-CMV-
26 
Expression plasmid for FLAG tagged 
wild type and mutant EZH2 and 
DNMT3A 
Dr. Joop Gaken 
pBABEPuro Plasmid contained GFP+ Puromycin Dr. Joop Gaken 







Primary Dilution for western blotting Stock conc Manufacturer 











1:1000 100 µg Abcam ab6002 









100 µg Abcam ab8580 
γ-Tubulin 1: 2000 200 µg 
Santa Cruz Biotechnology 
sc-7396 
β-Actin 1:300 --- Abcam ab8226 
















2.1.4 PCR, Gel electrophoresis and Sequencing Materials 
BigDye Terminator v3.1 Cycle sequencing kit Applied biosystems 
BigDye XTerminator purification kit Applied biosystems 
Ethidium Bromide Sigma 
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Gel cleaning kit QiAEX II, gel extraction kit Qiagen 
GoTaq Colourless Master Mix Promega 
Agarose, molecular biology grade/electrophoresis grade Melford 
O͛GeŶe ‘uler ladder ŵiǆ ;Ϭ.ϭμg/μlͿ Fermentas 
6x Orange DNA loading Dye Fermentas Fermentas 
Tris Acetate-EDTA buffer (TAE buffer) 50X Sigma 
Filtered and unfiltered micropipette tips Starlabs 
 
2.1.5 DNA and RNA extraction reagents 
TRIzol Invitrogen 
RNase free water Qiagen 
Phase lock Gel Heavy 2 ml 5 PRIME 
RNeasy Micro Kit Qiagen 
Chloroform Sigma 
2-Propanol (Isopropanol) Sigma 
Ethanol Sigma 
DNeasy blood and tissue kit Qiagen 
 
2.1.6 Cloning reagents 
Nuclease free water Ambion 
Trptone enzymatic digest Sigma -Aldrich 
Bacto Yeast extract Becton Dickinson 
BactoAgar Becton Dickinson 
Carbenicillin solution 100mg/ml in 50% Ethanol (10ml) Bioline 
Maxi prep kit Gen Elute plasmid maxi Prep kit Sigma 
Wizard® Plus SV Minipreps DNA Purification System Promega 
Topo TA cloning kit dual PROMOTER pcri-Topovector Invitrogen 
Pure Yield™ plasŵid MiŶi prep sǇsteŵ Promega 
OŶe Shot® MaĐhϭ™-T1R Chemically Competent E.coli Invitrogen 
MegaX DHϭϬB EleĐtroĐoŵp™ Cells Invitrogen 




2.1.7 Transfection reagents 
Amaxa cell line neuclofector kit V Lonza 
Lipofectamine® LTX with Plus Invitrogen 
Lipofectamine RNAiMAX Reagent Invitrogen 
Igenio Electroporation solution Mirus 
OptiMEM Reduced Serum Medium  Life technologies 
Polybrene Sigma 
G418 (neomycin) Sigma 
Puromycin Sigma 
 
2.1.8 Tissue culture reagents & equipment 
Roswell Park Memorial Institute medium (RPMI-1640) Sigma Aldrich 




15ml & 50ml Falcon tubes 
Vented tissue culture flasks 
5ml,10ml & 20ml Pipettes 
6,12 & 24 well plates 
 
VWR international ltd 
ϭ.ϱ ŵl ŵiĐroĐeŶtrifuge ͚EppeŶdorf tuďes͛ Starlabs 
Phosphate Buffered Saline (PBS) PPA 
L-Glutamine-Penicillin – Streptomycin solution Sigma 
Trypan Blue 0.4% , 0.85% NaCl Lonza 
Dimethyl sulfoxide (DMSO) (freezing cells) Sigma 





2.1.9 Cell lines 
Cell line Source Provider 
K562 Chronic myelogenous leukaemia Dr. David Darling 
MOLM13 Acute monocytic leukaemia DSMZ 
KG1 Acute myelogenous leukaemia Dr.Terry Gaymes 
 
2.1.10 qPCR reagents 
Universal Library probes Roche Diagnostics 
qPCR primers Integrated DNA technologies 
FastStart Universal Probe Master 12.5 ml Roche Diagnostics 
SuperSĐript® VILO™ ĐDNA SǇŶthesis Kit Life Technologies 




2.1.11 Western Blot reagents 
NuPage Bis-Tris gel Life technologies 
Novex Sharp Pre-stained Protein standard  Life technologies 
Bovine serum albumin (BSA) Fisher Scientific 
ECL Prime Western Blotting Detection Reagent GE Healthcare 
Non fat dried milk (Marvel) Sainsbury 
2-Mercaptoethanol Sigma 
Methanol Sigma 
Nupage® Tris –Acetate SDS Running buffer (20X) Invitrogen 
Nupage® LDS Sample buffer (4X) Invitrogen 
Nupage® Transfer buffer (20X) Invitrogen 
Nitrocellulose Membrane GE Healthcare 
TWEEN 20 Sigma 
2.1.12 Cell viability, proliferation and cell cycle reagents 
Tetrazoliumsalt[3-(4,5-Dimethylthiazol-2-yl) 
2,5diphenyltetrazolium- bromide] (MTT) 
Sigma 
Propodium Iodide (IP) Sigma 
Fluorescein isothiocyanate (FITC) Sigma 
Pacific Blue Annexin V BioLegend 
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Cell- based Assay Annexin V Binding buffer  Cayman 
7-Aminoactinomycin D (7-ADD) BioLegend 
2.1.13 Buffers and Solutions 
1X PBS 10 tablets were dissolved in 1 litre of dH20 
X-GAL 
20 mg of X-Gal was dissolved in 1 ml of 
dimethylformamide (DMF) to make a final conc of 
20 mg/ml.Solution was stored at -20°C. 
1X TAE 
Concentrated buffer powder (10X) was dissolved in 1L of dH2O to 
produce 1x TAE with 40mM Tris-acetate and 1 mM EDTA. Solution 
was stored at room temperature. 
1X sample buffer 
20 % (v/v) NuPAGE LDS Samples Buffer (4 x), 10 % ;ǀ/ǀͿ β- 
mercaptoethanol were made up in dH20 and stored at - 20°C. 
NuPage Transfer buffer 
50 ml 20X NuPage transfer buffer, 20  % Methanol (v/v), dH20 upto 1 
litre 
1x MES SDS Running 
buffer 
Buffer made by 1: 20 dilution of 20X Running buffer in dH20. The 1X 
Solution composed of 50 mM MES, 50mM Tris Base, 0.1 % SDS and 
1mM EDTA with pH7. 
MTT solubilisation buffer 
The solution was prepared by mixing 10 % (v/v) Triton X-100 with 90 
% (v/v) Isopropanol and 2 drops of HCL 37% (12M). Stored at room 
temperature. 
Luria-Bertoni (LB) broth 
1 % (w/v) bactotryptone, 0.5 % (w/v) yeast extract, 1 % (w/v) NaCl, 
2ml NaOH 
LB-Agar 
LB broth with 1.5 % (w/v) agar. Addition of ampicillin to a final 
concentration of 100 µg/ml after autoclaving 
Puromycin  
1 mg/ml working solution was made in dH20 from10 mg/ml stock 
solution. 
DNA loading dye 30 %(v/v) glycerol and 0.25 % (w/v) Orange R. 
MTT 
5 mg/ml was made by dissolving MTT powder in PBS. Solution was 
filtered and aliquots were frozen  
-20°C in dark. 
RNaseA 10 mg/ml dH2O stored at -20°C 
FITC ϭμg/ŵl PBS. Stored at 4°C in the dark 





ON-TARGETplusSMARTpool Human EZH2 (Cat No:  L-004218-00) was ordered from 
Dharmacon to target EZH2 in MOLM13.Non-specific or scrambled siRNA of the same type 
(smartpool, Dharmacon) was used as control.  
ENX-1 siRNA (Cat No: sc-35312) and control siRNA-A (Cat No: sc-37007) against EZH2 
was obtained from Santa Cruz Biotechnology to validate results generated by ON-
TARGETplusSMART pool siRNA against EZH2. 
2.3 shRNA used with pSUPER 
EZH2shRNA1_F 
 
5' - GAT CCC CAC CAG TTT GTT GGC 
GGA AGC GTG TCA AGA GCA CGC 
TTC CGC CAA CAA ACT GGT TTT TT 
- 3' 
Forward primer for EZH2 
shRNA at position 33 
EZH2shRNA1_R 
 
5' - TCG AAA AAA ACC AGT TTG TTG 
GCG GAA GCG TGC TCT TGA CAC 
GCT TCC GCC AAC AAA CTG GTG 
GG - 3' 
Reverse primer for EZH2 
shRNA at position 33 
EZH2shRNA2_F 
 
5' - GAT CCC CGA CTT CTG TGA GCT 
CAT TGC GCG TCA AGA GCG CGC 
AAT GAG CTC ACA GAA GTC TTT TT 
- 3' 
Forward primer for EZH2 
shRNA at position 213 
EZH2shRNA2_R 
 
5' - TCG AAA AAA GAC TTC TGT 
GAG CTC ATT GCG CGC TCT TGA 
CGC GCA ATG AGC TCA CAG AAG 
TCG GG - 3' 
Reverse primer for EZH2 
shRNA at position 213 
EZH2shRNA3_F 
 
5' - GAT CCC CCA GGC GCA CTT CCT 
CCT GAA TGT TCA AGA GAC ATT 
CAG GAG GAA GTG CGC CTG TTT 
TT - 3' 
Forward primer for EZH2 
shRNA at position 758 
EZH2shRNA3_R 
 
5' - TCG AAA AAA CAG GCG CAC 
TTC CTC CTG AAT GTC TCT TGA 
ACA TTC AGG AGG AAG TGC GCC 
TGG GG - 3' 
Reverse primer for EZH2 
shRNA at position 758 
EZH2shRNA4_F 
 
5' - GAT CCC CGC GGA AGA ACA 
CAG AAA CAG CTC TCA AGA GGA 
GCT GTT TCT GTG TTC TTC CGC TTT 
TT - 3' 
Forward primer for EZH2 
shRNA at position 935 
EZH2shRNA4_R 
 
5' - TCG AAA AAA GCG GAA GAA 
CAC AGA AAC AGC TCC TCT TGA 
GAG CTG TTT CTG TGT TCT TCC 
Reverse primer for EZH2 
shRNA at position 935 
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GCG GG - 3' 
2.4 Patient samples 
 
Bone marrow samples from 70 patients with MDS were collected from King’s College tissue 
bank under project number PR039 and ethical consent of the patients was obtained in 
accordance with King’s College guidelines for human sample collection. 
2.5 DNA Techniques 
2.5.1 DNA Extraction 
DNA was extracted from patient samples using the QIAamp DNA purification kit from 
Qiagen. The bone marrow cells were disrupted using 200 µl of the cell lysis buffer (AL 
buffer) and pulse-vortexing, after resuspending them in 200 µl PBS and 20 µl Protease. 
Incubation at 56 °C for an hour was followed by addition of 200 µl 96-100% (v/v) ethanol. 
The mixture was applied to a QIAamp Mini spin column and washed with 500 µl of AW1 
and AW2 buffer before eluting the DNA in 50 µl EB buffer.  
 
2.5.2 Determination of DNA concentration 
 
DNA concentration was determined by using Thermo Scientific Nanodrop (ND-8000; 
Nanodrop) spectrophotometer. The Nanodrop has an absorbance spectrum from 220-750 nm. 
The absorbance of the DNA solution (nucleic acid concentration) is measured at 260 nm. 
Typically, 1µl of DNA was placed on the nanodrop pedestal. Light absorbance by the sample 
is measured against that of the blank (EB/dH20 buffer) to eliminate background absorbance. 
The ratio of absorbance at 260/280 nm is a good representation of DNA purity. A ratio of less 
than 1.8 indicates protein contamination while more than 1.95 suggests RNA contamination. 





2.5.3 DNA Amplification 
The REPLI-g Midi Kits from Qiagen were utilised for amplification of samples from 70 
patients. The samples were suspended in TE at a concentration of 100 ng. 5 µl of this 
suspension was added to 5 µl of the D1 buffer (containing KOH & EDTA to denature the 
DNA) was prepared according to Table 2.1, vortexed and incubated for 3 min at room 
temperature (RT). 
Components Buffer D1 Buffer  N1 
Reconstituted DLB buffer  
(500 µl H2O + DLB buffer) 
9 µl - 
Stop solution - 12 µl 
Nuclease Free water 32 µl 68 µl 
Total Volume 41 µl 80 µl 
 
Table 2.1: Preparation of D1 and N1 buffer. 
 
Neutralization was done by adding 10 µl of buffer N1 (Table 2.1) and brief vortexing. Next, 
30 µl master mix containing the REPLI-g DNA Polymerase (1 µl), and REPLI-g Midi 
Reaction Buffer (29 µl) and 20 µl of the denatured DNA was prepared.An isothermal 
amplification reaction was then carried out at 30° C overnight and the enzyme was later 
inactivated by increasing the temperature to 65° C for 3 min. A negative control without the 
template DNA was used to ensure absence of contamination. Manufacturer claims a DNA 
yield of 40 µg. The amplified product was stored at -20° C. 
2.5.4 DNA quality Testing 
 
Human DNAOK multiplex Polymerase chain reaction (PCR) kit from Web Scientific was 
utilised for assessing the quality of the amplified DNA samples.  It consists of five primer 
pairs which amplify the DNA from five different regions as well as a positive control. If the 
DNA was partially degraded one or more PCR fragments were absent. Completely 
77 
 
disintegrated DNA sample produced only a positive PCR control product which was 
visualized on agarose gel. The components of the PCR and cycling profile are described in 
Table 2.2. The PCR product was loaded on 2 % TAE agarose gel and run alongside a 100 bp 
ladder for 25 min. 
Components Volume 
Human DNAOK mix 7.5 µl Denaturation at 95°C for 5 min 
30 Cycles: 
Step 1: 95°C for 30 secs 
Step 2: 63°C for 30 secs              
Step 3: 72° C for 45 secs 
MegaMiǆ˜ Gold 12.5 µl 
Sample DNA 5 µl 
 
Table 2.2: Preparation of Human DNAOK multiplex PCR master mix. 
 
2.6 Primer Designing 
 
Exon sequences for EZH1, BMI1, SUZ12, RING1B, EED, DNMT3A, RING1A, PHC1, PHC2 
and fifteen Jumonji genes were obtained from the Ensembl 
(http://www.ensembl.org/index.html). Primers for these genes were designed using default 
settings (Tm: 59° C) on Primer3 software (http://primer3.ut.ee/) and a product size of <350bp 
was achieved. A flanking region of atleast 50 bp was allotted on either side of the target 
sequence to enable accurate sequencing. Universal tag primers (refer appendix DVD) were 
incorporated into the primers. All the primers were obtained from Sigma or Integrated DNA 
technology. 
2.6.1 Primer Testing and PCR optimisation 
 
Dnase, Rnase free water was added to the lyophilized primers to make a stock solution of 100 
µM.All the primers were tested on 10 ng of genomic control DNA (Affymetrix, UK) using 
PCR and analysed on 1/ 2 % TAE agarose gel alongside O’Gene Ruler DNA ladder 
(Thermoscientific,UK).Electrophoresis was carried out at 120V for 20 min in 1X TAE buffer. 
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Table 2.3: a) PCR reaction mixture b) PCR programme on the thermocycler. 
2.7 Mutational analysis by Sanger Sequencing 
 
Amplicons were amplified using the primers and PCR programme detailed in table 2.3. The 
PCR products were cleaned using ExoSAP-IT from SLS (2 µl ExoSAP-IT + 6 µl of PCR 




Time Temp Comment 
15 min 37 °C 
 
Activation of (ExoSAP-IT) : 
Exonuclease I + Shrimp Alkaline Phosphatase and rSAP to remove  
phosphorylated ends of DNA+ single stranded DNA and dNTPs 
respectively. 
 
15 min 80 °C Inactivation of ExoSAP-IT 
 
Table 2.4: ExoSAP-IT clean–up programme. 
 
The purified product was used in another round of PCR to incorporate the dye into the DNA 
sequence. 
 
Table 2.5: a) PCR reaction mixture b) PCR programme. 
Purification of the post-sequencing reaction (10 µl) was carried out using 10 µl of the 
BigDyeXTerminator and 45 µl of the SAM solution from Applied Biosystems.  The mixture 
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was vortexed on a plate mixer for 30 min followed by centrifugation for 2 min at 1000 xg. 
Sanger sequencing (Geneservice, Cambridge, United Kingdom) was carried out by ABI 
3130X genetic analyzer and the sequences were analyzed for mutations using SeqScape 
Software (v2.5) and Sequencing Analysis software by Applied Biosystems (Foster City, CA). 
 
2.8 Next-generation sequencing of PRC2, DNMT3A and Jumonji genes 
2.8.1 Patient Cohort 
 
Amplified DNA samples from the same cohort of patients were utilized for next-generation 
sequencing of the PRC2 genes; EZH1, EED, SUZ12, DNA methyltransferase 3A (DNMT3A) 
and fifteen Jumonji genes (JMJD3, JMJD4, JMJD1B, JMJD2A, JARID2, JMJD1C, 
JARID1B, JMJD2C, UTX, JARID1C, JARID1A, JMJD2D, JHJD1A, JARID1D and JHJD1B). 
PCR was performed on 10 ng of amplified DNA as described in table 2.3.Subsequently, a 
second PCR was performed with 1or 1.γ µl of the ampliﬁed product from the first PCR and 
primers (1 µl) targeted to the aUS primers (refer appendix). These primers contained a 5' tag 
that identiﬁed forward and reverse strands for sequencing and also included a 5-base pair 
Multiplex Identifier (MIDs) sequence to identify individual patients. The following PCR 




Cycles Temperature Time Comment 
1 94 °C 5 min Enzyme activation 
8 
94 °C 35 sec Denaturaion 
62 °C 40 sec Primer annealing 
72 °C 45 sec Elongation 
1 72 °C 15 min 
Inserting the missing 
nucleotides 
 
Table 2.6:  Programme for the second round of PCR for 454 sequencing. 
 
Post-pcr amplified exons were quantified using picogreen dye (Invitrogen) on Rotor-Gene 
6000 Multiplexing System from Corbett Research. The readings were verified with band 
intensity on 2 % agarose gel. All the exons per patient were equalized in concentration based 
on the picogreen measurement and pooled. Subsequently, a second a picogreen measurement 
was performed to equalize the concentration of all the patient samples. 
2.8.2 Gel extraction and purification 
The mixture was loaded on a 2 % agarose gel in TAE buffer and electrophoresis was carried 
out at 120V for 45 min. The band was purified using QIAquick Gel Extraction kitfrom 
Qiagen.Gel slabs were submerged in QG buffer, heated to 50 °C for 15 min and vortexed 
every 2 min during the incubation.10 µl of (3M) sodium acetate was added to balance the pH 
of the solution and 100 µl/ slab of 100 % isopropanol was added to increase the yield of DNA 
fragments <500 bp. 700 µl of the solution was applied to columns containing Silica 
membrane and centrifugation was carried out at 300 xg for 1 min.  The column with the DNA 
adsorbed onto it was subsequently washed with 500 µl of QG buffer and 750 µl of PE buffer 
with ethanol to remove all the traces of salt, impurities etc. The DNA was then eluted using 




2.8.3 Bead Purification 
 
AgencourtAMPure XP magnetic beads (Beckman Coulter (USA)) were used to re-purify the 
amplicons obtained from gel purification. 60 µl of the gel purified filtrate was mixed with 6 
µl of Qiagen 10X buffer to adjust the pH. Magnetic beads (1.8 times) were mixed for every 1 
µl of the mixture and incubated at room temperature for 15 min. The mixture was placed on 
magnet particle concentrator (MPC) [Magnarack, Invitrogen] and the supernatant was 
discarded. The beads were washed two times with 200 µl 70% (v/v) ethanol and eluted by 
incubating at RT for 5 min in 60 µl of 1X TE. The mixture was placed on the MPC for 5 min 
and the supernatant containing the purified amplicons was collected. 
 
2.8.4 Library preparation 
 
A third picogreen measurement and concomitant gel electrophoresis was carried out to 
confirm the final DNA concentration. The concentration was converted to 1×107molecules/µl 
by adding appropriate amounts of molecular grade water. 
2.8.5 Sequencing 
 
GSFLX Titanium LV emPCR Kit (Lib-A) [Catalogue no: 05619114001] from Roche 
Applied Sciences was used to perform the emulsion PCR on the purified amplicons.Live & 





Table 2.7: Preparation of a) Live Amplification mix per capture bead solution b) Mock 
Amplification mix c) 1X Capture bead wash buffer. 
DNA Capture Beads A (with forward primer) & B (with reverse primer) were vortexed and 
centrifuged for 1min at 400 xg. The supernatant was discarded and the beads were washed 
twice with 1 ml of 1X Capture Bead Wash Buffer TW. After the second wash, 50-60 μl of the 
supernatant was left behind to avoid the beads from drying out. 
2.8.6 Emulsion PCR 
 
10 μl of the library mixture at 1×107 molecules/ μl (purified before) were added to capture 
bead A & B each. Next, 3.915 ml of the Live amplification mix (A or B) was added to the 
respective capture bead (A or B) +DNA library solution. Concurrently, two cups of emulsion 
oil were installed on the TissueLyzer and shaken for two min at 28 Hz. 5 ml of Mock 
amplification was added to each cup. Micelle formation was facilitated by shaking the cups at 
28 Hz for 5 min on the TissueLyzer.The Live amplification mix A + DNA library + capture 
beads A were added to one emulsion cup and similarly the solution for capture beads B was 
added to the other cup. The cups were mixed for 5 min at 12 Hz and the solution was then 
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dispensed (100 μl/ well) into 96 well plates using multistep dispenser pipette. PCR was 
carried out over night (Table 2.8). 
Cycles Temperature Time Comment 
1 94 °C 4 min Enzyme activation 
50 
94 °C 30 sec Denaturation 
68 °C 30 sec Primer annealing 
58 °C 4 min 30 sec Elongation 
 10 °C ∞  
 
Table 2.8: PCR conditions for clonal amplification in the emulsions. 
 
2.8.7 Vaccum assisted emulsion breaking 
Post-PCR emulsions were broken using the GS FLX Titanium emPCR breaking kitand 
breaking reagents [Catalogue number: 05233658001]. The breaking kit (shown in the figure) 
was attached to the vaccum source in the hood and the solution from the PCR plates was 
collected in tubes. Plates were washed three times with 150 μl of 100 % 2-propanol (v/v). 
Capture bead A and B solutions were mixed at this stage and the tubes were centrifuged for 
10 min at 1000 xg. The supernatant was discarded and the pellet was washed with 40 ml [EF] 
Enhancing fluid, 100 % (v/v) 2-propanol (two times), 100 % (v/v) ethanol and again with EF 
by centrifugation at 1000 xg for 10 min. The pellet was transferred to eppendorfs and washed 






Figure 2.1: Assembled set-up for vaccum assisted emulsion breaking and bead recovery 
(Reference: Roche emPCR method protocol). 
 
2.8.8 DNA library Bead Enrichment 
 
After the final wash, the supernatant was discarded and 1ml fresh Melt solution (19.5 ml of 
molecular grade water + 500 μl of 5M NaOH) was added followed by vigorous vortexing and 
incubation for 2 min at RT. The supernatant was discarded after centrifuging the eppendorfs 
at 1000 xg for 2 min and the denaturation step using the Melt solution was repeated again. 
The Melt solution was washed using 1 ml/eppendorf of Annealing buffer XT (two times) and 
centrifuging for 2 min at 1000 xg. The pellet was resuspended in 45 μl of annealing buffer. 
1β.5 μl of Enrichment primer A + 1β.5 μl of enrichment primer B [from the GSFLX Titanium 
MV emPCR Kit] were added to each eppendorf and placed on a heating dry-block at 65° C 
for 7-8 min to allow primer annealing.The reaction was stopped by placing the tubes on ice 
for 2 min. The beads were washed (two times) using 800 μl EF and centrifuging at 1000 xg 
for 2 min. The bead pellet was then resuspended in 800 μl EF (*). 
2.8.9 Preparation of Enrichment Beads 
 
The eppendorfs containing enrichment beads were vortexed and placed on magnetic particle 
concentrator (MPC). The supernatant was discarded and the beads were washed three times 
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with 1 ml EF. After the final wash 80 μl/eppendorf of enrichment beads were added to the 
pellet suspended in enhancing fluid earlier (*). The eppendorfs were placed on the rotator for 
15 min, pooled in 15 ml glass tubes and left on the MPC for 5 min and the supernatant was 
discarded. These washes were repeated 6-10 times with 3 ml EF till a clear supernatant was 
obtained. 
2.8.10 Collection of Enriched DNA beads 
 
Enriched beads were resuspended in 1.5 ml Melt solution (prepared earlier), vortexed and 
placed on MPC for 5 min. The supernatant was collected and the denaturation step was 
repeated once to ensure maximum yield. The beads were washed using 1 ml /eppendorf of 
Annealing buffer XT (two times) and centrifugation for 2 min at 1000 xg. The pellet was 
resuspended in 1 ml EF. 
2.8.11 Determine Bead enrichment 
γ μl aliquot of the beads was counted using Beckham Coulter Z1 particle counter. 
Parameter Dual Threshold 
Upper Size Ϯϱ μŵ 
Lower Size ϭϱ μŵ 
Count Mode between 
Aperture ϭϬϬ μŵ Upper Size ϭϬϬ μŵ 
 
Table 2.9: Coulter Counter Z1 models settings for bead counting 
% Bead Enrichment = Number of enriched beads× 106 beads/cup × 100 
                                                       35 
 
2.8.12 Sequencing Primer Annealing 
EF was discarded and the pellet was re-suspended in β00 μl annealing buffer. β5 μl of 
sequencing primer A [from the GSFLX Titanium LVemPCR Kit] + β5 μl of sequencing 
primer B was added to the eppendorf and placed on heating dry-block at 65° C for 7-8 min. 
The reaction was halted by placing the tubes on ice for 2 min. The library was washed using 
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1 ml /eppendorf of Annealing buffer XT (two times) and centrifugation for 2 min at 1000 xg 
and then stored in fridge overnight (ON) in 1 ml annealing buffer at 2°C to 8°C. 
2.8.13 Preparation of Bead Buffer 2 (BB2) 
 
 Bead wash buffer (200 ml) from the Roche kit was placed on ice for 10 min. 1.2 ml of the 
Supplement CB and γ4 μl of Apyrase was addedto make the Bead Buffer β (BBβ).  
 
BBϮ ;μlͿ PolǇŵerase CofaĐtor  ;μlͿ DNA PolǇŵerase ;μlͿ Total ;μlͿ 
1570 150 300 2020 
 
Table 2.10: Components of DBIM buffer. 
 
2.8.14 Bead Preparation [Titanium Sequencing Kit LR70 CatNo: 04932315001] 
1) Packing beads (stabilize and maintain all the immobilized components of the system 
within the wells) were washed two times by vortexing, adding 1ml BB2 and 
centrifugation at 1000 xg for 5 min. Discard the supernatant after each wash. 550 μl BBβ 
was later added and the beads were left on ice. 
2) PPiase (scavenge inorganic pyrophosphate (PPi) to reduce interference during each 
nucleotide flow) and Enzyme beads (sulfurylase and luciferase enzymes) were vortexed 
for 30 sec each and placed on MPC for 2 min. The supernatant was discarded. The PPiase 
beads were washed three times with 1 ml BB2 and left in 500 μl of BBβ. Similarly, the 
enzyme beads were washed and left in 1 ml BB2. Both the bead solutions were left on 
ice. 
3) DNA + Control beads (serve as an internal control for the sequencing reaction): The 
libraries were thawed the next day and measured two times using the bead counter as 
described previously.  1 ml of new annealing buffer was added to the libraries. The 
appropriate amount of DNA library beads (2 million beads per region) were separated and 
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mixed with (β0 μl / region) Amplicon control bead solution from Roche. The final 
volume should be approximately 50 μl or less. 950 μl/ region of DBIM was added to the 
mixture of DNA library + control beads and incubated at RT on the rotator for 15 min.  
2.8.15 Layer Preparation 
Layers 1, 3 and 4 were prepared according to the table in falcon tubes and placed on ice. 
Bead Layer BBϮ ;μlͿ EŶzǇŵe Beads ;μlͿ PPiase Beads ;μlͿ Total ;μlͿ 
Layer 1- Enzyme beads 3250 550 ---- 3800 
Layer 3- Enzyme beads 2500 1300 ---- 3800 
Layer 4- PPiase beads 3340 ----- 460 3800 
 
Table 2.11:  Dilution of beads for layer preparation. 
 
Layer β was prepared by combining β65 μl of packing beads with 1000 μl of the Library+ 





2.8.16 Assembling the BDD 
The Roche Pico Titre plate kit (Catalogue number: 05029082001) was washed and assembled 
as per manufacturer’s instructions as indicated in the figure below by placing the PTP device 
onto the BDD base and aligning the notched corners.  
 
 
Figure 2.2: Assembling the BDD(Reference: Roche emPCR method protocol). 
 
1.86 ml of each layer was loaded onto the PTP through the Loading ports. The plate was 
centrifuged for 10 min at 1620 xg.  Previous layers were aspirated after centrifuging each 
time before loading the subsequent layer. After the last layer was aspirated out, the plate was 





2.8.17 Run  Requirements 
One maintenance wash and two pre-washes were carried out before the run. Similarly, the 
PTP cartridge and camera face plate were cleaned and the sequencing kit reagents LR70 
required for each run were loaded on the machine as per the manufacturer’s instructions. 
2.9 Total RNA isolation 
Cell pellets in the range of 10×105-1×106 cells were resuspended in 1 ml of Trizol 
(Invitrogen) and vortexed vigorously. These pellets were either stored at -80 ◦C or the 
samples were processed immediately by incubating at RT for 5 min. The homogenised 
samples were mixed with 200 µl of chloroform and then centrifuged at 12,000 xg for 15 min 
at 4◦C. The separated upper aqueous phase was transferred into a fresh tube.  500 µl of 2-
Propanol was added to the aqueous phase and the mixture was incubated for 10 min at RT. 
The samples were centrifuged at 12,000 xg for 10 min at 4◦C. The supernatant was discarded 
and the RNA pellet was washed with 1000 µl of 75% (v/v) ethanol at 7500 xg for 5 min. The 
supernatant was discarded and the RNA pellet was air-dried for 10-15 min. The pellet was 
dissolved in 30 µl of RNase free water and the concentration was determined using Thermo 
Scientific Nanodrop sphectrophotometer. 
Alternatively, RNeasy Micro Kit - RNeasyMinElute Spin Columns were used for purification 
of concentrated total RNA when dealing with small numbers of cells as per manufacturer’s 
instructions. 
2.10 cDNA synthesis 
100 ng-1µg of total RNA was reverse transcribed with the SuperScript VILO™ cDNA 





10X SuperScript® Enzyme Mix 2 µl 
ϱX VILO™ ‘eaĐtioŶ Miǆ 4 µl 
RNA ( up to 1µg) x µl 
Water to 20 µl 
 
Table 2.12:  Preparation of master mix for cDNA synthesis 
 
The above mix was incubated at 25°C for 10 min and then at 42°C for 120 min. The reaction 
was terminated for 5 min at 85°C. The cDNa samples were stored at -20°C. Depending upon 
the starting concentration of the total RNA, the cDNA samples were either diluted (1:25, 1:50 
or 1:100) or used undiluted. 
 
2.11 Real Time PCR analysis 
Real time PCR was performed using FastStart Universal Probe Master mix and probes from 
Universal Probe Library (Roche Diagnostics). Each sample was run in triplicate to control for 
real-time PCR (qPCR) variations. 
Reagent Volume 
FastStart Universal Probe Master mix 10 µl 
cDNA 3-5 µl 
Primer foward& reverse (20 µM) 1 µl 
Probe 0.25 µl 
dH2O Upto 20 µl 
 
Table 2.13: Preparation of Real-time PCR master mix 
 
The thermo cycling conditions on the StepOnePlus Real-Time PCR (Applied Biosystems): 















For any given cDNA relative target abundance (fold change) was normalized against the 
house-keeping genes GAPDH, TUBULIN and B2M according to the formula: 
 2-∆∆Ct where ∆∆Ct= ∆Ct target - ∆Ct calibrator/wild type. 
∆Cttarget = Cttarget– CtGAPDH or B2M or TUBULIN, 
∆Ct calibrator/wild type= C calibrator/wild type– Ct GAPDH or B2M or TUBULIN 
where Ct is the threshold cycle. 
Analysis in patient samples (section 3.7.3.3 & 5.15) 
After calculation of  ∆Cttarget = Cttarget – CtGAPDH or B2M or TUBULIN , one patient sample was 
used as calibrator to obtain the relative fold change for the remaining patient 
samples and plotted as a scatter plot. 
Analysis in gene signature obtained in KO experiments (section 5.13.1) 
2-∆∆Ct where ∆∆Ct= ∆Ct target - ∆Ct calibrator/wild type. 
∆Cttarget = Cttarget– CtGAPDH or B2M or TUBULIN, 
∆Ct calibrator/wild type= C calibrator/wild type– Ct GAPDH or B2M or TUBULIN 
where Ct is the threshold cycle. 
The calibrator sample is expressed as zero and the remaining samples are expressed 








2.12 Affymetrix Human Transcriptome 2.0 gene expression profiling 
 
Total RNA was extracted from K562 cells on day 7 after transduction for shRNA against 
EZH2 in lentivirus and at 72 hr post-transfection for the EZH2 mutations (R690C & 
R690H).The quantity and purity of the starting RNA was assessed by the ND-8000 
(Nanodrop) spectrophotometer, and the integrity confirmed by Agilent 2100 Bioanalyzer. 
The protocol recommended between 50 – 500 ng of starting RNA. For all the experiments, 
100 - 150 ng of RNA was utilized. The workflow of the experiment is indicated in (Fig: 2.3) 
 
Figure 2.3: Work-flow for Affymetrix Human Transcriptome 2.0 gene expression array. 
Day 1 consists of first and second strand cDNA synthesis followed by cRNA amplification. 
Day 2 involves bead purification of the cRNA and subsequently ss-cDNA synthesis, 
purification followed by labelling and hybridization. 
 
 
2.12.1 Reverse transcription to synthesise first-strand cDNA 
All reagents were included in the WT amplification kit. Reactions were assembled on ice in 
96 well plates. 
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First-Strand Matser mix: 
Reagent Volume/reaction 
First-Strand Buffer 4 µl 
First-Strand Enzyme 1 µl 
Total Volume 5 µl 
 
5 μl of the First-Strand Master Mix was then added to 5 μl of total RNA + H2O mixture 
which was prepared as follows: 
 
Reagent Volume/reaction 
Total RNA sample (100 ng) variable 
Nuclease-free water variable 
Total Volume 5 µl 
  
Poly-A controls at this step were omitted to allow for the use of a greater volume of target 
total RNA (5 μl instead of γ μl). 
The two mixtures were mixed and incubated for 1 hr at 25 °C, then for 1 hr at 42 °C followed 
by at least 2 min at 4 °C. The lid was heated to 42 °C for the entire duration. Immediately 
after incubation the plate was centrifuged briefly before being placed on ice and immediately 
prepared for second strand cDNA synthesis. 
2.12.2 Second-strand cDNA synthesis 
The master mixes were assembled on ice as follows: 
Reagent Volume/reaction 
Second-strand buffer 18 µl 
Second-strand enzyme 2 µl 
Total Volume 20 µl 
 
20 µl of the above master mix was added to each (10 µl) first-strand cDNA sample for a final 
reaction volume of 30 µl. After mixing and brief centrifugation, the samples were incubated 
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for 1 hour at 16oC, then 10 min at 65oC, followed by at least 2 min at 4 °C before being 




2.12.3 In Vitro Transcription (IVT) to synthesise cRNA 
The IVT buffer was thawed at RT for ≥ 10 min and IVT master mix was prepared as follows: 
Reagent Volume/reaction 
IVT Buffer 24 µl 
IVT Enzyme 6 µl 
Total Volume 30 µl 
 
30 µl of the master mix was added to 30 µl second-strand cDNA sample for a final reaction 
volume of 60 µl. The mixture was vortexed briefly and incubated for 16 hr at 40 °C (lid temp: 
40 oC). The samples were placed on ice and immediately prepared for purification. 
2.12.4 cRNA Purification 
The cRNA elution buffer (Nuclease-free dH20) was pre-heated to 65o C for at least 10 min. 
The purification beads were mixed thoroughly by vortexing. 100 µl/ reaction of the beads 
were added to 60 µl of the cRNA reaction and transferred to a 96 well plate. The reactions 
were mixed by pipetting up and down 10 times and incubated for 10 min. The cRNA samples 
bind to the beads during the incubation. The plate was transferred to a 96 well magnetic stand 
(Agentcourt Bioscience) to capture the beads. When the capture was completedand the beads 
formed pellets against the magnetic stand. The supernatant was carefully aspirated and 
discarded.While on the magnetic stand the beads were washed three times with 200 µl of 80 
% ethanol and incubated for 30 sec. The beads were air-dried on the magnetic stand for 5 min 
and the cRNAwas eluted in 27 µl of preheated (65oC) Nuclease-free water and quantified by 
ND-8000 (Nanodrop) spectrophotometer. 
2.12.5 2nd-Cycle single-strand cDNA synthesis 
 
On ice, 625 ng/µl cRNA was prepared. This is equivalent to 15 µg cRNA in a volume of 24 
µl. This was combined with 4 µl of 2nd – Cycle Primers, mixed thoroughly and incubated for 
5 min at 70o C, then 5 min at 25o C followed by 2 min at 4 oC (lid temp: 70 oC). After 
annealing the primers, the reactions were mixed briefly and centrifuged.  
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- Cycle ss-cDNA buffer 8 µl 
2
nd
 –Cycle ss-cDNA enzyme 4 µl 
Total Volume 12 µl 
 
On ice 12 µl of the master mix was added to each (28 µl) cRNA/2nd-Cycle Primer reaction to 
get a final volume of 40 µl. After mixing briefly and centrifugation, the reactions were 
incubated for 10 min at 25o C, then 90 min at 42o C , 10 min at 70o C, followed by at least 2 
min at 4o C (lid temp: 70o C).The samples were placed immediately on ice and prepared for 
Hydrolysis. 
2.12.6 Hydrolyze RNA by RNase H 
 
4 µl of RNase H was added to each (40 µl) 2nd-cycle ss-cDNA sample for a final reaction 
volume of 44 µl. The reactions were incubated for 45 min at 37o C, then for 5 min at 95o C 
followed by atleast 2 min at 4o C (lid temp: 70o C) and then placed immediately on ice. 11 µl 
of Nuclease-free water was added to each reaction, mixed briefly and immediately prepared 
for purification. 
2.12.7 Purification of 2nd- Cycle single-strand cDNA 
 
Nuclease-free dH20 was pre-heated to 65o C for at least 10 min. The purification beads were 
mixed thoroughly by vortexing. 100 µl/ reaction of the beads were added to 55 µl of the 2nd-
cycle ss-cDNA sample and transferred to a 96 well plate. The samples were mixed with 150 
µl of 100 % ethanol by pipetting and incubated for 20 min. The plate was placed on a 
magnetic stand to capture the beads. When the capture was complete (≥ 5 min), the beads 
formed pellets against the magnetic stand. The supernatant was carefully aspirated and 
discarded. While on the magnetic stand the beads were washed three times with 200 µl of 80 
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% (v/v) ethanol and incubated for 30 sec. The beads were air-dried on the magnetic stand for 
5 min and the cRNA was eluted in 30 µl of preheated (65o C) Nuclease-free water and 
quantified by ND-8000 (Nanodrop) spectrophotometer. 
2.12.8 Fragmentation & Labelling single-strand cDNA 
 
On ice, 176 ng/ µl of purified ss-cDNA (equal to 5.5 µg in a total volume of 31.2 µl) was 
mixed with 16.8 µl of fragmentation master mix which was prepared as follows: 
Reagent Volume/reaction 
Nuclease-free dH20 10 µl 
10X cDNA fragmentation buffer 4.8 µl 
UDG,10 U/µl 1µl 
APE 1, 1,000 U/µl 1µl 
Total Volume 16.8 µl 
 
The samples were mixed gently and incubated for 1 hr at 37o C, then for 2 min at 93o C 
followed by at least 2 min at 4o C (lid temp: 93o C). The samples were placed immediately on 
ice. 45 µl of the fragmented ss-cDNA was transferred to new eppendorfs or wells for 96 well 
plates and mixed with 15 µl of the labelling master mix.  
Preparation of Labelling master mix 
Reagent Volume/reaction 
5X TdT Buffer 12µl 
DNA labelling reagent, 5mM 1 µl 
TdT, 30 U/µl 2µl 
Total Volume 15µl 
 
After mixing and brief centrifugation, the samples were incubated for 1 hr at 37o C, then for 
10 min at 70o C followed by 2 min at 4o C. Immediately after the incubation, the samples 
were briefly centrifuged and stored at -20o C. 
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2.12.9 WT Array Hybrdization 
 
DMSO was thawed prior to use. 20X Hybridization controls were denatured by heating for 5 
min at 65o C. Hybridization master mix was prepared at RT. 
Preparation of Hybrdidization master mix: 
Reagent 49 format Volume/reaction 
Control Oligo B2 (3 nM) 3.7 µl 
20X Hybridization Controls 
(bioB, bioC, bioD,cre) 
11 µl 
2X Hybridization Mix 110 µl 
DMSO 15.4 µl 
Nuclease-free water 19.9 µl 
Total Volume 160 µl 
 
The master mix was thoroughly homogenised and 160 µl was added to 5.2 µg (in 60 µl) of 
the fragmented and biotin-labelledss-cDNA samples. After mixing and brief centrifugation, 
the samples were incubated for 5 min at 99o C, then for 5 min at 45o C (lid temp:  99o C). 
After incubation, 200 µl of the samples were injected and hybridized to HT 2.0 expression 
arrays using GeneChipR Hybridization Oven 645 (Fig: 2.4). A pipette tip was inserted into 






Figure 2.4: Components of the array chip. The square in the centre indicates the probe 
arrays. 
 
After loading the samples, both septa were covered with tough spot stickers to minimize 
evaporation and to prevent leaks. The arrays were loaded on the hybridization trays and 
incubated with rotation at 60 rpm for 16 hr at 45o C. 
After 16 hours of hybridization the arrays were removed from hybridization oven and the 
hybridization cocktail was aspirated through the septum using a pipette. The array was 
refilled by 250 µl of wash solution A and placed into the GeneChipR Fluidics Station 450. 
Following instructions on the LCD of the fluidics station, the eppendorfs containing 600 μL 
Stain Cocktail 1, 600 μL Stain Cocktail 2 and 800 μL of Array Holding Buffer were placed 
on the holder. The needles were placed into position and the wash and stain was carried out 
for 90 min. 
2.12.10 Expression microarray data analysis 
Gene expression analysis was done under the guidance of Dr. Azim Mohamedali. The HT 
2.0 arrays were scanned using a GeneChipR 3000 Scanner (7G upgrade)to capture images 
(DAT files). The raw data from the DAT file is converted to CEL files (based on 
intensities). ITERPLIER normalization was used to generate the CHP file. Outliers were 
filtered using Principal component analysis, area under the curve and a 1-way ANOVA 
was used to detect differential gene expression between the scrambled shRNA and 
shRNA targeting EZH2 for the knock-down experiments. In case of EZH2 mutations, the 
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gene expression in cells transfected with the mutant was compared with that of cells 
transfected with the empty vector. The data was filtered using a fold-change cut-off of 2 
and an ANNOVA p value ≤0.05 to create a list of significantly up or down regulated 
genes. 
2.13 Protein Blotting 
2.13.1 Cell lysis 
Samples of 2.5x105 - 1x106 MOLM13, K562 or KG1 cells were collected in 1.5 ml eppendorf 
tubes and centrifuged at 300 xg for 5 min and the supernatants were discarded. The tubes 
were centrifuged at 300 xg for a few seconds to remove the traces of media were removed 
with a P200 pipiette. The dry pellets were flicked to disaggregate the cells and resuspended in 
25-40 µl Nupage LDS sample buffer (1X) + 10 % 2-Mercaptoethanol (preheated to 90°C) 
depending on the cell count. Following vigorous mixing, the samples were boiled at 100°C 
for 5 min. Samples could be stored indefinitely at -20°C at this stage. Samples were reheated 
at 100°C for 15-30 min prior to separation by SDS-PAGE to denature the proteins 
completely. Each tube was centrifuged at 13,000 xg for 5 min and the supernatant was 
utilized for SDS-PAGE separation. 
2.13.2 Western blot analysis 
Following protein sepperation by SDS-PAGE, western blotting was carried out on the 
samples. Nu-polyacrylamide gel (4-12 % Bis- Tris Gel) was placed in the electrophoresis 
tank which was filled with 1X running buffer. Protein samples were loaded along with Novex 
sharp pre-stained protein standard (Novex) to determine protein size. Electrophoresis was 
carried out at a constant voltage (200V) until the dye reached the bottom of the gel. Next, the 
NuPageBis-Tris gel was placed under a nitrocellulose-coated nylon membrane (Amersham 
HybondECL) and then sandwiched between blot paper (Biorad) and nylon pads soaked in 
NuPage transfer buffer. Proteins separated in the gel were transferred onto the nitrocellulose 
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membrane by electrophoresis at 20 A, 40V for 120 min. The histones contained in the gel 
were stained with 0.5 % (w/v) colloidal coomassie blue, 10 % (v/v) acetic acid and 10 % 
(v/v) methanol as positive controls for the experiment. The gel was destained (20 % (v/v) 
methanol, 10 % (v/v) acetic acid and 70 % (v/v) distilled water visualised in white light for 
histones. Where indicated Ȗ- tubulin, or actin was used as a loading control. After the 
transfer, the nitrocellulose membrane was blocked with 5 % (w/v) dried skimmed milk 
(Marvel) diluted in PBS- 0.1 % (v/v) Tween 20 and rinsed with PBS- 0.1 % (v/v) Tween20. 
The primary antibodies for the various proteins were used in the dilution indicated previously 
in 1% (w/v) dried skimmed milk, PBS 0.1% (v/v) Tween 20 overnight  at 4 °C. Membranes 
were subsequently washed two times in PBS-0.1% (v/v) Tween20 for 15 min. This was 
followed by incubation for 1 hr with the (1:1000, 1:2000, 1:5000) human anti-rabbit or anti-
mouse or anti-goat secondary antibody in 1% (w/v) dried skimmed milk, PBS 0.1% (v/v) 
Tween 20 at RT. Membranes were washed three times in PBS- 0.1 % (v/v) Tween20. Bound 
antibody was detected using Amersham ECL prime WesternBlot chemilumiscence detection 
solution. Post-incubation for 5 min, the membranes were sealed in Saran wrap and exposed to 
Hyper film ECL for the preferable time and subsequently developed. 
2.14 Cloning 
 
2.14.1 Restriction Digests 
Restriction digest reaction contained 2 µl of 10X restriction enzyme buffer, 0.5 µl of 
restriction enzyme (2000 units), 2 µl BSA (when needed), gel extracted or purified DNA 
(300 ng-1 µg) and dH20 in a total volume of 20 µl. When two restriction enzymes were used 
simultaneously in a digestion reaction, the buffer indicating maximum activity for both 
enzymes was used or else a single digest was carried out initially with the enzyme requiring 
less salt concentration followed by a second digest in the same mixture with the other 
enzyme. 1 mM NaCl solution was added to adjust the salt concentration during the second 
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digestion step. The reactions were incubated at 37 ◦C for 1-2 hr and heat inactivation of 
enzymes was carried out 65 ◦C for 20 min. Digested plasmid DNA was analysed by agarose 
gel electrophoresis. 
2.14.2 Conversion of extended DNA termini to blunt ends 
T4 DNA polymerase was used for the conversion of both γ’- and 5’ extended termini into 
blunt ends. Using a primer and a template, this enzyme catalyses the synthesis of DNA from 
the 5’to γ’ direction. T4 DNA polymerase also has a γ’ to 5’ exonuclease activity that can be 
utilized to remove γ’- overhangs to generate blunt ends. 
Reaction mix: 
Reagents Volume 
2 mM dNTPs 1.5 µl 
NEB 1/2/3/4 1 µl 
T4 DNA polymerase 1 µl 
H20 Upto 30 µl 
 
The mixture was incubated for 15 min at 12
◦C and the reaction was inactivated by heating 
the mixture for 20 min at 70◦C. 
2.14.3 Isolation and purification of DNA from agarose gels 
 
Agarose gels were prepared at 1 % w/v agarose (Melford) to 99 ml 1XTris-acetate/EDTA 
electrophoresis buffer (TAE). 1X TAE was made from a stock solution of 50 X stock solution 
concentration.  The agarose was dissolved by boiling the mixture and then ethidium bromide 
(Sigma) was added to a final concentration of (0.5 µg/ ml) after cooling down. The mixture 
was poured into an electrophoresis tray containing combs to create slots and the edges were 
sealed with tape. The gels were allowed to set at RT for 15 min. The combs were removed 
and the gel was placed in an electrophoresis tank containing 1X TAE. DNA samples were 
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prepared by addition of 1µl of 6X Orange loading dye (Fermentas)/ 6 µl of sample.DNA 
molecular weight marker (O’GeneRuler DNA Ladder Mix, 100-10,000 bp) was used as a 
reference for DNA fragment size. The gels were electrophoresed at 120V and visualized on 
a UV transilluminator. The purified fragments were treated with SuperTaqTMas per the 
manufacturer’s instructions to add dNTP “A” to the fragment. 
2.14.4 Topo cloning 
The gel purified fragment containing the mutation was cloned into the pCRII-TOPO vector 
(Invitrogen). The following reaction mixture was prepared: 
Reagent Volume 
PCR fragment ( 14-24 ng/ µl) 2 µl 
Salt 0.5 µl 
pCRII- TOPO vector 0.5 µl 
 
Table 2.15: Reaction mixture for topo cloning 
 
The above the mixture was incubated for 5 min at RT and then transformed into DH5αTM-
T1RE.Coli. 
2.14.5 Transformation into DH5α-T1 E.Coli 
 
Chemo-competent DH5α-T1E.Colicells (Life Technologies) were used for transformations. 
The cells were thawed on ice for 4-5 min. 1 µl of the ligation mixture was added to cells and 
the cells, covered in ice and incubated for 12-30 min. The cells were heat shocked at 42◦C for 
30 seconds on a water bath and immediately transferred to ice for 2 min. 350 µl of LB media 
at RT was added to the cells and were then incubated for 37◦C for 30 min- 1 hr. 100 µl of the 
LB media containing the cells were spread on ampicillin (100 mg/ ml) containing LB agar 
plates. The rest of the mixture was centrifuged briefly and resuspended in fresh 100 µl LB 




Concentrations of the gel purified components of the plasmid were determined using 
(Thermo Scientific) Nanodrop sphectrophotometer. In the ligation reactions a molar insert: 
vector ratio of (2:1)  and 0.5 µl 400 U of T4 DNA ligase (New England Biolabs), 1X ligase 
buffer (New England Biolabs) and dH20 in a total volume of 10 µl was used. The reactions 
were incubated for 1-5 hr at RT or ON at 4◦ C and then transformed in to DH10B competent 
cells. 
2.14.7 Transformation into DH10B cells 
MegaX DH10B™ T1RElectrocomp™ Cells were used for difficult transformations. 40 µl of 
DH10B cells were thawed on ice for 4-5 min. 0.1-0.3 µl of the ligation mixture was added to 
the cells and the mixture was transferred to 0.1 cm electroporation cuvettes (Invitrogen).All 
seven bacterial transformation programs were tested using DH10B cells and Lonza 
AmaxaNucleofactor II device. Program 4 was chosen to transform DH10B cells because it 
produced the maximum colonies. 1 ml of LB media at room temperature was immediately 
added to the cells after the electroporation procedure. The media containing the cells were 
transferred to 1.5 ml eppendorf tubes and allowed to recover at 37◦C for 1 hr. After an hour, 
100 µl of the LB media containing the cells were spread on ampicillin containing LB agar 
plates. The rest of the mixture was centrifuged briefly and resuspended in fresh 100 µl LB 
media and spread on a second plate. 
2.14.8 Miniprep: Alkaline lysis method 
Plasmid DNA was isolated from 3 ml bacterial culture by using the Pure Yield Plasmid 
(Promega) alkaline lysis method as described below. Bacterial colonies were picked from LB 
agar plates to inoculate 3 ml LB medium (ampicilin). The bacterial cultures were grown ON 
onInnova 4300 incubator shaker at 37◦ C. The grown cultures were pelleted for 10 min at 
2340 xg (Rotanta 460R Hettich centrifuge) and resupended in 600 µl of PBS. 100 µl of cell 
lysis buffer was added and mixed by inverting 6 times. This solution was neutralized using 
106 
 
350 µl of neutralization buffer (4-8◦ C) and mixed by inverting 6 times gently. The mixture 
was centrifuged at 13000 rpm for 3 min and the supernatant was transferred to 
PureYieldTMMinicolumn. The columns were centrifuged at 13000 rpm for 15 seconds.  The 
follow through was discarded and 200 µl of Endotoxin Removal Wash was added to the 
column. The column was centrifuged at 13000 rpm for 15 seconds and the follow through 
was discarded. The column was washed with 400 µl of Column wash solution by centrifuging 
at 13000 rpm for 30 seconds. The plasmid DNA was eluted by incubating the column for 1 
min at room temperature with 30 µl of Elution buffer followed by centrifugation at 13000 
rpm for 15 seconds. The eluted DNA was stored at -20◦ C. 
2.14.9 Miniprep: Wizard Plus SV miniprep 
Plasmid DNA could also be isolated from bacterial cultures using the Wizard Plus SV 
miniprep (Promega) as described below. The bacterial cultures grown ON on the orbital 
shaker were centrifuged at 2340 xg for 5 min. The cell pellet was resuspended in 250 µl of 
resuspension solution. 250 µl of cell lysis buffer & 10 µl of alkaline protease were mixed 
with the resuspended bacterial pellet. The mixture was incubated at RT for 5 min and the 
reaction was neutralized by adding 350 µl of cold neutralization (4-8 ◦C) buffer. The solution 
was centrifuged at 13000 xg for 10 min. The supernatant was transferred to the Miniprep spin 
columns and centrifuged for 1 min at 13000 xg. The follow through was discarded and the 
column was washed two times with 750 µl and 250 µl of column wash solution by 
centrifuging for 1 min and 2 min respectively.  The plasmid DNA was eluted by incubating 
the column for 1 min at room temperature in 100 µl of Rnase free water and centrifuging at 
2340 xg for 1 min. The eluted DNA was stored at -20 ◦C. 
2.14.10 Maxiprep: Qiagen Plasmid kit 
When large amounts of high purity plasmid DNA was required, it was obtained by using 
Qiagen plasmid purification kit. A single colony was selected for inoculation in a 100 ml 
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bacterial culture in LB media (ampicilin). This culture was grown ON as previously 
mentioned. The bacteria were harvested by centrifugation for 10 min at 2340 xg at 4◦ C. The 
pellet was completely resuspended in 12 ml of resuspension/ Rnase A solution. Lysis solution 
12 ml of was immediately mixed to the suspension and mixed gently by inverting. The 
mixture was incubated for 5 min at RT and then neutralized by adding 12 ml cold 
neutralization buffer (4-8◦ C).  A white aggregate consisting of cell debris, proteins etc is 
formed, to which 9 ml of Binding solution was added. This solution is immediately poured 
into the barrel of a syringe and allowed to incubate for 5 min. In the meanwhile, the Genelute 
HP Maxiprep Binding Column was prepared by adding 12 ml of Column preparation solution 
and centrifuged at 3000 xg for 2 min. Cell lysate from the syringe barrel was filtered onto the 
binding column and centrifugation was carried out at 3000 xg for 2 min. The column was 
washed two times with 12 ml of Wash solution A and B by centrifugation at 3000 xg for 2 
and 5 min respectively. The follow through and the collection tubes were discarded after the 
last wash and the column was transferred to new 50 ml collection tube. The plasmid DNA 
was eluted by adding 3 ml of Elution buffer to the column and centrifugation at 3000 xg for 5 
min. The concentration of the purified plasmid DNA was estimated using the Thermo 
Scientific Nanodrop (ND-8000; Nanodrop) spectrophotometer as described previously. 
2.15 Cell culture 
2.15.1 Culturing non-adherent myeloid cells lines 
Three cell lines were used for transfection i.e. K562 (chronic myelogenous leukemia), 
MOLM13 (acute monocytic leukemia) & KG1 (acute myelogenous leukemia). The cells were 
always kept at 2 x 105  viable cells/ml for KG1 and 1 x 106 cells/ml for MOLM13 and K562 
by diluting with fresh RPMI-1640 medium supplemented with 1 % Penicillin/Streptomycin 
(Sigma, Aldrich) and 10 % Fetal calf serum (Sigma, Aldrich). 
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2.15.2 Transfection using Lipofectamine LTX reagent 
MOLM13 and K562 cells were seeded in 12 or 6 well plates at a density of 2 x 105/ 5 x 
105and transfected with plasmid DNA pre-incubated with Lipofectamine LTX (4µl-12µl) and 
Plus reagent (1µl-2.5µl) according to the manufacturer’s instructions. Lipofectamine forms 
lipid complexes when mixed with plasmid DNA. These complexes are taken up efficiently by 
the cells when added to them. The transfected cells are selected by neomycin: G418 [Sigma, 
stock conc: 50 mg/ml] at a concentration range of 200-800 µg/ml or puromycin 2 µg/ml for 
K562 and 0.2 µg/ml for MOLM13 cells. 
2.15.3 RNAiMAX transfection protocol for siRNA experiment 
0.25x106 cells/well were seeded in 24 well plate. 3 µl of RNAiMAX (Life Technologies) 
solution was mixed with 100 µl of OptiMEM serum free medium and siRNA at varying 
concentrations (50-200 nM). The mixture was incubated for 30 min at RT and added drop 
wise to the seeded cells. 
2.15.4 Electroporation 
MOLM13 and K562 cells were seeded at a density of 2 x106 in 6 well plates and transfected 
with siRNA from Dharmacon (final conc.150 nM & 200 nM) resuspended in 100 µl of 
MirusBio Ingenioelectroporation solution using the Nucleofactor device II (program: O-017 
for MOLM13 and T-016 for K562). A non-targeting scrambled siRNA was used as a control.  
2.16 Knockdown of EZH2 
2.16.1 Constructing shRNA in pSUPER vector 
The exon sequence of EZH2 (Ensemble: ENST00000320356) was used to construct shRNAs 




Figure 2.5: Four shRNAs were designed against different positions along the 
gene(Top part of the figure with arrows indicates the target region on EZH2). shRNA3 & 
4 target the SET domain of EZH2. The shRNA sequences are indicated along with the 
plasmid map and multiple cloning sites were they were cloned. 
 
The sequences for BglI (gatcccc) and XhoI (ctcgag) were added to the 5’ and γ’ end of the 
shRNA to promote ligation to the pSUPER vector. The pSUPER vector was gel purified 
using the QIAquick Gel Extraction Kit. The plasmid was digested by BglI and XhoI as given 
below: 
Reagent Volume 
pSUPER (200 ng/ µl) 4 µl 
XhoI 0.5 µl 
BglI 0.5 µl 
NEB3 buffer 2 µl 
BSA 10X 2 µl 
Total Make up to 20 µl with dH20 
 
The digested product was gel and bead purified (as before). Meanwhile the hair-pin shaped 
shRNA sequences were linearized by mixing 5µl each of the forward and reverse primers 
(5µM) and incubating them in water heated to 90 ◦C. The shRNAs were left in the water till it 
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cooled down to 37◦ C. Subsequently, they were ligated to pSUPER using 1µl of 10X ligation 
buffer and 1 µl of T4 ligase. The concentration of pSUPER to the shRNA insert in the 
ligation mixture was calculated using the formula: 
 
Insert concentration= Insert size × vector concentration × 2 
                                                    vector size 
 
1µl of the ligation mixture was transformed into the chemo-competent DH5αTM-T1RE.Coli 
cells. Colonies were picked, and the insertion of thee shRNA was confirmed using M13 
primers by Sanger sequencing and by XhoI-PstI digest on the maxiprep. This maxiprep was 
transfected into MOLM13 and K562 cells using lipofectamine or electroporation. 
2.17 Lentivirus short-hairpin RNA (LVshRNA) virus particle production & 
concentration of the lentivirus vector 
 
Eight shRNAs against EZH2 were obtained of which four GFP labelled GIPZ EZH2 were 
targeting Lentiviral shRNAs (V2LHS_63068, V2LHS_17510 V2LHS_17507, and 
V2LHS_387505) from Fisher scientific and four shRNAs (TL304713) were obtained from 
Insight Biotechnology, UK.Lentiviral vector particles were generated by co-transfection of 
293T cells with four plasmids; pMDG (envelope plasmid encodes VSVG), pRRE (packaging 
plasmid includes Gag & Pol), pREV (packaging plasmid also includes REV) and the shRNA 
against EZH2 using a CaPO4 co-precipitation method.  
293T cells were seeded at a density of 1x107/ 1000 cm 5 layer flasks [T1000 flasks, 
Millipore] using DMEM (10 % FCS, 1 % Pen/Strep) media. The cells were incubated ON at 
37◦ C and 5 % CO2. Four plasmid mixture containing pMDG (45 µg), pRRE (75 µg), pREV 
(37.5 µg) and shRNA (50 µg) were mixed and diluted to a total volume of 3.75 ml with 
dH2O. 3.75 ml of 0.5 M CaCl2 was added to the mixture. Subsequently 7.5 ml of 2X HEBS 
was added drop wise to the mixture while vortexing and incubated for 30 min. 15 ml of the 
total volume was diluted in 150 ml of DMEM (10 % FCS, 1 % Pen/Strep). This was added to 
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the 293T cells and the cells were incubated for 16 hr at 37◦ C and 5 % CO2. The medium was 
replaced with fresh DMEM (10 % FCS, 1 % Pen/Strep) and incubated for further 24 hr. 
Supernatants containing the vector were collected 48 hr post transfection and concentrated at 
10,000 xg over night at 8◦C. The pellets were resuspended in 500 µl of RPMI-1640 medium 
and stored at -80◦ C. 
2.18 Mtt cell proliferation assay 
 
Tetrazolium salt [3-(4, 5-Dimethylthiazol-2-yl) 2,5diphenyltetrazolium- bromide] MTT assay 
is based on determining the metabolic activity of the cells and was used to assess cell 
proliferation rate. MTT (yellow) is reduced by NAD(P)H dependent oxidoreductase enzyme 
in metabolically active cells to generate purple insoluble formazan products. This assay was 
performed by seeding cells in 96 well plates (Flat bottom) at a density of γ0000 cells/ 100μl 
of RPMI.  Each sample was plated in triplicate and three wells were filled with medium alone 
and were used as a blank control. 20 μl of 5 mg/ml MTT was mixed with sample from each 
well and the plate was incubated for 2-4 hr in a humidified incubator 5% CO2 at 37° C. After 
incubation, 150 μl of solubilisation buffer was added to each well (including control wells) 
and the plate was incubated at 5% CO2 at 37° C in the dark for further 2 hr. The absorbance 
of each well was measured at 610 nm using a microtiter plate reader. Data was analysed by 
calculating the average value from the triplicate readings, normalizing the mean from each 
sample to the blank (sample - blank) and calculating the fold change compared to the sample 
containing the wild type cells. Cells were seeded for different time points and readings were 




2.19 Cell Cycle analysis 
2.19.1 Cell cycle staining 
 
1 ×10 6 cells were centrifuged at 300 xg for 5 min and washed once with PBS. The 
supernatant was discarded and the cells were resuspended in 1 ml of 70 % (v/v) ice-cold 
ethanol by vortexing. The cells were stored at -20◦ C. For cell cycle analysis, the cells were 
pelleted by centrifugation at 300 xg for 10 min and the ethanol was carefully aspirated out. 
The pellet was dried for 10 min by inverting the eppendorf tubes. The cells were resuspended 
in 400 µl of the staining solution and incubated for 30 min at 37◦ C followed by analysis 
using flow cytometry. 
Staining solution: 
Reagent Volume 
Propidium Iodide ( dye binds DNA) 400 µl 
FITC ( binds lysine residues of protein) 50 µl 
RNAase A 100 µl 
PBS Upto 10 ml 
 
2.19.2 Cell cycle analysis by flow cytometry 
 
The relative DNA and protein content of the cells were analysed on BD FACS CantoII flow 
cytometer using FlowJo. Double cell were discarded from the analysis using doublet 
discrimination gating strategy and PI (area) histogram was generated. The cell fractions were 
categorized according to cell size and DNA content. Cells in G0 have 2n DNA content, while 
those in G1 are larger than G0 but still have 2n DNA. The cells in S phase have a DNA 
content in the range of 2-4n while those in G2/M have 4n DNA. This difference in DNA 
content helped to segregate the cells into the different phases of the cell cycle and ascertain 
whether the KO of EZH2 had an impact on a particular phase of the cell cycle. 
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2.20 Annexin V staining 
 
Annexins are a family of calcium-dependent phospholipid-binding proteins that preferentially 
bind phosphatidylserine (PS). PS is predominantly located on the inner surface of the plasma 
membrane under normal conditions. Upon initiation of apoptosis, it is translocated to the 
extracellular membrane of the cells marked for phagocytosis. Annexin V staining facilitates 
distinction of cells in early apoptosis versus those in the late stages of apoptosis. Cells in 
early apoptotic phases have an intact cell membrane and therefore exclude dyes like 
propidium iodide (PI) making it impossible to segregate cells between early and late 
apoptotic phases using these methods (Koopman et al., 1994). Annexin V staining was 
carried out on cell pellets (2-5 x105) washed with ice cold PBS and centrifuged at 300 xg for 
5 min. Next, they were washed with 1X Binding buffer, and pelleted at 300 xg. The pellet 
was resuspended in 250 μl of 1X Binding buffer and stained with 3-5 μl of Annexin V, based 
on the cell number, and incubated in the dark at room temperature for 10 min. The stained 
cells were washed twice with the binding buffer, centrifuged at 300 xg for 10 min and 
resuspended in 250-500 μl binding buffer. Before analysing the cells on the flow cytometer, 
the cell suspension was stained with 3 μl of fluorescently labelled 7-AAD. 7-AAD can 
penetrate the membrane of dying cells and stain them to discriminate between dead and live 
cells and in apoptotic assay it is used to distinguish necrotic cells from apoptotic cells. FACS 




3 Chapter: SNP6 and Mutational 
Analysis of PRC1, PRC2, DNMT3A 




3.2 Involvement of PRC subunits, DNMT3A and the Jumonji genes in 
MDS/AML 
 
Aberrations of EZH2 were first identified by Ernst et al (2010) using SNP 6.0 arrays on 
peripheral blood /bone marrow samples from patients with MDS to discover acquired 
uniparental disomy of 7q and 7q36.1 microdeletion. Mutational analysis of this region 
revealed monoallelic or biallelic EZH2 mutations (detailed in section 1.7). The correlation of 
EZH2 and MDS suggested the involvement of other components of PRC2; SUZ12, EED and 
EZH1 in this disease. Apart from the PRC2 subunits, PRC1 complex is also involved in 
transcriptional regulation of target genes via ubiquitination of H2AK119 (detailed in section 
1.5.2 and 1.8), infact PRC1 is recruited via H3K27me3 marks caused by PRC2. Some of 
PRC1 genes like BMI-1, CBX8 are associated with MDS and MLL induced leukaemogenesis 
(detailed in section 1.7) but mutational analysis of the PRC1 genes (twelve) has not been 
carried out till date. 




PRC2 interaction with DNMT3A was illustrated by Vire et al (2006) wherein the H3K27me3 
mark caused by PRC2 function as sign-posts for the recruitment of DNMT3A. The SET 
domain of EZH2 bind to DNMT3A, affecting DNA methylation. DNMT3A in turn is 
responsible for further “deep silencing” of the target regions (Vire et al., 2006). The first 
association between DNMT3A and myeloid malignancies was established by Yashimata et al 
(2010) using DNA sequence arrays on leukemic genome and identified heterozygous 
mutations of DNMT3A (Yamashita et al., 2010).These findings were confirmed by Ley et al 
(2010) when they used parallel sequencing to identify somatic mutations of DNMT3A, in 
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AML patients with a normal karyotype. 22% of the patients carried DNMT3A mutations and 
the most frequent mutations were observed in exon 23 at position R882 (59 %) leading to 
R882H/ R88C or P904L amino acid substitutions. Other less common mutations included 
exon 19 causing L737R, R771L, S770W substitutions and rarely, exon 16, 10, 6 and 7 were 
also involved. Their study concluded that the DNMT3A mutations were enriched in patients 
with intermediate-risk cytogenetic profile and were associated with an adverse effect on the 
overall survival of the patients (12.3 months vs. 41.1 months, p <0.001) (Ley et al., 2010). 
The stability of DNMT3A mutations during disease evolution was demonstrated by Ewalt et 
al (2011) by mutational analysis on the bone marrow samples from 62 high-risk MDS 
patients (Ewalt et al., 2011). The incidence of mutations in the high-risk MDS patients was 
low (3.3 %) as compared to their occurrence in AML but the mutation at the R882 site was 
consistent even in this cohort, strongly implicating this mutation in disease pathogenesis.  
Mutational analysis (till 2010) had not focused on DNMT3A mutations in relation to EZH2 
status in patients or examined the mutational overlap between the two genes which could 
provide an important link between transcriptional silencing by DNA and histone methylation.  
3.3.2 Jumonji 
 
The Jumonji (jmj) family of histone demethylases are α-ketoglutarate-dependent oxygenases 
that demethylate lysine residues in histones in a site and methylation state specific context. 
Interaction of the Jumonji protein (JARID2) with PRC2 core components was explained in 
section 1.3.1 where it co localizes and assists the binding of PRC2 to H3K27me3 but 
simultaneously also inhibits its methyltransferase activity in embryonic stem cells (ES) (Peng 
et al., 2009; Shen et al., 2009).UTX is another important member of this group as it has an 
opposing function to EZH2 and causes demethylation of both di and tri-methylated H3K27 
but does not act as efficiently on the mono-methylation of H3K27 (Smith et al., 2008). Lack 
117 
 
of UTX causes enhanced levels of H3K27me3, reduced mRNA levels of the target genes 
(Tsai et al., 2010) and has been implicated in tumorogenesis (van Haaften et al., 
2009).Mutational analysis of UTX was carried out by Jankowska et al (2011) on 72 patients 
with CMML and MDS/MPN. 8 % of the cases were mutated at the UTX locus. These 
heterozygous and homozygous mutations might have an impact on the demethylation of the 
histones mentioned above and in turn govern the expression of target genes  (Jankowska et 
al., 2011). 
Other members of the Jumonji family have not been studied in detail in the context of 
MDS/AML and therefore in this study I have focused on seventeen Jumonji genes; JARID1A-
1D, JARID2, JMJD3, UTX, JMJD4, JMJD2A-2D, JMJD1A-1C, JHJDM1A-1B.Majority of 
these genes are involved in the demethylation of H3K4, H3K9, H3K27 or H3K36 histone 
tails while others associate with the PRC proteins. Understanding their role in eukaryotic 
transcription, genome integrity and epigenetic inheritance would assist in comprehending the 
interplay of Jumonji and PRC2 proteins which fine tunes the formation and maintenance of 
the H3K27me3 marks (Kruidenier et al., 2012). 
3.4 SNP6 Analysis 
 
As described earlier, the involvement of EZH2 in myeloid malignancies was discovered due 
to mutational analysis of a region with acquired CN (LOH) of chromosome 7q and 7q36.1 
microdeletion. Following a similar approach, I have examined SNP6 array karyotyping data 
available for 91MDS/MPD/AML patients from previous studies to identify deletions, 






 To identify aberrations in PRC1 and Jumonji genes using high density SNP data for 
91 patients with MDS/MPD/AML. To determine the prevalence and clonal size of 
mutations affecting patients with SNP6 abnormality using 454 sequencing and to 
correlate them to the SNP data. This would enable high throughput analysis and 
importantly, help identify the frequency and prognostic significance of somatic low 
level mutations in PRC1 and Jumonji genes. 
 To evaluate gene expression changes in Jumonji and PRC1 genes in patients with 
aberrations in copy number (deletion, amplification) by SNP6 analysis. 
 To determine the prevalence and clonal size of mutations affecting the core 
components of PRC2 (EED, SUZ12, EZH1) and DNMT3A in 61 patients (out of the 
91 patients) sequenced previously for EZH2 mutations using 454 sequencing to 
identify the frequency of mutations affecting these genes and to examine the overlap 
of mutations between the different components of PRC2, DNMT3A and EZH2. 
3.6 Patient samples 
 
91 cases of MDS/MPD/AML were examined in this study for SNP6 abnormalities and 












  Sex 
 Male [n (%)] 33 (55%) 
  WHO category 
 RA    [n (%)] 1 (1.6 %) 
RARS    [n (%)] 3 (5 %) 
RCMD   [n (%)] 19 (31.6 %) 
RAEBI/II   [n(%)] 25 (42 %) 
tMDS/AML   [n(%)] 2 (3.3 %) 
CMML & MPD/MDS-U   [n (%)] 6 (10 %) 
MDS with isloated 5q   [n (%)] 1 (1.6 %) 
  Polycythaemia Rubra Vera 1 (1.6 %) 
Unknown 2 (3.3 %) 
  Bone marrow blasts 
 Median (%) 7.5 
Range 0 -75 
  IPSS cytogenetic risk group n= 51 
Low risk (0) 8 
INT-1 (0.5-1) 13 
INT-2 (1.5-2) 19 
High risk (> 2.5) 11 
  Progression to AML 
 Yes [n (%)] 18 (30%) 
 
Table 3.1: Clinical characteristics of the patients studied (n=60). Patients were stratified 
by age, sex, WHO classification at the time of diagnosis, IPSS score, percentage of blasts and 
progression to AML. “n” represents number of patients; % - represents percentage of 
patients. 
3.6.1 Amplification of patient samples 
 
DNA from these patients was amplified (refer section 2.5.3) for sequencing. A small amount 
of non-amplified sample was stored for confirmation experiments. All samples corresponded 
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to Lane 2 confirming good quality of the DNA and were therefore utilised for all sequencing 
experiments. 
 
Figure 3.1: Human DNA OK results.Lane 1 – 100 bp DNA ladder, Lane 2 – Good 
quality intact DNA (6 bands), Lane 3 – partially degraded DNA (5 bands), Lane 4 – 
fully degraded DNA (only positive PCR control band is visible).(Reference: 
http://www.microzone.co.uk/products/quality-testing/human-dnaok/) 
 
3.7 SNP6 and Chas analysis 
 
SNP6 analysis was carried out on the 91 patients using SNP-A technology by Affymetrix 
(Santa Clara, CA) wherein; genomic DNA from patient samples was digested by restriction 
endonucleases, amplified, and labelled. The labelled patient DNA was hybridised to SNP 
arrays probes homologous to areas located throughout human genome. The resultant 
genotyping pattern helped in determination of either heterozygosity or homozygosity for each 
allele. At the same time, intensity of the hybridization signals allowed for determination of 
copy number changes at that genomic region [reviewed by (Maciejewski and Mufti, 2008)]. 
The SNP6 data used here was generated by Dr. Azim Mohamedali and formed part of 
previous studies conducted by our group. I visualised this data using CHromosome Analysis 
Suite (Chas) from Affymetrix for aberrations of seventeen Jumonji and twelve PRC1 genes. 
Examples of Chas aberrations are indicated in Fig: 3.2 c & f which show a gain in copy 
number from 2 to 3 suggesting segmental amplification of an allele at that locus. Fig: 3.2 b & 
e indicate a decrease in copy number from 2 to 1 and loss of heterozygosity as seen in Chas 
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while Fig: 3.2a & d indicate CN(LOH) where in there is loss of heterozygosity but the copy 




Figure 3.2: Visualisation of SNP6 data for the Jumonji and PRC1 genes by 
Chromosome Analysis Software (ChAS).Chromosome ideograms indicating the 
chromosomal location are indicated at the bottom of all the figures (grey) while the CNV 
probe log ratio scatter plot is seen in the middles as smooth signal panel. Dotted line indicates 
the location of the gene of interest (a) & (d) Illustrate CN (LOH) at JARID1A and PHC2 
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locus respectively indicating loss of heterozygosity but no variation in the copy number. (b) 
& (e) Illustrates deletion of JMJD2D and PHC1 locus is seen as change in copy number from 




17/91 (19 %)  patients were detected with SNP6 aberrations.5/12 genes exhibited either [gain/ 
del/ CN (LOH)] on SNP6 analysis (Figure: 3.2 d,e,f). Eleven patients showed CN (LOH) 
[size: ≤ 1.5 Mb] at the BMI-1 locus (chr: 10p12.31).These patients were selected because of 
the high frequency of CN (LOH) at this locus and also due the association of BMI-1 to MDS 
(refer section 1.8). Among the RING proteins, RING1A locus (chr: 6p21.32) was deleted in 
two patients while the RING1B locus (chr: 1q25.3) showed a CN gain in two patients and a 
CN (LOH) in one patient. In the polyhomeotic proteins, the PHC1 (chr: 12p13.31) locus was 
deleted in one patient while the PHC2 (chr:1p35.1) locus showed a CN gain in one patient 








Cytogenetics Gene SNP6 aberration 




PHC2 CN=3 (12.6) 
LSL1393 RARS 
45,XY,t(1;6;8)(p32;p21;q12
),-5,-7, +r [9]/46,XY [3] 
PHC2 CN(LOH) (108) 
RING1A del (0.2) 
LSL1590 RAEBI 
Complex including 
monosomy7, RING1A del (0.14) 
LSL1808 RCMD 46 XY, +1, der (1:7) BMI-1 CN(LOH) (1) 
LSL1848 tMDS/AML NA BMI-1 CN(LOH) (1) 
LSL2337 MDS/MPD Normal RING1B CN(LOH) (95) 
LSL2383 RCMD NA BMI-1 CN(LOH) (1) 
LSL2470 RAEBI/II 
47,XX,+1,add(1)(p11) 
add(7)(q11) [30] RING1B trisomy 1q (100) 
LSL2906 RAEBI/II NA RING1B trisomy 1q (100) 
LSL3066 RCMD Complex including (2;11) BMI-1 CN(LOH) (1) 





BMI-1 CN(LOH) (1) 
PHC1 del (7) 
LSL3241 RAEBI/II NA BMI-1 CN(LOH) (1) 
LSL3287 RCMD NA BMI-1 CN(LOH) (1) 
LSL3455 CMML NA BMI-1 CN(LOH) (1) 
LSL3532 RAEBI/II NA BMI-1 CN(LOH) (1.5) 
Table 3.2: SNP6 aberrations [deletion, amplification and CN (LOH)] in PRC1 genes. 
Numbers in brackets indicate size of the aberration in Mb (NA= data not available). The size 
of CN (LOH) was small at the BMI-1 locus but these patients were still included for sanger 
sequencing due to high frequency of occurrence of CN (LOH).  
3.7.2 Sanger sequencing 
 
17 patients (mentioned above) were selected and mutational analysis of the respective PRC1 
genes was carried out using sanger sequencing (refer section 2.7) on amplified patient 
samples (refer section 3.2.2). Primers for all exons of the PRC1 genes were designed (refer 
section 2.6) using Primer 3 software (http://primer3.ut.ee/)  and the PCR reactions were  
optimised using 10 ng of the patient samples and 5 µM of the primer (refer appendix for 
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primer sequence) concentration (Table 2.3). Data obtained from sanger sequencing was 
analyzed using Sequencing Analysis software by Applied Biosystems (Foster City, CA). 
Sequencing did not identify any mutations affecting the PRC1 genes concomitant with SNP6 
abnormalities indicating that the PRC1 genes are not frequently mutated in MDS/AML cases. 
Gene expression by qPCR could not be carried out on patients with copy number variations 
(CNVs) due to insufficient patient samples. 
3.7.3 Jumonji genes 
 
In our cohort, 15/17 Jumonji genes exhibited either one or more of the aberrations on SNP6 
analysis. 29/91 (31 %) patients showed del, gain or CN (LOH) at one or more Jumonji gene 
loci. The summation of loss or gain of CN was 22 out of which 16 were loss/deletions. The 
highest frequency of deletions (n=12) found in JMJD1B (chr 5q31.2) (Giagounidis et al., 
2006) while JARID2 (chr: 6p22.3) was deleted in three patients, JMJD3 (chr: 17p13.1 ), 
JMJD2D (chr: 11q21) & JARID1A (chr: 2p11.2) were deleted in two patients each. On the 
other hand, the highest frequency of gain (n= 3) was observed in JMJD2C, followed by 
JMJD2A (chr: 1 p34.1) and UTX (chr: X p11.2) (n= 2 each). Majority of the genes were 
either deleted or amplified but only three genes JARID2, JMJD4 (chr: 1q42.13) and JMJD2D 
showed both deletion and amplification in different patients in our cohort. One patient had 
del of both JMJD4 and JARID2. In addition to gains and deletions, the total number of CN 
(LOH) at different Jumonji gene loci was 12. JMJD2D (n=2) and JMJD4 (n= 3) had the 
highest frequency of CN (LOH) followed by JMJD3 (n= 3). The size of CN (LOH) was >20 
Mb in majority of the patients (except two patients; 7 & 8 Mb). The distribution of SNP6 





Figure 3.3: Total number of patients with SNP6 abnormalities. Deletions were observed 
in sixteen patients while amplifications & CN (LOH) were seen in seven and eleven patients 
respectively. Four patients had both deletions and CN (LOH) at different gene loci while only 
one patient carried both a gain and deletion. None of the patients had an overlap between gain 






MDS subtype Cytogenetic Gene SNP6 aberration 
LSL654 sAML del (7)(q22q36), -17 
JMJD3 del (10) 




JMJD2A CN=4 (12) 
LSL1393 RARS 
Complex including 
monosomy 7 and t(1;6;8) 
JARID2 del (11.5) 
JMJD1B del (37) 
JMJD2A CN (LOH)(108) 




JARID2 del (16.5) 
JMJD1B del (68) 
LSL1825 RCMD del 11q(q21q25), +6, +21 JARID2 trisomy 6 




JMJD1B del (3) 
LSL2337 MDS/MPD Normal JMJD4 CN (LOH) (105) 
LSL2214 RAEB II Not available 
JMJD2D del (43) 




JARID1B trisomy 1q (120) 
JMJD4 trisomy 1q (120) 
JMJD2C trisomy 9p (35) 
LSL2823 RAEBII 45 X isodiXq13(29) 
UTX trisomy Xp (60) 
JARID1C trisomy Xp (60) 
LSL3104 RAEB II Normal JMJD4 CN (LOH) (95) 
LSL3202 tMDS/tAML Not available 
JARID1A del (1) 
JMJD1B del (90) 
LSL4958 RAEBI/II Not available 
JMJD2D CN (LOH) (67) 






MDS subtype Cytogenetic Gene SNP6 aberration 




Not available JARID1D CN=1.5 (24) 
LSL3513 tMDS/tAML Not available 
JMJD1B del (50) 
JMJD4 CN(LOH) (50) 
LSL3532 RAEBI Not available 
JARID1A del (0.36) 




JMJD3 CN (LOH) (20) 
JMJD1B del (81) 
LSL3749 RAEBI/II Not available 
JMJD2A CN=3 (50) 




JMJD1B del (30) 




LSL3825 RAEBII Not available JMJD3 CN (LOH) (8) 




JMJD2D del (12) 
LSL4667 tMDS/tAML Not available JMJD1B del (76) 
LSL4737 RAEBI/II Not available 
JMJD4 del (15) 
JARID2 del (11.4) 
LSL4855 RAEBI/II Not available JMJD2C CN=4 (35) 
LSL4958 CMML Not available JMJD2D CN (LOH) (70) 
LSL6395 RAEBI/II Not available JMJD1B del (0.465) 
 
Table 3.3: Gain/ del/ copy neutral loss of heterozygosity the Jumonji genes. Numbers in 




CNVs were mutually exclusive; For e.g. Only one patient harbored a deletion of JARID2, 
JMJD1B and a gain at the JMJD2A locus. While the overlap between CN (LOH) and  
deletion was seen in four patients. However, none of the patients had an overlap between CN 
(LOH) & amplification of gene. The reason for the mutual exclusivity of the aberrations is 
still unclear and whether one type of aberration is favored over the other during disease 
progression needs further scrutiny.  
 
Stretches of homozygozity at times harbour mutations and have been formerly associated 
with MDS (Mohamedali et al., 2007). Therefore mutational analysis using 454 DNA 
sequencing (refer section 2.8 - 2.8.17) was performed on 29 patients (mentioned above) 
showing telomeric stretches of [CN (LOH)] (majority; size: > 20Mb), deletions and/or copy 
number (CN) gain at the fifteen Jumonji genes locus.  
3.7.3.1 Primer testing and PCR optimisation 
 
All the PCR reactions were carried out initially on genomic DNA from Affymetrix, UK 
(stock concentration: 50 ng/ µl) and later tested on patient samples due to availability of 
limited amount of patient samples. The primers to sequence the Jumonji genes were designed 
(refer appendix for sequence) as mentioned before using primer3 software and the PCR 
conditions were optimised using 10 ng of the patient samples and 5 µM of the primer 
concentrations (Table: 2.3).  Figure 3.4a shows PCR products visualized on 2 % agarose gel 
after the 1st round of PCR. All exons displayed a single good intensity band which 
corresponded with the anticipated product size on all patient samples. Subsequently, a second 
PCR reaction was carried out using 1or 1.γ µl of the ampliﬁed product with primers (1 µl) 
targeted to the aUS primers. These primers contained a 5' tag that identiﬁed forward and 
reverse strands for sequencing and also included a 5-base pair Multiplex Identifier (MIDs) 
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sequence to identify individual patients from the first round of PCR. Eight random wells/plate 
were selected from the 2nd round of PCR and visualised on agarose gel (Fig. 3.4b).  
 
Figure 3.4: Visualisation of PCR product for JMJD4 and JMJD1B on 2 % agarose for 
454 sequencing. (a) Visualisation of eleven primer pairs for JMJD4 in a patient sample after 
1st round of PCR (b) Visualisation of PCR product for JMJD1B exon 2 for twelve patients on 
2 % agarose gel after 2 nd round of PCR. All the products were in the range of 350-400 bp. 
3.7.3.2 454 parallel sequencing (Jumonji genes) 
 
All exons were quantified using picogreen dye and were in the range of 10 to 40 ng/ µl. The 
exons were equalized in concentration and pooled. A second picogreen measurement was 
done on the pooled samples to equalise the concentration of all the patient samples/gene. All 
the patients were in the range of 20-40 ng/ µl, their concentrations were equalised by 
combining the appropriate amounts of DNA to create a library of all exons and all 
patients.This library was gel and bead purified using QIAquick Gel Extraction Kit and 
AgencourtAMPure XP magnetic beads (refer section 2.8.2-2.8.3) from Beckman Coulter 
(USA) and used for 454 parallel sequencing (refer section 2.8- 2.8.17). The results were 
analyzed using Ingenuity Variant Analysis software 
(http://www.ingenuity.com/products/variant-analysis). The 454 sequencer generates data in 
FASTA format files which also contain the quality score file which scores for each base in 
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each sequence assigned to a particular region of the picotitre plate. Next the data is 
segregated according to different patient samples based on the nucleotide barcode tags 
attached to each sequence. Filtering out any low quality or ambiguous reads also takes place 
at this stage followed by alignment of the high-throughput reads to the input reference 
sequence provided by the user. The aligned reads are visualised using Vnode software to 
detect any variations in the sequence compared to the reference sequence provided by the 
user. Analysis of the sequencing data revealed that the Jumonji genes did not harbour any 
mutations concomitant with the SNP6 abnormalities even with a read depth of 350-450 reads/ 
amplicon.The absence of mutations in these genes suggests that other mechanisms and 
alterations in gene expression might contribute to the disease pathogenesis. 
3.7.3.3 Gene expression analysis by qPCR 
 
To elucidate changes in gene expression as a result of amplification/gain or deletion of 
genomic material, Real-time PCR (qPCR) [refer section 2.9 - 2.11] was performed on 22/29 
patients for twelve Jumonji genes. Six patients were excluded because they had only CN 
(LOH) but no CNVs. Patients without SNP6 abnormalities at the gene loci were used as 






















Figure 3.5: Gene expression analysis of Jumonji genes by qPCR. There was no change in 
the gene expression of ten Jumonji genes concomitant with CNVs. While complete loss of 
JARID1A (p value <0.0001) expression was observed in two patients with deletion of a 
region on chr 12p.One patient with trisomy Chr Xp showed concomitant increase in 
expression of UTX and JARID1C. Trisomy at the JARID2 locus was associated with 
increased expression of the gene. Patients without SNP6 aberrations at the Jumonji gene 
locus were used as controls and mRNA from K562 cell line was used as a technical control in 
all the experiments. Error bars calculated using SEM. 
 
UTX showed over expression (p value < 0.0001) concomitant with CNVs. Two patients had 
UTX aberrations on SNP6 analysis; trisomy in one patient and copy number of 4 in the other 
which compare with up regulation of the UTX expression seen on qPCR.  
In addition to UTX, other genes with deregulated expression were JARID1A, JARID1C and 
JARID2. JARID1A expression was reduced (p value < 0.0001) in two patients with deletion 
of the JARID1A locus as compared to the control samples (n=20) while JARID1C and 
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JARID2 was over expressed in one patient with trisomy. This confirms that CNVs detected 










3.8 PRC2 and DNMT3A 
 
EZH2 was previously sequenced by our group on 61 out of 91 patients (mentioned earlier)  
and therefore the same cohort of patients were selected for mutational analysis of the other 
core components of PRC2; SUZ12, EED, EZH1and DNMT3A to identify mutations in these 
genes and to examine the mutational overlap of these genes with EZH2.  
3.8.1 Primer testing and PCR optimisation (PRC2) 
 
As mentioned above, the PCR reactions were carried out initially on genomic DNA from 
Affymetrix, UK (stock concentration: 50 ng/ µl) and later tested on patient samples due to 
availability of limited amount of the samples. The PCR reaction was optimised at primer and 
template concentrations of 10 µM and 10 ng/µl, respectively. The PCR amplified product 
was visualized on 2 % agarose gel and the band size of the products were matched with the 
expected product size from the primer design software (Primer3, reference: 
http://primer3.ut.ee/). Primers for all the exons of SUZ12 worked except for exon 1 (a & b) 
(Fig: 3.6c blue arrows). These two primers were redesigned and optimised at a primer and 
template concentration of 10 µM & 10 ng/µl, respectively (refer appendix for primer 
sequences). Similarly, all primers for the EZH1 gene were also optimised at 10 µM primer & 
10 ng/µl of template concentrations except for exon 4 which showed primer-dimer formation 
at these concentrations (Fig: 3.6a) and therefore PCR for this exon was carried out using 8 
ng/µl template and 5 µM primer. EED primers were tested and optimised at 5µM primer 
concentration and 10 ng/µl of genomic DNA (Fig: 3.6b). All primers worked except exon 1 
which was redesigned and optimised at 5 µM primer concentration. Subsequently all primers 




Figure 3.6: Primer optimisation for EZH1, EED & SUZ12 using different primer and 
template DNA concentrations. The PCR products were visualized on 2 % TAE agarose 
geland blue arrows/black boxes indicate failed PCR reactions. Exon 1 of EED and SUZ12 
were redesigned while all the other exons worked with a template concentration between 8-
10 ng/µl and primer concentrations of 5-10 µM. A negative control containing water instead 
of the DNA template was used to rule out contamination (a). 
 
3.8.2 454 parallel sequencing (PRC2) 
 
1st round of PCR was carried out on 61 amplified patient samples using the optimised primer 
concentrations for the three genes (Fig. 3.6 a,b,c) and 4 random wells/sample were verified 
on 2% TAE agarose gel. All exons displayed a single good intensity band which 
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corresponded with the anticipated product size. 0.8 to 1.3µl of product from the 1st round of 
PCR was utilised for the 2nd PCR depending on the intensity of the product on gel. 
Eight random wells/plate were selected from the 2nd round of PCR for all the genes; EZH1, 
SUZ12 and EED (gel shown below) visualised on 2 % agarose gel (Fig. 3.7).  PCR for exon 1 
and exon 3 (one well each) did not work. The 2nd round of PCR was repeated successfully for 




Figure 3.7: Visualisation of the PCR product for EED after second round of PCR.8 
samples /exon were visualised on 2 % TAE agarose gel for the EED gene. Two patients 
(exon 1 and exon 3) showed no product and therefore the PCR reactions were repeated for 
these patients keeping the PCR conditions constant. The PCR worked well for these two 
patients when the experiment was repeated. 
 
After the second round of PCR, all the exons for each gene were quantified using picogreen 
dye on the Rotor-Gene 6000 Multiplexing System. EZH1, EED and SUZ12 exons were in the 
range of 8 to 61 ng/ µl, 11 to 51 ng/ µl and 22 to 51 ng/ µl respectively.  This measurement 
was used to equalize the concentration of all exons/gene. A second picogreen measurement 
was performed to equalize concentration of all the patient samples/gene. All samples of 
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EZH1, EED and SUZ12 were in the range of 23-98 ng/ µl, 19-66 ng/ µl and 22-76 ng/ µl 
concentrations respectively. These samples were equalized and pooled to form a single 
mixture of all the samples for each gene (3 libraries). 
These (three) libraries were visualised on a 2 % agarose gel for 45 min at 120V to obtain a 
single demarcated band as illustrated in Fig. 3.9 This band was purified two times using 
QIAquick Gel Extraction Kit and AgencourtAMPure XP magnetic beads (refer section 2.8.2-






Figure 3.8: SUZ12, EED, EZH1 library purification. (a) Libraries for SUZ12, EED, 
EZH1were visualized on 2 % agarose gel for purification. All the products were in the range 
of 350-400 bp in size. (b) Libraries visualized on gel after bead purification. 
 
These libraries were sequenced on Roche 454 sequencer (refer section 2.8.5 to 2.8.17) and 
the data was analyzed. Data analysis revealed that PRC2 genes namely; SUZ12, EZH1 and 
EED were not mutated in the 61 MDS/AML patients. Lack of mutations in these genes 
indicated that EZH2 is exclusively targeted for mutations in MDS as compared to the other 




3.8.3 Primer testing and PCR optimisation (DNMT3A) 
 
Similar to the genes of PRC2, PCR reactions were also set up for sequencing DNMT3A using 
5 µM of the primer concentration and 10 ng of genomic and patient DNA, abundant primer-




Figure 3.9: Optimisation of DNMT3A primers. 5 µM, 2.5 µM and 1.25 µM concentrations 
of primers were tested.  Primer-dimer was observed (red box) with 5 µM concentration of the 
primer while 1.25 µM conc was inadequate for some exons. All the experiments were 
therefore carried out with 2.5 µM primer concentration. 
 
Therefore, the reactions were repeated with 2.5 µM and 1.25 µM of primer concentrations. 
The bands were faint when the primer concentration was reduced to 1.25 µM. Hence 2.5 µM 
primer concentration was used for all subsequent experiments.  
1st round of PCR was conducted on 61 amplified samples using the optimised primer 
concentrations and 4 random wells/sample were verified on 2% TAE agarose gel. All exons 
displayed a single good intensity band which corresponded with the anticipated product size. 
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Next, four random wells/plate were selected from the 2nd round of PCR and visualized on 
agarose gel (Fig. 3.10a).  
 
Figure 3.10: DNMT3A library preparation. (a) Visualisation of 4 samples for each exon of 
DNMT3A after 2nd round of PCR. Exon 8 showed two bands suggesting contamination but 
the negative control containing water instead of template DNA showed no product. Error 
during sample loading on the gel could be the reason for the double bands. (b) Visualisation 
of the DNMT3A library on 2 % agarose gel for purification. All the products were in the 
range of 350-400 bp (c) Library visualised on gel after bead purification. 
 
Exon 8 showed two bands for all the four patients suggesting contamination but the negative 
control containing water instead of template DNA indicated no product. Error during sample 
loading on the gel was thought to be the probable cause and therefore the gel was repeated 
with new samples and contamination was ruled out. 
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3.8.4 454 parallel sequencing (DNMT3A) 
 
All exons were quantified using picogreen dye and were in the range of 12 to 43 ng/ µl. The 
exons were equalized in concentration and pooled. A second picogreen measurement was 
done on the pooled samples to equalise the concentration of all the patient samples/gene. All 
the patients were in the range of 16-40 ng/ µl and their concentrations were equalised by 
combining appropriate amounts of DNA to create a library of all exons and all patients. This 
library was visualised on 2 % agarose gel after 45 min at 120V to obtain a single demarcated 
band as illustrated in Fig. 3.10. This band was purified two times using QIAquick Gel 
Extraction Kit and AgencourtAMPure XP magnetic beads  from Beckman Coulter (USA) 
(Fig. 3.10 b & c) and the yield was verified on a 2% agarose gel and used for 454 parallel 
sequencing (refer section 2.8.5- 2.8.17). The results were analysed using Ingenuity Variant 
Analysis software (http://www.ingenuity.com/products/variant-analysis) as described 
previously and the aligned reads are visualised using Vnode to detect any variations in the 
sequence compared to the reference sequence provided by the user. Analysis of the 
sequencing data identified heterozygous mutations of DNMT3A in 10/61 (16 %) patients 
(clone size 20-44%) which are summarised in Table: 3.4 and all the mutations were 
confirmed by Sanger on unamplified DNA from patient samples. Sequencing depth for the 
amplicons was in the range of 400-600 reads. There was no significant difference in the 
median survival of monosomy 7 patients with or without DNMT3A mutations (p value = 0.6). 
Interestingly, patients with normal karyotype did not have any DNMT3A mutations, whereas, 
the frequency of these mutations was high in patients with monosomy 7 (n=6) with a WHO 
classification of RAEB or RAEBII implicating that DNMT3A mutations are more common in 
advanced stage of the disease. The R882 site (Fig: 3.11) was mutated in 2/10 patients and 
matched the findings of other research groups which have reported high frequency of this 
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mutation in their cohort. The mapping of the mutations to different domains of DNMT3A and 












LSL1898 RAEB Complex  42% E30A Y 0 
LSL1597 RAEB mon7 22% R326H Y 1 
LSL4014 RAEB mon7 22% R366H Y 1 
LSL2823 RAEBII isodiXq13 37% A376T Y 1 





LSL1667 RCMD mon 7 44% A741V Y 0 
LSL3532 RAEB Complex >22% T835A Y 1 
LSL4062 RAEB mon 7 34% R882C Y 1 
LSL3241 RAEB isodiXq13 34% R882H Y 0 
LSL1280 RAEB mon 7 
>20 % P904S Y 
1 
25% F751V Y 
 
Table 3.4: Mutational analysis of DNMT3A in ten patients with MDS/tAML using 454 
sequencing. Confirmation of these mutations by Sanger was carried out on unamplified DNA 
as indicated by “Y”. The R882 site was mutated in 2/10 patients and matched the findings of 
other research groups which have reported high frequency of this mutation in their cohort. All 
the mutations identified in this study are heterozygous (clone size 20-44 %) with 6/10 
patients having monosomy7 as the cytogenetic abnormality. “*” = Splice site junction, ** 





Figure 3.11: DNMT3A (R882C) mutation in patient (LSL4062) visualised by Vnode. The 
top row illustrates the reference sequence (Ensembl) of wild type DNMT3A to which the high 
throughput reads generated by 454 sequencing were aligned. In case of a base pair mismatch, 
a red line indicating the site of the mutation (C to T) was observed. The mutant clone size 
was 32 % (indicated on the left as variation %) and sequencing depth was 600 (indicated on 
the right). 
 
3.8.5 Mapping of DNMT3A mutations 
 
DNMT3A mutations were mapped to the different domains of the protein (Fig. 3.12). 
 
Figure 3.12: Mapping of mutations to the different domains of the DNMT3A protein. 
 
Nine non-synonymous mutations (green) were identified across the entire length of the gene. 
Five non-synonmyous mutations (including P904) were localized in the Mtase domain which 
is responsible for the methyltransferase activity of the enzyme. A splice site mutation 
between exon 18 and the intron preceding exon 19 was also observed in this domain. 
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Mutation at the R882 locus identified frequently by other research groups was observed in 
2/10 patients. The PWWP domain demonstrated one non-synonymous mutation. This domain 
is concerned with directing DNMT3A to heterochromatin. Three mutations were dispersed 
between the coding domains. 
3.8.6 Correlation with EZH2 mutations 
 
1/10 patients (LSL4062) showed mutations of both EZH2 and DNMT3A in this cohort. This 
patient had mutation at the R882 site (clone size = 34 %) along with a mutation in exon 16 of 
EZH2 at V626M (clone size = 27 %). Apart from one patient, mutations of EZH2 and 
DNMT3A did not show any specific overlap or exclusivity in their occurrence indicating that 
though EZH2, DNMT3A proteins interact with each other, the mutational status of these 







3.9.1 SNP6 and mutational analysis of PRC1 and Jumonji  genes 
 
Aberrations of EZH2, a core component of PRC2 were first identified by Ernst et al (2010) 
using SNP 6.0 arrays on peripheral blood /bone marrow samples from patients with MDS to 
discover acquired mutations of this gene associated with uniparental disomy of 7q and 7q36.1 
microdeletion (Ernst et al., 2010). In this study a similar approach was used to identify 
aberrations of the other polycomb and Jumonji genes. SNP6 data for 91 patients with MDS 
generated for earlier studies by our group was examined for CNVs (amplification/deletion) 
and CN (LOH) affecting the PRC1 and Jumonji genes. 17 (19 %) patients showed aberrations 
of 5 genes belonging to PRC1 while 29 patients (31 %) showed SNP6 abnormalities at 15 
Jumonji gene loci. Interestingly, this demonstrated that the frequency of SNP6 aberrations 
affecting the Jumonji genes was higher than the PRC1 genes. In the Jumonji genes the 
highest frequency of deletions was observed in JMJD1B (chr 5q31.2) [n=12] while in PRC1, 
RING1A (chr 6p21.32) was deleted with high frequency (n= 2). Patients with deletion of 
JMJD1B had 5q deletion which is a common cytogenetic abnormality associated with MDS. 
Whether loss of JMJD1B contributes to the 5q syndrome phenotype is unknown. RING1A on 
the other hand is essential to reduce self-polyubiquitination of RING1B and thus prevent its 
degradation (Wong et al., 2007). Whether reduced levels of RING1A due deletion of the 
RING1A locus affects RING1B mediated repression of transcription needs further 
clarification. Apart from amplifications, the occurrence of CN (LOH) was also noted in this 
cohort wherein the highest frequency was seen in JMJD4 (n= 3) and BMI-1 (n=11) genes. 
Literature on role of JMJD4 in myeloid cells and its exact mechanism of action is not 
available and studies need to be undertaken to understand the effects of modulation of JMJD4 
expression in detail. In the case of BMI-1,the size of the CN (LOH) observed at this locus 
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were very small (≤ 1 Mb) raising a question of whether they were real but mutational analysis 
of these patients for BMI-1 was still carried out due their high frequency of incidence (n= 11).  
In addition to the presence of deletions and CN (LOH) in the PRC1 and Jumonji genes, 
amplifications/ gain were also observed in our patient cohort. The highest frequency of gain 
or amplifications (n= 3) were observed in JMJD2C and in the PRC1 genes at the RING1B 
locus [chr: 1q25.3] (n= 2). JMJD2C is a histone demethylase involved in removal of 
H3K9me3 marks. This enzyme has been studied in the context of embryonic stem cells (ES) 
wherein KO of JMJD2C levels followed by gene expression profiling showed gene signature 
similar to that of differentiated ES cells. Restoring the levels of JMJD2C in ES enhanced 
their growth and self renewal capacity.JMJD2C targets identified by both gene expression 
and ChIP seq overlapped with the H3K27me3 marks, EZH2 and SUZ12 (Das et al., 2014). It 
would be interesting to observe whether modulation of JMJD2C levels would interfere with 
PRC2 regulation of target genes and whether this connection between Jumonji and PRC2 is 
prevalent in even in myeloid cells. On the other hand, RING1B is a key component in 
transcriptional regulation because of its role in H2AK119Ub and its restraining effect on 
RNA polymerase II at the promoters of target genes. Inactivation of RING1B resulted in 
global loss of H2AK119Ub marks and release of RNA pol II enzyme (Stock et al., 2007). As 
explained in section 1.8, RING1B KO is linked to increased proliferation of myeloid 
progenitor cells by up regulation of cyclinD2 and cdc6. There is concomitant up regulation of 
p16INK4A causing decrease in the number of mature myeloid and lymphoid precursor cells 
(Cales et al., 2008). However it is unclear whether RING1B over expression has an opposite 
effect of reduced myeloid progenitor cells, increased mature myeloid precursor cells and 




Mutational analysis of all the patients with SNP6 abnormalities was carried out by sanger and 
454 parallel sequencing but no mutations were identified in the Jumonji and PRC1 genes 
indicating that (a) the SNP6 status was not predictive of the presence of mutations in these 
genes and (b) the frequency of mutations of the Jumonji and PRC1 genes if present at all was 
very low in MDS/AML. Similar findings were reported by Score et al (2012) when they 
identified JARID2 mutations (R717Q, D744N, and I1052V) in peripheral blood and bone 
marrow of 3/148 cases of MDS/MPN but did not find any association between CN (LOH) of 
chr 6p with these mutations. Therefore it can be concluded that mutations of PRC1 and 
Jumonji genes are rare in MDS/AML and are not associated with SNP6 abnormalities of 
these genes. 
Next, I examined changes in gene expression of the Jumonji genes as a result of CNVs 
detected by SNP6 at these gene loci by qPCR. Due to insufficient quantities of patient 
samples qPCR could not be carried out for the PRC1 genes.  
Altered expression of Jumonji proteins have been reported previously in carcinogenesis; Up 
regulation of JHDM1B in leukaemia facilitates proliferation of hematopoietic progenitor cells 
via demethylation of H3K36me2 and affects target p15INK4B (He et al., 2011). Another 
Jumonji gene associated with leukaemia is JMJD1B which is up regulated in acute 
lymphoblastic leukaemia (ALL) and causes repression of cancer cell differentiation (Kim et 
al., 2012).Besides leukaemia, over expression of JMJD3 and JMJD1A have been shown to 
correlate with advance disease stage of prostate cancer (Xiang et al., 2007) and bladder 
cancer respectively.  In bladder cancer, JMJD1A knock out (KO) caused G1 arrest of cancer 
cells suppressing proliferation (Cho et al., 2012).This indicates that the modulation of 
Jumonji gene expression can contribute to carcinogenesis and therefore these genes can be 
utilised as potential targets in cancer therapy (Sroczynska et al., 2014). In this study it was 
found that the expression of four Jumonji genes; JARID2, JARID1A, JARID1C and UTX was 
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modulated concomitant with SNP6 abnormality of these genes. JARID2 expression was 
upregulated in one patient with trisomy of the JARID2 locus while JARID1A locus (chr 
12p13.33) was deleted (CN= 1) in two patients while a single patient had trisosmy (CN= 3) 
of JARID1C (Xp11.22), UTX (chr Xp11.3). CN= 4 was also observed at UTX locus in one 
patient. Deletion of JARID1A locus was linked with reduced gene expression (p value 
<0.0001) in both the patients while increased expression of UTX and JARID1C due to gain in 
copy number was seen in a single patient. UTX levels were also increased 5 fold concomitant 
with CN= 4 in another patient. Inactivating mutations and deletions of UTX have been 
reported in AML and CML cases (van Haaften et al., 2009) but over expression of UTX is a 
novel finding. Studies to understand the mechanistic effect of UTX have used small molecule 
inhibitors of UTX in human promyelocytic leukemic cell line with promising effects on 
reducing proinflammatory cytokine production by human primary macrophages (Kruidenier 
et al, Nature, 2012). However, downstream effects of UTX inhibition need further 
clarification. Chromosomal translocation of JARID1A is implicated in leukaemia with 
Nuclear pore complex protein (NUP98) as its binding partner (de Rooij et al., 2013;van 
Zutven et al., 2006; Wang et al., 2009). Functional analysis of the fusion protein 
demonstrated arrested in haematopoietic differentiation (Wang et al., 2009). This effect might 
be due to inability of the fusion protein to bind to its target H3K4me3 affecting the 
downstream targets of this histone mark. Whether JARID1A deletion mimics the fusion 
protein in its mechanism of leukemogenesis needs to be ascertained. On the other hand, 
JARID1C is implicated in mental retardation, renal carcinoma and cervical cancer. Mutations 
of this gene (30%) are associated with mental retardation (Blair et al., 2011). However its link 




3.9.2 Mutational analysis of PRC2 and DNMT3A 
 
EZH2 was previously sequenced by our group on 61 out of 91 patients (mentioned earlier)  
and therefore the same cohort of patients were selected for mutational analysis of the other 
core components of PRC2; SUZ12, EED, EZH1 and DNMT3A to identify mutations in these 
genes and to examine the mutational overlap of these with EZH2. PRC2 genes were not 
mutated in our cohort of patients suggesting that the frequency of mutation of the other 
components of PRC2 is low compared to EZH2. Subsequently, similar findings were 
published by two research groups; Score et al (2012) and Brecqueville et al (2011) wherein 
the first group reported only 1.4 % (2/148) frequency of SUZ12 mutation in their cohort with 
all the mutations affecting the VEFS domain. However, their study included cases with MDS, 
Myeloproliferative neoplasms (MPN) as well as myelofibrosis in their cohort. One of the 
mutations in SUZ12 was identified in patient with MPN and was associated with CN (LOH) 
of 17q. This group also analyzed EED and identified 1% (1/148) frequency of mutation in 
this gene. They demonstrated that mutations of both SUZ12/EED caused loss of H3K27me3 
levels (Score et al., 2012). On the other hand, Brecqueville et al (2011) focused entirely on 
SUZ12 in MPN, chronic myelomonocytic leukaemia and polycythemia vera (PV) cases and 
found three missense mutations (2 MPN & 1 PV cases) /186 patients (1.6 %) of this gene 
(Brecqueville et al., 2011). Therefore it can be conclude that mutations of EZH2 are more 
frequent in cases with MDS than those of SUZ12, EED or EZH1 and therefore the focus 
needs to be on the functional analysis of EZH2 in the context of myeloid cells. Since 
mutations in any component of PRC2 resulted in loss of H3K27me3, it emphasizes the 
importance of this mark and suggests that deregulation of the epigenetic control of gene 
expression plays an important role in the development of myeloid disorders. 
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In contrast mutational analysis of DNMT3A in the same cohort identified 10/61 patients with 
heterozygous mutations (clone size 20-44 %) of this gene. Interestingly, these mutations were 
seen predominantly (n= 6) in patients with monosomy 7/del 7q and not observed in patients 
with normal karyotype but were classified in RAEBI/II of the WHO classification suggesting 
the association of this gene with advanced stage of the disease. The precise role of these 
mutations in leukaemogenesis remains elusive but a number of studies have investigated their 
potential prognostic significance in AML. For this purpose, Shivarovet al (2013) examined 
4582 AML patients and derived that, DNMT3A mutations appeared to be an independent 
adverse prognostic factor in younger patients with normal cytogenetics AML [Overall 
Survival (OS) [p = 0.01], Relapse Free Survival (RFS) [p= 0.0005]] and therefore can be 
used for risk stratification of AML patients in connection to integrated mutational profiling 
(Shivarov et al., 2013).More recently, Tie et al (2014) reviewed 12 studies (n= 6377) 
focusing on implications of DNMT3A mutations on OS in de novo AML and concluded that 
patients with DNMT3A mutations had slightly shorter OS (HR = 1.60; 95% CI, 1.31–1.95; p 
<0.001), as compared to wild-type carriers. In addition, mutant DNMT3A predicted inferior 
OS (HR = 2.30; 95% CI, 1.78–2.97; p = 0.862) in patients with unfavourable genotype 
abnormalities but there was no significant prognostic impact on the OS in the favourable 
genotype subgroup. They also looked at event, relapse-free survival and found similar results 
(Tie et al., 2014), (Ribeiro et al., 2012). In contrast, there was no significant difference in the 
median survival of monosomy 7 patients with or without DNMT3A mutations (p value = 0.6) 
in our cohort with inconclusive impact on prognosis of the patients with mutated DNMT3A 




3.9.3 Mutational overlap 
 
A single patient was mutated for both EZH2 and DNMT3A in this study. This patient had 
mutation at the R882 site (clone size = 34 %) along with a mutation in exon 16 of EZH2 at 
V626M (clone size = 27 %) site. The functional significance of these overlapping mutations 
is not clearly understood and have not been studied so far. Apart from one patient, mutations 
of EZH2 and DNMT3A did not show any specific overlap or exclusivity in their occurrence. 
Similar results were observed by Haferlach et al (2014) when they sequenced 944 patients 
belonging to various subtypes of MDS and found DNMT3A to be amongst the commonly 
mutated genes (> 10 %) but they did not find any particular link between EZH2 and 
DNMT3A mutations. DNMT3A mutations in their study showed overlap with SF3B1 
(Splicing Factor 3b) mutations but were mutually exclusive with SRSF2 and ASXL1 
mutations (Haferlach et al., 2014). DNMT3A mutations in AML are often found with 
mutations of Nucleophosmin (NPM1), Fms-Related Tyrosine Kinase 3 (FLT3), IDH1 or 
IDH2 (isocitrate dehydrogenase1/2) but never with RUNX1 (Runt-Related Transcription 
Factor) (Shah and Licht, 2011).The functional consequence of these overlapping mutations 
and their individual or cumulative effect on the pathogenesis of MDS needs to be ascertained. 
3.10 Conclusion 
 
SNP6 karyotyping facilitated identification of CNVs (deletions, amplifications) and CN 
(LOH) in Jumonji and PRC1 genes. The frequency of SNP6 abnormalities in the Jumonji 
genes was high (approx double) as compared to PRC1. Though SNP6 abnormalities were not 
associated with mutations of the Jumonji and PRC1 genes, gene expression modulations were 
identified in the patients with CNVs at the Jumonji loci suggesting changes in gene 
expression as a important mechanism for disease pathogenesis.  
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Sanger and 454 parallel sequencing of EZH1, SUZ12, EED and twelve genes belonging to 
PRC1 did not identify mutations associated with these genes confirming that among the 
polycomb proteins, EZH2 is the most important link to MDS/AML. Therefore the next part 
of my thesis is focused on examining the functional consequences of EZH2 mutations, 
knock down and over expression of this gene in the context of myeloid cell lines. 
16 % patients in this study were mutated for DNMT3A. The high frequency of mutations 
associated with this gene identified by us and other research groups, their adverse impact on 
the prognosis of haematological malignancies and the site specificity of the mutation (R882) 
is evidence that the enzymatic activity of this gene gets altered/ compromised in myeloid 
malignancies making it a crucial target for therapies designed to treat MDS. Therefore a 
part of this thesis is based on constructing the R882 mutation in plasmid vectors and 








4 Chapter: Role of EZH2 mutations 







As discussed in Chapter 1 (refer section 1.7), the incidence of EZH2 mutations is 8 % in 
patients with MDS/MPN and 2 % in AML. In contrast to patients with lymphomas where the 
Y641 site of EZH2 is most frequently mutated, there is no hotspot for mutation observed in 
myeloid malignancies. Truncation mutations occur throughout the gene while missense 
mutations were commonly found in the conserved SET domain (Ernst et al., 2010b). 
Mutations affecting the R690 site in the SET domain of EZH2 have been reported in many 
studies (Ernst et al., 2010; Jerez et al., 2012; Makishima et al., 2010; Nikoloski et al., 2010) 
including by us though the frequency of occurrence of this mutation in a single cohort was 
not high. Two mutations R690C and R690H are identified and frequently correlate with the 
absence of H3K27me3 mark (Ernst et al., 2010) but the precise downstream targets affected 
by these mutations have not been examined till date. Their strategic location in the SET 
domain of EZH2 which is responsible for the histone methyltransferase activity of the 
enzyme makes them an ideal candidate to study the role of EZH2 in myeloid malignancies. 
4.2 Aim 
 
 To construct R690C and R690H mutations of EZH2 in a plasmid vector. To generate 
Flag-tagged wild type EZH2 in order to over express the wild type. Transfect both 
mutants and the Flag-tagged wild type EZH2 in myeloid cell lines.  
 To examine the effect of the two mutations and over expression of EZH2 on its target; 
H3K27me3 protein levels in myeloid cell lines.  
 To identify and compare the gene signature as a consequence of the mutations and 




4.3 Constructing the R690C & R690H mutations in pCMV sport6 vector 
 
Wild type EZH2 cDNA cloned in pCMV-SPORT6 (IRATp970F1210D) was obtained from 
Source Bioscience and was used for all experiments (refer appendix). This EZH2 cDNA 
sequence was verified using different primer pairs (refer appendix) by Sanger sequencing. 
To introduce the R690C and R690H mutations in the wild type EZH2 cDNA (Fig: 4.1), the 
plasmid was digested by SalI-NotI restriction enzymes (refer 2.14.1) which generated two 
fragments (size: 4396 & 2500 bp) as visualized on 1 % agarose gel (Fig: 4.2a). The large 
fragment (4396 bp) was excised under UV light and purified by Qiagen gel purification kit as 
per the manufacturer’s instructions while the small fragment was discarded. Secondly, 
pCMV-SPORT6 was digested with SalI-EcoRI restriction enzymes which generated two 
fragments (size: 5000 & 2335 bp) (Fig: 4.2b) of which the small fragment was gel purified 





Figure 4.1: Cloning strategy for introducing the R690C and R690H mutation in pCMV-
SPORT6.Red cross indicates the site of the mutation. Generation of the mutant in the EcoRI-
NotI fragment has been illustrated using two pairs of primers (of each pair one primer flanked 
the mutational site and a second primer overlapped the mutation site and introduced the 
mutation), using a PCR based approach (See text). 
 
Figure 4.2: Digestion of pCMV-SPORT6 vector containing EZH2 cDNA(a) pCMV-
SPORT6 digested by SalI-NotI to generate the empty vector (4396 bp). (b) pCMV-SPORT6 




4.3.1 Generation of fragment containing R690C & R690H mutation 
 
The mutation was generated using two sets of primers; the first pair of primers overlapped the 
position 690 [mutational primer F (MF) and mutational primer reverse (MR)]. This primer 
pair was different for the R690C and R690H mutation. The change in the base pair to be 
introduced was positioned exactly at the centre of the primer. The second pair of primer or 
flanking primers [flanking forward (FF) and flanking reverse (FR)] were same for both the 
mutations and were designed just outside EcoRI-NotI restriction enzyme sites. PCR 
amplification using these primers was carried out on wild type pCMV-SPORT6 vector at a 
range of temperatures (For R690C: 41◦C, 45◦C, 49◦C, 53◦C, 57◦C & 61◦C and for R690H: 







Figure 4.3: Generation of mutational fragment R690C and R690H.Table (a) and (b) show 
reaction mixture and the PCR conditions used to generate the fragment of EZH2 cDNA 
containing either R690C or R690H mutations. Gel picture (c) for R690C and (d) for R690H 
indicate visualisation of the PCR products at different temperatures (41-61◦C) using forward 
flanking primer + reverse mutational primer (*) and reverse flanking primer + forward 
mutational primer (**). Visualisation of the second round of PCR product using only the 
flanking primers for both mutations is shown in (e). Gene O’Ruler ladder was used in all the 
gel pictures except for (c) were the gene ruler 1 kb ladder was utilised. 
 
The product from the second PCR (R690C & R690H: 61◦C) was gel purified, the fragments 
were treated with SuperTaq and incubated for 30 min at 72 ◦C to add dNTP “A” to the 
fragment. 
Subsequently, 2 µl of the above mixture was cloned in to pCRII- TOPO vector and 
transformed into DH5α-T1 E.Coli cells (refer 2.14.4). After over night incubation of the LB 
agar + 100 mg/ml ampicilin +Xgal (20 µg/ml) plates, five colonies were selected and 
miniprep was carried out using the Wizard Plus SV kit (Promega, UK).  All the colonies 
showed correct band size (700 bp) (Fig: 4.4) when verified by digesting the plasmid with 
Reagents Volume 
PCR fragment  (24.34 ng/ µl) 12 µl 
dNTPs (2 mM) 1 µl 
Super Taq 0.25  µl 
10X buffer 2 µl 
H20 upto 20 µl 
 
Table 4.1: Reaction mix for treatment of plasmid DNA with SuperTaq to add dNTP 




EcoRI restriction enzyme (refer 2.14.1). The presence of the mutations (R690C and R690H) 
was confirmed by sanger sequencing of the respective colonies using M13 primers (data not 
shown).  
 
Figure 4.4: Verification of the correct colony after cloning the PCR fragment in pCRII- 
TOPO vector.Five colonies were digested by EcoRI restriction enzyme and all the colonies 
showed the correct band size (700 bp) 
 
A single colony was verified by EcorI digest and sanger sequencing for each mutant and was 
next digested by EcoRI-NotI, the fragment (700 bp) was gel purified and stored for ligation. 
4.3.2 Three-way ligation 
 
The concentrations of the plasmid DNA for all three fragments generated by restriction 
enzymes; SalI-NotI, SalI-EcoRI (both these fragments were common for the R690C and 
R690H mutations) and the fragment containing the mutation (EcoRI-NotI) (separate for each 
mutant) were measured using Thermo Scientific Nanodrop (ND-8000; Nanodrop) 
spectrophotometer and ligated using T4 DNA ligase. The control reaction contained only the 
empty vector but none of the other fragments. This control was used to check the number of 






(For 50 ng) 
Empty vector (SalI-NotI: 4390 bp) [16.2  ng/ µl] 3.1µl 
SalI-EcoRI: 2335 bp (18.25 ng/ µl) 2.9µl 
EcoRI-NotI: 700 bp [fragment containing R690C (12.19 ng/ µl) 
or R690H mutation (22.10 ng/ µl] 
R690C (1.3µl) 
OR R690H (0.72 µl) 
10X Ligase buffer 1 µl 
T4 DNA ligase 0.5 µl 
H20 upto 10µl 
Table 4.2 :Ligation mixture for three fragments (SalI-NotI, SalI-EcoRI & EcoRI-NotI) 
of pCMV-SPORT6. Empty vector: Insert ratio for ligation was 1:2.  
 
0.2 µl of the ligation mixture was transformed into MegaX DH10B T1 Electrocomp cells 
(refer 2.14.7) and plated on LB agar + 100 mg/ml ampicilin plates for 16 hr at 37◦C. Four 
colonies for R690C and three for R690H mutants were selected and accurate ligation was 
confirmed by SalI-NotI digest (band size: 2500 bp) and sanger sequencing using M13 
primers. All colonies showed the correct size fragment on SalI-NotI digest and contained 
either the R690C or R690H mutant. One colony for each mutant was selected and maxiprep 






Figure 4.5: Confirmation of R690C and R690H mutant in pCMV-SPORT6 vector. (a) 
Digestion of seven colonies (four for R690C and three for R690H) by SalI-NotI restriction 
enzymes illustrate correct band size of the insert (2500 bp) for all the colonies. Sanger 
sequencing of one colony per mutant [R690C: (b)] and [R690H: (c)] confirm the change in 
amino acid [grey arrows] from Arginine (CGT) to Cysteine (TGT) for R690C and for R690H 
from Arginine (CGT) to Histidine (CAT). Two silent mutations were observed, one in the 
fragment carrying the R690C mutation [CGC to CGT (Arginine to Arginine)] and the second 





4.4 Cloning R690C & R690H mutants into p3XFLAG-myc-CMV-26 
expression vector 
 
A selectable marker (neomycin) and a Flag tag were attached to the R690C and R690H EZH2 
mutants to help distinguish it from the endogenous EZH2 in the cells. Therefore EZH2 
cDNAs containing R690C or R690H in pCMV sport 6 vector were cloned into p3XFLAG-
myc-CMV-26 Expression Vector (Sigma Aldrich, UK) (Fig: 4.6). To study the effect of 
over expressing wild type EZH2 in myeloid cells, EZH2 cDNA without the mutations 
was also cloned into p3XFLAG-myc-CMV-26 Expression vector. 
 
Figure 4.6: Cloning Strategy. Cloning strategy for inserting EZH2 cDNA containing 
R690C/ R690H and the Flag tagged wild type gene from pCMV-SPORT6 to pX3FLAG-myc.  
The insert containing the mutations and the Flag tagged wild type EZH2 were isolated from 
pCMV-SPORT6 by restriction enzymes SalI-NotI. p3XFLAG-myc was linearised using 
HindIII-NotI and the insert containing EZH2 was ligated into this vector by joining the NotI 
digested ends of both the plasmids. 
 
4.4.1 Linearise the p3XFLAG-myc-CMV-26 expression vector for ligation 
 
p3XFLAG-myc-CMV-26 expression vector (Sigma, UK) was digested by restriction enzyme 
HindIII for 1 hr at 37◦ C (refer section 2.14.1) followed by conversion of DNA termini to 
blunt ends (refer section 2.14.2) and digested by NotI restriction enzyme for 1hr at 37◦ C. The 
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linearised plasmid was visualized on 1 % agarose gel (Fig: 4.7a), the band was excised under 
UV light and purified by Qiagen gel purification kit as per the manufacturer’s instructions.  
 
Figure 4.7: Cloning EZH2 cDNA into p3XFLAG-myc-CMV. (a) p3XFLAG-myc-CMV 
vector was linearised using HindIII-NotI restriction enzymes and visualised on 1 % 
agarose gel. (b) EZH2 cDNA containing R690C/R690H or wild type EZH2 were isolated 
from pCMV sport6 using restriction enzymes SalI-NotI (size = 2500 bp). 
 
4.4.2 Isolation of EZH2 cDNA from pCMV sport6 vector 
 
pCMV sport6 vectors containing either R690C/R690H or wild type EZH2 were digested 
using restriction enzyme SalI for 1 hr at 37 ◦C (refer section 2.14.1) followed by conversion 
of DNA termini to blunt ends (refer section 2.14.2) and digested next by NotI restriction 
enzyme for 1hr at 37 ◦C to isolate EZH2 cDNA from pCMV sport6 plasmid (Fig: 4.7b). The 
band (2400 bp) was visualized on 1 % agarose gel, excised under UV light and purified by 
Qiagen gel purification kit as per the manufacturer’s instructions. 
4.4.3 Ligation of EZH2 cDNA and p3XFLAG-myc-CMV-26 expression vector 
 
Gel purified EZH2 cDNA (R690C/R690H/wild type) was ligated to the linear p3XFLAG-
myc-CMV-26 using the conditions mentioned in table 4.3. 0.2 µl of the ligation mixture was 
transformed into MegaX DH10B T1 Electrocomp cells (refer 2.14.7) and plated on LB agar + 
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100 mg/ml ampicilin plates for 16 hr at 37◦C. Five colonies each for the two mutants and the 
wild type EZH2 were selected and accurate ligation was confirmed by HindIII-NotI digest 
(Fig: 4.8). Sanger sequencing was carried out using primers designed against EZH2 cDNA to 
verify the presence of the mutations. One accurate colony for R690C, R690H and wild type 
EZH2 each was selected for maxiprep using the Qiagen Maxi Prep plasmid kit (refer 
2.14.10). 
 
Figure 4.8: Verification of accurate ligation of EZH2 cDNA into p3XFLAG-myc-CMV 
plasmid.  Five colonies per mutant R690C/R690H and wild type EZH2 were selected and 
digested by HindIII-NotI restriction enzymes. The correct colonies carrying wild type EZH2, 
R690C and R690H mutants are indicated by red box and contained the correct band sizes 
(1000 bp, 1800 bp and 6000 bp). 
Reagents 
Volume 
(For 50 ng) 
Linear p3XFLAG-myc-CMV-26 (23 ng/µl) 2.17µl 
cDNA EZH2 
(R690C: 8.6 ng/ µl, R690H: 8.3 ng/ µl, wild type EZH2: 8.4 ng/ µl) 
R690C: 5.4 µl, R690H: 2.8µl, 
wild type: 5.4 µl 
10X Ligase buffer 1 µl 
T4 DNA ligase 0.5 µl 
H20 upto 10µl 
Table 4.3 :Ligation of EZH2 cDNA (R690C /R690H/ wild type EZH2) into p3XFLAG-
myc-CMV-26 expression vector. Linear p3XFLAG-myc-CMV-26: Insert ratio for ligation 
was 1:2.  
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4.5 Transfection of R690C/R690H & wild type EZH2 into myeloid cell lines 
 
Five myeloid cell lines; U937, KG1, NB4, K562 and MOLM13 were screened for EZH2 
expression levels. RNA was extracted from the cell lines, converted to cDNA using the 
Superscript Vilo kit and qPCR (refer section 2.9-2.11) was performed to estimate EZH2 
mRNA levels (Fig: 4.9). 
 
Figure 4.9: Endogenous expression of EZH2 in myeloid cell lines (U937, KG1, NB4, 
K562 and MOLM13) by qPCR analysis. K562, NB4 and MOLM13 cell lines showed a 
higher expression of EZH2 compared to U937, HL60 and KG1 which did not express 
endogenous EZH2. Therefore MOLM13 (wild type TP53) and K562 (TP53 null) cell lines 
were selected for all experiments.(Y axis: Fold change compared to endogenous control 
GAPDH) Error bars= SEM in two experiments. 
 
K562, NB4 and MOLM13 cell lines showed a higher expression of EZH2 compared to U937, 
HL60 and KG1 which did not express EZH2. TP53 expression levels are deregulated in K562 
(insertion in exon 5 of TP53 (Law et al., 1993)), NB4 (missense mutation in codon 319 and 
344) (Fleckenstein et al., 2002) but MOLM13 cells carry wild type TP53 (Kojima et al., 
2005) therefore K562 (TP53 null) and MOLM13 (wild type TP53) cell lines were selected for 
all subsequent experiments. The presence of wild type EZH2 in both K562 and MOLM13 
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cells was confirmed by sanger sequencing using primers designed against EZH2 cDNA 
sequence. 
4.5.1 Electroporation& Lipofectamine transfection methods 
 
p3XFLAG-myc-CMV-26 carrying the R690C/ R690H/ wild type EZH2 were transfected 
using lipofectamine (refer section 2.15.2) and electroporation (refer section 2.15.4) methods 
into both K562 and MOLM13 cell lines. The experimental workflow is detailed in the Figure 
4.10. 95% of the MOLM13 and 65% K562 cells were dead at 48 hr as estimated by Trypan 
blue staining which could be attributed to electroporation since similar percentage of cell 
death was also observed in the mock-transfected cells. Therefore Lipofectamine LTX was 
used for all subsequent transfections and cells were selected using neomycin (400 µg/ml) 48 
hr after transfection. 
 
Figure 4.10: Experimental workflow for transfection by Lipofectamine 
LTX.MOLM13/K562 cells were seeded at a density of 5 x105 in 6 well plates and transfected 
with 2 µg of p3XFLAG-myc-CMV-26 vector carrying either R690C or R690H mutant or 
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wild type EZH2 using Lipofectamine LTX solution as per the manufacturer’s instructions 
(refer section 2.16.2). Mock transfected cells were used as a ctl for alterations caused due to 
the transfection procedure. The untransfected cells were used as a ctl to estimate the end point 
of neomycin selection for the cells. 
 
Neomycin selection was continued for 18-20 days till all the untransfected cells (ctl) were 
dead by trypan blue dye exclusion method. Cells were harvested at 48 hr after transfection 
before neomycin selection and on day 21 after neomycin selection for qPCR (Fig: 4.11).  
  
 
Figure 4.11: qPCR analysis of EZH2 expression in MOLM13 cells, 48 hr and 21 days 
after transfection.EZH2 mRNA levels were high (1000-5500 fold) in cells transfected with 
R690C, R690H or flag tagged wild type (wt flag) EZH2 compared to those transfected with 
empty p3XFLAG-myc-CMV-26 without EZH2 cDNA and mock transfected cells at 48 hr. 
However, these levels reduced and were variable (0.56 to 17.5 fold) at day 21 after neomycin 
selection indicating CMV promoter deactivation. Error bars= SEM in three experiments. 
 
EZH2 mRNA expression was high (1000-5500 fold) in cells transfected with R690C, R690H 
or FLAG tagged wild type (wt flag) EZH2 compared to those transfected with empty 
p3XFLAG-myc-CMV-26 without EZH2 cDNA and mock transfected cells at 48 hr. The 
expression level of EZH2 in cells selected by neomycin on day 21 was variable ranging 
between 0.56 to 17.5 fold compared to the mock tranfected cells in both cell lines (Fig: 4.11, 
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data not shown for K652). The probable cause for reduced EZH2 expression over time might 
be due to its promoter inactivity. Cytomegalovirus (CMV) promoter drives the expression of 
EZH2 in p3XFLAG-myc-CMV-26. Although the CMV promoter allowed for a very strong 
short-term expression (48 hr after transfection) of EZH2, it declined within 3-4 weeks and in 
some samples was barely detectable at the end of neomycin selection (day 21-24). CMV 
promoter can undergo methylation of CpG islands after few weeks of transfection making it 
inactive. To test whether CpG methylation of the CMV promoter was responsible for 
decreased EZH2 expression, cells transfected with wt flag and R690H (since EZH2 
expression in these cells was lower than endogenous EZH2 expression levels in mock 
transfected cells) were treated with 5-Azacytidine (500 nM, 1 µM, 5 µM) and the expression 
of EZH2 was examined 48 and 72 hr after drug treatment by qPCR (Fig: 4.12). These time 
points were chosen to allow the cycles to undergo cell cycle so that the drug could  
incorporate into the replicating DNA to block DNA methyltransfearse resulting in 
demethylation of the CpG islands. 
 
Figure 4.12: qPCR analysis of EZH2 expression in MOLM13 cells, 48 and 72 hr after 5-
Azacytidine treatment. Three concentrations (500 nM, 1 µM and 5 µM) of the drug were 
used to treat MOLM13 cells transfected with Flag tagged wild type EZH2 (a) and R690H 
mutant (b). EZH2 mRNA levels (wt flag) increased from 0.5 fold (Fig: 4.11) in untreated 
cells to 1.4-5.8 fold in cells treated with 5-Azacytidine. The time points were chosen to allow 
the cells to undergo cell cycle and for the 5-Azacytidine to incorporate into the DNA. Higher 
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concentrations of the drug (1 µM and 5 µM) were associated with better recovery of EZH2 
expression levels indicating a dose dependent response. Similar association between EZH2 
expression and drug dose was also observed in cells transfected with R690H mutant except 
for cells treated with 500 nM of 5-Azacytidine which showed reduced EZH2 expression at 48 
hr. This was observed in two independent experiments and the cause of this remained 
unclear. Error bar= SEM in two independent experiments, Yaxis: ∆∆ CT Fold change 
compared to untreated cells containing wtflag. 
  
The expression levels of EZH2 recovered after 5-Aza treatment at both 48 and 72 hr time 
points in cells transfected with Flag tagged wild type EZH2 confirming that the reduced 
expression of the transgene was due its promoter methylation. The level of EZH2 at 48 hr in 
cells carrying the R690H mutation was lower than the untreated cells which could not be 
explained even after repeated experiments and still remains unclear. However the expression 
of R690H EZH2 recovered similar to the wt flag EZH2 at both the time points at 1 and 5 µM 
concentrations. Therefore to avoid long selection periods, I cloned all (R690C, R690H and wt 
flag EZH2cDNA) into p3XFLAG-myc-CMV-26 containing GFP and puromycin markers 
instead of neomycin. GFP and puromyin markers were isolated from pBABE puromycin 
vector (gifted by Dr. Joop Gaken, Department of haematological medicine, KCL) and ligated 
into empty pX3FLAG-myc-CMV (26) (data not shown). This empty vector containing GFP 




4.6 Cloning EZH2 cDNA into p3XFLAG-myc-CMV-26 containing GFP and 
puromycin 
4.6.1 Construction of  wild type EZH2 
 
Wild type EZH2 present in p3XFLAG-myc-CMV-26 was digested by; 1) restriction enzyme 
HindIII for 1 hr at 37 ◦C (refer section 2.14.1) followed by conversion of DNA termini to 
blunt ends (refer section 2.14.2) and digestion by BstEII restriction enzyme for 1hr at 60 ◦C. 
2) The  plasmid was also digested by HindIII for 1 hr at 37 ◦C (refer section 2.14.1) followed 
by conversion of DNA termini to blunt ends (refer section 2.14.2) and digestion by BsiWI 
restriction enzyme for 1hr at 55 ◦C and 3) wild type EZH2  was digested by BstEII at 60 ◦C 
for 30 min followed by BsiWI at 55 ◦C for 30 min. Fragment size of 380 bp (HindIII-BstEII), 
4400 bp (HindIII-BsiWI) and 4200 bp (BstEII-BsiWI) were visualized on 1 % TAE agarose 
gel, excised under UV light and purified by Qiagen gel purification kit as per the 
manufacturer’s instructions (Fig: 4.13). 
 
Figure 4.13: Cloning EZH2 cDNA into p3XFLAG-myc-CMV-26 containing GFP and 
puromycin. Wild type EZH2 in p3XFLAG-myc-CMV-26 was digested by:(a) restriction 
enzyme HindIII for 1 hr at 37 ◦C followed by conversion of DNA termini to blunt ends and 
next by BstEII restriction enzyme for 1hr at 60 ◦C. The band at 380 bp (blue arrow) was gel 
purified. (b) The plasmid was also digested by HindIII for 1 hr at 37 ◦C, DNA termini 
converted to blunt ends and digested by BsiWI restriction enzyme for 1hr at 55 ◦C (band size; 
4400 bp). Lastly,wild type EZH2 in p3XFLAG-myc-CMV-26 was digested (c)by BstEII at 
60 ◦C for 30 min followed by BsiWI at 55 ◦C for 30 min to isolate a fragment of 4200 bp 





The three gel purified fragments were ligated under following conditions: 
Reagents Volume (for 50 ng) 
Fragment (HindIII-BstEII): 380 bp 1µl 
Fragment (HindIII-BsiWI): 4400 bp 3.5 µl 
Fragment (BstEII-BsiWI): 4200 bp 2.7 µl 
10X T4 Ligase buffer 1 µl 
T4 DNA ligase 0.5 µl 
H20 upto 10µl 
Table4.4: Ligation of wild type EZH2 into p3XFLAG-myc-CMV-26 expression vector 
containing GFP + puromycin markers. The fragments (HindIII-BsiWI, BstEII-BsiWI): Insert 
(HindIII-BstEII) ratio for ligation was 1:2.  
 
2 µl of the ligation mixture was transformed into DH5α-T1 E.Coli (refer 2.14.5) chemo-
competent cells and plated on LB agar + 100 mg/ml ampicilin plates for 16 hr at 37◦C. Eleven 
colonies were selected and accurate ligation was confirmed (Fig: 4.14 - 4.15) by HindIII 
digest and sanger sequencing using primers designed against EZH2 cDNA to verify that the 
Flag tag and the gene were inframe (Expasy translator :http://web.expasy.org/translate/). One 
accurate colony was selected and maxiprep was carried out using Qiagen Maxi Prep plasmid 
kit (refer 2.14.10). 
 
Figure 4.14: Confirmation of accurate ligation of wild type EZH2 cDNA into 
p3XFLAG-myc-CMV plasmid. HindIII digest on eleven colonies showed three colonies 




Figure 4.15: Confirmation of the FLAG and EZH2 sequences by Sanger sequencing. 
The read out obtained by sanger sequencing was used as an input sequence in Expasy 
translator online software to confirm that both the Flag and EZH2 sequences (blue arrows) 
were inframe (γ’5’). 
 
4.6.2 Construction of R690C and R690H EZH2 mutants 
 
Cloning strategy for generating the R690C and R690H mutants was based on using the wild 
type EZH2 cloned in p3XFLAG-myc-CMV-26 containing GFP and puromycin as a starting 
point. This plasmid was digested by BsaBI and SfiI restriction enzymes and the fragment at 
1600 bp was discarded (Fig: 4.16). p3XFLAG-myc-CMV-26 with neomycin containing the 
R690C or R690H mutation (generated earlier) was also digested using restriction enzymes 
BsaBI and SfiI which isolated the fragment containing the mutation (1600 bp) which was gel 
purified on 1 % TAE agarose gel and ligated into the p3XFLAG-myc-CMV-26 (GFP and 





Figure 4.16:Ligation of fragment containing R690C or R690H mutant in to wt Flag 
p3XFLAG-myc-CMV (GFP+puromycin). (a) Flag tagged wild type EZH2 cloned into 
p3XFLAG-myc-CMV was digested by restriction enzymes BsaBI-SfiI to isolate and discard 
the fragment at 1600 bp. The remaining plasmid (red box) was gel purified and used for 
ligation (b) The mutants R690C and R690H in p3XFLAG-myc-CMV (neomycin) were 
digested by BsaBI-SfiI restriction enzymes to isolate and purify the fragment containing the 
mutation (red box: 1600 bp). The plasmid isolated from wtflag EZH2 and the fragments 
containing the mutations were ligated using T4 DNA polymerase (Ladder: Gene ruler 1kb 
ladder). 
 
Reagents Volume (for 50 ng) 
Fragment R690C & R690H 
(BsaBI-SfiI): 1600 bp 
1µl 
wild type EZH2 p3XFLAG-myc-CMV-26 containing GFP 
and puromycin (BsaBI-SfiI): 7000 bp 
3.5 µl 
10X T4 Ligase buffer 1 µl 
T4 DNA ligase 0.5 µl 
H20 upto 10µl 
Table 4.5: Ligation of EZH2 cDNA (R690C /R690H/ wild type EZH2) into p3XFLAG-
myc-CMV-26 expression vector containing GFP+Puromycin.Vector: Insert ratio for 
ligation was 1:2.  
2 µl of the ligation mixture was transformed into DH5α-T1 E.Coli (refer 2.14.5) chemo-
competent cells and plated on LB agar + 100 mg/ml ampicilin plates for 16 hr at 37◦C. Five 
colonies per mutant were selected and accurate ligation was confirmed by BsaBI-SfiI digest 
and sanger sequencing using primers designed against EZH2 cDNA to verify the presence of 
the mutant and also confirm that the Flag tag and the gene were inframe (Expasy translator: 
http://web.expasy.org/translate/). Sanger traces for the mutations and results from Expasy to 
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show that the gene and the flag are in the same frame have not been shown to avoid repetition 
because they look the same as shown in previous sections. One accurate colony for each 
mutant was selected and maxiprep was carried out using the Qiagen Maxi Prep plasmid kit 
(refer 2.14.10). 
4.7 Transfection of R690C/R690H/wild type EZH2 in p3XFLAG-myc-CMV-
26 (GFP + Puromycin) into myeloid cell lines 
 
p3XFLAG-myc-CMV-26 (GFP+ puromycin) containing R690C/ R690H/ wild type EZH2 
were transfected using lipofectamine into both K562 and MOLM13 cell lines as previously 
described in Figure 4.10. The percentage of GFP+ cells were analyzed (FACS BD Fortessa) 
after 48 hr which reflected the transfection efficiency. MOLM13 cells showed poor (0.5- 2 % 
GFP+ cells) while K562 showed moderate transfection efficiency (15-20 % GFP+ cells) (data 
not shown). Puromycin 0.2 µg/ml and 2 µg/ml was added after 48 hr of transfection to 
MOLM13 and K562 cells respectively. 98 % cell death was observed by trypan blue staining 
in MOLM13 cells during selection which matched the tranfection efficiency calculated by the 
percentage of GFP+ cells and the remaining 2 % took > 6 weeks to recover. EZH2 expression 
in these cells was reduced compared to mock transfected cells, similar to that observed after 
neomycin selection therefore I discontinued using this cell line for subsequent experiments.  
Similar to MOLM13 cells, K562 cells also showed a long duration of recovery (4 weeks) 
when selected by puromycin and therefore I FACS sorted GFP+ cells (BD Facs Aria) to 
isolate cells containing the transgene from the untransfected cells. The time point for sorting 
cells was estimated by analyzing the percentage of GFP+ cells (BD Fortessa) on each day 
after transfection. There was a sudden drop in GFP+ cells observed on day 4 after 




Figure 4.17: FACS BD Fortessa analysis of GFP+ K562 cells transfected with R690C 
mutant. (a) Illustrates GFP+ cells (15.4 %) 48 hr after transfection while (b) and (c) indicate 
GFP+ cells (15%) and (9%) on 72 and 96 hr post transfection respectively. (d) Specify mock 
transfected cells with plasmid DNA (0% GFP). There was reduction GFP+ cells at 96 hr post 




4.8 Impact of EZH2 mutation on H3K27me3 
 
K562 cells were collected at day 3 post FACs sort for GFP+ cells to evaluate the functional 
effect of the R690C/ R690H/ over expression of wild type EZH2 on the protein levels of 
EZH2 and on its target H3K27me3 by western blot. 
 
Figure 4.18: Western blot analysis at 72 hr post transfection. Top row illustrates EZH2 
expression in cells transfected with R690C mutant, R690H mutant, Flag-tagged wild type 
EZH2 (wtflag), empty p3XFLAG-myc-CMV-26 (GFP+Puromycin) and mock transfected 
cells. As expected there was over expression of EZH2 transgene (first three lanes) as 
compared to the cells transfected with the empty vector and the mock transfected cells. 
However, H3K27me3 levels remained unaltered in all samples suggesting that these levels 
were not affected by the transgene expression levels but were maintained by the endogenous 
EZH2 present in the cells. 
 
Western blot analysis showed elevated protein levels of mutant EZH2 (R690C and R690H) as 
well as Flag tagged wild type EZH2 compared to empty p3XFLAG-myc-CMV-26 (GFP+ 
puromycin) and mock transfected cells. ACTIN was used as a loading control. Surprisingly, 
there was no change in H3K27me3 protein levels though elevated levels of both wild type 
and mutant EZH2 proteins were evident. Previously two studies (Ernst et al., 2010; 
Makishima et al., 2010) have shown a decrease in H3K27me3 levels in the presence of EZH2 
mutation (R690C and R690H). Makishima et al, examined and reported decreased 
H3K27me3 levels in one patient with homozygous R690H EZH2 mutation [CN(LOH) 
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7q31.33] while Ernst et al, (2010) conducted immunoprecipitation of EZH2 on Sf9 insect 
cells transduced with baculovirus expressing Flag tagged EZH2 mutant (R690C) and 
confirmed the presence of all components of PRC2 (SUZ12,EED and EZH2) but decreased 
H3K27me3 levels. The system used in this study reflects a heterozygous mutational status of 
both R690H and R690C EZH2 mutants since the background endogenous levels of EZH2 in 
K562 cells could not be eliminated. Western blot findings in this study suggest that (a) 
homozygous state of EZH2 mutants are essential to observe their effects on H3K27me 3 
levels or (b) The time point used in this study needs to be revised since the half life of 
H3K27me3 protein is long and therefore its degradation may not be detected at 72 hr post 
transfection or (c) The mutant proteins and Flag tagged wild type EZH2 over expressed in 
K562 cells were incapable of interacting with H3K27me3 due to modification in the structure 
of the protein as a consequence of the cloning procedure [p3XFLAG-myc-CMV-26 
(GFP+puromycin)] and therefore H3K27me3 levels detected on western blot analysis are 
only a reflection of the endogenous EZH2 levels in K562 cells and not related to the 
transgene expression. 
To rule out defects in EZH2 cDNA (deletion of a part of the gene) cloned in p3XFLAG-myc-
CMV-26 (GFP+puromycin) the entire gene was sequenced using primers designed along the 
whole length of the gene, expression levels of EZH2 at 72 hr post sort were analyzed by 
qPCR. The RNA extracted from these cells was used to generate cDNA which was 
sequenced a second time to validate the presence of the mutation. The sequencing results in 
both instances showed presence of both the entire gene as well as the mutation in p3XFLAG-
myc-CMV-26 (GFP+puromycin). The qPCR results showed 12 to 14 fold increase in mRNA 
levels of EZH2 ruling out defects introduced in the gene during cloning. 
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Due to time constrain, it was not possible to repeat the experiments at variable time points to 
evaluate long term effects of mutant and wild type EZH2 over expression on H3K27me3 
protein levels. 
4.9 Microarray analysis of EZH2 mutants and over expressed wild type 
EZH2 reveals novel EZH2 targets 
 
Though H3K27me3 levels evaluated on western blot analysis remained unaltered after over 
expression of both mutant and wild type EZH2 in K562 cells, I examined the changes in gene 
signature as a consequence of elevated mRNA levels of EZH2 to evaluate if mechanisms 
(other than modulation of H3K27me3) were at work. To examine the effect of EZH2 
mutations (R690C and R690H) and over expression of EZH2 on transcription, microarray 
gene expression profiling was carried out on K562 cells sorted for GFP + on day 3. RNA 
form these experiments was extracted and the presence of mutations was confirmed a second 
time by sequencing cDNA generated from the RNA. Samples confirmed for EZH2 mutations 
were used to probe gene expression microarrays (Affymetrix Human Transcriptome 2.0 
arrays).  Data analysis identified (refer section 2.10.12), a list of genes either induced or 
down regulated in cells with R690C or R690H EZH2 mutants or wild type EZH2 versus those 
containing the empty p3XFLAG-myc-CMV-26 (GFP + Puromycin).  69 and 42 genes were 
down and up regulated (>2 average fold difference, p <0.05, ANOVA) in cells transfected 
with R690C mutant compared to empty p3XFLAG-myc-CMV-26 vector respectively. Cells 
transfected with R690H mutant 46 and 35 genes were down and up regulated when compared 
to empty p3XFLAG-myc-CMV-26 vector while those transfected with Fag tagged wild type 




































(690c vs. empty) 
LIPT2 4.83 0.013483 
MLLT10 3.62 0.0355 
TYRP1 2.29 0.032842 
PHF17 -2.03 0.030244 
HEPACAM2 -2.03 0.039919 
TNFRSF9 -2.04 0.025053 
GSR -2.06 0.042063 
EML5 -2.06 0.040441 
CCL4 -2.06 0.015373 
MAGI2-AS2 -2.07 0.016422 
CELF2 -2.08 0.032546 
PLA2G4C -2.13 0.006493 
CDH11 -2.14 0.038518 
RIMS1 -2.15 0.027053 
MIR552 -2.16 0.038518 
GALNT13 -2.17 0.037307 
MYNN -2.19 0.019809 
MAP1LC3B2 -2.19 0.022536 
IL26 -2.22 0.043248 
SLITRK1 -2.25 0.014988 
ATF3 -2.26 0.009051 
MIR432 -2.28 0.007388 
CBR1 -2.3 0.002382 
OR5AP2 -2.35 0.012135 
RNASEH1 -2.38 0.001732 
ZCCHC13 -2.51 0.036682 
SCLT1 -2.53 0.000826 
SLITRK5 -2.68 0.008916 
LIG4 -2.93 0.037784 
FPGT -2.99 0.035472 
SEMA3A -3.09 0.000703 
MIR515-1 -3.23 0.015623 
MIR515-2 -3.23 0.015623 
MIR4266 -3.74 0.048431 






(690h vs. empty) 
LIPT2 4.81 0.00022 
MLLT10 4.69 0.004707 
ACTRT1 2.51 0.020135 
MT1A 2.43 0.035517 
MT1G 2.33 0.027381 
DLGAP2 2.32 0.02309 
MUC20 2.1 0.015925 
CLLU1 2.04 0.003531 
MT1B 2.04 0.039413 
MT1F 2.02 0.038223 
MIR583 -2.08 0.005463 
PRDM9 -2.08 0.003931 
MIR552 -2.09 0.042168 
SEMA3A -2.1 0.019244 
PLA2G4C -2.12 0.009438 
SCN2A -2.13 0.03316 
LECT1 -2.13 0.001891 
GALNT13 -2.14 0.012031 
MIR3199-2 -2.2 0.012892 
FAM84B -2.37 0.043775 
SNORD115-2 -2.42 0.043292 
MIR4768 -2.43 0.038326 
ATF3 -2.46 0.011086 
MMP1 -2.88 0.048788 
SNORD115-30 -4 0.019045 
BEST1 -4.36 0.002728 
MIR4503 -4.54 0.000012 
NKAIN2 -4.61 0.02876 
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 p-value  






 p-value  
(wtflag vs. empty) 
ALKBH8 -2.02 0.045186 
 
MTMR6 -2.26 0.039634 
OPN3 -2.02 0.043913 
 
PEX12 -2.26 0.019967 
LYSMD3 -2.03 0.047898 
 
ATF6 -2.27 0.026472 
ZNF23 -2.03 0.036535 
 
NUBPL -2.27 0.017355 
ZNF429 -2.04 0.042857 
 
PTPLB -2.27 0.008965 
LACE1 -2.05 0.031688 
 
NUDT2 -2.3 0.049146 
KIF3A -2.06 0.04697 
 
ADAM9 -2.31 0.033381 
ODF2L -2.06 0.027571 
 
ASCC3 -2.31 0.041902 
OR10X1 -2.06 0.006979 
 
SNX13 -2.35 0.041864 
EXD2 -2.07 0.043868 
 
MIRLET7C -2.4 0.017915 
CCL4L1 -2.08 0.01042 
 
WDR19 -2.41 0.041815 
DHX57 -2.08 0.0371 
 
GAS2L3 -2.44 0.043646 
INTS6 -2.08 0.021098 
 
TNFSF4 -2.46 0.048582 
SEMA3A -2.08 0.006543 
 
MIR2052 -2.49 0.016142 
SLC35D1 -2.08 0.033395 
 
ELTD1 -2.54 0.045997 
SCN2A -2.09 0.013443 
 
LMLN -2.58 0.048924 
NAT1 -2.11 0.042346 
 
ULBP1 -2.59 0.008235 
PLCB4 -2.11 0.024082 
 
SNORD115-31 -2.61 0.010197 
RNF20 -2.11 0.046718 
 
KCTD9 -2.65 0.0498 
FBXO21 -2.12 0.015772 
 
ATF3 -2.67 0.001905 
EPT1 -2.14 0.049051 
 
METTL21B -2.67 0.041785 
GABRG1 -2.14 0.003088 
 
TULP3 -2.67 0.049277 
GPHN -2.14 0.030876 
 
MBTPS2 -2.69 0.042893 
MTHFD1L -2.14 0.03587 
 
DDX60L -2.72 0.04772 
ATP7A -2.16 0.024671 
 
RHOH -2.72 0.019758 
FPGT-TNNI3K -2.16 0.023018 
 
MIR379 -2.85 0.029877 
ULBP3 -2.16 0.015435 
 
TLDC1 -2.86 0.044648 
LRRC28 -2.17 0.030789 
 
SEPHS2 -2.87 0.049575 
NEK3 -2.17 0.015698 
 
PIGN -2.9 0.029635 
XBP1 -2.18 0.027967 
 
TNFRSF9 -3.1 0.015765 
CSTF3 -2.19 0.037384 
 
MIR515-1 -3.39 0.033914 
MAPK6 -2.2 0.038302 
 
MIR515-2 -3.39 0.033914 
FAM185A -2.22 0.039883 
 
MIR4696 -4.4 0.047037 
TMEM26 -2.22 0.045321 
 
BEST1 -5.34 0.003953 
ITPR3 -2.23 0.034441 
 
MIR1-1 -8.16 0.001045 
GPR183 -2.25 0.036653 
 























LIPT2 4.13 0.00076 
 
SEMA3A LIPT2  TNFRSF9 CLLU1  
MIR374C 3.49 0.048986 
 
ATF3 MLLT10  MIR515-1   
DNAH6 2.98 0.020855 
 
BEST1 PLA2G4C MIR515-2   
MIR523 2.94 0.006925 
 
LIPT2  MIR552     
MIR513B 2.63 0.040622 
 
MLLT10  GALNT13     
OR56A5 2.61 0.010178 
 
  ATF3     
CLLU1 2.6 0.002826 
 
  SEMA3A     
TNFAIP3 2.43 0.025021 
 
  BEST1     
RHOG 2.36 0.036901 
     PTH 2.35 0.020579 
     DISP1 2.34 0.023018 
     MLLT10 2.23 0.038961 
     MT1F 2.22 0.047923 
     NLRP8 2.19 0.034632 
     FANC 2.18 0.043105 
     GAS1 2.17 0.017134 
     WNT16 2.17 0.035242 
     PML 2.16 0.008881 
     NAV3 2.15 0.028588 
     EGFLAM 2.12 0.037886 
     SEC61B 2.12 0.01111 
     ACTRT1 2.09 0.005839 
     CHD9 2.09 0.005786 
     SLITRK1 2.08 0.034375 
     SNORD115-15 2.08 0.036645 
     CCDC140 2.07 0.022275 
     VTA1 2.07 0.023057 
     CNTNAP5 2.04 0.02977 
     CACNA1C 2.03 0.043119 
     GPD1 2.02 0.048848 
     PLCXD3 2.02 0.031544 
     CTPS 2.01 0.010357 
     SNORD115-10 2.01 0.002024 
     Table 4.6: List of genes modulated by over expression of wild type and mutant EZH2 by 
micro array gene expression profiling. (a) Genes over or under expressed in cells 
transfected by R60C versus empty vector, (b) R690H versus empty vector and (c) Flag-
tagged wild type EZH2 and (d) List of common genes between both the mutants and the flag 
tagged wild type EZH2 (column 1), in the two mutants (column 2), between R690C and flag 





Microarray gene expression profiling showed 105, 111 and 81 genes modulated by Flag 
tagged wild type EZH2, R690C and R690H respectively. Table 4.6 illustrates the filtered 
gene list based on gene functionality. Non coding RNAs, genes not coding for proteins and 
pseudogenes have been excluded from this list. Table 4.6 indicate genes common between 
the two mutants (R690C & R690H), in all three (R690C, R690H and wtflag) and between 
each mutant and the cells transfected with wtflag. MLLT10 (Mixed lineage leukaemia 
translocated to 10) gene expression was enhanced in cells transfected with R690C (3.62 fold), 
R690H (4.69 fold) as well as wild type EZH2 (2.23 fold). This gene is located on 
chromosome 10p12 and encodes a transcription factor. It is recognised as a partner gene in 
multiple gene translocations resulting in leukaemogenesis (discussed later).  
Other genes associated with haematological malignancies which were enhanced or inhibited 
by over expressing wild type EZH2 but not affected by mutant EZH2 were PML 
(promyelocytic leukemia) [up regulated by 2.16 fold] and FANCL (Fanconi Anemia, 
Complementation Group L) [up regulated by 2.18 fold] (discussed later). Amongst the down 
regulated genes, none of the genes had an association with MDS and none of them were 
known EZH2 target genes. Pathways Analysis was carried out using Metacore but the p 
values were high suggesting that the mutations as well as the wild type over expressed gene 
did not have a strong effect on a single pathway (data not shown). Such networks are 








Mutations of EZH2 were first discovered by Ernst et al (2010) using SNP 6.0 arrays on 
peripheral blood /bone marrow samples (n=614 MDS/MPN patients) and were associated 
with UPD7q and 7q36.1 microdeletion. One patient (WHO: aCML, cytogenetics: not 
available) without del 7q36.1 or UPD 7q carried a heterozygous mutation at site R690 (R to 
C) (Ernst et al., 2010). These findings were confirmed by Nikoloski et al (2010) wherein 
EZH2 mutations were identified in a cohort 102 MDS patients. Both heterozygous and 
homozygous mutations were reported including a heterozygous mutation (R690C) occurring 
in the SET domain of EZH2 in one patient (WHO: RCMD, IPSS: low, cytogenetics: normal 
karyotype) (Nikoloski et al., 2010).Truncation mutations were identified throughout the gene 
while missense mutations were commonly found in the conserved SET domain (detailed in 
section 1.7) responsible for the methyltransferase activity of EZH2.  Homozygous mutations 
affecting the R690 site have also been identified in patients (WHO: RCMD, CMML) with 
UPD 7q31.33 where there is conversion of arginine to histidine (R to H) (Makishima et al., 
2010). However the frequency of this mutation was not high (n=1 or 2) enough to qualify it 
as a hot spot of EZH2 mutation. But since it was reported in all cohorts of patients analyzed 
so far for EZH2 mutations and has a strategic location in the SET domain of the enzyme, 
these two mutations (R690C and R690H) were selected to understand their role in myeloid 
malignancies.  
These mutations had been previously examined in insect cells Sf9 transduced with 
baculovirus expressing Flag tagged EZH2 mutant (R690C) and also in patient samples 
carrying homozygous R690H mutation (Ernst et al., 2010; Makishima et al., 2010). My study 
is the first attempt reported so far to construct these mutations in p3XFLAG-myc-CMV-26 
(GFP+ puromycin) and transfect in to human myeloid cell lines.  
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4.10.1 Cloning R690C/R690H and Flag tagged wild type EZH2 into p3XFLAG-myc-CMV-26 
(neomycin) 
 
R690C and R690H mutations were generated by using a PCR based cloning method 
involving two primer pairs (one flanking primer pair and second pair overlapping the 
mutation). Both mutations and Flag tagged wild type EZH2 were cloned into p3XFLAG-
myc-CMV-26 vector containing the neomycin selectable marker and transfected into myeloid 
cell lines. qPCR analysis of five myeloid cell lines (U927, NB4, K562, MOLM13 and KG1) 
indicated high expression of EZH2 in K562 (chronic myelogenous leukemia) and MOLM13 
(acute monocytic leukemia) cells. In addition to EZH2, TP53 expression levels were also 
assessed in order to consider for a appropriate cell line selection since expression of both 
EZH2 and TP53 are closely linked; high levels of EZH2 are linked to presence of TP53 
mutations in breast cancer (Pietersen et al., 2008) while in oral squamous carcinoma aberrant 
EZH2 expression was associated with TP53 alteration (Shiogama et al., 2013). TP53 
expression is deregulated in K562 (insertion in exon 5 of TP53)(Law et al., 1993) cells but 
MOLM13 cells carry wild type TP53 (Kojima et al., 2005) therefore K562 (TP53 null) and 
MOLM13 (wild type TP53) cell lines were used for the transfection experiments and selected 
using neomycin. The expression level of EZH2 in cells selected by neomycin on day 21 was 
variable ranging between 0.56 to 17.5 fold compared to the mock transfected cells in both 
cell lines. The predicted cause for reduced EZH2 expression over time might be due to its 
promoter inactivity. Cytomegalovirus (CMV) promoter drives the expression of EZH2 in 
p3XFLAG-myc-CMV-26. The CMV promoter contains at least four types of repetitive 
sequence elements; 17, 18, 19, and 21 bp which form complexes with nuclear proteins 
(Ghazal et al., 1987), transcription factors therefore enhancing the transcription of the 
transgene, in this case EZH2 (Loser et al., 1998).The 18 and 19 bp repeats contain consensus 
binding sites for NFκB and CREB/ATF, respectively, and enhance CMV promoter activity 
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(Sambucetti et al., 1989). While the 21bp repeat binds to negative regulators like YY1 and is 
suggested to repress CMV promoter-dependent transcription (Sinclair et al., 1992). In 
addition to different binding partners and their effect on the CMV promoter activity, studies 
have shown that the promoter undergoes methylation of CpG islands after few weeks of 
transfection making it inactive (Brooks et al., 2004; Herbst et al., 2012). The effect of 
methylation on the CMV promoter is independent of the vector system, the method of 
tranfection and might attract inhibitory proteins that bind to the methylated CpG or those that 
may interfere directly with binding of transcription factors. Although the CMV promoter 
allowed for a very strong short-term expression (48 hr after transfection) of EZH2, it declined 
within 3-4 weeks and in some samples was barely detectable at the end of neomycin selection 
(day 21-24). To test whether CpG methylation of the CMV promoter was responsible for 
decreased EZH2 expression, neomycin selected cells were treated with 5-Azacytidine (500 
nM, 1 µM, 5 µM). 5-Azacytidine is a DNA methyltransferase inhibitor that is routinely used 
in the treatment of Intermediate or high risk subtypes of MDS. Its mechanisms of action 
depends on conversion of Azacitidine to 5-aza-β′-deoxycytidine-triphosphate which acts as a 
substrate and is incorporated into host DNA as azacytosine instead of cytosine. These 
residues are recognised by DNA methyltransferases as natural substrates and therefore bind 
to it initiating the process of DNA methylation. The formation of this covalent bond blocks 
the DNA methyltransferase at that site resulting in loss of methylation marks during DNA 
replication in cells treated with 5-Azacytidine (Stresemann and Lyko, 2008). In my 
experiments, EZH2 expression recovered (1.4-5.8 fold) in all cells (R690H) and (Flag tagged 
wild type EZH2) at both 48 and 72 hr post 5-Azacytidine treatment. This time point was 
chosen to allow cells to undergo cell cycle and for the 5-Azacytidine to incorporate into the 
DNA. Recovery of EZH2 expression suggests that reduced expression of the transgene was 
due to methylation of its CMV promoter. To avoid long duration of selection, EZH2 mutants 
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and Flag-tagged EZH2 were cloned into p3XFLAG-myc-CMV-26 containing GFP + 
puromycin markers and transfected into MOLM13 and K562 cell lines. Due to poor 
transfection efficiency of MOLM13 cells (0.5-2% GFP + cells) even after extensive 
optimization using a range of plasmid DNA concentrations, both lipofectamine, 
electroporation methods and verifying GFP content at different time points, this cell line was 
discontinued.  
K562 cell line transfected with the mutant (R690C and R690H) and Flag tagged wild type 
EZH2 were sorted at 72 hr post transfection for GFP+. Western blot analysis of these cells 
showed elevated protein levels of mutant EZH2 (R690C and R690H) as well as Flag tagged 
wild type EZH2 compared to empty p3XFLAG-myc-CMV-26 (GFP+ puromycin) and mock 
transfected cells. Surprisingly, there was no change in H3K27me3 protein levels with 
increase in EZH2 expression. Two reports have (Ernst et al., 2010; Makishima et al., 2010) 
carried out studies on EZH2 mutants (R690C and R690H) wherein they have shown decrease 
in H3K27me3 levels with presence of the mutation. However, Makishima et al (2010) 
examined the effect of homozygous R690H mutation on the levels of H3K27me3 in a single 
patient by western blot analysis while in my thesis, a heterozygous expression of EZH2 
R690H mutant was achieved since the endogenous EZH2 present in the cells could not be 
eliminated (Makishima et al., 2010). This suggests that the heterozygous mutation does not 
have a dominant negative effect on the H3K27me3 levels in the transfected cells and that 
these levels are maintained by the endogenous wild type EZH2. The second study focused on 
R690C mutant infected in Sf9 insect cells wherein; expression of EZH2 protein remained 
unaltered but its catalytic activity was reduced (H3K27me3). This system mimics the 
experimental design presented in my work wherein the expression of the mutant is 
heterozygous rather than homozygous. However, it is important to note that the model system 
used in both studies is different i.e insect cells versus human myeloid cells (K562). To date, it 
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is not known whether there are any species related changes in modulation of H3K27me3 
levels by EZH2 and more work needs to be done in this area.  
In addition to the possibility of species related differences or the effect of homozygous versus 
heterozygous EZH2 expression, the half life of H3K27me3 protein levels needs to be 
considered and the time point of sample collection (72 hr post transfection) needs to be 
revised. This time point was chosen based on the maximum number of GFP positive cells that 
could be sorted after transfection. There was a decline in GFP+ cells from 12-15 % on day 3 
to 9 % on day 4 post transfection. However, the reduction in GFP+ cells at day 4 might be 
due to the absence of puromycin selection pressure on the transfected cells. One way to 
circumvent this problem would be continue selection of cells by puromycin after sorting at 72 
hr. This may provide more time to examine the effect on H3K27me3 protein levels. 
However, due to insufficient time, it was not possible to repeat the experiments at variable 
time points using the above strategy to evaluate long term effects of mutant and Flag tagged 
wild type EZH2 over expression on H3K27me3 protein levels. 
Though H3K27me3 levels evaluated on western blot analysis remained unaltered after over 
expression of both mutant and wild type EZH2 in K562 cells was at work. Four genes 
implicated previously in leukaemogenesis were identified with enhanced or reduced 
expression levels. MLLT10 (Mixed lineage leukaemia translocated to 10) gene expression 
was enhanced in cells transfected with R690C (3.62 fold), R690H (4.69 fold) as well as wild 
type EZH2 (2.23 fold). The MLLT10 gene is located on chromosome 10p12 and is implicated 
in the pathogenesis of AML (adult as well as paediatric) [reviewed by (Marschalek, 2011; 
Meyer et al., 2013). The protein produced by this fusion gene is predicted to interact with and 
enhance H3K79me2/3 marks via DOT1L histone methyltransferase. Recent reports on T-cell 
lymphoblastic leukaemia have established that the fusion proteins of MLLT10 assist in up 
regulating the expression of the HOXA genes (Brandimarte et al., 2013).In this study, 
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expression of MLLT10 gene is enhanced by over expression of both mutant (R690C/R690H) 
and Flag tagged wild type EZH2 suggesting that the mutations do not affect the function of 
the wild type EZH2 in regulating this gene. HOXA genes are known targets of EZH2 and are 
up regulated in EZH2 mutated leukemic cell line like SKM-1 (Khan et al., 2013). There is an 
inverse relation of EZH2 and HOXA expression levels (especially HOXA9 and HOXA10). 
The association between EZH2-MLLT10-HOXA genes need further investigation.  
Unlike MLLT10, PML (promyelocytic leukaemia) [up regulated by 2.16 fold] and FANCL 
(Fanconi Anaemia, Complementation Group L) [up regulated by 2.18 fold] genes were only 
over expressed in Flag tagged wild type EZH2 cells. FANCL forms a part of the core Fanconi 
anaemia complex and posses a strong E3 ligase activity essential for ubquitination of 
FANCD2. Monoubiquitination of FANCD2 is induced by DNA damage and is predicted in 
transcriptional activation of tumour suppressor genes (Park et al., 2013) and activation of the 
Fanconi anaemia pathway (Huang et al., 2014). On the other hand the promyelocytic 
leukaemic (PML) gene is causally linked to acute promyelocytic leukaemia caused due to 
fusion of the N-terminus of PML to the C terminus of the retinoic acid receptor-a (RARa) 
transcription factor resulting in a balanced t (15; 17) translocation.The disease is defined by  
(a) morphological features (hypergranular cells with low white blood cell count (FAB M3)], 
(b) coagulopathy associated with hypofibrinogenaemia and (c) presence of PML-RARα 
(Degos and Wang, 2001).RARa is a nuclear receptor which in the absence of its ligand 
retinoic acid (RA) reduces the transcription of target genes by recruiting histone deacetylases 
and co-repressor molecules. In the presence of the fusion gene (PML-RARα) there is 
ineffectual effect on transcription of the downstream target genes (Dos Santos et al., 2013). 
Studies in granulocytes have shown that RARα unbound to retinoic acid negatively regulates 
granulocyte differentiation while RARα bound to RA promotes granulocyte differentiation 
(Mistry et al., 2003).  Both PML-RARα and FANCL are not directly implicated in the 
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pathogenesis of MDS/AML but it would be important to verify the findings of the micro 
array gene expression profiling on patient samples with R690C or R690H mutation to 
evaluate the effect of the mutations on the expression of the two genes.  
4.11 Conclusion 
 
Over expression of wild type EZH2 and its mutants (R690C & R690H) did not affect the 
target H3K27me3 levels in K562 cells.  It was predicted to be due to heterozygous expression 
of the transgene suggesting that the heterozygous mutation does not have a dominant 
negative effect on the H3K27me3 levels. The second explanation could be that the half life of 
H3K27me3 protein is long therefore 72 hr post transfection was not an ideal time point to 
observe any alterations in its levels. 
Gene expression profiling identified MLLT10 gene to be up regulated by both mutant and 
wild type EZH2. This finding could provide an insight into EZH2 dependant regulation of 
HOXA genes via modulation of MLLT10 gene expression. PML and FANCL genes implicated 
in acute promyelocytic leukaemia and fanconi anaemia were up regulated in cells over 
expressing the wild type but not the mutant EZH2 suggesting that the mutation might alter the 





5 Chapter: Role of EZH2 inhibition 





5.2 Knock out (KO) of EZH2 in cancer 
 
The role of EZH2 varies in context of different types of tissues for e.g. in ovarian cancer 
increased expression levels of EZH2 correlates with more aggressive histological grade of the 
tumour. In fact the association is robust enough to qualify EZH2 as an independent 
prognosticator for predicted shortened survival (Rao et al., 2010). EZH2 over expression also 
predicts poor survival in patients with prostate (Bryant et al., 2007; Varambally et al., 2002), 
breast (Mu et al., 2013), renal (Zhang et al., 2011) and colon cancer with strong correlation to 
tumour metastasis(Yu et al., 2012).  
Knock out (KO) of EZH2 using siRNA (small interfering RNA) in ovarian cancer 
demonstrated G1 phase cell cycle arrest, reduced cell proliferation and cell migration (Rao et 
al., 2010).p21 was established as an important protein in G1 to S phase check point inducing 
cell cycle arrest. EZH2-p21 association has been validated by ChIP studies.Western blot 
analysis after KO of over expressed EZH2 demonstrate recovery of typically down regulated 
p21 expression in ovarian cancer (Seward et al., 2013). In prostate cancer, EZH2 KO using 
siRNA in cancer stem cells inhibited cell cycle and progression to apoptosis (Li et al., 2013) 
while in breast cancer, EZH2 KO had no impact on apoptosis but decreased proliferation with 
delayed G2/M cell-cycle transition and up regulation of BRCA1 (Gonzalez et al., 2009). 
Other studies on prostate cancer indicate similar results with reduced cell invasion (Mu et al., 
2013) (seen on Matrigel) and proliferation (observed on MTT assay) (Bryant et al., 2007). In 
renal cancer, cell proliferation and invasion caused by down regulation of EZH2 is due to the 
regulation of the WNT/ȕ-catenin signalling pathway (Yuan et al., 2012). Interestingly, similar 
impact on proliferation and cell invasion was observed in endometrial cancer wherein down 
regulation of EZH2 was concomitant with reduced expression levels of ȕ-catenin (Eskander 
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et al., 2013) and WNT3A (Yuan et al., 2012). The impact of EZH2 on cell proliferation can be 
utilised for therapeutic effect as demonstrated by Chen et al (2007) who showed that 
intratumor injection of lentiviral shRNA (short hairpin RNA) or siRNA targeting EZH2 
resulted in tumour regression of hepatocellular carcinoma (Chen et al., 2007). In subsequent 
studies they also showed that EZH2 inhibition reduced pancreatic tumour growth and liver 
metastasis (Chen et al., 2010).                 
EZH2 has a specific role in haematological malignancies. Missense mutations (Y646) of 
EZH2 observed in lymphoma are associated with up regulation of gene expression and 
siRNA mediated KO results in G1/S phase cell cycle arrest (Velichutina et al., 2010). Results 
on natural killer/T-cell lymphoma (NKTL) implicate EZH2 as an oncogene with reduction in 
its levels closely linked to cancer cell growth retardation (Yan et al., 2013). While EZH2 acts 
as an oncogene in lymphoma, in myeloid malignancies it has a tumour suppressor role. Cross 
et al (2010) and Makishima et al (2011) showed that both the R690C & R690H mutations 
seen in MDS/AML patients reduced the protein levels of H3K27me3 on western blot (Cross 
et al, 2010; Makishima et al, 2011). However, further analysis of EZH2 down regulation on 
the downstream targets has not been studied till date. 
5.3 RNA interference 
 
The discovery of RNAi revolutionised the approach to gene silencing and our understanding 
of post transcriptional gene regulation. RNAi technology has improved tremendously since 
its advent and now provides a simple and effective way to reduce the expression levels of the 




Figure 5.1: Schematic representation of RNA interference in cells. Step 1: double 
stranded RNA (dsRNA) is cleaved by enzyme Dicer into fragments of 21-23 base pairs 
(siRNA). Step 2: siRNAs combines with the multiprotein complex: RNA Induced Silencing 
Complex (RISC) and one strand (the passenger strand) is degraded, while the guide strand 
remains attached to RISC and serves as a template for the silencing reaction. Step 3: the 
guide strand assembled into the siRNA-RISC complex targets the complementary mRNA. 
Step 4: The target mRNA is degraded and is dissociated from the siRNA. The siRNA-RISC 
complex is released to process further mRNA targets (Cuccato et al., 2011). 
 
A major problem in RNAi experiments is the widespread off target effects despite sequence 
specific targeting (Jackson et al., 2003; Lin et al., 2005; Sledz et al., 2003), (Birmingham et 
al., 2006; Jackson et al., 2006). Off target effects can be sequence related and specific to 
individual siRNA/shRNA or sequence independent and caused by siRNA/shRNA in general. 
Introducing double stranded RNA; dsRNA (one step prior to siRNA) into the cells can mimic 
a viral threat and trigger an interferon response (IFN) with widespread consequences on 
cellular processes such as cessation of protein synthesis (Bantounas et al., 2004). However 
the use of synthetic siRNA has helped circumvent IFN to a large extent. However some 
studies suggest that the vectors carrying shRNA can have effects that are similar to the 
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shRNA  (Jackson and Linsley, 2004). This response is not always activated and avoiding high 
concentrations of siRNA/shRNA is an effective control against it (Jackson and Linsley, 2004; 
Sledz et al., 2003). 
Off target effects of RNAi are sequence dependant and caused by non-specific binding to 
partially complementary mRNA transcripts. Initially it was believed that siRNA/shRNA 
contained a 7nt seed region (between base positions 2-8) at its 5’end which could bind and 
silence only those mRNAs which had the exact complementary sequence to this region. But 
many studies show that this is may not be the case (Birmingham et al., 2006; Lin et al., 
2005), (Jackson et al., 2006). Imperfect matches between the siRNA/shRNA and the mRNA 
transcripts have been observed resulting in silencing of undesired genes. These off target 
effects do not always result from transcript cleavage but may be caused by inhibition of 
translation like miRNAs (Zeng et al., 2003). Sequence homology to a 7nt siRNA seed region 
elsewhere in the genome is unavoidable making sequence specific off target effects almost 
inevitable and difficult to predict. Despite the high incidence of off target effects, RNAi 
technology is still extremely informative as long as the limitations are considered and 
carefully controlled for. In the knockdown experiments carried out in this study, possible 
non-specific effects as a result of the procedure or the addition of siRNA/shRNA are 
controlled for by using mock transfections and negative controls.  
5.4 Aim 
 
 Achieve KO of EZH2 expression in myeloid cells using siRNA or shRNA and 
identify the downstream targets of EZH2 using microarray gene expression profiling. 
 Examine the effect of EZH2 KO on cell viability, proliferation, cell cycle kinetics and 
compare it with observations made in other cancers. 
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 Validate the gene signature obtained in myeloid cell lines in patient samples. Evaluate 
whether R690H/C mutation of EZH2 commonly seen in patients with MDS mimic the 
KO of EZH2. 
5.5 Transient knockdown of EZH2 
 
Two pre-designed siRNAs were obtained from Dharmacon (ON-Target Plus SMARTPool) 
and Santacruz targeting EZH2 mRNA transcripts. A negative control siRNA (scrambled) was 
utilised which did not have any known targets in the transfected cells (Refer Appendix). 
Mock transfected cells were used to control for variations caused as a result of the procedure. 
MOLM13 and K562 cell lines were used for all experiments for the reasons mentioned in the 
previous chapter. 
5.5.1 Silencing Efficiency of siRNA (Dharmacon) in MOLM13 & K562 cells using 
RNAiMAX 
 
Cell density and confluence at the time of transfection is important for transfection efficiency 
and cell viability during the experiment. Cell density of 0.25x 106 cells/well was found to 
achieve suitable confluence for transfection with good cell viability. siRNA concentrations 
(60 nM, 300 nM and 600 nM) were tested for a maximal silencing effect by RNAiMAX 
(refer section 2.15.3 for protocol). Samples were collected at 24, 48 (Fig: 5.2), 72 hr and 






Figure 5.2: EZH2 expression levels at 48 hr by qPCR. EZH2 expression levels in 
MOLM13 (a) and K562 (b) cells calculated relative to the mock transfected cells (Y axis: 
∆∆CT) at 48 hr post transfection by siRNA. GAPDH (data shown), B2M and TUBULIN were 
used as endogenous controls and the error bars mark the standard error between three 
independent experiments. The mRNA levels of EZH2 were unaltered post siRNA 
transfection. Note: ‘*’= 60 nM, ‘**’= γ00 nM and ‘***’= 600 nM concentration of the 
control and siRNA against EZH2.  
 
 
Down regulation in EZH2 expression was not observed in both MOLM13 and K562 cells at 
24, 48 (Fig: 5.2) or 72 hr indicating either a poor transfection efficiency by RNAiMAX 
protocol or an ineffective siRNA. Data for the 24 hr and 72 hr time point is not shown 
because none of the samples showed down regulation of EZH2 expression.  
To improve the transfection efficiency, electroporation was used for subsequent experiments. 
5.5.2 Silencing Efficiency of siRNA (Dharmacon) in MOLM13 & K562 cells using 
electroporation 
 
Electroporation results in massive cell death and therefore cell seeding density was increased 
to 2 x 106 cells/well to allow for sufficient live cells for post transfection assays. siRNA 
concentration of 150 nM was tested in both K562 and MOLM13 cells (refer section 2.15.4 
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for protocol) and samples were collected at 24, 48 and 72 hr followed by assessment of EZH2 
silencing by qPCR. 
 
  
Figure 5.3: EZH2 expression levels by qPCR using 150 nM siRNA (Dharmacon) 
concentration. EZH2 expression in MOLM13 (a) and K562 (b) cells was calculated relative 
to the mock transfected cells (Y axis: ∆∆CT) at β4, 48 and 7β hr post transfection by siRNA. 
GAPDH (data shown), B2M and TUBULIN were used as endogenous controls. Error bars 
mark the standard error between three independent experiments. mRNA levels of EZH2 
remained unchanged in K562 cells while in MOLM13 35% EZH2 down regulation was 
observed in siRNA transfected cells compared to cells transfected with the scrambled (24 hr) 




35 % reduction in EZH2 mRNA level was observed in MOLM13 cells (24 hr) by 
electroporation confirming no error in siRNA functionality and transfection efficiency 
dependent improvement in EZH2 KO. Inhibition of EZH2 was maximal at 24 hr compared to 
48 and 72 hr. However, further reduction in EZH2 levels was required to correlate it to KO 
levels caused by EZH2 mutations which can be both heterozygous and homozygous.  
In K562 cells, EZH2 levels remained unchanged at all time points indicating that the siRNA 
was ineffective in these cells at 150 nM concentration. To improve the level of EZH2 KO in 
both the cell lines, the siRNA concentration was increased to 200 nM while other conditions 





Figure 5.4: Measurement of EZH2 expression levels by qPCR using 200 nM 
concentration of siRNA (Dharmacon).EZH2 expression in MOLM13 cells was calculated 
relative to the mock transfected cells (Y axis:∆∆CT) at β4, 48 and 7β hr post transfection by 
siRNA. GAPDH, B2M and TUBULIN (data shown) were used as endogenous controls. Error 
bars mark the standard error between three independent experiments. Maximal KO was 
observed at 24 hr (65-70 %) in cells transfected with siRNA versus those transfected by 
scrambled siRNA with gradual recovery of EZH2 levels at the subsequent time points. 
 
Increasing the siRNA concentration to 200 nM increased the level of EZH2 KO (65-70 %) at 
24 hr with gradual recovery of EZH2 levels (35 %) at 48 hr. In contrast, EZH2 levels 
remained unaltered in K562 cells (data not shown) even at 200 nM concentration and 




5.6 Impact of EZH2 KO on H3K27me3 
 
MOLM13 cells were collected at 24 hr and 48 hr post siRNA transfection (200 nM) for 
evaluating the effect of the KO on the protein levels of EZH2 and on its target H3K27me3 by 
western blot. 
 
Figure 5.5: Western blot analysis of siRNA mediated KO of EZH2 in MOLM13 cells at 
24 and 48 hr.65 % inhibition of EZH2 levels was observed at 24 hr compared to the 
scrambled and mock transfected cells with recovery of EZH2 levels at 48 hr. However, there 
was no concomitant decrease in H3K27me3 levels.Tubulin was used as a loading control. 
 
Western blot results confirmed the findings of qPCR wherein the maximal KO (approx 65 %) 
of EZH2 expression was observed at 24 hr post transfection with gradual recovery in the 
EZH2 levels at 48 hr (KO 40 %) indicating that 24 hr is the optimal time point to carry out 
subsequent experiments. Interestingly, the H3K27me3 levels remained unaltered at both 24 
and 48 hr suggesting that a stronger KO of EZH2 expression is required to perceive 
modifications in the target expression or that the half life of H3K27me3 protein is long and 




5.7 Cell Cycle analysis 
 
EZH2 is closely linked to cell proliferation and proteins associated with cell cycle (refer 
section 5.2) therefore the kinetics of cell cycle entry after EZH2 KO was examined by flow 
cytometric analysis (PI/FITC) (section 2.19) and the percentage of cells in each cell cycle 
phase as well as the apoptotic cells (sub G0) were studied on samples collected at 24 hr in 
MOLM13 cells (Fig: 5.6). 
  
Figure 5.6: Cell cycle profile of MOLM13 at 24 hr post transfection.Samples were fixed 
(70% ethanol v/v) and stained with PI (DNA content) and FITC (protein content).The 
percentage of cells in sub G0, G0/G1, S and G2/M phases of the cell cycle remained 
unaltered in the cells transfected with the siRNA versus those transfected with the scrambled 
or the mock transfected cells. Data represents three independent experiments. 
 
There were no variations in the percentage of cells in the four phases of the cell cycle (sub 
G0, G1/M, S and G2/M) between cells transfected with the siRNA and those transfected with 
the scrambled or the mock transfected cells. This suggests that either a stronger KO of EZH2 
expression is required in order to detect changes in the cell cycle kinetics or else EZH2 
expression levels did not affect cell cycle proteins in MOLM13 cells. To test this hypothesis, 
higher concentrations of the siRNA were employed to accomplish a stronger KO of EZH2 
and its target; H3K27me3 in MOLM13 cells. Increasing concentrations of siRNA did not 
lead to further down regulation of EZH2 or H3K27me3 but increased the risk of off target 
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effects caused by non-specific binding of the siRNA to partially complementary mRNA 
transcripts. Therefore observations noted at 200 nM concentration of the siRNA (Dharmacon) 
were considered as final results and an additional siRNA or shRNA mediated KO EZH2 was 
utilised to confirm the findings of the first siRNA (Dharmacon). 
5.8 Silencing Efficiency of siRNA (Santacruz) in MOLM13 & K562 cells 
using electroporation 
 
As previously described, MOLM13 cells were seeded at a density of 2x 106 cells/well and 
transfected by electroporation (refer section 2.15.4) with siRNA from Santacruz 
Biotechnology at varying concentrations (50-200 nM). Samples were collected at 24 (Fig: 
5.7), 48 and 72 hr followed by assessment of EZH2 silencing by qPCR. There was no 
noticeable KO of EZH2 at 48 and 72 hr and therefore the data has not been shown. 
 
 
Figure 5.7: EZH2 expression levels at 24 hr after transfection with siRNA from 
Santacruz biotechnology by qPCR. EZH2 expression in MOLM13 cells was calculated 
relative to the mock transfected cells (Y axis: ∆∆CT). GAPDH (data shown), B2M and 
TUBULIN were used as endogenous controls. Error bars mark the standard error between two 
independent experiments. Note: ‘*’= 50 nM, ‘**’= 100 nM and ‘***’= 150 nM and ‘****’= 
200 nM concentration of the control and siRNA against EZH2.The expression of EZH2 
varied markedly with increasing concentrations of the scrambled. At 150 and 200 nM of 




At 24 hr, increasing concentrations of the siRNA (50 to 200 nM) correlated with down 
regulation of the EZH2 levels. However, this effect was also observed in cells transfected 
with the scrambled (-ve control) which showed > 60 % KO at 150 and 200 nM 
concentrations. This unfavourable effect of the scrambled siRNA was absent at low 
concentrations (50 & 100 nM). However, lowering the concentration (50 or 100 nM) of the 
siRNA against EZH2 to match that of the scrambled resulted in absence EZH2 KO.  
Therefore the experimental strategy was changed to using shRNA mediated KO of EZH2. 
5.9 Stable knockdown of EZH2 using shRNA in pSUPER 
 
To achieve long term down regulation of EZH2 to assess the effect on H3K27me3 protein 
levels, a stable system of gene suppression was required. This was accomplished by adapting 
the method of RNAi from siRNAs to the more sustainable short hairpin RNA (shRNA) 
mediated approach. shRNA is expressed in the cell from a DNA construct encoding the sense 
and antisense strands of the siRNA separated by a short loop sequence. The RNA transcripts 
fold at the loop and self anneal to form dsRNA stem loop structure: a short hairpin RNA. The 
shRNA is processed like a miRNA by the RNAi machinery to mediate target silencing. 
Conventionally RNA polymerase III promoters U6 and H1 are used for shRNA expression, 
generating transcripts lacking a long poly (A) tail that may hinder subsequent RNAi 
processing machinery. In this study four shRNAs against EZH2 were designed and cloned in 
to the pSUPER vector (refer section 2.16.1) which is driven by H1 promoter (Amarzguioui et 
al., 2005; Brummelkamp et al., 2002; Gou et al., 2003). The plasmid was transfected into 
MOLM13 and K562 cells using both eletroporation and lipofectamine methods. The 
experimental work flow is detailed in Fig: 5.8. Post puromycin selection, RNA was extracted, 




Figure 5.8: Experimental workflow for transfection of pSUPER containing shRNA 
against EZH2 into MOLM13 and K562 cells. The cells were seeded in 6 well plates and 
transfected with either with 1 µg/well of individual shRNA or 1,3 and 5 µg/well of 
combination of all four shRNAs resuspened in 100 µl of MirusBio Ingenio electroporation 
solution using the Nucleofactor device II (program: O-017 for MOLM13 and T-016 for 
K562). Mock transfected cells were technical control for alterations caused due to the 
transfection procedure. Untransfected cells were exposed to puromycin to estimate the end 
point of puromycin selection for the cells. 
 
qPCR results for both electroporation and lipofectamine showed similar level of EZH2 KO in 
both cell lines and therefore data for MOLM13 has been illustrated. shRNA4 and 
combination of all four shRNAs showed more KO as compared to shRNA1, shRNA2 or 
shRNA3 and combination of all at 5 µg/well (Fig: 5.9). Three independent experiments were 
conducted using shRNA4 and the combination of all the shRNAs (Fig: 5.10) using 1 and 3 
µg/well of the plasmid. However the level of EZH2 KO achieved after puromycin selection 
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was only 40-50 %. To improve the level of EZH2 KO, shRNAs cloned in lentiviral vector 
were used in the subsequent experiments. 
 
 
Figure 5.9: EZH2 expression levels after puromycin selectionin cells transfected with 
shRNA in pSUPER vector by qPCR. EZH2 expression levels in MOLM13 cells were 
calculated relative to the mock transfected cells (Y axis: ∆∆CT). GAPDH, B2M and 
TUBULIN (data shown) were used as endogenous controls. Error bars mark the standard error 
between two independent experiments. Note: ‘*’= 1 µg/well, ‘**’= γ µg/well and ‘***’= 5 
µg/well concentration of the control and shRNA against EZH2. shRNA4 and combination of 
all four shRNAs at 1 and 3 µg/well concentrations (blue bars) showed higher levels of KO 
(40-50 %) as compared to shRNA1,2,3. 
 
Figure 5.10: qPCR analysis of EZH2 expression after puromycin selectionin cells 
transfected with shRNA in pSUPER vector. EZH2 expression in MOLM13 cells was 
calculated relative to the mock transfected cells (Y axis: ∆∆CT). GAPDH, B2M and 
206 
 
TUBULIN (data shown) were used as endogenous controls. Error bars mark the standard error 
between three independent experiments. Note: ‘*’= 1µg/well and ‘**’= γ 
µg/wellconcentration of the control and shRNA against EZH2. shRNA4 and combination of 
all four shRNAs at 1 and 3 µg/well concentrations (blue bars) showed 40-50 % KO of EZH2. 
5.10 Stable knockdown of EZH2 using shRNA in lentivirus 
 
5.10.1 shRNA (Insight Biotechnology) 
 
Four shRNAs (TL304713) were obtained from Insight Biotechnology (UK) and lentiviral 
particles were generated (refer section 2.17). K562 and MOLM cells were transduced with 
the virus containing the shRNA and EZH2 expression was analyzed by qPCR at 48 hr and 
subsequently on each day till day7. Downregulation of EZH2 was not observed in both the 
cell lines at any of time points on the contrary the levels of EZH2 were elevated at day 7 post 
transduction (Fig: 5.11). Two independent experiments were conducted on both cell lines 
with similar results confirming that the shRNAs were ineffective against the target gene and 
were discontinued for further experiments. 
 
Figure 5.11: qPCR analysis of EZH2 expression levels at day7 post infection by shRNA 
(Insight Biotechnology).EZH2 expression levels were calculated relative to the untransduced 
cells (Y axis: ∆∆CT). GAPDH (data shown), B2M and TUBULIN were used as endogenous 
controls. Error bars mark the standard error between two independent experiments. The 
expression of EZH2 was up regulated in cells transduced with all shRNAs including the 
scrambled confirming that they were ineffective in knocking down EZH2. 
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5.10.2 shRNA (Fisher Scientific) 
 
Four shRNAs were obtained from Fisher Scientific (labelled A-D) and lentiviral particles 
containing these shRNAs were generated (refer section 2.17). K562 (Fig: 5.12) and 
MOLM13 cells were transduced with the virus carrying the shRNA and the transduced cells 
were selected by puromycin. Cells subjected to puromycin selection, after 48 hr of 
transduction showed 80-90 % cell death with very slow recovery of the remaining cells (15-
18 days). This was observed in spite of 40-50 % of the transdcued cells being GFP positive 
(BD LSRFortesssa) at 48 hr post transduction indicating moderate infection efficiency. But 
repeated experiments indicated that GFP positivity and puromycin resistance were not 
concomitant in all instances. The GFP expression in the transduced cells was more consistent 
at a given time point for a particular concentration of the shRNA in majority of the 
experiments and therefore this parameter was used for cell selection instead of employing 
puromycin selection. GFP positive cells were sorted [BD Fluorescence-activated cell sorter 
FACS) Aria I] at day 7 to obtain pure population of cells transduced by the shRNA. In 
MOLM13 cell line the percentage of GFP positive cells at all time points (24 hr – 7 day) was 
very low rendering it difficult to sort enough cells for subsequent assays. The level of EZH2 
KO in MOLM13 was negligible (10 %) which correlated with the percentage of GFP positive 
cells at all time points.  
In K562 cells, EZH2 expression was analyzed by qPCR at 48 hr post infection (a) and on 
subsequent days with the maximal KO observed at day 7 (b). This time point was used to sort 
(BD Facs Aria I) GFP positive cells using a 100 μM nozzle, sheath pressure of 20 psi and 
post sort purity of 97-99 % to segregate cells carrying the shRNA from the untransduced 
cells. This enabled collection of pure population of GFP positive cells carrying the shRNA 




Figure 5.12: qPCR analysis of EZH2 expression levels at 48 hr and 7 days after 
transduction with lentivirus containing shRNA (Fisher Scientific) in K562 cells. EZH2 
expression levels were calculated relative to the untransduced cells (Y axis: ∆∆CT). GAPDH, 
B2M (data shown) and TUBULIN were used as endogenous controls. Error bars mark the 
standard error between two (a) and three (b) independent experiments. shRNA_D showed 50 
% KO at day 7 and therefore this shRNA was used for subsequent experiments. 
 
The level of EZH2 KO was minimal at 48 hr with all four shRNAs but gradual increase in the 
down regulation of EZH2 was observed in cells transduced with shRNA_D with the maximal 
KO noted at day 7 post transduction. To increase the level of EZH2 KO the virus (shRNA_D) 
was concentrated by centrifugation and different quantities (range 10-100 µl) of the 
concentrated virus were tested on both the cell lines. MOLM13 cells transduced with the 
concentrated virus showed no change in EZH2 expression by qPCR while the level of KO 
increased when the viral titre was increased in K562 cells (Fig: 5.13). The poor transduction 
efficiency of the MOLM13 cells by lentivirus made it difficult to achieve a significant down 




Figure 5.13: qPCR analysis of EZH2 expression at day 7 after transduction with the 
concentrated lentivirus containing shRNA (Fisher Scientific) in K562 cells. EZH2 
expression levels were calculated relative to the untransduced cells (Yaxis: ∆∆CT). GAPDH 
(data shown), B2M and TUBULIN were used as endogenous controls. Error bars mark the 
standard error between three independent experiments. Maximal KO was observed when 100 
µl of the virus was used. However with both 50 and 100 µl of the virus, massive cell death 
was observed due to viral toxicity. Using 40 µl of the virus resulted in significant KO of 
EZH2 expression in the scrambled shRNA, therefore 30 µl (red arrow) of the viral 
concentration was used for all subsequent experiments which achieved 80-85 % down 
regulation of EZH2 mRNA levels. 
 
Maximal KO (80%) was observed when 100 µl of the virus was used. However using large 
quantities of the virus (50 & 100 µl) resulted in markedly increased cell death due to viral 
toxicity. Lowering the concentration to 40 µl of the virus resulted in the KO of EZH2 
expression in the scrambled shRNA and therefore 30 µl (red arrow) of the viral concentration 
was chosen for all subsequent experiments which achieved 80-95 % down regulation of 
EZH2 mRNA levels. 
5.11 Effect of shRNA_D on EZH1 expression 
 
EZH1 is a paralogue of EZH2 with 65% and 94% conservation of amino acids and SET 
domainsequence respectively between the two (refer 1.4.3). Therefore it was important to 
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evaluate the effect of shRNA_D on EZH1 expression levels in addition to its effect on EZH2. 
In the event of both EZH2 and EZH1 down regulation by shRNA_D it would be difficult to 
interpret the individual effect of EZH2 KO in downstream assays. Therefore, it was important 
that shRNA_D regulated KO was limited only to EZH2 gene and not EZH1. This was 
evaluated by qPCR using primers against the EZH1 gene. 
 
Figure 5.14:qPCR analysis of EZH1 expression levels at day 7 after transduction with 
shRNA_D in K562 cells.EZH1 expression levels were calculated relative to the uninfected/ 
untransduced cells (Y axis: ∆∆CT). GAPDH (data shown), B2M and TUBULIN were used as 
endogenous controls. Error bars mark the standard error between three independent 
experiments. The expression of EZH1 was not altered by shRNA_D (<10 % KO) confirming 
that shRNA_D was specific against EZH2. 
 
qPCR analysis illustrated  that shRNA_D did not alter EZH1 levels at day 7 post transduction 
in GFP + sorted cells. EZH2 levels decreased >85 % at the same time point in all the samples 
confirming that shRNA_D specifically targeted EZH2 expression and could be reliably used 




5.12 Impact of EZH2 KO on H3K27me3 
 
K562 cells were collected at day 7 post FACs sort for GFP positive cells to evaluate the 
functional effect of the KO on the protein levels of EZH2 and on its target H3K27me3 by 
western blot. 
 
Figure 5.15: Western blot analysis of shRNA mediated KO of EZH2 in K562 cells on 
day 7 post FACs sorting for GFP positive cells. 95-100 % KO in the EZH2 and H3K27me3 
protein levels were observed in cells transduced with shRNA_D compared to those 
transduced with the scarmbled shRNA and the wild type cells. The impact of H3K27me3 
downregulation was evaluated on other histone 3 related marks (H3K4me3 & H3K9me3) and 
no change was observed in their protein levels. Tubulin was used as a loading control. Note: 
All data are representative of findings from five independant experiments. 
 
Western blot analysis confirmed the findings of qPCR wherein shRNA_D down regulated the 
expression levels of EZH2. In fact the KO of EZH2 at the protein level was higher (95-100%) 
than that observed at the mRNA level (85%). The reason for the difference in EZH2 mRNA 
and protein levels of was not clear and was observed in multiple experiments. Western blot 
results suggested that a robust EZH2 down regulation was required to down regulate its 
functional target H3K27me3. The samples were also collected at a later time point (day 7 
versus 24 hr for the siRNA experiment) compared to siRNA experiment therefore allowing 
sufficient time for degradation of H3K27me3 protein. The loss of H3K27me3 had no impact 
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on other histone 3 marks (H3K9me3 and H3K4me3) suggesting that their levels were 
independent of each other. 
5.13 Microarray gene expression analysis of shRNA transduced cells 
reveals novel EZH2 targets 
 
EZH2 is directly linked with modulation of gene transcription by targeting H3K27 
trimethylation. As shown in the previous section, shRNA mediated EZH2 down regulation 
resulted in loss of H3K27me3 levels in K562 cells. To examine the effect of EZH2 loss on 
gene expression profile, microarray analysis was carried out on K562 cells transduced with 
the shRNA, scramble shRNA and the untransduced cells sorted for GFP + on day 7. RNA 
from these experiments was extracted and used to probe gene expression microarrays 
(Affymetrix Human Transcriptome 2.0 arrays). Data analysis identified (refer section 
2.12.10), a list of genes either induced or down regulated in the cells carrying shRNA against 
EZH2 versus those carrying the scrambled shRNA (Table: 5.1). 10 genes were up regulated 
and 66 were down regulated (>2 average fold difference, p <0.05, ANOVA) in the EZH2 
shRNA transduced cells. The downstream effectors of EZH2 classified functionally into four 
major groups encoding cell adhesion, Immune response & Apoptosis and survival. Top 
enriched pathways and processes were determined Metacore Analysis and the following p 
values were obtained for top three pathways: Cell adhesion_Chemokines and adhesion (p 
value 0.001), Cell adhesion_ECM remodeling (p value 0.0017), Apoptosis and survival_p53-
dependent apoptosis (p value 0.007) and process; Cell adhesion_Cell-matrix interactions (p 
value 0.001), Signal Transduction_BMP and GDF signaling (p value 0.005), 
Development_Blood  vessel morphogenesis (p value 0.009). The p values are high suggesting 
that EZH2 KO did not have a strong effect on a single pathway but affected genes belonging 
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Figure 5.16: Illustrates schematic representation of top enriched pathways (a) and 
processes (b) for all up and down regulated genes after EZH2 KO. Indicated pathways 
and processes were determined by Metacore Analysis. The log p value for each pathway is 
mentioned at the top. Genes involved in cell adhesion were ranked at top followed by those 
involved in Immune responses and apoptosis. However the p values were high suggesting 
that EZH2 KO does not have a strong effect on a single pathway but affects genes belonging 







(shrna vs. scr) 
Fold 
Change 
SLC16A7 0.034 4.77 
C5orf42 0.002 3.1 
MIR1302-5 0.012 2.44 
MIR4653 0.038 2.38 
HBZ 0.022 2.23 
HBM 0.012 2.16 
RASL10A/RRP22 0.047 2.05 
TRIM66 0.038 2.04 
SLC25A48 0.036 2.04 
NHLH1 0.026 2.02 
 
Down regulated  
Gene Symbol 
p-value 
 (shrna vs. scr) 
Fold  
Change  
CD44 0.040 -8.12 
SNORD45 0.002 -6.37 
OLAH 0.004 -5.99 
MIR4791 0.022 -5.74 
MIR676 0.044 -4.96 
COL6A3 0.011 -4.69 
UPP1 0.023 -4.54 
FLT1 0.038 -4.03 
SLC22A15 0.029 -4 
MIR4432 0.020 -3.67 
CCDC152 0.018 -3.67 
PAG1 0.030 -3.37 
TSLP 0.023 -3.24 
ETS1 0.001 -3.21 
IFI16 0.014 -3.11 
MIR101-2 0.009 -3.1 
NRP1 0.023 -3.09 
GPR65 0.030 -2.86 
ANXA3 0.001 -2.67 
TGFBR2 0.008 -2.64 
AREG, AREGB 0.020 -2.64 
SNORD115-6 0.025 -2.62 
CSTA 0.019 -2.55 
PLAU 0.020 -2.55 
CD3D 0.016 -2.53 









Down regulated  
Gene Symbol 
p-value 
 (shrna vs. scr) 
Fold  
Change  
ARHGAP25 0.005 -2.47 
SRPX 0.002 -2.46 
CALB1 0.033 -2.42 
AREG, AREGB 0.015 -2.36 
SUCNR1 0.048 -2.36 
HVCN1 0.009 -2.33 
SLC24A2 0.001 -2.33 
SLC9A7 0.043 -2.32 
ZCWPW1 0.039 -2.3 
SLC27A6 0.011 -2.29 
ARHGAP20 0.003 -2.28 
MPZL3 0.005 -2.28 
AMIGO2 0.020 -2.28 
SDC4 0.009 -2.28 
PPIC 0.043 -2.25 
C7orf23 0.043 -2.24 
HOXA10 0.005 -2.2 
RAP1B 0.002 -2.18 
BCL2 0.001 -2.14 
SERPINB8 0.002 -2.13 
MTX3 0.034 -2.12 
GADD45B 0.011 -2.11 
CD83 0.001 -2.1 
ATF3 0.019 -2.1 
SERPINE2 0.009 -2.1 
NEK3 0.022 -2.09 
EPS8 0.005 -2.08 
CXorf66 0.042 -2.07 
C1orf198 0.010 -2.06 
TTC39B 0.017 -2.05 
NRIP3 0.002 -2.05 
C10orf55 0.036 -2.03 
MIR376B 0.014 -2.02 
ST6GALNAC3 0.008 -2.01 
LGALS3 0.005 -2.01 
CYLD 0.016 -2.01 
ACRC 0.020 -2.01 
TNFRSF9 0.021 -2.01 
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Table 5.1: List of genes modulated by loss of EZH2 expression.Ten genes were up 
regulated and 66 were down regulated (>2 average fold difference, p <0.05, ANOVA). Nine 
genes (highlighted) were chosen for qPCR based validation because of their most pronounced 
change in expression and prior correlation to haematological malignancies. 
5.13.1 Validation of EZH2 targets 
 
qPCR was used to confirm the results obtained by microarray gene expression analysis (Fig: 
5.17). The genes investigated (highlighted in the table) were; BCL2, FLT1, HOXA10, CD44, 
CD83, TSLP, IFI16 and PAG1. These genes were chosen based on the degree of fold change 
[CD83, TLSP, PAG1, IFI16], known correlation to haematological malignancies [BCL2, 










Figure 5.17: qPCR validation of genes modulated due to loss of EZH2 in K562 cells.Gene 
expression levels were calculated relative to the transduced cells (Y axis: ∆∆CT). GAPDH 
(data shown), B2M and TUBULIN were used as endogenous controls and the error bars mark 
the standard error between three independent experiments.The level of KO mentioned in the 
text is compared to the cells infected with the scrambled shRNA.The genes associated with 
apoptosis (BCL2, PAG1 & IFI16) showed -4 to -6 fold reduction in their expression while 
those linked to immune modulation (CD44, CD83, TLSP) were down regulated to -2.5 to -7 
fold  and FLT1 and HOXA10 expressions were reduced to -4 fold change. 
 
mRNA used for qPCR based validation of genes was collected from three independent 
experiments and was separate from mRNA collected for microarray gene expression studies. 
The deregulation of genes due to loss of EZH2 observed in microarray gene expression 
experiment were confirmed, FLT1 and HOXA10 (associated with cell differentiation) 
expressions showed a direct association to EZH2 levels with loss of one leading to reduced 
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expression of the other. Other genes were categorised as; a) those associated with immune 
modulation (CD44, CD83, TLSP) which were down regulated to -2.5 to -7 fold change and b) 
genes associated with apoptosis (BCL2, PAG1 & IFI16) which showed a fold change of -4 to 
-6 of BCL2 and PAG1expression causeing decreased cell proliferation while reduced 
expression of IFI16 induces cell proliferation (discussed later). This paradoxical effect of 
EZH2 modulated genes on cell proliferation can contribute to disease pathogenesis of MDS. 
MDS is closely linked to apoptosis/deregulated cell proliferation leading to peripheral blood 
cytopenias with paradoxical bone marrow hypercellularity. Cytopenias are generally 
classified as deficiency or immune mediated, induced by BM failure or idiopathic. 
Cytopenias in MDS are caused due to bone marrow failure and are important or sometimes 
are the only clinical indication to diagnose this disease in its early stages (Valent, 2012). 
Apart from their role in disease detection, they are also critical in predicting the prognosis of 
the disease. International Prognostic Scoring system (IPSS) evaluates prognosis of the 
patients based on the number of lineages (anaemia, thrombocytopenia, neutropenia) affected 
by cytopenias. Increasing clinical stages of MDS, shortened OS and time to evolution were 
observed in patients with severe cytopenias (Kao et al., 2008). The importance of cell 
proliferation and apoptosis in this disease needs further clarification and to this end I 
examined the effects of EZH2 KO on apoptosis (Annexin V staining), cell proliferation (MTT 
assay, trypan blue staining) and cell cycle kinetics (PI/FITC staining) in K562 cells. 
218 
 
5.14 Impact of EZH2 KO on cell viability & proliferation 
 
5.14.1 Trypan blue staining 
 
To assess cell viability and proliferation, Trypan blue dye exclusion method was utilised. 
Trypan blue does not stain live cells (intact cell membrane) but it traverses the cell membrane 
of dead cells staining them with a distinctive blue colour under the microscope.  
Cell suspension was inoculated (triplicates) in 12-6 well plates and on each day post 
transduction with lentivirus containing shRNA_D, 10 µl of the cell suspension was mixed 
with 10 µl of 0.4% Trypan blue solution (w/v) (Lonza). The mix was incubated at room 
temperature for 3 min and the cells were counted using a dual chamber haemocytometer and 
a light microscope. The cell count/ml was calculated using formula: 
Total number of cells (four corner squares of haemocytometer) x dilution factor x 104 





Figure 5.18: Cell count of K562 cells using Trypan blue staining post shRNA lentiviral 
infection. X axis = number of days post transduction, Y axis = Total cell count (x 106). Very 
few (< 0.5 %) dead cells (staining blue) were observed in the three experimental conditions at 
all time points. There was no difference in the proliferation rates of cells transduced with 
shRNA_D against EZH2 (red), scrambled (black) and the wild type cells (blue) suggesting 




Trypan blue dye exclusion method indicated nearly identical cell counts in all three 
experimental conditions at a given time point. The number of dead cells (staining blue) were 
low (<0.5 %) in all the samples suggesting that there was no difference in cell viability and 
proliferation rate in cells transduced with shRNA_D against EZH2 versus the cells transduced 
with the scrambled shRNA and the wild type cells.  
5.14.2 MTT  tetrazolium cell proliferation assay 
 
To confirm the effect of EZH2 inhibition on cell proliferation, K562 cells were transduced 
with shRNA _D and scrambled shRNA. At day 7 (95 % KO), the cells containing GFP were 
sorted (BD FACS Aria) and were seeded at a density of 30,000 cells/ well in 100 µl RPMI 
media for different time points (24, 48 and 72 hr). All samples were seeded in triplicates 
including wild type cells. Three wells without cells but with media (RPMI) were used as 
control (blank) to negate background signal. MTT assay was performed (refer section 2.18) 
and readings were measured at 570 nm using a plate reader. The data was analysed by 
calculating the average for the triplicates in each sample and normalizing this mean value 
with the average of the blank (sample-blank). Fold change was determined by dividing the 
normalized average of the samples by the normalized average of the calibrator sample (wild 
type cells). Though wild type cells are used as calibrator, the change in the proliferation rate 
and the p vaules are mentioned compared to the cells transduced with scrambled shRNA. 
There was no significant (p =0.1 - 0.4) reduction in the metabolic activity of the cells 
transduced with shRNA_D versus those transduced with scrambled shRNA or wild type cells 
confirming that EZH2 KO has a minimal, non significant effect on myeloid cell proliferation 
(Fig: 5.19). 




Figure 5.19:Cell proliferation assessment by MTT assay on day 7 after transduction in 
K562 cells.Cells were seeded at a density of 30,000/well in 100 µl RPMI for three time 
points (24, 48 and 72 hr). Cell proliferation by MTT assay revealed minimal reduction in 
proliferation of cells (p = 0.1 to 0.4) with EZH2 inhibition (95 %) at all time points. Results 
are expressed as fold change relative to the wild type cells while the p values are calculated 
relative to the scrambled. Error bars represent standard error for five independent 
experiments each performed in triplicate.  
 
The results from trypan blue dye exclusion method and MTT assay confirm that KO of EZH2 
(95 %) does not have a significant effect on cell proliferation in K562 cells.  
5.14.3 Annexin V staining 
 
To examine the effect of EZH2 inhibition on cell viability and to confirm the findings of 
Trypan blue dye exclusion method, cells transduced with shRNA_D (against EZH2) were 
stained with Annexin V (refer section 2.20). Annexin V staining provided an advantage in 




Figure 5.20: Annexin V and 7-AAD staining of K562 cells at 48 hr post shRNA 
transduction (top panel) and on day 7 post sorting for GFP positive cells (bottom panel). 
The difference between the percentage of live (Q4 = double -ve for annexin and 7-AAD), 
early apoptotic (Q3 = + ve annexin and - ve 7-AAD) and late apoptotic cells (Q2 = double 
+ve for annexin and 7-AAD) was not significant between cells transduced by shRNA_D 
versus those transduced by scrambled shRNA and wild type cells indicating that EZH2 KO 
does not affect cell viability in myeloid neoplasms. Note = data represents three independent 
experiments. 
 
Fig: 5.20 illustrate Annexin V and 7-AAD staining in K562 cells at two time points (48 hr 
post shRNA transduction and day 7 post sorting for GFP positive cells). There was no 
difference in the percentages of live, early apoptotic and late apoptotic cells transduced by 
shRNA_D versus those transduced by scrambled shRNA and wild type cells. The results 
imply that loss of EZH2 expression does not affect cell viability in K562 cells confirming the 
findings of cell count by trypan blue. 
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5.14.4 Cell Cycle analysis 
 
The close association of EZH2 to cell cycle has been shown in various types of cancers and 
has been discussed in section 5.2. To study the change in kinetics of cell cycle entry after 
EZH2 inhibition, flow cytometric analysis (PI/FITC) (section 2.19) and the percentage of 
cells in each cell cycle phase as well as apoptotic cells (sub G0) were studied in GFP positive 
K562 cells sorted on day 7 (Fig: 5.21).  
 
Figure 5.21:Cell cycle profile in K562 cells on day 7 after sorting for GFP positive cells. 
Samples were fixed (70% ethanol v/v) and stained with PI (DNA content) and FITC (protein 
content).The percentage of cells in sub G0, G0/G1, S and G2/M phases of the cell cycle were 
determined by flow cytometry and remained unaltered in the cells transduced with the 
shRNA (KO 95 %) versus those transduced with the scrambled or wild type cells. The 
percentage of apoptotic cells (sub G0) varied marginally between the wild type cells (3.39 %) 
and those transduced with the shRNA (1.07 %) and the scrambled (1.75 %) but the difference 
was variable between the experiments and not significant. Note = data represents findings 
from three independent experiments.  
 
Down regulation of EZH2 (95 %) in K562 cells did not alter the protein content (i.e. cell size) 
or the DNA content (PI stain) in myeloid cells (K562), a finding consistent with results 
obtained by siRNA mediated EZH2 KO (65 %) in MOLM13 cell line (refer section 5.7). The 
percentage of cells in the different phases of the cell cycle (G1/M, S and G2/M) as well as the 
apoptotic cells (sub G0) remained unaltered after EZH2 KO. The role of EZH2 in cell cycle 
kinetics of myeloid cells (MOLM13 and K562) was not as a enhancer of proliferation as 
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compared to its functionality in other cancers (ovarian cancer G1 phase arrest and 
prostate cancer G2/M phase delay) wherein down regulation of EZH2 had profound 
impact on cell proliferation and cell invasion indicating an extremely cell type specific 
role of this gene.  
5.15 Confirmation of gene signature in patient samples 
 
Bone marrow samples from 61 patients were previously sequenced by our group (refer 
chapter 3) and nine patients were identified with EZH2 mutations. The previous chapter was 
focused on constructing and studying EZH2 R690H mutation located in the SET domain of 
this enzyme. One of the nine patients in our cohort carried the R690H mutation (Table: 5.2). 











Normal No RCMD Low 2 % 
LSL/001240 Normal No RCMD Int-I <5 % 
LSL/000961 complex No RAEB 1 Int-II 2 % 
LSL/002025 Monosomy 7 No RCMD Int-II 2% 
LSL/002029 Normal No RCMD Int-I 1% 
LSL/001904 Normal No RARS Int-I 4% 
Table 5.2: Characteristics of patients used for confirmation of gene signature obtained 
by microarray gene expression profiling. LSL/001326 patient is mutated for EZH2 
(R690H) while the other five patients contain wild type EZH2. 
 
To evaluate whether this mutation mimics loss of EZH2 in patients, qPCR was carried out on 
RNA extracted from this patient and compared to five control patients (Table: 5.2) without 
EZH2 mutation. Genes identified by microarray analysis were tested (BCL2, PAG1, IFI16, 
CD44, CD83, HOXA10, RAP1B, FLT1and TSLP) on patient samples. Two additional genes 
EZH1 and CDKN2A were also examined due to their association with EZH2. Statistical tests 
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to calculate significance (p value) could not be carried out for this experiment since the 
sample size in each category was very small [n=1 (R690H mutant)]. Five genes HOXA10, 
FLT1, PAG1B, EZH1 and TLSP (Fig: 5.22) were up regulated in the patient carrying the 
R690H mutant compared to the control patients while other genes showed no change in their 
expression levels. Interestingly, these results were opposite to the findings observed with 
inhibition of EZH2 expression using shRNA in lentivirus where these genes were down 






Figure 5.22: qPCR analysis of patient samples with (R690H) or without EZH2 mutation. 
Gene expression levels were calculated relative to GAPDH (data shown) and B2M (Y axis: 
∆CT) which were used as endogenous controls. 5/11 genes showed change in their expression 
in patient with EZH2 mutation (R690H) (n=1) versus the control patients (n=5). Interestingly, 
these results were reverse to the findings observed with inhibition of EZH2 expression using 
shRNA_D suggesting that EZH2 mutation does not mimic loss of function of the gene. 




Target genes and binding partners of histone methyltransferase EZH2 are extremely tissue 
specific and vary depending upon the stage of cell differentiation. Over expression of EZH2 
has been confirmed in ovarian, renal, colorectal, breast, prostate cancer and the level of EZH2 
expression has been correlated negatively to disease prognosis and relapse free survival. In 
contrast, its role in haematological cancers differs in lymphoid malignancies were mutations 
of this gene were linked to it’s over expression while in myeloid malignancies they were 
associated with loss of its methyltransferase activity. The involvement of EZH2 in H3K27 
methylation makes it a key regulator of transcription. 
5.16.1 Transcription and gene expression profiling 
 
Transcription is an intricate process which is regulated by both genetic and epigenetic factors. 
Epigenetic marks, such as DNA methylation and modification of histone tails are crucial in 
transcriptional regulation. As mentioned above, EZH2 modifies H3K27 tails and hence has 
widespread influence on gene expression. Therefore it is not surprising that this gene is 
disrupted in cancers including MDS/AML. Understanding the deregulation of EZH2 and its 
influence on transcriptional regulation of target genes is at the heart of understanding the role 
of this gene in the pathogenesis of MDS/AML(Young et al., 2011). The data presented here 
show that inhibition of EZH2 expression in myeloid cells caused loss of H3K27me3 marks as 
seen on western blot analysis. Transient KO of EZH2 by siRNA (Dharmacon) in MOLM13 
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cells reduced the expression of EZH2 by 65% but a concomitant loss of H3K27me3 was not 
perceived at both 24 and 48 hr time points indicating that either a more effective KO of EZH2 
was essential or H3K27me3 had a long half life and therefore the degradation of this protein 
is not observed at 24 hr (Budhavarapu et al., 2013). Therefore lentiviral based shRNA 
(against EZH2) transduction was carried out resulting in 95 % KO of both EZH2 and 
H3K27me3 expression levels in K562 cells at Day7 after sorting for GFP positive cells. The 
effect of H3K27me3 loss on gene expression can be multi-dimensional as studies using ChIP-
sequencing on murine embryonic fibroblasts and human embryonic cells have generated 
genome wide maps of H3K27me3 marks and found that the position of these marks across 
the gene dictated the resultant transcriptional inhibition (H3K27me3 marks across the body of 
the gene), transcriptional activation (H3K27me3 marks at the promoter) or both (H3K27me3 
marks at the transcriptional start site). H3K27me3 marks at the transcriptional start site are 
bivalent and usually related to H3K4me3 at these sites (Young et al., 2011). Apart from 
individual gene occupancy, these marks can also be found in large domains that spread over 
hundreds of kilobases and regulate entire gene families. To define a gene signature caused by 
loss of H3K27me3 as a result of EZH2 inhibition in K562 myeloid cells, microarray gene 
expression profiling was carried out which identified BCL2, FLT1, HOXA10, CD44, CD83, 
TLSP, IFI16and PAG1 genes to be down regulated. Gene expression profile obtained in this 
study was compared to gene signatures data available from studies conducted in other types 
of cancers (Table: 5.3) to examine overlapping genes signatures. As expected, there was no 
overlap of EZH2 targets between the data sets confirming that EZH2 target genes differ in the 
context of cell/ tissue type. The exact reason for the varying mechanisms in EZH2 mediated 
transcriptional regulation in different cell types is still unclear though the effect on cell 
proliferation and differentiation was invariable between epithelial ovarian cancer, epidermal 
progenitor cells,neural stem cells and Ewing tumour. 
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Top genes Tissue type EZH2 KO (Functional effect) Reference 
Up regulated: 





of stem cells in EOC 
cells by altering 
ALDH1AL levels. 
(Li et al., 
2012) 
Down regulated: 
EMP1, GFAP, GAP43, EPHB2, 
ALCHAM, NGFR 
Ewing tumour 

















proliferation of basal 
progenitors by 
repressing the 
INK4A locus. Loss 





Expression alters according to 
differentiation status of NSC: 
TAL1, SIX1, TLX3, PHOX2B, 
OTP, PDGFR-A, NKX2-2 
Neural stem cells 
(NSC) 
Decreased EZH2 is 
associated with loss 





(Sher et al., 
2012) 
Table 5.3: Gene expression profiling in different cell types/ cancers after KO of EZH2. 
As expected, there was no overlap of gene signatures in different cancers suggesting 
extremely tissue specific role of EZH2 in transcriptional regulation. However, the next effect 
on stem cell differentiation and proliferation was constant in these cells. 
 
HOXA10 is a transcription factor associated with cellular differentiation and closely linked to 
T, B and Natural killer cells. It showed 2-fold down regulation after KO of EZH2 in K562 
cells. HOXA10 drives the differentiation of hematopoietic precursor cells into myeloid or 
lymphoid lineages and over expression of this gene affects differentiation of human stem 
cells wherein it causes severe deregulation of the lymphoid (T, B, and NK) cells 
development. Some studies show that HOXA10 deregulation affects terminal differentiation 
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in myeloid cells (Buske et al., 2001) while others indicate an enhanced monocytic 
differentiation with inhibition of only granulocytic precursor cells differentiation towards 
polymorphonuclear leukocytes (Taghon et al., 2002). Dysregulation of HOXA10 expression 
is also correlated with abnormal expansion of granulocyte macrophage progenitor cells 
(GMP) (Bei et al., 2012). Increased expression of HOXA10 is associated with poor prognosis 
in AML with increased myeloproliferation (Bjornsson et al., 2001). Decreased HOXA10 
levels after EZH2 KO might indicate a tumour suppressor role of EZH2 in myeloid 
malignancies.  
In addition to cell differentiation, EZH2 KO also modulated proteins involved in immune 
responses like CD44, CD83 and TLSP. CD44 is a cell adhesion molecule expression of which 
is elevated in MDS and AML. Soluble CD44 retain sbiological functions and competes with 
cell bound CD44 in ligand binding, cellular activation, induction of apoptosis and inhibition 
of tumour growth. Serum concentrations of soluble CD44 increase with increasing grade of 
the disease. Differential expression in various FAB or WHO subtypes, display the lowest 
levels in del5q MDS and the highest levels in RAEB, CMML and in secondaryAML evolved 
from MDS. The levels are also high in patients with relapsed disease and low in patients with 
remission. Therefore serum CD44  has been suggested as a marker for monitoring response to 
treatment and disease progression to acute leukaemia (Loeffler-Ragg et al., 2011). Cell bound 
CD44 molecule exhibit a trend similar to the serum soluble CD44 with high levels (15 to 35 
%) observed in MDS. Cell bound CD44 molecule was not expressed in healthy controls (Xie 
et al., 2010). In addition to CD44, CD83 molecule expressed on the cell surface of mature 
dendritic cells was also down regulated along with the Thymic stromal lymphopoietin (TSLP) 
which mainly impacts myeloid cells, induces the release of T cell attracting chemokines and 
enhances the maturation of myeloid dendritic cells. Within the thymus TSLP activation of 
both myeloid and plasmacytoid (CD123+) dendritic cells results in the production of 
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regulatory T cells (Hanabuchi et al., 2010). The downstream targets and the effect of their 
modulation on the pathogenesis of MDS/AML need further clarification.  
Apart from genes involved in cell differentiation and immune modulation, reduced FLT1 
expression was observed after EZH2 KO. FLT1 also known as VEGFR1 binds to VEGFB and 
placental growth factor (PIGF). PlGF signals directly through FLT1 in various cell types 
including angiogenesis-competent myeloid progenitors thereby promoting tumour 
angiogenesis and formation of premetastatic niche. PIGF expression is not crucial for 
vascular development in healthy cells but contributes to angiogenic and inflammatory switch 
in cancer cells. Myeloid cells confer resistance to therapies that target VEGF by secreting 
more pro-angiogenic factors. Monoclonal antibody against PlGF enhances the responsiveness 
to VEGF targeted therapies by inhibiting macrophage recruitment and therefore this antibody 
can be used against PIGF to eliminate the source of angiogenic factors that contributes to 
anti-angiogenic escape of tumours (Fischer et al., 2008). High expression of FLT1 gene is 
associated with poor prognosis and/or unfavorable outcome in MDS but does not correlate 
with peripheral blood blast counts (Kracmarova et al., 2008). FLT1 is regulated by mir145 
which is down regulated in 5q- syndrome seen in MDS. Whether down regulation of mir145 
causes concomitant up regulation of FLT1 is unclear. It is unknown whether down regulation 
of FLT1 modulates mir145 expression or influences the 5q- phenotype of MDS and further 
research is required to decipher the association of FLT1 to MDS. 
5.16.2 Effect of EZH2 on cell cycle, cell viability and cell cycle kinetics 
 
Three genes related to cell proliferation; BCL2, PAG1 and IFI16 were down regulated by 
EZH2 inhibition. Reduction of BCL2 (-7 fold) and PAG1 (-4.5 fold) causes decreased cell 
proliferation while decreased expression of IFI16 (-6 fold) induces cell proliferation PAG1 
(Glycosphingolipid-enriched microdomains 1) is a transmembrane adaptor protein which has 
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been studied in B-cell non-hodgkin’s lymphoma wherein KO of PAG1 is associated with 
reduced cell proliferation. Reduced PAG1 expression is also linked to abnormal response to 
antigen stimulation in germinal centre derived B-cell non-hodgkin’s lymphoma (Rubbi et al., 
2011). IFI16 on the other hand is a nucleoprotein expressed during differentiation of myeloid 
precursor cells. It is expressed inherently in T and B cell lines but also inducible in myeloid 
cell in response to Interferon Ȗ stimulation (Dawson and Trapani, 1995). IFI16 controls 
cellular proliferation by binding and modulating p53 and the retinoblastoma protein pRb. The 
nucleoprotein is expressed in monocytic lineage but is down regulated in other myeloid 
precursor cells (Dawson et al., 1998). Similar to PAG1, BCL2 also enhances cell 
proliferation. This gene and its association with apoptosis/ proliferation has been studied in 
detail compared to IFI16 and PAG1 due its role in BCR-ABL induced chronic myelogenous 
leukaemia. BCL2 over expression can block apoptosis leading to improved peripheral blood 
counts and prevents disease progression to AML (Slape et al., 2012). A recent study 
confirmed that high FLT3 + KIT/BCL2 ratio was an independent prognostic factor for poor 
event free survival (EFS) and overall survival (OS). Interrelationship rather than individual 
expression levels of the proliferative and antiapoptotic transcripts are critical in predicting the 
outcome in paediatric AML patients(Sharawat et al., 2014).MDS is closely linked to 
apoptosis/deregulated cell proliferation leading to peripheral blood cytopenias with 
paradoxical bone marrow hypercellularity. The two major pathways of apoptosis are the 
extrinsic pathway linked with death receptors and the intrinsic or mitochondria associated 
pathways. The extrinsic pathway is triggered by death receptor (For e.g. Fas, TNFR1 etc) 
engagement with activation of caspase-8 which in turn initiates both caspase-3 activation and 
the release of cytochrome c by mitochondria. Caspase-3 activation causes degradation of 
cellular proteins necessary for cell survival. In the intrinsic pathway regulated by the BCL2 
family of proteins, is triggered by various apoptotic stimuli to release cytochrome c from the 
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mitochondria independent of caspase-8 activation. Cytochrome c interacts with APAF1 and 
caspase-9 to promote the activation of caspase-3 with downstream degradation of cell 
maintenance and cell survival proteins (reviewed in (Youle and Strasser, 2008)). 
BCL2 prevents apoptosis by interacting with and inhibiting BH123 proteins on the 
mitochondrial outer membrane. In the presence of an apoptotic stimulus, BH3-only proteins 
areactivated and bind to BCL2 proteins so that they can no longer interact with BH123. bh123 
proteins can then aggregate on the outer mitochondrial membrane and promote the release of 
intermembrane mitochondrial cytochrome c. Data gathered from gene expression study in my 
thesis show that EZH2 modulated reduction of BCL2 gene expression in K562 (chronic 
myeloid leukemic cell line) was mild (2 fold) but still an interesting finding because this cell 
line expresses the BCR-ABL fusion gene which is known to induce expression of BCL2 
evading apoptosis of cancerous cells. Modulation of cell proliferation, viability related genes 
in gene expression profiling and the clinical, prognostic importance of cytopenias in MDS 
and myeloid malignancies made examination of cell viability, proliferation and cell kinetics a 
focal point of investigation in this study. Therefore trypan blue dye exclusion method, MTT 
assay, Annexin V staining and cell cycle kinetics were examined for alterations in apoptosis, 
proliferation and cell cycle dynamics respectively. Trypan blue dye exclusion method at day 
1 to day 7 after transduction and Annexin V staining at day 7 after sorting for GFP+ cells 
showed no alterations in the cell viability of cells transduced with shRNA against EZH2 
compared to wild type cells or cells transduced with scrambled. Similarly, cell proliferation 
measured by MTT assay at three time points (24, 48 and 72 hr) after sorting GFP+ K562 cells 
at day 7 showed minimal but not significant (p =0.1 to 0.4) reduction in the proliferation rate 
of the cells with EZH2 KO. In addition to examining cell viability and proliferation, cell 
cycle kinetics after EZH2 and H3K27me3 down regulation was assessed due to previously 
reported connection of EZH2 KO to G1 phase cell cycle arrest in ovarian cancer, delayed 
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G2/M phase transition in prostate cancer.  Additionally, there is a close association between 
H3K27me3 epigenetic marks and cell cycle. The propagation of these marks to the next 
generation of cells takes place via cell cycle. Cell cycle kinetics examined in synchronised 
Hela cells indicated that formation of H3K27 methylation begins during post replication S 
phase of the cell cycle and gets completed during the G1 phase of the subsequent cell cycle. 
H3K27 methylation change within approximately 10% in abundance across cell cycle but 
modifications in EZH2 levels during the phases of cell cycle have not been reported. H3K27 
dimethylation occurs via two pathways; processive methylation and nonprocessive 
methylation. Processive methylation occurs when methyltransferase binds to unmodified 
substrate and carries on with the next methylation step without releasing the histone. While 
nonprocessive dimethylation occurs when the methyltransferase releases the histone after 
transferring a methyl group and binds a new substrate to form a dimethylated peptide (Zee et 
al., 2012). In this study 95 % inhibition of H3K27me3 marks was observed after loss of 
EZH2 and the different phases of the cell cycle (sub G0, G0/G1, S and G2/M) were examined 
by staining the cells with PI (DNA content) and FITC (protein content).The percentage of 
apoptotic cells (sub G0) varied marginally between the wild type K562 cells (3.39 %) and 
those transduced with the shRNA (1.07 %) and the scrambled (1.75 %) but the difference was 
variable between experiments and not significant suggesting that EZH2 and H3K27me3 
inhibition did not affect the cell cycle entry of K562 cells. EZH2 KO in MOLM13 cells 
showed similar results as K562 wherein in the cell cycle profile remained unaltered after 65 
% inhibition of EZH2. Therefore it can be concluded that the role of EZH2 in cell cycle 
regulation, cell viability and proliferation in myeloid cells is distinct compared to its 
functionality in other cancers wherein down regulation of EZH2 had profound impact on cell 
proliferation, cell invasion and in some cancers was linked with G1 phase arrest or delayed 
G2/M phase of the cell cycle indicating an extremely cell type specific role of this gene.There 
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might be other mechanisms at work like a) substitution of EZH2 in PRC2 by its paralogue 
EZH1 compensating for the loss of EZH2 b) EZH2 dependent modulation of cell proliferation 
reducing (IFI16) and proliferation enhancing (BCL2 and PAG1) genes balancing out the net 
effect on proliferation or c) absence of cell cycle regulator; p16INK a target of EZH2 in K562 
cell line (deletion of CDKN2A locus) because of which effect of EZH2 loss on cell 
proliferation is not evident in this cell line. In MOLM13 cells, the CDKN2A locus is present 
which suggests that either EZH2 has no effect on the cell cycle profile or else a stronger KO 
of EZH2 is required to detect changes in the cell cycle profile. Unfortunately further KO of 
EZH2 levels in this cell line was not achievable using either siRNA or shRNA methodologies 
and hence it was not possible to conclude the reason behind these findings. 
5.16.3 Gene signature in patient samples 
 
EZH2 histone methyltransferase gene is mutated in 8 % patients with MDS/MPN and 2 % in 
AML. These mutations are discussed in detail in the previous chapter wherein it was 
observed that there is no hot spot of mutation in EZH2 associated with myeloid malignancies. 
In the previous chapter, R690H mutation in EZH2 was constructed and studied. To evaluate 
whether this mutation mimics the gene signature obtained by loss of EZH2 in patient 
samples, six patients (one with R690H and five control samples with wild type EZH2) were 
selected and qPCR was carried out on RNA extracted from these patients for expression 
levels of BCL2,PAG1, IFI16, CD44, CD83, HOXA10, RAP1B, FLT1, TSLP, EZH1 and 
CDKN2A. The selected patients were age and AML evolution matched. Statistical tests to 
calculate significance (p value) could not be carried out for this experiment since the sample 
size in each category was very small (number of patients with R690H mutant was one). Five 
genes HOXA10, FLT1, PAG1B, EZH1 and TLSP were up regulated in the patient with R690H 
mutant compared to the control patients while the other genes showed no change in their 
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expression levels. Interestingly, these results contrast with findings (except for EZH1) 
observed with inhibition of EZH2 expression using shRNA in lentivirus where HOXA10, 
FLT1, PAG1B and TLSP were all down regulated. This incongruity in the gene 
signature between patient sample with R690H mutations and K562 cell line with 95 % 
KO of EZH2 suggest that EZH2 mutation does not mimic loss of function of the gene. 
 In contrast to other genes, EZH1 mRNA levels remained unchanged with loss of EZH2 in 
K562 cells while they were elevated in patients carrying EZH2 R690H mutation. EZH1 
mRNA levels have not been examined in the context of EZH2 mutations before. Nikosolski 
et al (2010) examined the effect of R690H mutation introduced in Sf9 insect cells on the 
levels of SUZ12, EED and found no change in their expression. But concurrent EZH1 levels 
were not evaluated (Nikoloski et al., 2010). Up regulation of EZH1 in this study indicate that 
EZH1 may compensate for loss EZH2 function. However decrease in H3K27me3 levels have 
been reported with EZH2 mutations and were also observed in this study after decrease in 
EZH2 levels. This study suggests a different mechanism of transcriptional regulation of 
EZH1 which is distinct from its H3K27 trimethylation activity. Immunoprecipitation studies 
of flag tagged EZH1 in Sf9 cells demonstrated that EZH1 forms part of the PRC2 complex 
but KO studies of EZH1 indicate that it does not affect H3K27me3 levels as drastically as 
loss of EZH2. In fact EZH1-PRC2 H3K27 methyltransferase activity was 20 fold less then 
EZH2-PRC2. Analysis of mouse kidney cells illustrates that EZH1-PRC2 compacts 
chromatin in the absence of the methyltransferase cofactor SAM indicating that H3K27me3 
is not the main target of EZH1-PRC2 (Margueron et al., 2008). These findings are in 
agreement with the data presented here wherein EZH1 is not associated with H3K27me3 
levels while EZH2 expression is closely linked to this mark. Western blot analysis of the 
patient samples was carried out to confirm the status of H3K27me3 with increased EZH1 
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Loss of 95 % of EZH2 expression in myeloid cell line K562 (TP53 null) did not alter cell 
viability, cell proliferation or cell cycle kinetics. Observations in MOLM13 cell line (TP53 
wild type) were similar to findings in K562 cells in the context of cell cycle kinetics. Gene 
signature obtained by microarray gene expression profiling demonstrated down regulation of 
genes involved in (a) Apoptosis and proliferation: BCL2, PAG1, IFI16 (b) Immune 
modulation: CD44, CD83, TLSP (c) Cell differentiation: HOXA10 and FLT1. Qpcr analysis 
of this gene signature in patient samples (R690H versus EZH2 wild type) show up regulation 
instead of down regulation of HOXA10, FLT1, PAG1B, EZH1 and TLSP genes confirming 
that EZH2 KO does not mimic EZH2 mutations. Assessment of cell viability and proliferation 
showed no alteration in cells with 95% inhibition of EZH2 compared to the scrambled 
shRNA suggesting the role of compensatory mechanism. Up regulation of EZH1 in patient 
with R690H suggest substitution of EZH1 to compensate for mutation in EZH2 causing 




6 Chapter: Role of DNMT3A 







DNMT3A mutations have been detailed in chapter 3 in the context of their incidence in 
MDS/AML, the mutational hotspot R882, prognostic value of these mutations and their 
correlation to other genes mutated in MDS/AML.Gene expression profiling of AML patients 
with/without DNMT3A mutations revealed that patients carrying the R882 mutation showed 
under expression of DNMT3A suggesting that the mutation knocks down the enzymatic 
activity of the gene (Huang et al., 2013). However, this mutation has not been studied in 
detail in the context of MDS/AML.  
6.2 Aim 
 
 To construct the R882H mutation commonly seen patients with DNMT3A mutation in 
p3XFLAG-myc-CMV26 vector. 
 To transfect and examine the effect of this mutation in myeloid cell line. 
6.3 Constructing the R88H mutant in pCMV sport6 vector 
 
Wild type DNMT3A cDNA cloned in pCMV-SPORT6 (IRATp970A0473D) was obtained 
from Source Bioscience and was used for all experiments (refer appendix).The DNMT3A 
cDNA sequence was verified using different primer pairs (refer appendix) by Sanger 
sequencing. 
To introduce the mutation in the wild type DNMT3A cDNA (Fig: 6.1), the plasmid was 
digested by NruI-NotI restriction enzymes (refer section 2.14.1) which generated two 
fragments (size: 1800 & 8000 bp) as visualised on 1 % agarose gel. The large fragment (8000 
bp) was isolated under UV light and purified by Qiagen gel purification kit as per the 
manufacturer’s instructions (refer section 2.14.3) while the small fragment was discarded. 
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Secondly, pCMV-SPORT6 was digested with XbaI-NotI restriction enzymes to generate two 
fragments (size: 8000 & 600 bp) (Fig: 6.2) of which the small fragment was gel purified 
while the large fragment was discarded. 
 
Figure 6.1: Cloning strategy for introducing the R882H mutation in pCMV-SPORT6. 
Generation of the mutant in the NruI-XbaI fragment has been illustrated using two pairs of 
primers (of each pair; one primer flanked the mutational site and a second primer overlapped 
the mutation site and introduced the mutation) using a PCR based approach. Red cross 




Figure 6.2: Digestion of pCMV-SPORT6 vector containing DNMT3A cDNA.(a) pCMV-
SPORT6 was digested by NruI-NotI restriction enzymes to generate the empty vector (8000 
bp).(b) pCMV-SPORT6 was digested by XbaI-NotI restriction enzymes to generate a 
fragment of the DNMT3A cDNA (size: 600 bp). These framents were gel purified and used 
for ligation later. 
 
6.3.1 Generating the fragment containing the R882 mutation 
 
The mutation was generated using two sets of primers; the first pair of primers overlapped the 
position 882 [mutational primer F (MF) and mutational primer reverse (MR)]. The change in 
the base pair to be introduced was positioned exactly at the centre of the primer. The second 
pair of primer or flanking primers [flanking forward (FF) and flanking reverse (FR)] were 
designed just outside XbaI-NruI restriction enzyme sites. PCR amplification using these 
primers was carried out on wild type pCMV-SPORT6 vector at a range of temperatures (52 
◦C, 56◦C & 60◦C) [Fig: 6.3]. 
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Figure 6.3: PCR based generation of the mutational (R882H) fragment in DNMT3A 
cDNA (a) Table indicates reaction mix for pcr containing either flanking primer forward plus 
mutational primer reverse or flanking primer reverse plus mutational primer forward (b) 
Illustrates PCR conditions on the thermocycler to generate these fragments (c) Visualisation 
of the PCR products at a range of temperatures on 1 % agarose gel. Products obtained at 60 
◦C were used for a second PCR reaction. O’Gene Ruler DNA ladder (Fermentas, UK) was 
used to evaluate correct size of the product. 
 
The pcr product was analysed on 1% TAE agarose gel alongside O‘Gene Ruler DNA ladder 
(Fermentas, UK). Samples were electrophoresed at 120V for 40 min in 1X TAE buffer. The 
bands were isolated under UV light and purified by Qiagen gel purification kit as per the 
manufacturer’s instructions. The products from the first round PCR (60 ◦C) were used for a 
second PCR using only the flanking primers and the elongation time of the PCR reaction was 
increased from 30 to 45 seconds due to the large size of the fragment (1200 bp). Due to the 
extensive overlap of the products from the above PCR reaction the products will anneal 
together and will be amplified by the flanking primers. Four different temperatures (gradient 
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PCR) were used (51◦C, 55◦C, 57◦C & 60◦C). The rest of the PCR conditions were kept 
constant: 
 
Figure 6.4: Second PCR to generate the mutational (R882H) fragment in DNMT3A 
cDNA(a) Illustrates reaction mix for second round of pcr using the product from the first 
PCR reaction. PCR amplification in this instance was carried out using only the flanking 
primers. (b) Visualisation of the PCR product (size: 1200 bp) on 1 % agarose gel. 
 
The product from the second PCR (57◦C) was gel purified as before and the fragments were 
treated with SuperTaq and incubated for 30 min at 72 ◦C to add dNTP “A” to the fragment. 
 
Subsequently, 2 µl of the above the mixture was cloned in to the pCRII- TOPO vector and 
transformed into DH5α-T1 E.Coli cells (refer section 2.14.5). After overnight incubation of 
Reagents Volume 
Plasmid DNA (37 ng/ µl) 10 µl 
dNTPs (2 mM) 1µl 
Super Taq 0.25 µl 
10X buffer 2 µl 
H20 upto 20 µl 
 
Table 6.1:  Reaction mix for treatment of plasmid DNA with SuperTaq to add dNTP 
"A" to the fragment.The reaction mix was incubated for 30 min at 72◦C. 
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the LB agar + 100mg/ml ampicillin +Xgal (20 µg/ml) plates, four colonies were selected and 
miniprep was carried out using the Wizard Plus SV kit (refer section 2.14.9). Colonies with 
the correct band size (1200 bp) were verified by digesting the plasmid with XbaI-NruI 
restriction enzymes (refer method) and sanger sequencing was used to confirm the presence 
of the R882H mutation (data not shown). 
 
Figure 6.5 Visualisation of four colonies on 1 % agarose gel aftertreatment with XbaI-
NruI restriction enzymes. The verification was carried out after Topo cloning of the PCR 
fragment. All four colonies showed the correct band size (1200 bp) 
 
6.3.2 Ligation of mutation into pCMV-SPORT6 
 
The concentration of plasmid DNA for all three fragments generated by restriction enzymes; 
NruI-NotI, XbaI-NotI and the fragment containing the mutation (XbaI-NruI) were measured 
using Thermo Scientific Nanodrop (ND-8000; Nanodrop) spectrophotometer and ligated 
using T4 DNA ligase. The control reaction contained only the empty vector but none of the 
other fragments. This control was used to check the number of background non-specific 





Empty vector (NruI-NotI) [21.66 ng/ µl] 2.31 µl 
XbaI-NotI (12.35 ng/ µl) 1.3 µl 
XbaI-NruI (fragment containing R882H mutation) [7.65 ng/ µl] 4.4 µl 
10X Ligase buffer 1 µl 
T4 DNA ligase 0.5 µl 
H20 0.49 µl 
Total volume 10 µl 
Table 6.2: Ligation mixture for three fragments (NruI-XbaI, XbaI-NotI&NruI-NotI) of 
pCMV-SPORT6. Vector :Insert ratio of 1:2 was used for the ligation. 
 
0.2 µl of the ligation mixture was transformed into MegaX DH10B T1 Electrocomp cells 
(refer section 2.14.7). No colonies were observed after incubating the LB agar + 100 mg/ml 
ampicilin plates for 16 hr at 37◦C. Therefore the ligation reaction was repeated and the 
duration of ligation was increased to over night (ON) at 4 ◦C. As done previously the plasmid 
was transformed into MegaX DH10B T1 Electrocomp cells and eight colonies were selected 
after 16 hr incubation at 37◦C. Accurate ligation of all the fragments was confirmed by 
digesting the plasmid with NruI-XbaI (Fig: 6.6a) restriction enzymes and the R882H 
mutation was verified by sanger sequencing using M13 primers and primers designed against 
DNMT3A cDNA (refer appendix). The first colony was selected based on results obtained by 
sanger sequencing (Fig: 6.6b), digestion by restriction enzyme results and maxiprep was 




Figure 6.6: Confirmation of the presence of R882H mutant in pCMV-SPORT6 vector 
using sanger sequencing. (a) Digestion of eight colonies by NruI-XbaI restriction enzymes. 
Four of the colonies (1, 2, 3 & 6) indicate correct band size (1200 bp). (b) Sanger sequencing 
of colony 1 illustrated the change in amino acid CGC (Arginine) to CAC (Histidine) 
confirming the presence of the R882 mutation in the colony. 
 
6.3.3 Cloning R882H mutation into p3XFLAG-myc-CMV-26 expression vector 
 
To insert a selectable marker (neomycin) and to attach a Flag tag to the R882H DNMT3A 
mutant to distinguish it from endogenous DNMT3A in cells post transfection, DNMT3A 
cDNA from pCMV-SPORT6 vector was cloned into p3XFLAG-myc-CMV-26 vector (Sigma 
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Aldrich, UK). To achieve this, two primers incorporating the SalI (GTCGAC) and HindIII 
(AAGCTT) restriction sites were designed: 
Primer name Sequence Function 
DNMT3A_flag_F 
 
5' - AAGTCG ACAAGC TTA TGC CCG CCA TGC CCT CC - 
3' 
To get the gene in frame by 




5' - CTT TGG TGG CAT TCT TGT CC - 3' 
To get the gene in frame by 
reŵoǀiŶg the ϱ͛ UT‘ before start 
codon 
 
PCR using this primer pair was carried out on wild type DNMT3A cDNA in pCMV Sport6. 
The PCR product was visualized on 1 % agarose gel as seen in Fig: 6.7a and purified as 
mentioned previously.  
 
Figure 6.7: Cloning the R882H DNMT3A mutation into p3XFLAG-myc-CMV-26 
expression vector. (a) PCR fragment using the primers designed to introduce SalI 
(GTCGAC) and HindIII (AAGCTT) enzyme sites in the sequence. (b) Confirmation of 
accurate colonies obtained after TOPO cloning the PCR fragment by digesting the plasmid by 




The gel purified product was treated with SuperTaq, cloned into pCRII- TOPO vector and 
transformed into DH5α-T1 E.Coli. Ten colonies were selected and the correct colony was 
verified by digesting the plasmid with SaI-Bpu10I (Fig: 6.7b) restriction enzymes. The 
fragment (size: 1200 bp) was gel purified and concentration of the plasmid DNA was 
measured using Thermo Scientific Nanodrop (ND-8000; Nanodrop) spectrophotometer. 
Secondly, pCMV-SPORT6 plasmid containing the R882H mutant was digested using SalI-
Bpu10I (Fig: 6.8) restriction enzymes and the large fragment (size: 8000 bp) was gel purified. 
The two fragments; size 1200 bp and 8000 bp were ligated using T4 DNA ligase as 
mentioned previously and transformed into DH5α-T1 E.Coli.  
 
Figure 6.8: Digestion of pCMV-SPORT6 containing R882H mutant by SalI-Bpu10I 
restriction enzymes.  
 
However, no colonies were observed post ligation. The ligation reaction was repeated several 
times by increasing the concentration of both the fragments and increasing the duration of 
ligation. The plasmid DNA obtained from the colonies after each attempt was digested using 





Figure 6.9: Digestion of colonies obtained after ligation of inframe DNMT3A cDNA into 
pCMV-SPORT6 expression vector by HindIII-NotI restriction enzymes. The ligation 
failed since the band indicating the presence of the insert was not obtained. 
Therefore cloning of the PCR product (size: 892 bp) into the pCRII- TOPO vector and 
transformation into DH5α-T1 E.Coli was repeated. Five colonies were selected, plasmid 
DNA digested by EcoRI restriction enzyme (Fig: 6.10a) showed band of the correct size; 892 
bp in colony 1, 4 and 5. Sequencing these colonies confirmed the presence of the insert (data 
not shown). 
 
Figure 6.10: Second attempt to ligate DNMT3A into p3XFLAG-myc-CMV-26 
plasmid.(a) The colonies were digested using EcoRI restriction enzyme to confirm the 
presence of the insert in five colonies after topo cloning. Three colonies (1, 4 and 5) showed 
the correct size bands (red boxes) while colony 2& 3 were false positives. (b) One of the 





The plasmid DNA from the colonies was digested using SalI-Bpu10I (Fig: 6.10b) and the 
band at 1200 bp was gel purified. Ligation of the two bands (size: 1200 and 8000 bp) was 
repeated as before and six colonies were selected. Plasmid DNA after miniprep from these 
colonies was digested first by ScaI-NotI followed by HindIII partial digest (Fig: 6.11).Three 
out of six colonies generated bands of the correct size; 1200, 3000 & 4300 bp. The fragment 
at size 4300 bp (DNMT3A gene) was gel purified. 
 
Figure 6.11: Plasmid DNA from six colonies was digested by ScaI-NotI restriction 
enzymes followed by partial digest by HindIII.Partial digest by HindIII enzyme:Five 
eppendorfs containing all the reagents required for restriction digest except the enzyme were 
prepared. A separate eppendorf with the same reagents without plasmid DNA was prepared 
and all the contents from this were mixed into the first of the five eppendorfs. 20 µl of this 
mix was added to the second eppendorf and so on making a serial dilution of the enzyme. 
After adding the mix to the fifth eppendorf, 20 µl was taken and added to a clean eppendorf. 





6.3.4 Ligation of DNMT3A cDNA and p3XFLAG-myc-CMV 
 
The p3XFLAG-myc-CMV vector was linearlized by digesting the plasmid with HindIII-NotI 
restriction enzymes and gel purifying the fragment.  
 
Figure 6.12: Digestion of p3XFLAG-myc-CMV-26 plasmid by HindIII-NotI restriction 
enzymes. 
 
The linear plasmid was ligated with DNMT3A cDNA generated above (size: 4300 bp) using 
T4 DNA ligase as mentioned previously but the fragments failed to ligate. The ligation 
reaction was optimised by increasing the DNA concentrations of both the insert and the 
vector, increasing the duration of ligation from 3-4 hr at room temperature to ON at 4◦C and 
treating the fragment after HindIII-NotI digest with CIP (0.1 µl, incubate 37◦C for 30 min) to 
prevent self-ligation of the digested ends. But none of these modifications resulted in  
successful ligation of DNMT3A into p3XFLAG-myc-CMV vector and therefore, the ligation 
strategy was reconsidered with a view to simplify the procedure by ligating fragments of 
smaller size. 
6.3.5 Ligation of Flag tag into pCMV-SPORT6 
 
A different approach was used wherein; the Flag sequence was removed from p3XFlag-myc-
CMV vector and ligated into pCMV-SPORT6 containing R882H mutation (Fig: 6.13). 2 µg 
of p3XFLAG-myc-CMV vector was digested using SnabI-HindIII restriction enzymes and 
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visualised on 1 % agarose gel (Fig: 6.14a). The fragment at 320 bp was purified and the DNA 
concentration was measured using Thermo Scientific Nanodrop (ND-8000; Nanodrop) 
spectrophotometer. 
 




Figure 6.14: (a) Digestion of p3XFLAG-myc-CMV by SnabI-HindIII restriction 




Secondly, R882H in pCMV-SPORT6 was digested using first SnabI for 1 hr at 37◦C followed 
by a partial digest by HindIII (Fig: 6.14b) to generate a fragment of size 8000 bp. This 
fragment was purified, quantified and used for ligation. Two fragments (320 & 8000 bp) were 
ligated using T4 DNA ligase as previously described and transformed into DH5α-T1 E.Coli 
and the colonies were verified using sanger sequencing. Similar to R882H, wild type 
DNMT3A cDNA was also ligated with Flag tag to study the effect of over expressing the wild 
type gene. Empty pCMV-SPORT6 vector without cDNA of DNMT3A was used as a control 
for all experiments. 
6.4 Transfection of R882H-mutant into myeloid cell lines 
 
MOLM13 and KG1 (acute myelogenous leukaemia) cell lines were used for all experiments. 
The reasons for using MOLM13 cells were described in the previous chapter. The second cell 
line; KG1 was utilized because it contains wild type DNMT3A (Tiacci et al., 2012) and the 
expression levels of DNMT3A were easily detected by qPCR facilitating easy monitoring of 
variations in DNMT3A gene expression due to the R882H mutation. 
6.4.1 Electroporation 
 
pCMV-SPORT6 does not contain a mammalian selectable marker therefore the plasmid was 
transfected along with pBABE-puro (gifted by Dr. Joop Gaken) which contains puromycin. 
The experimental workflow is detailed in figure 6.15. 95% of the MOLM13and 65% KG1 
cells were dead at 48 hr as estimated by Trypan blue staining which could be attributed to 
electroporation since similar percentage of cell death was also observed in the mock-




Figure 6.15: Experimental workflow for transfection by electroporation. MOLM13/Kg1 
cells were seeded at a density of 2 x106 in 6 well plates and transfected with 1.8 µg  of 
pCMV-SPORT6  R882H + 0.2 µg of pBABE-puro vector  per well resuspened in 100 µl of 
Mirus BioIngenio electroporation solution using the Nucleofactor device II (program: O-017 
for MOLM13 and V-0001 for KG1). Wild type DNMT3A and empty pCMV-SPORT6 vector 
+ pBABE-puro were transfected in separate wells. Mock transfected cells were used as ctl for 
alterations caused due to the transfection procedure. Untransfected cells were used as a ctl to 
estimate the end point of puromycin selection for the cells. 
 
6.4.2 Lipofectamine LTX reagent 
 
The transfection methodology was changed to Lipofectamine LTX while other experimental 
conditions were kept constant. The transfection protocol was optimised using 24, 12 and 6 
well plates as (http://www.lifetechnologies.com/uk/en/home/references/protocols.htm and 
combining the transfection protcol for K562 suspension cell line) as per manufacturer’s 
instructions. The transfected cells are selected by puromycin at a concentration at 0.2 µg /ml 
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for MOLM13 cells and 2 µg /ml for KG1 cells for six days. DNMT3A expression was 
measured by qPCR at 48 hr and day 9 after transfection (Fig: 6.16). 
 
 
Figure 6.16: DNMT3A expression in MOLM13 (48hr post transfection) and in 
KG1(48hr/ Day 9 post transfection) cell lines.MOLM13 cells did not survive the 
puromycin selection and therefore the day 9 qPCR profile for this cell line is not available. 
Both the cell lines were seeded at a density of 2 x 105 - 5 x 105cells/well and transfected with 
plasmid DNA pre-incubated with Lipofectamine LTX (4µl-12µl) and Plus reagent (1µl-





Post-selection DNMT3A gene expression was highly variable between experiments in KG1 
cell line (a example is shown in figure 6.17). Despite conducting multiple experiments the 
expression of either wild type DNMT3A or R882H was low (below the DNMT3A expression 
level in the untransfected cells). It is unclear whether the CMV promoter driving gene 
transcription of DNMT3A in the plasmid was switched off or other biological compensatory 
mechanisms were at work.The time taken to conduct these experiments and the degree of 
uncertainty involved was a concern. Having already spent considerable time on cloning and 
transfecting the DNMT3A mutation, after careful evaluation it was decided to discontinue 
work on this mutation. 
6.5 Discussion 
 
Studying the functional consequences of the R882H mutation has been attempted by various 
research groups including our group in this study. Large size of the DNMT3A gene provided 
numerous technical difficulties in cloning this gene into p3XFLAG-myc-CMV-26 vector to 
allow for easy detection of the FLAG tagged transgene expression in the transfected cell 
lines. Ligation was attempted many times by varying the concentration of vector: insert ratio, 
duration of the ligation (2-6 hr at RT to over night at 4◦C) and treating the fragment with CIP 
(0.1 µl, incubate 37◦C for 30 min) to prevent self-ligation of the digested ends and reduce the 
background. However, all the strategies to clone cDNA of DNMT3A into p3XFLAG-myc-
CMV-26 were unsuccessful and therefore the FLAG tag from p3XFLAG-myc-CMV-26 was 
isolated and ligated into pCMV-SPORT6. This plasmid was transfected along with pBABE 
(containing puromycin marker) into myeloid cell lines but extremely poor transfection 
efficiency was observed in both MOLM13 and KG1 cells (more so in MOLM13 cells) 
resulting in long recovery period of the cells post puromycin selection. This resulted in 
variable expression levels (lower than mock transfected in some instances) of DNMT3A 
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mRNA. CMV promoter drives the expression of DNMT3A in pCMV-SPORT6 vector and as 
discussed in chapter 4, inactivity of the CMV promoter due to methylation of CpG islands in 
its promoter could be the cause for the variable expression of DNMT3A. However, due to 
insufficient time, this hypothesis could be tested and therefore work on R882H DNMT3A 
mutation was discontinued. 
6.5.1 Literature survey 
 
Ley et al (2010) first examined global methylation levels in DNMT3A-mutant and wild-type 
AMLs using liquid chromatography-tandem mass spectrometry (LC-MS) and found no 
difference in global 5-mC levels in patient samples. DNA methylation profiling in R882H-
mutant AMLs using MeDIP-chip showed 182 regions that were differentially methylated 
between R882H versus wild-type AMLs, all of which were hypomethylated in the patients 
carrying R882H (Ley et al., 2010). Similar findings were reported by Yan et al (2011) and 
Kim et al (2013) when they examined contribution of aberrant DNMT3A activity to the 
pathogenesis of acute monocyticleukemia (Yan et al., 2011) and the in vivo effects of R878H 
mutation in murine (equivalent to R882H in humans) embryonic stem cells and found 
reduced global methylation as compared to wild type DNMT3A respectively (Kim et al., 
2013).In addition to changes in global DNA methylation patterns, researchers have also 
examined gene expression patterns of R882H mutant versus  wild type DNMT3A. These 
studies have revealed1,323 up regulated and 563 down regulated genes in patients carrying 
the R882 mutant. Among the genes with altered expression, IDH1 (Yan et al., 2011) and 
RUNX1 (Challen et al, 2012) have been linked to MDS/AML previously. Rest of the genes 
were involved either in cell adhesion, proliferation & migration. However an obvious patient 
cluster clearly linking to mutational status of the gene is not evident. microRNA profiling, on 
younger and older patients has been carried out which did not reveal a gene signature 
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associated with DNMT3A mutations in the younger group. In contrast, a signature consisting 
of 12 microRNAs associated with DNMT3A mutations was evident in the older patients 
(Marcucci et al., 2012). 
In vivo research on loss of DNMT3A on HSC function suggests that it has no effect no HSC 
differentiation potential (Tadokoro et al., 2007). Recently, Challen et al (2012) looked at 
DNMT3A knockout mouse model combined with serial transplantation assays and found an 
increased expansion of the HSC compartment in the serial transplants with impairment of 
HSC differentiation over serial transplantation but an overt phenotype was not observed and 
the mice did not develop spontaneous leukaemia (Challen et al., 2012). In contrast, Xu et al 
(2014) examined the transformation ability of the R882H mutant on murine hematopoietic 
stem/progenitor cells (HSPCs) and found that the mutant gene can induce aberrant 
proliferation of hematopoietic stem/progenitor cells. At 12 month post bone marrow 
transplant, all mice developed chronic myelomonocyticleukaemia with thrombocytosis (Xu et 
al., 2014).  
Structural studies on interactions of the mutant protein with wild type DNMT3A to 
understand their differences in functionality, supports the theory of dominant-negative effect 
of mutant. The interaction of the R882H mutant with wild type DNMT3A, 3B or 3L remains 
unchanged but R878H mutant protein antagonized wild type DNMT3A and DNMT3B in 
MDS/AML(Kim et al., 2013).Similar observations were made by Russler-Germainet al 
(2014) were they found that the enzymatic activity of DNMT3A was reduced by 80 % in the 
cells carrying the mutant and they attributed this to the failure of the R882H mutant DNMT3A 
to form homotetramers (Russler-Germain et al., 2014).However, further genome-wide and 
functional studies are needed to address the exact role of mutant DNMT3A inaberrant DNA 






In spite of genome wide studies to understand the role of DNMT3A mutations, additional 
functional studies both in vitro and in vivo are essential to discover the precise of role of this 
gene in connection to its downstream targets and its contribution to the pathogenesis and 




7 Chapter: General Conclusions 
and Future work  
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7.1 Identification of SNP6 abnormalities and mutations affecting 
Polycomb genes and their binding partners (DNMT3A and Jumonji) 
 
The importance of polycomb protein EZH2 in epigenetic regulation of transcription by its 
histone methyltransferase activity and the mutational analysis of this gene in haematological 
malignancies, including MDS has been addressed by previous studies as described in the 
introduction. Mutations of EZH2 have been associated with SNP6 abnormalities like 7q CN 
(LOH) and 7q36.1 microdeletion (Ernst et al., 2010). However, SNP6 and mutational 
analysis of other components of the polycomb complex (PRC1 and PRC2) in MDS have not 
been reported and therefore the aim of my PhD was to study the PRC2 components (EZH1, 
EED, SUZ12) and twelve genes belonging to PRC1 to identify genomic aberrations affecting 
them using SNP6 arrays and to link these findings to the mutational status of these genes. In 
addition, I have also sequenced DNMT3A and seventeen Jumonji genes which have been 
reported to interact with the polycomb proteins and have been discussed in the Introduction 
chapter. 
SNP6 data used in this study was generated by Dr. Azim Mohamedali and formed part of 
previous research projects conducted by our group. I visualised this data using CHromosome 
Analysis Suite (Chas) from Affymetrix and identified five PRC1 genes in 17/91 (19 %) 
patients with either CNVs or CN (LOH).  Eleven patients showed CN (LOH) [size: ≤ 1.5 Mb] 
at the BMI-1 locus. Though the size of the CN (LOH) indicated strongly that these could be 
not real these patients were still selected for mutational analysis based on the high frequency 
of CN(LOH) (n= 11) and due to the association of BMI-1 with MDS discussed in detail in 
chapter 1. Among the ring proteins, RING1A was deleted in two patients while RING1B 
showed CN gain in two patients and a CN (LOH) in one patient. The polyhomoetic gene, 
PHC1 was deleted in one patient while PHC2 showed CN gain in a single patient and a CN 
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(LOH) in another patient. Sanger sequencing of patients with SNP6 aberrations for the five 
PRC1 genes did not identify any mutations associated these genes.  
Similar to the PRC1 genes, seventeen Jumonji genes were also investigated for SNP6 
aberrations in the same cohort of patients. 29 patients (31 %) showed either CNVs or CN 
(LOH) at 15 Jumonji gene loci. Interestingly, the frequency of SNP6 aberrations affecting the 
Jumonji genes was higher than the PRC1 genes. The highest frequency of deletions was 
observed in JMJD1B [n=12] while JMJD4 and JMJD2C locus showed maximum number of 
CN (LOH) [n= 4] and amplifications [n= 3] respectively. These 29 patients were sequenced 
using 454 parallel sequencing for mutational analysis of the fifteen Jumonji genes. There 
were no mutations detected in these patients suggesting that mutations of PRC1 and Jumonji 
genes are rare in MDS and not associated with genominc abnormalities of these genes. 
Similar findings were reported by Score et al (2012) when they identified only 2 % patients 
with JARID2 mutations in the peripheral blood and bone marrow of patients with MDS/MPN 
but did not find any association between CN (LOH) of chr 6p with these mutations (Score et 
al., 2012). 
To elucidate changes in gene expression as a result of amplification or deletion of genomic 
material, qPCR was performed on 22/28 patients for thirteen Jumonji genes. Patients without 
SNP6 abnormalities at the gene loci were used as controls while K562 cells were used as a 
positive technical control in all experiments. Due to insufficient patient material, gene 
expression studies were not carried out on PRC1 genes. The expression of three Jumonji 
genes; JARID1A, JARID1C and UTX was modulated concomitant with CNVs of these genes. 
Deletion of JARID1A locus was associated with reduced gene expression (p value <0.0001) 
in two patients while trisomy of JARID1C and UTX in a single patient was associated with 
increased expression of both the genes. One patient with CN=4 at the UTX locus showed 5 
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fold increase in its expression. Altered expression of Jumonji proteins have been reported 
previously in carcinogenesis and discussed in chapter 3 
EZH2 was previously sequenced by our group on 61 out of 91 patients and therefore the same 
cohort of patients were selected for mutational analysis using 454 parallel sequencing of the 
other core components of PRC2; SUZ12, EED, EZH1 and DNMT3A to identify mutations and 
to examine their mutational overlap with EZH2. PRC2 genes were not mutated in this cohort 
of patients. Subsequently, similar findings were published in two reports wherein SUZ12 and 
EED mutations were identified in only 1.4 % and 1% of patients respectively (Brecqueville et 
al., 2011; Score et al., 2012).This confirmed that among the polycomb and Jumonji family of 
proteins, mutations of EZH2 were most frequent establishing the importance of EZH2 in 
MDS. Therefore the second aim of this work was to focus on the functional analysis of EZH2 
in the context of myeloid cells. Since mutations in any component of PRC2 resulted in loss of 
H3K27me3, it emphasizes the importance of this mark and suggests that deregulation of the 
epigenetic control of gene expression plays an important role in the development of myeloid 
disorders. 
In contrast to PRC1 and Jumoji genes, sequencing of DNMT3A in the same cohort of patients 
identified 10/61 patients with heterozygous mutations (clone size 20-44 %).Interestingly, 
these mutations were seen predominantly (n= 6) in patients with monosomy 7/del 7q, not 
observed in patients with normal karyotype and were classified as RAEBI/II according to the 
WHO classification suggesting the association of this gene with advanced stage of the 
disease.Nine non-synonymous mutations were identified throughout the gene; four of which 
were localized to the Mtase domain responsible for the methyltransferase activity of  
DNMT3A. A splice site mutation between exon 18 and the intron preceding exon 19 was also 
observed in this domain. Mutation at the R882 locus identified as a mutational hot spot by 
other research groups was observed in 2/10 patients. The Zinc finger domain and the PWWP 
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domain demonstrated one non-synonymous mutation each while three mutations were 
dispersed between the coding domains. The PWWP domain directs DNMT3A to 
heterochromatin while the Zinc finger domain helps it to bind firmly to the DNA sequence. 
Only one patient with the R882H mutations was also mutated for EZH2 suggesting that there 
was very little association between mutations of these genes, a finding which was confirmed 
by other reports(Haferlach et al., 2014).Studies have observed connection between DNMT3A 
mutations and poor prognosis in patients but our data showed no significant difference in the 
median survival of monosomy 7 patients with or without DNMT3A mutations (p value = 0.6)  
cohort with inconclusive impact on prognosis of the patients with mutated DNMT3A. The 
high frequency of mutations affecting this gene, their adverse effect on the prognosis of the 
disease and the identification of a mutational hot spot (R882) makes DNMT3A an important 
gene for functional analysis and therefore in addition to functional analysis of EZH2, I have 
also examined the functional effect of DNMT3A mutations in my project. 
7.2 Functional analysis in myeloid malignancies: R690C/R690H 
mutations, over expression and knock down of EZH2. 
 
Functional analysis of EZH2 was carried out by constructing the R690C, R690H mutations 
and Flag tagged wild type EZH2 in p3XFLAG-myc-CMV-26 (GFP+ puromycin) vector as 
described in chapter 4.These two mutations were investigated because they were reported in 
many studies including in our cohort and located in the SET domain of the enzyme. They 
have been previously examined in insect cells and in patient samples carrying the 
homozygous form of the mutation. This is the first attempt to study the consequence of the 
R690C/R690H mutations and the over expression of Flag tagged EZH2 in human myeloid 
cell lines. To achieve this, plasmid containing the mutants (R690C/R690H) and Flag tagged 
EZH2 were transfected in myeloid cell line K562 using Lipofectamine LTX according to the 
manufacturer’s instructions and GFP+ cells were sorted at 7β hr. Western blot analysis at this 
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time point, to evaluate alterations in EZH2 proteins levels and their effect on its target 
H3K27me3 illustrated high expression of both R690C/R690H mutants and Flag tagged wild 
type EZH2 compared to cells transfected with the empty vector and the mock transfected 
cells. Surprisingly, the H3K27me3 protein levels remained unaltered in all samples. These 
findings were in contrast to two studies; one reported decreased H3K27me3 levels in the 
presence of homozygous R690H mutation in patient samples from MDS/AML (Ernst et al., 
2010; Makishima et al., 2010) and the second looked at heterozygous effect of R690C 
mutation in insect cells respectively. This system mimics the experimental design presented 
in my thesis wherein the expression of the mutant is heterozygous rather than homozygous. 
However, the model system used in both the studies is different i.e. insect cells versus human 
myeloid cells (K562) and it is unknown whether H3K27me3 modulation by EZH2 has 
species related alterations.Another explanation for these findings was a long half-life of 
H3K27me3 protein making it impossible to detect changes in its levels at 72 hr post 
transfection. Time restrictions did not allow further experiments to optimise additional time 
points for sample collection to evaluate long term effects of mutant and Flag tagged wild type 
EZH2 over expression on H3K27me3 protein levels. 
To investigate the effects of elevated EZH2 (both mutant and wild type) on transcription, 
microarray gene expression analysis using Affymetrix Human Transcriptome 2.0 arrays was 
carried out in K562 cells (72 hr time point) which identified up regulation (2.2 fold in wild 
type and 3.6 - 4.6 fold in R690C/R690H mutants) of MLLT10 gene in mutated as well as wild 
type EZH2 suggesting that the mutations do not affect the function of the wild type EZH2 in 
regulating this gene. Reports on increase of HOXA gene expression by MLLT10 fusion 
proteins (Brandimarte et al., 2013) as well as an inverse correlation of EZH2 and HOXA gene 
expression have been published (Khan et al., 2013). It would be important to examine the 
EZH2-MLLT10-HOXAconnection in myeloid cells to ascertain whether regulation of HOXA 
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genes by EZH2 occurs via modulation of MLLT10. Unlike MLLT10 which was up regulated 
in both wild type and mutant EZH2 genes, PML (promyelocytic leukaemia) [up regulated by 
2.16 fold] and FANCL (Fanconi Anaemia, Complementation Group L) [up regulated by 2.18 
fold] genes were modulated exclusively in cells over expressing the Flag tagged wild type 
EZH2.Both PML and FANCL are not related to the pathogenesis of MDS but are implicated 
in promyelocytic leukaemia and Fanconi anaemia respectively. It would be important to 
examine the above mentioned genes in patient samples with R690C or R690H mutation to 
validate the results observed in the myeloid cell line. 
Effects of EZH2 knock down (KO) in myeloid cells assessed by transfecting MOLM13 cells 
with siRNA (200 nM) and transducing K562 cells with lentiviral based shRNA as described 
in chapter 5.In MOLM13 cells, 65% KO (24 hr post transfection) while in K562 cells 95 % 
KO (Day 7 after transduction) of both mRNA and protein levels of EZH2 were observed by 
qPCR and western blot analysis respectively. Interestingly, western blot analysis 
demonstrated unaltered H3K27me3 levels in MOLM13 cells at 24 hr post transfection while 
95-100 % reduction in H3K27me3 levels were observed at day 7 post transduction in K562 
cells.This inconsistency in the effect of EZH2 KO on H3K27me3 in MOLM13 and K562 
cells suggested that either a stronger KO of EZH2 (> 65%) expression is required to detect 
H3K27me3 modulation or that the half life of H3K27me3 protein is long and therefore 
protein degradation is not observed at 24 hr. Since a strong reduction (>95 %) in both EZH2 
and H3K27me3 expression was observed in K562 cells, microarray gene expression profiling 
using Affymetrix Human Transcriptome 2.0 arrayswas carried out as per the manufacturer’s 
instructions. BCL2 (70%), FLT1 (40%), HOXA10 (30 %), CD44 (30%), CD83 (30%), TLSP 
(50%), IFI16 (50%) and PAG1 (50%) genes were down regulated in cells transduced with 
shRNA against EZH2 compared to the scrambled and wild type K562 cells. Comparison of 
this gene signature to data available in other types of cancers by different research groups did 
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not identify any overlap between EZH2 targets confirming that EZH2 target genes vary 
considerably between different cell types (Ezhkova et al., 2009; Li et al., 2012; Richter et al., 
2009; Sher et al., 2012). These were categorised by their functions in to genes associated with 
cell differentiation (HOXA10), cell proliferation (BCL2, IFI16 and PAG1) and Immune 
response (CD44, CD83 and TLSP). A strong association between EZH2 and cell 
proliferation/viability has been studied in various cancers as detailed in chapter 5 and 
therefore the next aim of my project was to study the effect of EZH2 KO on cell proliferation, 
viability and cell cycle kinetics. Effects on cell viability were assessed by trypan blue dye 
exclusion method and Annexin V staining of GFP+ K562 cells sorted on day 7. Difference 
between the percentage of live, early apoptotic and late apoptotic cells stained by Annexin V 
was not significant between cells transduced by shRNA against EZH2 compared to scrambled 
shRNA and wild type cells confirming that EZH2 KO does not affect cell viability in K562 
myeloid cells.MTT assay performed at 24, 48 and 72 hr on cells sorted for GFP+ K562 cells 
to inspect altered cell proliferation rates, revealed minimal effect on cell proliferation (p = 0.1 
to 0.4) with EZH2 inhibition (95 %) at all time points. In addition to cell viability and 
proliferation, changes in the kinetics of cell cycle entry after EZH2 inhibition was examined 
by flow cytometric analysis using PI/FITC staining. There was no difference in the 
percentage of cells in each cell cycle phase as well as apoptotic cells (sub G0) between cells 
with EZH2 inhibition compared to wild type K562 cells. These findings are in contrast to 
reports published in other cancers wherein EZH2 KO reduces cell proliferation, affects cell 
cycle kinetics and could be attributed to the lack of CDKN2A locus in K562 cells which is the 
major downstream target of EZH2 through which it governs the entry into cell cycle. 
The gene signature obtained in K562 cells was verified in patient samples containing the 
R690H mutation (n= 1) and compared to control patients (n = 5) with wild type EZH2. Five 
genes HOXA10, FLT1, PAG1B, EZH1 and TLSP were up regulated in the patient with R690H 
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mutant compared to the control patients while the other genes showed no change in their 
expression levels. Interestingly, these results are in contrast to the findings (except for EZH1) 
observed with EZH2 inhibition where HOXA10, FLT1, PAG1B and TLSP were down 
regulated. Elevated levels of EZH1 in patient sample suggest that EZH1 may compensate for 
loss EZH2 function. However this has not been shown in K562 cells. This incongruity in the 
gene signature between patient with R690H mutation and K562 cell line with 95 % KO of 
EZH2 suggest that EZH2 mutation does not mimic loss of function of the gene. 
7.3 Functional analysis of DNMT3A in myeloid malignancies 
 
 Investigating the functional consequences of the R882H mutation has been attempted by 
various research groups described in chapter 6. The aim of this project was to construct 
R882H DNMT3A mutation and transfect it into myeloid cell lines to observe the in vitro 
effect of this mutation. However, large size of the DNMT3A gene provided numerous 
technical difficulties in cloning this gene into p3XFLAG-myc-CMV-26 vector to allow for 
easy detection of the FLAG tagged transgene expression in the transfected cell lines. Ligation 
was attempted several times, however all strategies to clone DNMT3AcDNA into p3XFLAG-
myc-CMV-26 were unsuccessful. This problem was circumvented by isolating the FLAG tag 
from p3XFLAG-myc-CMV-26 and ligating it into pCMV-SPORT6 vector containing the 
R882H mutation. This plasmid was transfected along with pBABE (containing puromycin 
marker) into myeloid cell lines but very poor transfection efficiency was observed in both 
MOLM13 and KG1 cells resulting in long recovery period of cells after puromycin selection 
probably causing inactivation of the CMV promoter which drives the expression of the 
transgene in the vector. Variable expression levels (lower than mock transfected in some 
instances) of DNMT3A mRNA were observed by qPCR analysis. Due to insufficient time the 
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7.4 Future Work 
 
The results obtained in this thesis raised questions, which can be addressed in future studies. 
 To investigate alterations in the known targets of UTX, JARID1A and JARID1C by 
qPCR or western blot analysis due to changes in gene expression of these genes 
(Chapter 3) in MDS patients. 
 To optimise and prolong the time point for sample collection in cells transfected with 
R690C/R690H mutants and to evaluate the long term effects of these mutations on 
H3K27me3 expression. Perform gene expression profiling on samples collected at a 
later time point if it is associated with alterations in H3K27me3 levels and verify this 
gene signature with the one mentioned in chapter 4 to determine overlapping genes. 
 To KO EZH2 in other myeloid cell line like KG1 (with wild type CDKN2A) and 
observe its effect of cell proliferation/viability and cell cycle kinetics. Compare these 
results to the findings obtained in K562 cells in chapter 5. 
 Validate the findings of the first shRNA mentioned in chapter 5 using another shRNA 







Acquaviva, C., Gelsi-Boyer, V., and Birnbaum, D. (2010). Myelodysplastic syndromes: lost between 
two states? Leukemia 24, 1-5. 
Akasaka, T., Takahashi, N., Suzuki, M., Koseki, H., Bodmer, R., and Koga, H. (2002). MBLR, a new RING 
finger protein resembling mammalian Polycomb gene products, is regulated by cell cycle-dependent 
phosphorylation. Genes to Cells 7, 835-850. 
Akasaka, T., Tsuji, K., Kawahira, H., Kanno, M., Harigaya, K., Hu, L., Ebihara, Y., Nakahata, T., Tetsu, 
O., Taniguchi, M., et al. (1997). The role of mel-18, a mammalian Polycomb group gene, during IL-7-
dependent proliferation of lymphocyte precursors. Immunity 7, 135-146. 
Amarzguioui, M., Rossi, J.J., and Kim, D. (2005). Approaches for chemically synthesized siRNA and 
vector-mediated RNAi. FEBS Lett 579, 5974-5981. 
Amat, R., and Gudas, L.J. (2011). RARgamma is required for correct deposition and removal of Suz12 
and H2A.Z in embryonic stem cells. Journal of Cellular Physiology 226, 293-298. 
Bains, A., Luthra, R., Medeiros, L.J., and Zuo, Z. (2011). FLT3 and NPM1 mutations in myelodysplastic 
syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia. Am 
J Clin Pathol 135, 62-69. 
Bantounas, I., Phylactou, L.A., and Uney, J.B. (2004). RNA interference and the use of small 
interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33, 545-557. 
Beck, S.A., Falconer, E., Catching, A., Hodgson, J.W., and Brock, H.W. (2010). Cell cycle defects in 
polyhomeotic mutants are caused by abrogation of the DNA damage checkpoint. Developmental 
Biology 339, 320-328. 
Beerman, I., Bock, C., Garrison, B.S., Smith, Z.D., Gu, H., Meissner, A., and Rossi, D.J. (2013). 
Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem 
cell aging. Cell Stem Cell 12, 413-425. 
Beguelin, W., Popovic, R., Teater, M., Jiang, Y., Bunting, K.L., Rosen, M., Shen, H., Yang, S.N., Wang, 
L., Ezponda, T., et al. (2013). EZH2 is required for germinal center formation and somatic EZH2 
mutations promote lymphoid transformation. Cancer Cell 23, 677-692. 
Bei, L., Shah, C., Wang, H., Huang, W., Roy, R., and Eklund, E.A. (2012). beta-Catenin activates the 
HOXA10 and CDX4 genes in myeloid progenitor cells. J Biol Chem 287, 39589-39601. 
Bejar, R. (2014). Clinical and genetic predictors of prognosis in myelodysplastic syndromes. 
Haematologica 99, 956-964. 
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., 
Raza, A., Levine, R.L., Neuberg, D., et al. (2011). Clinical effect of point mutations in myelodysplastic 
syndromes. N Engl J Med 364, 2496-2506. 
Ben-Saadon, R., Zaaroor, D., Ziv, T., and Ciechanover, A. (2006). The polycomb protein Ring1B 
generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. 
Molecular Cell 24, 701-711. 
Bennett, J.M., Brunning, R.D., and Vardiman, J.W. (2002). Myelodysplastic syndromes: from French-
American-British to World Health Organization: a commentary. Blood 99, 3074-3075. 
Bernstein, E., Duncan, E.M., Masui, O., Gil, J., Heard, E., and Allis, C.D. (2006a). Mouse polycomb 
proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative 
heterochromatin. Mol Cell Biol 26, 2560-2569. 
Bernstein, E., Duncan, E.M., Masui, O., Gil, J., Heard, E., and Allis, C.D. (2006b). Mouse polycomb 
proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative 
heterochromatin. Mol Cell Biol 26, 2560-2569. 
Birmingham, A., Anderson, E.M., Reynolds, A., Ilsley-Tyree, D., Leake, D., Fedorov, Y., Baskerville, S., 
Maksimova, E., Robinson, K., Karpilow, J., et al. (2006). 3' UTR seed matches, but not overall identity, 
are associated with RNAi off-targets. Nat Methods 3, 199-204. 
Bjornsson, J.M., Andersson, E., Lundstrom, P., Larsson, N., Xu, X., Repetowska, E., Humphries, R.K., 
and Karlsson, S. (2001). Proliferation of primitive myeloid progenitors can be reversibly induced by 
HOXA10. Blood 98, 3301-3308. 
270 
 
Blair, L.P., Cao, J., Zou, M.R., Sayegh, J., and Yan, Q. (2011). Epigenetic Regulation by Lysine 
Demethylase 5 (KDM5) Enzymes in Cancer. Cancers (Basel) 3, 1383-1404. 
Bracken, A.P., Pasini, D., Capra, M., Prosperini, E., Colli, E., and Helin, K. (2003). EZH2 is downstream 
of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22, 5323-5335. 
Brandimarte, L., Pierini, V., Di Giacomo, D., Borga, C., Nozza, F., Gorello, P., Giordan, M., Cazzaniga, 
G., Te Kronnie, G., La Starza, R., et al. (2013). New MLLT10 gene recombinations in pediatric T-acute 
lymphoblastic leukemia. Blood 121, 5064-5067. 
Brecqueville, M., Cervera, N., Adelaide, J., Rey, J., Carbuccia, N., Chaffanet, M., Mozziconacci, M.J., 
Vey, N., Birnbaum, D., Gelsi-Boyer, V., et al. (2011). Mutations and deletions of the SUZ12 polycomb 
gene in myeloproliferative neoplasms. Blood Cancer J 1, e33. 
Brinkman, A.B., Gu, H., Bartels, S.J., Zhang, Y., Matarese, F., Simmer, F., Marks, H., Bock, C., Gnirke, 
A., Meissner, A., et al. (2012). Sequential ChIP-bisulfite sequencing enables direct genome-scale 
investigation of chromatin and DNA methylation cross-talk. Genome Res 22, 1128-1138. 
Brooks, A.R., Harkins, R.N., Wang, P., Qian, H.S., Liu, P., and Rubanyi, G.M. (2004). Transcriptional 
silencing is associated with extensive methylation of the CMV promoter following adenoviral gene 
delivery to muscle. J Gene Med 6, 395-404. 
Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system for stable expression of short 
interfering RNAs in mammalian cells. Science 296, 550-553. 
Bryant, R.J., Cross, N.A., Eaton, C.L., Hamdy, F.C., and Cunliffe, V.T. (2007). EZH2 promotes 
proliferation and invasiveness of prostate cancer cells. Prostate 67, 547-556. 
Budhavarapu, V.N., Chavez, M., and Tyler, J.K. (2013). How is epigenetic information maintained 
through DNA replication? Epigenetics Chromatin 6, 32. 
Buske, C., Feuring-Buske, M., Antonchuk, J., Rosten, P., Hogge, D.E., Eaves, C.J., and Humphries, R.K. 
(2001). Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. Blood 
97, 2286-2292. 
Cai, L., Rothbart, S.B., Lu, R., Xu, B., Chen, W.Y., Tripathy, A., Rockowitz, S., Zheng, D., Patel, D.J., Allis, 
C.D., et al. (2013). An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates 
PRC2 complex targeting. Mol Cell 49, 571-582. 
Cales, C., Roman-Trufero, M., Pavon, L., Serrano, I., Melgar, T., Endoh, M., Perez, C., Koseki, H., and 
Vidal, M. (2008). Inactivation of the polycomb group protein Ring1B unveils an antiproliferative role 
in hematopoietic cell expansion and cooperation with tumorigenesis associated with Ink4a deletion. 
Molecular and Cellular Biology 28, 1018-1028. 
Cao, R., Tsukada, Y., and Zhang, Y. (2005). Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox 
gene silencing. Molecular Cell 20, 845-854. 
Cao, R., Wang, H., He, J., Erdjument-Bromage, H., Tempst, P., and Zhang, Y. (2008). Role of hPHF1 in 
H3K27 methylation and Hox gene silencing. Mol Cell Biol 28, 1862-1872. 
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S., and Zhang, Y. 
(2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-
1043. 
Challen, G.A., Sun, D., Jeong, M., Luo, M., Jelinek, J., Berg, J.S., Bock, C., Vasanthakumar, A., Gu, H., 
Xi, Y., et al. (2012). Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44, 23-
31. 
Chandler, H., Patel, H., Palermo, R., Brookes, S., Matthews, N., and Peters, G. (2014). Role of 
polycomb group proteins in the DNA damage response - a reassessment. PLoS One 9, e102968. 
Chang, C.J., Yang, J.Y., Xia, W., Chen, C.T., Xie, X., Chao, C.H., Woodward, W.A., Hsu, J.M., Hortobagyi, 
G.N., and Hung, M.C. (2011). EZH2 promotes expansion of breast tumor initiating cells through 
activation of RAF1-beta-catenin signaling. Cancer Cell 19, 86-100. 
Chen, Y., Lin, M.C., Yao, H., Wang, H., Zhang, A.Q., Yu, J., Hui, C.K., Lau, G.K., He, M.L., Sung, J., et al. 
(2007). Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits 
hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46, 200-208. 
271 
 
Chen, Y., Xie, D., Yin Li, W., Man Cheung, C., Yao, H., Chan, C.Y., Xu, F.P., Liu, Y.H., Sung, J.J., and 
Kung, H.F. (2010). RNAi targeting EZH2 inhibits tumor growth and liver metastasis of pancreatic 
cancer in vivo. Cancer Lett 297, 109-116. 
Chiang, P.K. (1998). Biological effects of inhibitors of S-adenosylhomocysteine hydrolase. Pharmacol 
Ther 77, 115-134. 
Chiyomaru, T., Fukuhara, S., Saini, S., Majid, S., Deng, G., Shahryari, V., Chang, I., Tanaka, Y., Enokida, 
H., Nakagawa, M., et al. (2014). Long non-coding RNA HOTAIR is targeted and regulated by miR-141 
in human cancer cells. J Biol Chem 289, 12550-12565. 
Cho, H.S., Toyokawa, G., Daigo, Y., Hayami, S., Masuda, K., Ikawa, N., Yamane, Y., Maejima, K., 
Tsunoda, T., Field, H.I., et al. (2012). The JmjC domain-containing histone demethylase KDM3A is a 
positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 
gene. Int J Cancer 131, E179-189. 
Chou, D.M., Adamson, B., Dephoure, N.E., Tan, X., Nottke, A.C., Hurov, K.E., Gygi, S.P., Colaiacovo, 
M.P., and Elledge, S.J. (2010). A chromatin localization screen reveals poly (ADP ribose)-regulated 
recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl 
Acad Sci U S A 107, 18475-18480. 
Chubb, D., Weinhold, N., Broderick, P., Chen, B., Johnson, D.C., Forsti, A., Vijayakrishnan, J., 
Migliorini, G., Dobbins, S.E., Holroyd, A., et al. (2013). Common variation at 3q26.2, 6p21.33, 
17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet 45, 1221-1225. 
Conway O'Brien, E., Prideaux, S., and Chevassut, T. (2014). The epigenetic landscape of acute 
myeloid leukemia. Adv Hematol 2014, 103175. 
Cuccato, G., Polynikis, A., Siciliano, V., Graziano, M., di Bernardo, M., and di Bernardo, D. (2011). 
Modeling RNA interference in mammalian cells. BMC Syst Biol 5, 19. 
Das, P.P., Shao, Z., Beyaz, S., Apostolou, E., Pinello, L., De Los Angeles, A., O'Brien, K., Atsma, J.M., 
Fujiwara, Y., Nguyen, M., et al. (2014). Distinct and combinatorial functions of Jmjd2b/Kdm4b and 
Jmjd2c/Kdm4c in mouse embryonic stem cell identity. Mol Cell 53, 32-48. 
Dawson, M.J., Elwood, N.J., Johnstone, R.W., and Trapani, J.A. (1998). The IFN-inducible 
nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-
regulated in other myeloid precursor populations. J Leukoc Biol 64, 546-554. 
Dawson, M.J., and Trapani, J.A. (1995). IFI 16 gene encodes a nuclear protein whose expression is 
induced by interferons in human myeloid leukaemia cell lines. J Cell Biochem 57, 39-51. 
de la Cruz, C.C., Kirmizis, A., Simon, M.D., Isono, K., Koseki, H., and Panning, B. (2007). The polycomb 
group protein SUZ12 regulates histone H3 lysine 9 methylation and HP1 alpha distribution. 
Chromosome Research 15, 299-314. 
de Napoles, M., Mermoud, J.E., Wakao, R., Tang, Y.A., Endoh, M., Appanah, R., Nesterova, T.B., Silva, 
J., Otte, A.P., Vidal, M., et al. (2004). Polycomb group proteins Ring1A/B link ubiquitylation of histone 
H2A to heritable gene silencing and X inactivation. Dev Cell 7, 663-676. 
de Rooij, J.D., Hollink, I.H., Arentsen-Peters, S.T., van Galen, J.F., Berna Beverloo, H., Baruchel, A., 
Trka, J., Reinhardt, D., Sonneveld, E., Zimmermann, M., et al. (2013). NUP98/JARID1A is a novel 
recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene 
expression pattern. Leukemia 27, 2280-2288. 
Degos, L., and Wang, Z.Y. (2001). All trans retinoic acid in acute promyelocytic leukemia. Oncogene 
20, 7140-7145. 
Dimri, G.P., Martinez, J.L., Jacobs, J.J., Keblusek, P., Itahana, K., Van Lohuizen, M., Campisi, J., Wazer, 
D.E., and Band, V. (2002). The Bmi-1 oncogene induces telomerase activity and immortalizes human 
mammary epithelial cells. Cancer Res 62, 4736-4745. 
Dos Santos, G.A., Kats, L., and Pandolfi, P.P. (2013). Synergy against PML-RARa: targeting 
transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp 
Med 210, 2793-2802. 
272 
 
Elderkin, S., Maertens, G.N., Endoh, M., Mallery, D.L., Morrice, N., Koseki, H., Peters, G., Brockdorff, 
N., and Hiom, K. (2007). A phosphorylated form of Mel-18 targets the Ring1B histone H2A ubiquitin 
ligase to chromatin. Molecular Cell 28, 107-120. 
Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, 
F.M., Reiter, A., et al. (2010a). Inactivating mutations of the histone methyltransferase gene EZH2 in 
myeloid disorders. Nat Genet 42, 722-726. 
Ernst, T., Chase, A.J., Score, J., Hidalgo-Curtis, C.E., Bryant, C., Jones, A.V., Waghorn, K., Zoi, K., Ross, 
F.M., Reiter, A., et al. (2010b). Inactivating mutations of the histone methyltransferase gene EZH2 in 
myeloid disorders. Nat Genet 42, 722-726. 
Eskander, R.N., Ji, T., Huynh, B., Wardeh, R., Randall, L.M., and Hoang, B. (2013). Inhibition of 
enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell 
proliferation, migration, and invasion in endometrial cancer cell lines. Int J Gynecol Cancer 23, 997-
1005. 
Ewalt, M., Galili, N.G., Mumtaz, M., Churchill, M., Rivera, S., Borot, F., Raza, A., and Mukherjee, S. 
(2011). DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute 
myeloid leukemia. Blood Cancer Journal 1, e9. 
Ezhkova, E., Pasolli, H.A., Parker, J.S., Stokes, N., Su, I.H., Hannon, G., Tarakhovsky, A., and Fuchs, E. 
(2009). Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem 
cells. Cell 136, 1122-1135. 
Farcas, A.M., Blackledge, N.P., Sudbery, I., Long, H.K., McGouran, J.F., Rose, N.R., Lee, S., Sims, D., 
Cerase, A., Sheahan, T.W., et al. (2012). KDM2B links the Polycomb Repressive Complex 1 (PRC1) to 
recognition of CpG islands. Elife 1, e00205. 
Federico, A., Pallante, P., Bianco, M., Ferraro, A., Esposito, F., Monti, M., Cozzolino, M., Keller, S., 
Fedele, M., Leone, V., et al. (2009). Chromobox protein homologue 7 protein, with decreased 
expression in human carcinomas, positively regulates E-cadherin expression by interacting with the 
histone deacetylase 2 protein. Cancer Res 69, 7079-7087. 
Ferrari, K.J., Scelfo, A., Jammula, S., Cuomo, A., Barozzi, I., Stutzer, A., Fischle, W., Bonaldi, T., and 
Pasini, D. (2014). Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and 
enhancer fidelity. Mol Cell 53, 49-62. 
Fischer, C., Mazzone, M., Jonckx, B., and Carmeliet, P. (2008). FLT1 and its ligands VEGFB and PlGF: 
drug targets for anti-angiogenic therapy? Nat Rev Cancer 8, 942-956. 
Fleckenstein, D.S., Uphoff, C.C., Drexler, H.G., and Quentmeier, H. (2002). Detection of p53 gene 
mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-
derived cell lines. Leuk Res 26, 207-214. 
Fu, L., Nara, N., and Tohda, S. (2007). Involvement of Notch signaling in myelodysplastic syndrome. 
Leukemia Research 31, 1160-1161. 
Fujisaki, S., Ninomiya, Y., Ishihara, H., Miyazaki, M., Kanno, R., Asahara, T., and Kanno, M. (2003). 
Dimerization of the Polycomb-group protein Mel-18 is regulated by PKC phosphorylation. 
Biochemical and Biophysical Research Communications 300, 135-140. 
Fujiwara, T., Saitoh, H., Inoue, A., Kobayashi, M., Okitsu, Y., Katsuoka, Y., Fukuhara, N., Onishi, Y., 
Ishizawa, K., Ichinohasama, R., et al. (2014). 3-Deazaneplanocin A (DZNep), an inhibitor of S-
adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation. J Biol Chem 
289, 8121-8134. 
Gagnidze, K., Weil, Z.M., Faustino, L.C., Schaafsma, S.M., and Pfaff, D.W. (2013). Early histone 
modifications in the ventromedial hypothalamus and preoptic area following oestradiol 
administration. J Neuroendocrinol 25, 939-955. 
Gao, Z., Zhang, J., Bonasio, R., Strino, F., Sawai, A., Parisi, F., Kluger, Y., and Reinberg, D. (2012). PCGF 




Ghazal, P., Lubon, H., Fleckenstein, B., and Hennighausen, L. (1987). Binding of transcription factors 
and creation of a large nucleoprotein complex on the human cytomegalovirus enhancer. Proc Natl 
Acad Sci U S A 84, 3658-3662. 
Giagounidis, A.A., Germing, U., and Aul, C. (2006). Biological and prognostic significance of 
chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 12, 5-10. 
Ginjala, V., Nacerddine, K., Kulkarni, A., Oza, J., Hill, S.J., Yao, M., Citterio, E., van Lohuizen, M., and 
Ganesan, S. (2011). BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A 
ubiquitination and repair. Mol Cell Biol 31, 1972-1982. 
Gong, Y., Wang, X., Liu, J., Shi, L., Yin, B., Peng, X., Qiang, B., and Yuan, J. (2005). NSPc1, a mainly 
nuclear localized protein of novel PcG family members, has a transcription repression activity related 
to its PKC phosphorylation site at S183. FEBS Letters 579, 115-121. 
Gong, Y., Yue, J., Wu, X., Wang, X., Wen, J., Lu, L., Peng, X., Qiang, B., and Yuan, J. (2006). NSPc1 is a 
cell growth regulator that acts as a transcriptional repressor of p21Waf1/Cip1 via the RARE element. 
Nucleic Acids Res 34, 6158-6169. 
Gonzalez, I., Mateos-Langerak, J., Thomas, A., Cheutin, T., and Cavalli, G. (2014). Identification of 
regulators of the three-dimensional polycomb organization by a microscopy-based genome-wide 
RNAi screen. Mol Cell 54, 485-499. 
Gonzalez, M.E., Li, X., Toy, K., DuPrie, M., Ventura, A.C., Banerjee, M., Ljungman, M., Merajver, S.D., 
and Kleer, C.G. (2009). Downregulation of EZH2 decreases growth of estrogen receptor-negative 
invasive breast carcinoma and requires BRCA1. Oncogene 28, 843-853. 
Gou, D., Jin, N., and Liu, L. (2003). Gene silencing in mammalian cells by PCR-based short hairpin 
RNA. FEBS Lett 548, 113-118. 
Grau, D.J., Chapman, B.A., Garlick, J.D., Borowsky, M., Francis, N.J., and Kingston, R.E. (2011). 
Compaction of chromatin by diverse Polycomb group proteins requires localized regions of high 
charge. Genes Dev 25, 2210-2221. 
Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, 
T., Oscier, D., et al. (1997). International scoring system for evaluating prognosis in myelodysplastic 
syndromes. Blood 89, 2079-2088. 
Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, 
D., Fenaux, P., Dreyfus, F., et al. (2012). Revised international prognostic scoring system for 
myelodysplastic syndromes. Blood 120, 2454-2465. 
Guo, J.U., Su, Y., Zhong, C., Ming, G.L., and Song, H. (2011). Hydroxylation of 5-methylcytosine by 
TET1 promotes active DNA demethylation in the adult brain. Cell 145, 423-434. 
Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., Kundgen, A., 
Lubbert, M., Kunzmann, R., Giagounidis, A.A., et al. (2007). New insights into the prognostic impact 
of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 
patients. Blood 110, 4385-4395. 
Haferlach, T., Nagata, Y., Grossmann, V., Okuno, Y., Bacher, U., Nagae, G., Schnittger, S., Sanada, M., 
Kon, A., Alpermann, T., et al. (2014). Landscape of genetic lesions in 944 patients with 
myelodysplastic syndromes. Leukemia 28, 241-247. 
Hagarman, J.A., Motley, M.P., Kristjansdottir, K., and Soloway, P.D. (2013). Coordinate regulation of 
DNA methylation and H3K27me3 in mouse embryonic stem cells. PLoS One 8, e53880. 
Hanabuchi, S., Ito, T., Park, W.R., Watanabe, N., Shaw, J.L., Roman, E., Arima, K., Wang, Y.H., Voo, 
K.S., Cao, W., et al. (2010). Thymic stromal lymphopoietin-activated plasmacytoid dendritic cells 
induce the generation of FOXP3+ regulatory T cells in human thymus. J Immunol 184, 2999-3007. 
Hatano, A., Matsumoto, M., Higashinakagawa, T., and Nakayama, K.I. (2010). Phosphorylation of the 
chromodomain changes the binding specificity of Cbx2 for methylated histone H3. Biochemical and 
Biophysical Research Communications 397, 93-99. 
He, J., Nguyen, A.T., and Zhang, Y. (2011). KDM2b/JHDM1b, an H3K36me2-specific demethylase, is 
required for initiation and maintenance of acute myeloid leukemia. Blood 117, 3869-3880. 
274 
 
He, J., Shen, L., Wan, M., Taranova, O., Wu, H., and Zhang, Y. (2013). Kdm2b maintains murine 
embryonic stem cell status by recruiting PRC1 complex to CpG islands of developmental genes. Nat 
Cell Biol 15, 373-384. 
Herbst, F., Ball, C.R., Tuorto, F., Nowrouzi, A., Wang, W., Zavidij, O., Dieter, S.M., Fessler, S., van der 
Hoeven, F., Kloz, U., et al. (2012). Extensive methylation of promoter sequences silences lentiviral 
transgene expression during stem cell differentiation in vivo. Mol Ther 20, 1014-1021. 
Hidalgo, I., Herrera-Merchan, A., Ligos, J.M., Carramolino, L., Nunez, J., Martinez, F., Dominguez, O., 
Torres, M., and Gonzalez, S. (2012). Ezh1 is required for hematopoietic stem cell maintenance and 
prevents senescence-like cell cycle arrest. Cell Stem Cell 11, 649-662. 
Huang, X., Ma, D., Dong, W., Li, P., Lu, T., He, N., Tian, T., Liu, N., Du, Y., and Ji, C. (2013). Gene 
expression profiling of the DNMT3A R882 mutation in acute leukemia. Oncol Lett 6, 268-274. 
Huang, Y., Leung, J.W., Lowery, M., Matsushita, N., Wang, Y., Shen, X., Huong, D., Takata, M., Chen, 
J., and Li, L. (2014). Modularized functions of the Fanconi anemia core complex. Cell Rep 7, 1849-
1857. 
Ishikawa, F., Yoshida, S., Saito, Y., Hijikata, A., Kitamura, H., Tanaka, S., Nakamura, R., Tanaka, T., 
Tomiyama, H., Saito, N., et al. (2007). Chemotherapy-resistant human AML stem cells home to and 
engraft within the bone-marrow endosteal region. Nat Biotechnol 25, 1315-1321. 
Ismail, I.H., Andrin, C., McDonald, D., and Hendzel, M.J. (2010). BMI1-mediated histone 
ubiquitylation promotes DNA double-strand break repair. J Cell Biol 191, 45-60. 
Ismail, I.H., Gagne, J.P., Caron, M.C., McDonald, D., Xu, Z., Masson, J.Y., Poirier, G.G., and Hendzel, 
M.J. (2012). CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage. 
Nucleic Acids Res 40, 5497-5510. 
Isono, K., Fujimura, Y., Shinga, J., Yamaki, M., J, O.W., Takihara, Y., Murahashi, Y., Takada, Y., 
Mizutani-Koseki, Y., and Koseki, H. (2005). Mammalian polyhomeotic homologues Phc2 and Phc1 act 
in synergy to mediate polycomb repression of Hox genes. Molecular and Cellular Biology 25, 6694-
6706. 
Itahana, K., Zou, Y., Itahana, Y., Martinez, J.L., Beausejour, C., Jacobs, J.J., Van Lohuizen, M., Band, V., 
Campisi, J., and Dimri, G.P. (2003). Control of the replicative life span of human fibroblasts by p16 
and the polycomb protein Bmi-1. Mol Cell Biol 23, 389-401. 
Itzykson, R., and Fenaux, P. (2014). Epigenetics of myelodysplastic syndromes. Leukemia 28, 497-
506. 
Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., 
Koseki, H., et al. (2004). Enhanced self-renewal of hematopoietic stem cells mediated by the 
polycomb gene product Bmi-1. Immunity 21, 843-851. 
Jackson, A.L., Bartz, S.R., Schelter, J., Kobayashi, S.V., Burchard, J., Mao, M., Li, B., Cavet, G., and 
Linsley, P.S. (2003). Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 
21, 635-637. 
Jackson, A.L., Burchard, J., Schelter, J., Chau, B.N., Cleary, M., Lim, L., and Linsley, P.S. (2006). 
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence 
complementarity. RNA 12, 1179-1187. 
Jackson, A.L., and Linsley, P.S. (2004). Noise amidst the silence: off-target effects of siRNAs? Trends 
Genet 20, 521-524. 
Jankowska, A.M., Makishima, H., Tiu, R.V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, 
Y., Prince, C., O'Keefe, C., et al. (2011). Mutational spectrum analysis of chronic myelomonocytic 
leukemia includes genes associated with epigenetic regulation: UTX, EZH2 and DNMT3A. Blood. 
Jeltsch, A. (2006). On the enzymatic properties of Dnmt1: specificity, processivity, mechanism of 
linear diffusion and allosteric regulation of the enzyme. Epigenetics 1, 63-66. 
Jerez, A., Sugimoto, Y., Makishima, H., Verma, A., Jankowska, A.M., Przychodzen, B., Visconte, V., Tiu, 
R.V., O'Keefe, C.L., Mohamedali, A.M., et al. (2012). Loss of heterozygosity in 7q myeloid disorders: 
clinical associations and genomic pathogenesis. Blood 119, 6109-6117. 
275 
 
Kajiume, T., Ninomiya, Y., Ishihara, H., Kanno, R., and Kanno, M. (2004). Polycomb group gene mel-
18 modulates the self-renewal activity and cell cycle status of hematopoietic stem cells. 
Experimental Hematology 32, 571-578. 
Kamminga, L.M., Bystrykh, L.V., de Boer, A., Houwer, S., Douma, J., Weersing, E., Dontje, B., and de 
Haan, G. (2006). The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 
107, 2170-2179. 
Kao, J.M., McMillan, A., and Greenberg, P.L. (2008). International MDS risk analysis workshop 
(IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. 
Am J Hematol 83, 765-770. 
Kerppola, T.K. (2009). Polycomb group complexes--many combinations, many functions. Trends Cell 
Biol 19, 692-704. 
Ketel, C.S., Andersen, E.F., Vargas, M.L., Suh, J., Strome, S., and Simon, J.A. (2005). Subunit 
contributions to histone methyltransferase activities of fly and worm polycomb group complexes. 
Mol Cell Biol 25, 6857-6868. 
Khan, S.N., Jankowska, A.M., Mahfouz, R., Dunbar, A.J., Sugimoto, Y., Hosono, N., Hu, Z., Cheriyath, 
V., Vatolin, S., Przychodzen, B., et al. (2013). Multiple mechanisms deregulate EZH2 and histone H3 
lysine 27 epigenetic changes in myeloid malignancies. Leukemia 27, 1301-1309. 
Kim, C.A., Gingery, M., Pilpa, R.M., and Bowie, J.U. (2002). The SAM domain of polyhomeotic forms a 
helical polymer. Nature Structural Biology 9, 453-457. 
Kim, C.A., Sawaya, M.R., Cascio, D., Kim, W., and Bowie, J.U. (2005). Structural organization of a Sex-
comb-on-midleg/polyhomeotic copolymer. Journal of Biological Chemistry 280, 27769-27775. 
Kim, J.Y., Kim, K.B., Eom, G.H., Choe, N., Kee, H.J., Son, H.J., Oh, S.T., Kim, D.W., Pak, J.H., Baek, H.J., 
et al. (2012). KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in 
leukemia. Mol Cell Biol 32, 2917-2933. 
Kim, S.J., Zhao, H., Hardikar, S., Singh, A.K., Goodell, M.A., and Chen, T. (2013a). A DNMT3A mutation 
common in AML exhibits dominant-negative effects in murine ES cells. Blood 122, 4086-4089. 
Kim, W., Bird, G.H., Neff, T., Guo, G., Kerenyi, M.A., Walensky, L.D., and Orkin, S.H. (2013b). Targeted 
disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 9, 643-650. 
Kirmizis, A., Bartley, S.M., and Farnham, P.J. (2003). Identification of the polycomb group protein 
SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2, 113-121. 
Klauke, K., Radulovic, V., Broekhuis, M., Weersing, E., Zwart, E., Olthof, S., Ritsema, M., Bruggeman, 
S., Wu, X., Helin, K., et al. (2013). Polycomb Cbx family members mediate the balance between 
haematopoietic stem cell self-renewal and differentiation. Nat Cell Biol 15, 353-362. 
Ko, M., Huang, Y., Jankowska, A.M., Pape, U.J., Tahiliani, M., Bandukwala, H.S., An, J., Lamperti, E.D., 
Koh, K.P., Ganetzky, R., et al. (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers 
with mutant TET2. Nature 468, 839-843. 
Kojima, K., Konopleva, M., Samudio, I.J., Shikami, M., Cabreira-Hansen, M., McQueen, T., Ruvolo, V., 
Tsao, T., Zeng, Z., Vassilev, L.T., et al. (2005). MDM2 antagonists induce p53-dependent apoptosis in 
AML: implications for leukemia therapy. Blood 106, 3150-3159. 
Kolybaba, A., and Classen, A.K. (2014). Sensing cellular states--signaling to chromatin pathways 
targeting Polycomb and Trithorax group function. Cell Tissue Res 356, 477-493. 
Kondo, Y., Shen, L., Cheng, A.S., Ahmed, S., Boumber, Y., Charo, C., Yamochi, T., Urano, T., Furukawa, 
K., Kwabi-Addo, B., et al. (2008). Gene silencing in cancer by histone H3 lysine 27 trimethylation 
independent of promoter DNA methylation. Nat Genet 40, 741-750. 
Koopman, G., Reutelingsperger, C.P., Kuijten, G.A., Keehnen, R.M., Pals, S.T., and van Oers, M.H. 
(1994). Annexin V for flow cytometric detection of phosphatidylserine expression on B cells 
undergoing apoptosis. Blood 84, 1415-1420. 
Kracmarova, A., Cermak, J., Brdicka, R., and Bruchova, H. (2008). High expression of ERCC1, FLT1, 
NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome. 
Leuk Lymphoma 49, 1297-1305. 
276 
 
Kruidenier, L., Chung, C.W., Cheng, Z., Liddle, J., Che, K., Joberty, G., Bantscheff, M., Bountra, C., 
Bridges, A., Diallo, H., et al. (2012). A selective jumonji H3K27 demethylase inhibitor modulates the 
proinflammatory macrophage response. Nature 488, 404-408. 
Kuzmichev, A., Jenuwein, T., Tempst, P., and Reinberg, D. (2004). Different EZH2-containing 
complexes target methylation of histone H1 or nucleosomal histone H3. Molecular Cell 14, 183-193. 
Law, J.C., Ritke, M.K., Yalowich, J.C., Leder, G.H., and Ferrell, R.E. (1993). Mutational inactivation of 
the p53 gene in the human erythroid leukemic K562 cell line. Leuk Res 17, 1045-1050. 
Lee, H.J., Shin, D.H., Kim, K.B., Shin, N., Park, W.Y., Lee, J.H., Choi, K.U., Kim, J.Y., Lee, C.H., and Sol, 
M.Y. (2014). Polycomb protein EZH2 expression in diffuse large B-cell lymphoma is associated with 
better prognosis in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisone. Leuk Lymphoma 55, 2056-2063. 
Lessard, J., Baban, S., and Sauvageau, G. (1998). Stage-specific expression of polycomb group genes 
in human bone marrow cells. Blood 91, 1216-1224. 
Lessard, J., Schumacher, A., Thorsteinsdottir, U., van Lohuizen, M., Magnuson, T., and Sauvageau, G. 
(1999a). Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell 
proliferation. Genes Dev 13, 2691-2703. 
Lessard, J., Schumacher, A., Thorsteinsdottir, U., van Lohuizen, M., Magnuson, T., and Sauvageau, G. 
(1999b). Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell 
proliferation. Genes Dev 13, 2691-2703. 
Leung, R.K., and Whittaker, P.A. (2005). RNA interference: from gene silencing to gene-specific 
therapeutics. Pharmacol Ther 107, 222-239. 
Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., 
Baty, J., Welch, J., et al. (2010a). DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363, 
2424-2433. 
Ley, T.J., Ding, L., Walter, M.J., McLellan, M.D., Lamprecht, T., Larson, D.E., Kandoth, C., Payton, J.E., 
Baty, J., Welch, J., et al. (2010b). DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363, 
2424-2433. 
Li, B., Zhou, J., Liu, P., Hu, J., Jin, H., Shimono, Y., Takahashi, M., and Xu, G. (2007). Polycomb protein 
Cbx4 promotes SUMO modification of de novo DNA methyltransferase Dnmt3a. Biochemical Journal 
405, 369-378. 
Li, E. (2002). Chromatin modification and epigenetic reprogramming in mammalian development. 
Nat Rev Genet 3, 662-673. 
Li, G., Margueron, R., Ku, M., Chambon, P., Bernstein, B.E., and Reinberg, D. (2010). Jarid2 and PRC2, 
partners in regulating gene expression. Genes Dev 24, 368-380. 
Li, H., Bitler, B.G., Vathipadiekal, V., Maradeo, M.E., Slifker, M., Creasy, C.L., Tummino, P.J., Cairns, P., 
Birrer, M.J., and Zhang, R. (2012). ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer 
identified by genome-wide approaches. Cancer Prev Res (Phila) 5, 484-491. 
Li, K., Liu, C., Zhou, B., Bi, L., Huang, H., Lin, T., and Xu, K. (2013). Role of EZH2 in the Growth of 
Prostate Cancer Stem Cells Isolated from LNCaP Cells. Int J Mol Sci 14, 11981-11993. 
Lin, X., Ruan, X., Anderson, M.G., McDowell, J.A., Kroeger, P.E., Fesik, S.W., and Shen, Y. (2005). 
siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res 33, 
4527-4535. 
Lindroth, A.M., Park, Y.J., McLean, C.M., Dokshin, G.A., Persson, J.M., Herman, H., Pasini, D., Miro, X., 
Donohoe, M.E., Lee, J.T., et al. (2008). Antagonism between DNA and H3K27 methylation at the 
imprinted Rasgrf1 locus. PLoS Genet 4, e1000145. 
Liu, J., Cao, L., Chen, J., Song, S., Lee, I.H., Quijano, C., Liu, H., Keyvanfar, K., Chen, H., Cao, L.Y., et al. 
(2009). Bmi1 regulates mitochondrial function and the DNA damage response pathway. Nature 459, 
387-392. 
Loeffler-Ragg, J., Germing, U., Sperr, W.R., Herrmann, H., Zwierzina, H., Valent, P., Ulmer, H., and 
Stauder, R. (2011). Serum CD44 levels predict survival in patients with low-risk myelodysplastic 
syndromes. Crit Rev Oncol Hematol 78, 150-161. 
277 
 
Loser, P., Jennings, G.S., Strauss, M., and Sandig, V. (1998). Reactivation of the previously silenced 
cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J 
Virol 72, 180-190. 
Maciejewski, J.P., and Mufti, G.J. (2008). Whole genome scanning as a cytogenetic tool in 
hematologic malignancies. Blood 112, 965-974. 
Maciejewski, J.P., Tiu, R.V., and O'Keefe, C. (2009). Application of array-based whole genome 
scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol 146, 479-
488. 
Makishima, H., Jankowska, A.M., Tiu, R.V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., 
Guinta, K., Keddache, M.A., Putnam, P., et al. (2010). Novel homo- and hemizygous mutations in 
EZH2 in myeloid malignancies. Leukemia 24, 1799-1804. 
Marcucci, G., Metzeler, K.H., Schwind, S., Becker, H., Maharry, K., Mrozek, K., Radmacher, M.D., 
Kohlschmidt, J., Nicolet, D., Whitman, S.P., et al. (2012). Age-related prognostic impact of different 
types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J 
Clin Oncol 30, 742-750. 
Margueron, R., Justin, N., Ohno, K., Sharpe, M.L., Son, J., Drury, W.J., 3rd, Voigt, P., Martin, S.R., 
Taylor, W.R., De Marco, V., et al. (2009). Role of the polycomb protein EED in the propagation of 
repressive histone marks. Nature 461, 762-767. 
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dynlacht, B.D., and Reinberg, D. 
(2008a). Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 32, 
503-518. 
Margueron, R., Li, G., Sarma, K., Blais, A., Zavadil, J., Woodcock, C.L., Dynlacht, B.D., and Reinberg, D. 
(2008b). Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Molecular Cell 
32, 503-518. 
Marschalek, R. (2011). Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 152, 
141-154. 
Martin, C., Cao, R., and Zhang, Y. (2006). Substrate preferences of the EZH2 histone 
methyltransferase complex. Journal of Biological Chemistry 281, 8365-8370. 
Martinez, A.M., Schuettengruber, B., Sakr, S., Janic, A., Gonzalez, C., and Cavalli, G. (2009). 
Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling. Nature 
Genetics 41, 1076-1082. 
Meers, S. (2014). The Myelodysplastic Syndromes: The Era Of Understanding. Eur J Haematol. 
Meissner, A., Mikkelsen, T.S., Gu, H., Wernig, M., Hanna, J., Sivachenko, A., Zhang, X., Bernstein, B.E., 
Nusbaum, C., Jaffe, D.B., et al. (2008). Genome-scale DNA methylation maps of pluripotent and 
differentiated cells. Nature 454, 766-770. 
Metzeler, K.H., Maharry, K., Radmacher, M.D., Mrozek, K., Margeson, D., Becker, H., Curfman, J., 
Holland, K.B., Schwind, S., Whitman, S.P., et al. (2011). TET2 mutations improve the new European 
LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J 
Clin Oncol 29, 1373-1381. 
Meyer, C., Hofmann, J., Burmeister, T., Groger, D., Park, T.S., Emerenciano, M., Pombo de Oliveira, 
M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013). The MLL recombinome of acute 
leukemias in 2013. Leukemia 27, 2165-2176. 
Mian, S.A., Smith, A.E., Kulasekararaj, A.G., Kizilors, A., Mohamedali, A.M., Lea, N.C., Mitsopoulos, K., 
Ford, K., Nasser, E., Seidl, T., et al. (2013). Spliceosome mutations exhibit specific associations with 
epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica 98, 
1058-1066. 
Mihara, K., Chowdhury, M., Nakaju, N., Hidani, S., Ihara, A., Hyodo, H., Yasunaga, S., Takihara, Y., and 
Kimura, A. (2006). Bmi-1 is useful as a novel molecular marker for predicting progression of 
myelodysplastic syndrome and patient prognosis. Blood 107, 305-308. 
278 
 
Mistry, A.R., Pedersen, E.W., Solomon, E., and Grimwade, D. (2003). The molecular pathogenesis of 
acute promyelocytic leukaemia: implications for the clinical management of the disease. Blood Rev 
17, 71-97. 
Miyazaki, M., Kawamoto, H., Kato, Y., Itoi, M., Miyazaki, K., Masuda, K., Tashiro, S., Ishihara, H., 
Igarashi, K., Amagai, T., et al. (2005). Polycomb group gene mel-18 regulates early T progenitor 
expansion by maintaining the expression of Hes-1, a target of the Notch pathway. Journal of 
Immunology 174, 2507-2516. 
Mohamedali, A., Gaken, J., Twine, N.A., Ingram, W., Westwood, N., Lea, N.C., Hayden, J., Donaldson, 
N., Aul, C., Gattermann, N., et al. (2007). Prevalence and prognostic significance of allelic imbalance 
by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110, 3365-
3373. 
Mohamedali, A.M., Smith, A.E., Gaken, J., Lea, N.C., Mian, S.A., Westwood, N.B., Strupp, C., 
Gattermann, N., Germing, U., and Mufti, G.J. (2009). Novel TET2 mutations associated with UPD4q24 
in myelodysplastic syndrome. J Clin Oncol 27, 4002-4006. 
Montgomery, N.D., Yee, D., Chen, A., Kalantry, S., Chamberlain, S.J., Otte, A.P., and Magnuson, T. 
(2005a). The murine polycomb group protein Eed is required for global histone H3 lysine-27 
methylation. Curr Biol 15, 942-947. 
Montgomery, N.D., Yee, D., Chen, A., Kalantry, S., Chamberlain, S.J., Otte, A.P., and Magnuson, T. 
(2005b). The murine polycomb group protein Eed is required for global histone H3 lysine-27 
methylation. Curr Biol 15, 942-947. 
Montgomery, N.D., Yee, D., Montgomery, S.A., and Magnuson, T. (2007). Molecular and functional 
mapping of EED motifs required for PRC2-dependent histone methylation. Journal of Molecular 
Biology 374, 1145-1157. 
Morin, R.D., Johnson, N.A., Severson, T.M., Mungall, A.J., An, J., Goya, R., Paul, J.E., Boyle, M., 
Woolcock, B.W., Kuchenbauer, F., et al. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular 
and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42, 181-185. 
Mousavi, K., Zare, H., Wang, A.H., and Sartorelli, V. (2012). Polycomb protein Ezh1 promotes RNA 
polymerase II elongation. Mol Cell 45, 255-262. 
Mu, Z., Li, H., Fernandez, S.V., Alpaugh, K.R., Zhang, R., and Cristofanilli, M. (2013). EZH2 knockdown 
suppresses the growth and invasion of human inflammatory breast cancer cells. J Exp Clin Cancer 
Res 32, 70. 
Mufti, G.J., Bennett, J.M., Goasguen, J., Bain, B.J., Baumann, I., Brunning, R., Cazzola, M., Fenaux, P., 
Germing, U., Hellstrom-Lindberg, E., et al. (2008). Diagnosis and classification of myelodysplastic 
syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) 
consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. 
Haematologica 93, 1712-1717. 
Nekrasov, M., Klymenko, T., Fraterman, S., Papp, B., Oktaba, K., Kocher, T., Cohen, A., Stunnenberg, 
H.G., Wilm, M., and Muller, J. (2007). Pcl-PRC2 is needed to generate high levels of H3-K27 
trimethylation at Polycomb target genes. EMBO J 26, 4078-4088. 
Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., Tonnissen, E.R., van der 
Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T., et al. (2010a). Somatic mutations of the 
histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genetics 42, 665-667. 
Nikoloski, G., Langemeijer, S.M., Kuiper, R.P., Knops, R., Massop, M., Tonnissen, E.R., van der 
Heijden, A., Scheele, T.N., Vandenberghe, P., de Witte, T., et al. (2010b). Somatic mutations of the 
histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42, 665-667. 
Oguro, H., Iwama, A., Morita, Y., Kamijo, T., van Lohuizen, M., and Nakauchi, H. (2006). Differential 
impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in 
Bmi1-deficient mice. Journal of Experimental Medicine 203, 2247-2253. 
Ohta, H., Sawada, A., Kim, J.Y., Tokimasa, S., Nishiguchi, S., Humphries, R.K., Hara, J., and Takihara, Y. 
(2002). Polycomb group gene rae28 is required for sustaining activity of hematopoietic stem cells. 
Journal of Experimental Medicine 195, 759-770. 
279 
 
Pandey, R.R., Mondal, T., Mohammad, F., Enroth, S., Redrup, L., Komorowski, J., Nagano, T., Mancini-
Dinardo, D., and Kanduri, C. (2008). Kcnq1ot1 antisense noncoding RNA mediates lineage-specific 
transcriptional silencing through chromatin-level regulation. Molecular Cell 32, 232-246. 
Park, E., Kim, H., Kim, J.M., Primack, B., Vidal-Cardenas, S., Xu, Y., Price, B.D., Mills, A.A., and 
D'Andrea, A.D. (2013). FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol 
Cell 50, 908-918. 
Park, I.K., Qian, D., Kiel, M., Becker, M.W., Pihalja, M., Weissman, I.L., Morrison, S.J., and Clarke, M.F. 
(2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 
423, 302-305. 
Pasini, D., Bracken, A.P., Jensen, M.R., Lazzerini Denchi, E., and Helin, K. (2004). Suz12 is essential for 
mouse development and for EZH2 histone methyltransferase activity. EMBO Journal 23, 4061-4071. 
Pasini, D., Cloos, P.A., Walfridsson, J., Olsson, L., Bukowski, J.P., Johansen, J.V., Bak, M., Tommerup, 
N., Rappsilber, J., and Helin, K. (2010). JARID2 regulates binding of the Polycomb repressive complex 
2 to target genes in ES cells. Nature 464, 306-310. 
Peng, J.C., Valouev, A., Swigut, T., Zhang, J., Zhao, Y., Sidow, A., and Wysocka, J. (2009). 
Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in 
pluripotent cells. Cell 139, 1290-1302. 
Peters, A.H., Kubicek, S., Mechtler, K., O'Sullivan, R.J., Derijck, A.A., Perez-Burgos, L., Kohlmaier, A., 
Opravil, S., Tachibana, M., Shinkai, Y., et al. (2003). Partitioning and plasticity of repressive histone 
methylation states in mammalian chromatin. Mol Cell 12, 1577-1589. 
Pietersen, A.M., Horlings, H.M., Hauptmann, M., Langerod, A., Ajouaou, A., Cornelissen-Steijger, P., 
Wessels, L.F., Jonkers, J., van de Vijver, M.J., and van Lohuizen, M. (2008). EZH2 and BMI1 inversely 
correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 10, R109. 
Pizzatti, L., Binato, R., Cofre, J., Gomes, B.E., Dobbin, J., Haussmann, M.E., D'Azambuja, D., Bouzas, 
L.F., and Abdelhay, E. (2010). SUZ12 is a candidate target of the non-canonical WNT pathway in the 
progression of chronic myeloid leukemia. Genes, Chromosomes and Cancer 49, 107-118. 
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H., Lin, Y., et al. (2012). 
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl 
Acad Sci U S A 109, 21360-21365. 
Raaphorst, F.M., van Kemenade, F.J., Fieret, E., Hamer, K.M., Satijn, D.P., Otte, A.P., and Meijer, C.J. 
(2000). Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages 
in human germinal centers. Journal of Immunology 164, 1-4. 
Rao, Z.Y., Cai, M.Y., Yang, G.F., He, L.R., Mai, S.J., Hua, W.F., Liao, Y.J., Deng, H.X., Chen, Y.C., Guan, 
X.Y., et al. (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of 
TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 31, 1576-
1583. 
Reddington, J.P., Perricone, S.M., Nestor, C.E., Reichmann, J., Youngson, N.A., Suzuki, M., Reinhardt, 
D., Dunican, D.S., Prendergast, J.G., Mjoseng, H., et al. (2013). Redistribution of H3K27me3 upon 
DNA hypomethylation results in de-repression of Polycomb target genes. Genome Biol 14, R25. 
Reddington, J.P., Sproul, D., and Meehan, R.R. (2014). DNA methylation reprogramming in cancer: 
does it act by re-configuring the binding landscape of Polycomb repressive complexes? Bioessays 36, 
134-140. 
Ribeiro, A.F., Pratcorona, M., Erpelinck-Verschueren, C., Rockova, V., Sanders, M., Abbas, S., 
Figueroa, M.E., Zeilemaker, A., Melnick, A., Lowenberg, B., et al. (2012). Mutant DNMT3A: a marker 
of poor prognosis in acute myeloid leukemia. Blood 119, 5824-5831. 
Richie, E.R., Schumacher, A., Angel, J.M., Holloway, M., Rinchik, E.M., and Magnuson, T. (2002). The 
Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of 
carcinogen-induced T-cell lymphomas. Oncogene 21, 299-306. 
Richter, G.H., Plehm, S., Fasan, A., Rossler, S., Unland, R., Bennani-Baiti, I.M., Hotfilder, M., Lowel, D., 
von Luettichau, I., Mossbrugger, I., et al. (2009). EZH2 is a mediator of EWS/FLI1 driven tumor 
280 
 
growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci 
U S A 106, 5324-5329. 
Rizo, A., Dontje, B., Vellenga, E., de Haan, G., and Schuringa, J.J. (2008). Long-term maintenance of 
human hematopoietic stem/progenitor cells by expression of BMI1. Blood 111, 2621-2630. 
Rizo, A., Olthof, S., Han, L., Vellenga, E., de Haan, G., and Schuringa, J.J. (2009). Repression of BMI1 in 
normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood 114, 
1498-1505. 
Rubbi, L., Titz, B., Brown, L., Galvan, E., Komisopoulou, E., Chen, S.S., Low, T., Tahmasian, M., Skaggs, 
B., Muschen, M., et al. (2011). Global phosphoproteomics reveals crosstalk between Bcr-Abl and 
negative feedback mechanisms controlling Src signaling. Sci Signal 4, ra18. 
Russler-Germain, D.A., Spencer, D.H., Young, M.A., Lamprecht, T.L., Miller, C.A., Fulton, R., Meyer, 
M.R., Erdmann-Gilmore, P., Townsend, R.R., Wilson, R.K., et al. (2014). The R882H DNMT3A 
mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form 
active tetramers. Cancer Cell 25, 442-454. 
Sambucetti, L.C., Cherrington, J.M., Wilkinson, G.W., and Mocarski, E.S. (1989). NF-kappa B 
activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell 
stimulation. EMBO J 8, 4251-4258. 
Schanz, J., Tuchler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, 
M.L., Ohyashiki, K., et al. (2012). New comprehensive cytogenetic scoring system for primary 
myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from 
an international database merge. J Clin Oncol 30, 820-829. 
Schmitges, F.W., Prusty, A.B., Faty, M., Stutzer, A., Lingaraju, G.M., Aiwazian, J., Sack, R., Hess, D., Li, 
L., Zhou, S., et al. (2011). Histone methylation by PRC2 is inhibited by active chromatin marks. Mol 
Cell 42, 330-341. 
Score, J., Hidalgo-Curtis, C., Jones, A.V., Winkelmann, N., Skinner, A., Ward, D., Zoi, K., Ernst, T., 
Stegelmann, F., Dohner, K., et al. (2012). Inactivation of polycomb repressive complex 2 components 
in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 119, 1208-1213. 
Scott, C.L., Gil, J., Hernando, E., Teruya-Feldstein, J., Narita, M., Martinez, D., Visakorpi, T., Mu, D., 
Cordon-Cardo, C., Peters, G., et al. (2007). Role of the chromobox protein CBX7 in lymphomagenesis. 
Proc Natl Acad Sci U S A 104, 5389-5394. 
Senthilkumar, R., and Mishra, R.K. (2009). Novel motifs distinguish multiple homologues of Polycomb 
in vertebrates: expansion and diversification of the epigenetic toolkit. BMC Genomics 10, 549. 
Seward, S., Semaan, A., Qazi, A.M., Gruzdyn, O.V., Chamala, S., Bryant, C.C., Kumar, S., Cameron, D., 
Sethi, S., Ali-Fehmi, R., et al. (2013). EZH2 blockade by RNA interference inhibits growth of ovarian 
cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53. Cancer Lett 336, 
53-60. 
Shah, M.Y., and Licht, J.D. (2011). DNMT3A mutations in acute myeloid leukemia. Nat Genet 43, 289-
290. 
Sharawat, S.K., Bakhshi, R., Vishnubhatla, S., and Bakhshi, S. (2014). High receptor tyrosine kinase 
(FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently predicts inferior 
outcome in pediatric acute myeloid leukemia. Blood Cells Mol Dis. 
Shen, X., Kim, W., Fujiwara, Y., Simon, M.D., Liu, Y., Mysliwiec, M.R., Yuan, G.C., Lee, Y., and Orkin, 
S.H. (2009). Jumonji modulates polycomb activity and self-renewal versus differentiation of stem 
cells. Cell 139, 1303-1314. 
Sher, F., Boddeke, E., Olah, M., and Copray, S. (2012). Dynamic changes in Ezh2 gene occupancy 
underlie its involvement in neural stem cell self-renewal and differentiation towards 
oligodendrocytes. PLoS One 7, e40399. 
Shiogama, S., Yoshiba, S., Soga, D., Motohashi, H., and Shintani, S. (2013). Aberrant expression of 
EZH2 is associated with pathological findings and P53 alteration. Anticancer Res 33, 4309-4317. 
281 
 
Shivarov, V., Gueorguieva, R., Stoimenov, A., and Tiu, R. (2013). DNMT3A mutation is a poor 
prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res 37, 1445-
1450. 
Simon, J.A., and Kingston, R.E. (2013). Occupying chromatin: Polycomb mechanisms for getting to 
genomic targets, stopping transcriptional traffic, and staying put. Mol Cell 49, 808-824. 
Sinclair, J.H., Baillie, J., Bryant, L.A., Taylor-Wiedeman, J.A., and Sissons, J.G. (1992). Repression of 
human cytomegalovirus major immediate early gene expression in a monocytic cell line. J Gen Virol 
73 ( Pt 2), 433-435. 
Slape, C.I., Saw, J., Jowett, J.B., Aplan, P.D., Strasser, A., Jane, S.M., and Curtis, D.J. (2012). Inhibition 
of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome. 
Blood 120, 2475-2483. 
Sledz, C.A., Holko, M., de Veer, M.J., Silverman, R.H., and Williams, B.R. (2003). Activation of the 
interferon system by short-interfering RNAs. Nat Cell Biol 5, 834-839. 
Smith, E.R., Lee, M.G., Winter, B., Droz, N.M., Eissenberg, J.C., Shiekhattar, R., and Shilatifard, A. 
(2008). Drosophila UTX is a histone H3 Lys27 demethylase that colocalizes with the elongating form 
of RNA polymerase II. Mol Cell Biol 28, 1041-1046. 
Smith, L.L., Yeung, J., Zeisig, B.B., Popov, N., Huijbers, I., Barnes, J., Wilson, A.J., Taskesen, E., Delwel, 
R., Gil, J., et al. (2011). Functional crosstalk between Bmi1 and MLL/Hoxa9 axis in establishment of 
normal hematopoietic and leukemic stem cells. Cell Stem Cell 8, 649-662. 
Sneeringer, C.J., Scott, M.P., Kuntz, K.W., Knutson, S.K., Pollock, R.M., Richon, V.M., and Copeland, 
R.A. (2010). Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated 
hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad 
Sci U S A 107, 20980-20985. 
Son, J., Shen, S.S., Margueron, R., and Reinberg, D. (2013). Nucleosome-binding activities within 
JARID2 and EZH1 regulate the function of PRC2 on chromatin. Genes Dev 27, 2663-2677. 
Sroczynska, P., Cruickshank, V.A., Bukowski, J.P., Miyagi, S., Bagger, F.O., Walfridsson, J., Schuster, 
M.B., Porse, B., and Helin, K. (2014). shRNA screening identifies JMJD1C as being required for 
leukemia maintenance. Blood 123, 1870-1882. 
Steensma, D.P., McClure, R.F., Karp, J.E., Tefferi, A., Lasho, T.L., Powell, H.L., DeWald, G.W., and 
Kaufmann, S.H. (2006). JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 
activation is common and remains unexplained. Leukemia 20, 971-978. 
Stock, J.K., Giadrossi, S., Casanova, M., Brookes, E., Vidal, M., Koseki, H., Brockdorff, N., Fisher, A.G., 
and Pombo, A. (2007). Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at 
bivalent genes in mouse ES cells. Nat Cell Biol 9, 1428-1435. 
Stresemann, C., and Lyko, F. (2008). Modes of action of the DNA methyltransferase inhibitors 
azacytidine and decitabine. Int J Cancer 123, 8-13. 
Tadokoro, Y., Ema, H., Okano, M., Li, E., and Nakauchi, H. (2007). De novo DNA methyltransferase is 
essential for self-renewal, but not for differentiation, in hematopoietic stem cells. J Exp Med 204, 
715-722. 
Taghon, T., Stolz, F., De Smedt, M., Cnockaert, M., Verhasselt, B., Plum, J., and Leclercq, G. (2002). 
HOX-A10 regulates hematopoietic lineage commitment: evidence for a monocyte-specific 
transcription factor. Blood 99, 1197-1204. 
Tan, J., Jones, M., Koseki, H., Nakayama, M., Muntean, A.G., Maillard, I., and Hess, J.L. (2011). CBX8, 
a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 20, 563-
575. 
Tanaka, S., Miyagi, S., Sashida, G., Chiba, T., Yuan, J., Mochizuki-Kashio, M., Suzuki, Y., Sugano, S., 
Nakaseko, C., Yokote, K., et al. (2012). Ezh2 augments leukemogenicity by reinforcing differentiation 
blockage in acute myeloid leukemia. Blood 120, 1107-1117. 
Tiacci, E., Spanhol-Rosseto, A., Martelli, M.P., Pasqualucci, L., Quentmeier, H., Grossmann, V., 
Drexler, H.G., and Falini, B. (2012). The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-
AML3 cell lines carry DNMT3A mutations. Leukemia 26, 554-557. 
282 
 
Tie, R., Zhang, T., Fu, H., Wang, L., Wang, Y., He, Y., Wang, B., Zhu, N., Fu, S., Lai, X., et al. (2014). 
Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid 
leukemia: a systematic review and meta-analysis. PLoS One 9, e93353. 
Tiu, R.V., Gondek, L.P., O'Keefe, C.L., Elson, P., Huh, J., Mohamedali, A., Kulasekararaj, A., Advani, 
A.S., Paquette, R., List, A.F., et al. (2011). Prognostic impact of SNP array karyotyping in 
myelodysplastic syndromes and related myeloid malignancies. Blood 117, 4552-4560. 
Tokimasa, S., Ohta, H., Sawada, A., Matsuda, Y., Kim, J.Y., Nishiguchi, S., Hara, J., and Takihara, Y. 
(2001). Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell 
developmental stage. Experimental Hematology 29, 93-103. 
Tong, Q., He, S., Xie, F., Mochizuki, K., Liu, Y., Mochizuki, I., Meng, L., Sun, H., Zhang, Y., Guo, Y., et al. 
(2014). Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 
cell responses mediating aplastic anemia in mice. J Immunol 192, 5012-5022. 
Tonini, T., D'Andrilli, G., Fucito, A., Gaspa, L., and Bagella, L. (2008). Importance of Ezh2 polycomb 
protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. 
Journal of Cellular Physiology 214, 295-300. 
Tonkin, E., Hagan, D.M., Li, W., and Strachan, T. (2002). Identification and characterisation of novel 
mammalian homologues of Drosophila polyhomeoticpermits new insights into relationships 
between members of the polyhomeotic family. Human Genetics 111, 435-442. 
Trojer, P., Cao, A.R., Gao, Z., Li, Y., Zhang, J., Xu, X., Li, G., Losson, R., Erdjument-Bromage, H., 
Tempst, P., et al. (2011). L3MBTL2 protein acts in concert with PcG protein-mediated 
monoubiquitination of H2A to establish a repressive chromatin structure. Mol Cell 42, 438-450. 
Tsai, M.C., Wang, J.K., and Chang, H.Y. (2010). Tumor suppression by the histone demethylase UTX. 
Cell Cycle 9. 
Ueda, K., Yoshimi, A., Kagoya, Y., Nishikawa, S., Marquez, V.E., Nakagawa, M., and Kurokawa, M. 
(2014). Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage 
leukemia fusion leukemia through upregulation of p16. Cancer Sci 105, 512-519. 
Ura, H., Usuda, M., Kinoshita, K., Sun, C., Mori, K., Akagi, T., Matsuda, T., Koide, H., and Yokota, T. 
(2008). STAT3 and Oct-3/4 control histone modification through induction of Eed in embryonic stem 
cells. Journal of Biological Chemistry 283, 9713-9723. 
Valent, P. (2012). Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology 
Am Soc Hematol Educ Program 2012, 485-491. 
van den Boom, V., Rozenveld-Geugien, M., Bonardi, F., Malanga, D., van Gosliga, D., Heijink, A.M., 
Viglietto, G., Morrone, G., Fusetti, F., Vellenga, E., et al. (2013). Nonredundant and locus-specific 
gene repression functions of PRC1 paralog family members in human hematopoietic 
stem/progenitor cells. Blood 121, 2452-2461. 
van der Lugt, N.M., Domen, J., Linders, K., van Roon, M., Robanus-Maandag, E., te Riele, H., van der 
Valk, M., Deschamps, J., Sofroniew, M., van Lohuizen, M., et al. (1994). Posterior transformation, 
neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the 
bmi-1 proto-oncogene. Genes Dev 8, 757-769. 
van der Vlag, J., and Otte, A.P. (1999). Transcriptional repression mediated by the human polycomb-
group protein EED involves histone deacetylation. Nature Genetics 23, 474-478. 
van Haaften, G., Dalgliesh, G.L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., 
O'Meara, S., Teague, J., et al. (2009). Somatic mutations of the histone H3K27 demethylase gene UTX 
in human cancer. Nat Genet 41, 521-523. 
van Zutven, L.J., Onen, E., Velthuizen, S.C., van Drunen, E., von Bergh, A.R., van den Heuvel-Eibrink, 
M.M., Veronese, A., Mecucci, C., Negrini, M., de Greef, G.E., et al. (2006). Identification of NUP98 
abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes 
Cancer 45, 437-446. 
Varambally, S., Dhanasekaran, S.M., Zhou, M., Barrette, T.R., Kumar-Sinha, C., Sanda, M.G., Ghosh, 
D., Pienta, K.J., Sewalt, R.G., Otte, A.P., et al. (2002). The polycomb group protein EZH2 is involved in 
progression of prostate cancer. Nature 419, 624-629. 
283 
 
Velichutina, I., Shaknovich, R., Geng, H., Johnson, N.A., Gascoyne, R.D., Melnick, A.M., and Elemento, 
O. (2010). EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation 
and lymphomagenesis. Blood 116, 5247-5255. 
Verena I. Gaidzik, M., Richard F. Schlenk, MD2, Peter Paschka, MD2*, Claus-Henning Köhne, 
MD3*, Gerhard Held, MD4*, Marianne Habdank5*, Juliane Gohlke2*, Hans-Günther Mergenthaler, 
MD6*, Hans J. Salwender, MD7*, Lars Bullinger8, Hartmut Döhner, MD2 and Konstanze Döhner, MD2 
(2010). 97 TET2 mutations in Acute Myeloid Leukemia (AML): results on 783 patients treated within 
the AML HD98A study of the AML Study Group (AMLSG). ASH abstract. 
Vidal, M. (2009). Role of polycomb proteins Ring1A and Ring1B in the epigenetic regulation of gene 
expression. International Journal of Developmental Biology 53, 355-370. 
Vincenz, C., and Kerppola, T.K. (2008). Different polycomb group CBX family proteins associate with 
distinct regions of chromatin using nonhomologous protein sequences. Proceedings of the National 
Academy of Sciences of the United States of America 105, 16572-16577. 
Vire, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., 
Bernard, D., Vanderwinden, J.M., et al. (2006). The Polycomb group protein EZH2 directly controls 
DNA methylation. Nature 439, 871-874. 
Walker, E., Chang, W.Y., Hunkapiller, J., Cagney, G., Garcha, K., Torchia, J., Krogan, N.J., Reiter, J.F., 
and Stanford, W.L. (2010). Polycomb-like 2 associates with PRC2 and regulates transcriptional 
networks during mouse embryonic stem cell self-renewal and differentiation. Cell Stem Cell 6, 153-
166. 
Wang, G.G., Song, J., Wang, Z., Dormann, H.L., Casadio, F., Li, H., Luo, J.L., Patel, D.J., and Allis, C.D. 
(2009). Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. 
Nature 459, 847-851. 
Wang, J., Ai, X., Gale, R.P., Xu, Z., Qin, T., Fang, L., Zhang, H., Pan, L., Hu, N., Zhang, Y., et al. (2013a). 
TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res 37, 305-311. 
Wang, R., Taylor, A.B., Leal, B.Z., Chadwell, L.V., Ilangovan, U., Robinson, A.K., Schirf, V., Hart, P.J., 
Lafer, E.M., Demeler, B., et al. (2010). Polycomb group targeting through different binding partners 
of RING1B C-terminal domain. Structure 18, 966-975. 
Wang, X., Dai, H., Wang, Q., Xu, Y., Wang, Y., Sun, A., Ruan, J., Chen, S., and Wu, D. (2013b). EZH2 
mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute 
myeloid leukemia. PLoS One 8, e61341. 
Wong, C.K., Chen, Z., So, K.L., Li, D., and Li, P. (2007a). Polycomb group protein RING1B is a direct 
substrate of Caspases-3 and -9. Biochimica et Biophysica Acta 1773, 844-852. 
Wong, C.K., Chen, Z., So, K.L., Li, D., and Li, P. (2007b). Polycomb group protein RING1B is a direct 
substrate of Caspases-3 and -9. Biochim Biophys Acta 1773, 844-852. 
Wu, X., Gong, Y., Yue, J., Qiang, B., Yuan, J., and Peng, X. (2008). Cooperation between EZH2, NSPc1-
mediated histone H2A ubiquitination and Dnmt1 in HOX gene silencing. Nucleic Acids Res 36, 3590-
3599. 
Xiang, Y., Zhu, Z., Han, G., Lin, H., Xu, L., and Chen, C.D. (2007). JMJD3 is a histone H3K27 
demethylase. Cell Res 17, 850-857. 
Xie, H., Xu, J., Hsu, J.H., Nguyen, M., Fujiwara, Y., Peng, C., and Orkin, S.H. (2014). Polycomb 
repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-
specific manner. Cell Stem Cell 14, 68-80. 
Xie, W., Wang, X., Du, W., Liu, W., Qin, X., and Huang, S. (2010). Detection of molecular targets on 
the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes. Cytometry A 77, 840-
848. 
Xu, F., Li, X., Wu, L., Zhang, Q., Yang, R., Yang, Y., Zhang, Z., He, Q., and Chang, C. (2011a). 
Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: 
relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 90, 643-653. 
Xu, J., Wang, Y.Y., Dai, Y.J., Zhang, W., Zhang, W.N., Xiong, S.M., Gu, Z.H., Wang, K.K., Zeng, R., Chen, 
Z., et al. (2014). DNMT3A Arg882 mutation drives chronic myelomonocytic leukemia through 
284 
 
disturbing gene expression/DNA methylation in hematopoietic cells. Proc Natl Acad Sci U S A 111, 
2620-2625. 
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Xiao, M.T., Liu, L.X., et al. 
(2011b). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-
dependent dioxygenases. Cancer Cell 19, 17-30. 
Yadav, A.K., Sahasrabuddhe, A.A., Dimri, M., Bommi, P.V., Sainger, R., and Dimri, G.P. (2010). 
Deletion analysis of BMI1 oncoprotein identifies its negative regulatory domain. Mol Cancer 9, 158. 
Yamashita, Y., Yuan, J., Suetake, I., Suzuki, H., Ishikawa, Y., Choi, Y.L., Ueno, T., Soda, M., Hamada, T., 
Haruta, H., et al. (2010). Array-based genomic resequencing of human leukemia. Oncogene 29, 
3723-3731. 
Yan, J., Ng, S.B., Tay, J.L., Lin, B., Koh, T.L., Tan, J., Selvarajan, V., Liu, S.C., Bi, C., Wang, S., et al. 
(2013). EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage 
independently of histone methyltransferase activity. Blood 121, 4512-4520. 
Yan, X.J., Xu, J., Gu, Z.H., Pan, C.M., Lu, G., Shen, Y., Shi, J.Y., Zhu, Y.M., Tang, L., Zhang, X.W., et al. 
(2011). Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in 
acute monocytic leukemia. Nat Genet 43, 309-315. 
Yap, D.B., Chu, J., Berg, T., Schapira, M., Cheng, S.W., Moradian, A., Morin, R.D., Mungall, A.J., 
Meissner, B., Boyle, M., et al. (2011). Somatic mutations at EZH2 Y641 act dominantly through a 
mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 
117, 2451-2459. 
Yap, K.L., Li, S., Munoz-Cabello, A.M., Raguz, S., Zeng, L., Mujtaba, S., Gil, J., Walsh, M.J., and Zhou, 
M.M. (2010). Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 
by polycomb CBX7 in transcriptional silencing of INK4a. Molecular Cell 38, 662-674. 
Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., Arai, S., Sato, T., 
Shimabe, M., Nakagawa, M., et al. (2011). Evi1 represses PTEN expression and activates 
PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117, 3617-3628. 
Youle, R.J., and Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate cell 
death. Nat Rev Mol Cell Biol 9, 47-59. 
Young, M.D., Willson, T.A., Wakefield, M.J., Trounson, E., Hilton, D.J., Blewitt, M.E., Oshlack, A., and 
Majewski, I.J. (2011). ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with 
transcriptional activity. Nucleic Acids Res 39, 7415-7427. 
Yu, H., Simons, D.L., Segall, I., Carcamo-Cavazos, V., Schwartz, E.J., Yan, N., Zuckerman, N.S., Dirbas, 
F.M., Johnson, D.L., Holmes, S.P., et al. (2012). PRC2/EED-EZH2 complex is up-regulated in breast 
cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation 
in situ. PLoS One 7, e51239. 
Yuan, J.B., Yang, L.Y., Tang, Z.Y., Zu, X.B., and Qi, L. (2012). Down-regulation of EZH2 by RNA 
interference inhibits proliferation and invasion of ACHN cells via the Wnt/beta- catenin pathway. 
Asian Pac J Cancer Prev 13, 6197-6201. 
Yuan, W., Xu, M., Huang, C., Liu, N., Chen, S., and Zhu, B. (2011). H3K36 methylation antagonizes 
PRC2-mediated H3K27 methylation. J Biol Chem 286, 7983-7989. 
Zee, B.M., Britton, L.M., Wolle, D., Haberman, D.M., and Garcia, B.A. (2012). Origins and formation 
of histone methylation across the human cell cycle. Mol Cell Biol 32, 2503-2514. 
Zeidler, M., Varambally, S., Cao, Q., Chinnaiyan, A.M., Ferguson, D.O., Merajver, S.D., and Kleer, C.G. 
(2005). The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia 7, 
1011-1019. 
Zeng, Y., Yi, R., and Cullen, B.R. (2003). MicroRNAs and small interfering RNAs can inhibit mRNA 
expression by similar mechanisms. Proc Natl Acad Sci U S A 100, 9779-9784. 
Zhang, J., Grindley, J.C., Yin, T., Jayasinghe, S., He, X.C., Ross, J.T., Haug, J.S., Rupp, D., Porter-
Westpfahl, K.S., Wiedemann, L.M., et al. (2006). PTEN maintains haematopoietic stem cells and acts 
in lineage choice and leukaemia prevention. Nature 441, 518-522. 
285 
 
Zhang, Y., Li, X., Chen, Z., and Bepler, G. (2014). Ubiquitination and degradation of ribonucleotide 
reductase M1 by the polycomb group proteins RNF2 and Bmi1 and cellular response to gemcitabine. 
PLoS One 9, e91186. 
Zhang, Y.B., Niu, H.T., Chang, J.W., Dong, G.L., and Ma, X.B. (2011). EZH2 silencing by RNA 
interference inhibits proliferation in bladder cancer cell lines. Eur J Cancer Care (Engl) 20, 106-112. 
 
 
